KR102075697B1 - 피리미딘피롤 화합물, 그 제조 방법, 약학 조성물 및 그 응용 - Google Patents
피리미딘피롤 화합물, 그 제조 방법, 약학 조성물 및 그 응용 Download PDFInfo
- Publication number
- KR102075697B1 KR102075697B1 KR1020177034588A KR20177034588A KR102075697B1 KR 102075697 B1 KR102075697 B1 KR 102075697B1 KR 1020177034588 A KR1020177034588 A KR 1020177034588A KR 20177034588 A KR20177034588 A KR 20177034588A KR 102075697 B1 KR102075697 B1 KR 102075697B1
- Authority
- KR
- South Korea
- Prior art keywords
- phenyl
- pyrrolo
- diamine
- pyrimidine
- methoxy
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 149
- 238000000034 method Methods 0.000 title claims abstract description 42
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 8
- 150000003839 salts Chemical class 0.000 claims abstract description 32
- 239000002904 solvent Substances 0.000 claims abstract description 23
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 20
- -1 2-morpholino Ethyl Chemical group 0.000 claims description 611
- 229910052757 nitrogen Inorganic materials 0.000 claims description 149
- 238000006243 chemical reaction Methods 0.000 claims description 108
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 71
- 229910052739 hydrogen Inorganic materials 0.000 claims description 29
- 102100033793 ALK tyrosine kinase receptor Human genes 0.000 claims description 28
- 101710168331 ALK tyrosine kinase receptor Proteins 0.000 claims description 28
- 239000001257 hydrogen Substances 0.000 claims description 28
- 210000004027 cell Anatomy 0.000 claims description 24
- 150000002431 hydrogen Chemical class 0.000 claims description 23
- BGNGWHSBYQYVRX-UHFFFAOYSA-N 4-(dimethylamino)benzaldehyde Chemical compound CN(C)C1=CC=C(C=O)C=C1 BGNGWHSBYQYVRX-UHFFFAOYSA-N 0.000 claims description 22
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 18
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 18
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 18
- 229910052794 bromium Inorganic materials 0.000 claims description 18
- 239000000460 chlorine Substances 0.000 claims description 18
- 229910052801 chlorine Inorganic materials 0.000 claims description 18
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 17
- 230000002378 acidificating effect Effects 0.000 claims description 17
- 125000006260 ethylaminocarbonyl group Chemical group [H]N(C(*)=O)C([H])([H])C([H])([H])[H] 0.000 claims description 17
- 229910052731 fluorine Inorganic materials 0.000 claims description 17
- 239000011737 fluorine Substances 0.000 claims description 17
- 125000004458 methylaminocarbonyl group Chemical group [H]N(C(*)=O)C([H])([H])[H] 0.000 claims description 17
- 125000004193 piperazinyl group Chemical group 0.000 claims description 17
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 16
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 16
- 125000005929 isobutyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])OC(*)=O 0.000 claims description 15
- 125000005928 isopropyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(OC(*)=O)C([H])([H])[H] 0.000 claims description 15
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims description 15
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 15
- 125000004742 propyloxycarbonyl group Chemical group 0.000 claims description 15
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 15
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 15
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 13
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 13
- 229910052717 sulfur Inorganic materials 0.000 claims description 13
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 13
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 13
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 12
- 229910052760 oxygen Inorganic materials 0.000 claims description 12
- 238000006467 substitution reaction Methods 0.000 claims description 12
- 125000005936 piperidyl group Chemical group 0.000 claims description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 10
- 125000001424 substituent group Chemical group 0.000 claims description 10
- 125000006125 ethylsulfonyl group Chemical group 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 9
- 238000011282 treatment Methods 0.000 claims description 9
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 8
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 8
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 8
- 108091000080 Phosphotransferase Proteins 0.000 claims description 8
- 238000005576 amination reaction Methods 0.000 claims description 8
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 claims description 8
- 229910052763 palladium Inorganic materials 0.000 claims description 8
- 102000020233 phosphotransferase Human genes 0.000 claims description 8
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 8
- 201000011510 cancer Diseases 0.000 claims description 7
- 206010073478 Anaplastic large-cell lymphoma Diseases 0.000 claims description 6
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 claims description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical group [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
- 208000032004 Large-Cell Anaplastic Lymphoma Diseases 0.000 claims description 5
- 208000007727 Muscle Tissue Neoplasms Diseases 0.000 claims description 5
- 125000000217 alkyl group Chemical group 0.000 claims description 5
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 5
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 claims description 5
- 230000002757 inflammatory effect Effects 0.000 claims description 5
- 208000024305 myofibroblastoma Diseases 0.000 claims description 5
- 125000002733 (C1-C6) fluoroalkyl group Chemical group 0.000 claims description 4
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 claims description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 4
- 206010029260 Neuroblastoma Diseases 0.000 claims description 4
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 4
- 125000005228 aryl sulfonate group Chemical group 0.000 claims description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 4
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- ORTFAQDWJHRMNX-UHFFFAOYSA-N hydroxidooxidocarbon(.) Chemical group O[C]=O ORTFAQDWJHRMNX-UHFFFAOYSA-N 0.000 claims description 4
- 230000011987 methylation Effects 0.000 claims description 4
- 238000007069 methylation reaction Methods 0.000 claims description 4
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 125000004434 sulfur atom Chemical group 0.000 claims description 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 150000008052 alkyl sulfonates Chemical class 0.000 claims description 3
- 125000004428 fluoroalkoxy group Chemical group 0.000 claims description 3
- 201000007270 liver cancer Diseases 0.000 claims description 3
- 208000014018 liver neoplasm Diseases 0.000 claims description 3
- 125000005429 oxyalkyl group Chemical group 0.000 claims description 3
- 239000001301 oxygen Substances 0.000 claims description 3
- 125000001731 2-cyanoethyl group Chemical group [H]C([H])(*)C([H])([H])C#N 0.000 claims description 2
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims description 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical group N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 2
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims description 2
- 240000000662 Anethum graveolens Species 0.000 claims description 2
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 claims description 2
- 101000779641 Homo sapiens ALK tyrosine kinase receptor Proteins 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims description 2
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 2
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical group [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 claims description 2
- 229940077388 benzenesulfonate Drugs 0.000 claims description 2
- SXDBWCPKPHAZSM-UHFFFAOYSA-M bromate Inorganic materials [O-]Br(=O)=O SXDBWCPKPHAZSM-UHFFFAOYSA-M 0.000 claims description 2
- SXDBWCPKPHAZSM-UHFFFAOYSA-N bromic acid Chemical compound OBr(=O)=O SXDBWCPKPHAZSM-UHFFFAOYSA-N 0.000 claims description 2
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 210000002919 epithelial cell Anatomy 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims description 2
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims description 2
- 125000002883 imidazolyl group Chemical group 0.000 claims description 2
- 229910052740 iodine Inorganic materials 0.000 claims description 2
- 239000011630 iodine Substances 0.000 claims description 2
- 125000006262 isopropyl amino sulfonyl group Chemical group 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 201000005249 lung adenocarcinoma Diseases 0.000 claims description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 2
- 125000006261 methyl amino sulfonyl group Chemical group [H]N(C([H])([H])[H])S(*)(=O)=O 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 2
- 125000006216 methylsulfinyl group Chemical group [H]C([H])([H])S(*)=O 0.000 claims description 2
- 150000002823 nitrates Chemical class 0.000 claims description 2
- 125000004043 oxo group Chemical group O=* 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 2
- 125000002467 phosphate group Chemical class [H]OP(=O)(O[H])O[*] 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 201000000849 skin cancer Diseases 0.000 claims description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 2
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims description 2
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 claims description 2
- 150000003467 sulfuric acid derivatives Chemical class 0.000 claims description 2
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 claims description 2
- 210000001519 tissue Anatomy 0.000 claims description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 2
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 claims 14
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 7
- 239000003054 catalyst Substances 0.000 claims 6
- 230000001404 mediated effect Effects 0.000 claims 6
- YRVFFJPIDUOMAI-UHFFFAOYSA-N 4-(2-propan-2-ylsulfonylphenyl)-1,5-dihydropyrrolo[3,2-d]pyrimidine-2,4-diamine Chemical compound C(C)(C)S(=O)(=O)C1=C(C=CC=C1)C1(C2=C(N=C(N1)N)C=CN2)N YRVFFJPIDUOMAI-UHFFFAOYSA-N 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 4
- YAAWASYJIRZXSZ-UHFFFAOYSA-N pyrimidine-2,4-diamine Chemical compound NC1=CC=NC(N)=N1 YAAWASYJIRZXSZ-UHFFFAOYSA-N 0.000 claims 4
- 125000004484 1-methylpiperidin-4-yl group Chemical group CN1CCC(CC1)* 0.000 claims 3
- PKVBGLXWHVWKSE-UHFFFAOYSA-N 4-[[5-methyl-4-(2-methylsulfanylanilino)pyrrolo[3,2-d]pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound CN1C=CC=2N=C(N=C(C=21)NC1=C(C=CC=C1)SC)NC1=CC=C(C=C1)S(=O)(=O)N PKVBGLXWHVWKSE-UHFFFAOYSA-N 0.000 claims 3
- QOLNXBSTFLWNNN-UHFFFAOYSA-N CN1C=CC=2N=C(N=C(C=21)NC1=C(C=CC=C1)SC)NC1=CC=C(C=C1)N1CCC(CC1)O Chemical compound CN1C=CC=2N=C(N=C(C=21)NC1=C(C=CC=C1)SC)NC1=CC=C(C=C1)N1CCC(CC1)O QOLNXBSTFLWNNN-UHFFFAOYSA-N 0.000 claims 3
- NMNANMOIWBRYSD-UHFFFAOYSA-N 1-[3-ethoxy-4-[[5-methyl-4-(2-methylsulfonylanilino)pyrrolo[3,2-d]pyrimidin-2-yl]amino]phenyl]piperidin-4-ol Chemical compound CN1C=CC=2N=C(N=C(C=21)NC1=C(C=CC=C1)S(=O)(=O)C)NC1=C(C=C(C=C1)N1CCC(CC1)O)OCC NMNANMOIWBRYSD-UHFFFAOYSA-N 0.000 claims 2
- PDLINNDAZAXSAA-UHFFFAOYSA-N 1-[3-ethoxy-4-[[5-methyl-4-[(2-methylsulfanylphenyl)methylamino]pyrrolo[3,2-d]pyrimidin-2-yl]amino]phenyl]piperidin-4-ol Chemical compound CN1C=CC=2N=C(N=C(C=21)NCC1=C(C=CC=C1)SC)NC1=C(C=C(C=C1)N1CCC(CC1)O)OCC PDLINNDAZAXSAA-UHFFFAOYSA-N 0.000 claims 2
- OFIDQKBQVRPWKC-UHFFFAOYSA-N 1-[3-ethoxy-4-[[5-methyl-4-[(2-methylsulfonylphenyl)methylamino]pyrrolo[3,2-d]pyrimidin-2-yl]amino]phenyl]piperidin-4-ol Chemical compound CN1C=CC=2N=C(N=C(C=21)NCC1=C(C=CC=C1)S(=O)(=O)C)NC1=C(C=C(C=C1)N1CCC(CC1)O)OCC OFIDQKBQVRPWKC-UHFFFAOYSA-N 0.000 claims 2
- JFQITIRZLRFLFS-UHFFFAOYSA-N 1-[4-[[5-methyl-4-(2-methylsulfonylanilino)pyrrolo[3,2-d]pyrimidin-2-yl]amino]phenyl]piperidin-4-ol Chemical compound CN1C=CC=2N=C(N=C(C=21)NC1=C(C=CC=C1)S(=O)(=O)C)NC1=CC=C(C=C1)N1CCC(CC1)O JFQITIRZLRFLFS-UHFFFAOYSA-N 0.000 claims 2
- HDVOFVMMORESGH-UHFFFAOYSA-N 1-[4-[[5-methyl-4-(2-propan-2-ylsulfonylanilino)pyrrolo[3,2-d]pyrimidin-2-yl]amino]phenyl]piperidin-4-ol Chemical compound CN1C=CC=2N=C(N=C(C=21)NC1=C(C=CC=C1)S(=O)(=O)C(C)C)NC1=CC=C(C=C1)N1CCC(CC1)O HDVOFVMMORESGH-UHFFFAOYSA-N 0.000 claims 2
- WNSPKHRZNVBAKI-UHFFFAOYSA-N 1-[4-[[5-methyl-4-[(2-methylsulfanylphenyl)methylamino]pyrrolo[3,2-d]pyrimidin-2-yl]amino]phenyl]piperidin-4-ol Chemical compound CN1C=CC=2N=C(N=C(C=21)NCC1=C(C=CC=C1)SC)NC1=CC=C(C=C1)N1CCC(CC1)O WNSPKHRZNVBAKI-UHFFFAOYSA-N 0.000 claims 2
- GLIHOEHKBAGERF-UHFFFAOYSA-N 1-[4-[[5-methyl-4-[(2-methylsulfonylphenyl)methylamino]pyrrolo[3,2-d]pyrimidin-2-yl]amino]phenyl]piperidin-4-ol Chemical compound CN1C=CC=2N=C(N=C(C=21)NCC1=C(C=CC=C1)S(=O)(=O)C)NC1=CC=C(C=C1)N1CCC(CC1)O GLIHOEHKBAGERF-UHFFFAOYSA-N 0.000 claims 2
- MBSFKVPFWWFSLL-UHFFFAOYSA-N 1-[4-[[5-methyl-4-[(2-propan-2-ylsulfanylphenyl)methylamino]pyrrolo[3,2-d]pyrimidin-2-yl]amino]phenyl]piperidin-4-ol Chemical compound CN1C=CC=2N=C(N=C(C=21)NCC1=C(C=CC=C1)SC(C)C)NC1=CC=C(C=C1)N1CCC(CC1)O MBSFKVPFWWFSLL-UHFFFAOYSA-N 0.000 claims 2
- JXPHMFGXEHKVOH-UHFFFAOYSA-N 2-N-[2-methoxy-4-(4-methylpiperazin-1-yl)phenyl]-5-methyl-4-N-(2-methylsulfanylphenyl)pyrrolo[3,2-d]pyrimidine-2,4-diamine Chemical compound CN1C=CC=2N=C(N=C(C=21)NC1=C(C=CC=C1)SC)NC1=C(C=C(C=C1)N1CCN(CC1)C)OC JXPHMFGXEHKVOH-UHFFFAOYSA-N 0.000 claims 2
- HHLHBEGZKFALGC-UHFFFAOYSA-N 2-N-[2-methoxy-4-(4-methylpiperazin-1-yl)phenyl]-5-methyl-4-N-(2-methylsulfonylphenyl)pyrrolo[3,2-d]pyrimidine-2,4-diamine Chemical compound CN1C=CC=2N=C(N=C(C=21)NC1=C(C=CC=C1)S(=O)(=O)C)NC1=C(C=C(C=C1)N1CCN(CC1)C)OC HHLHBEGZKFALGC-UHFFFAOYSA-N 0.000 claims 2
- QCOQZAPQWLCFQO-UHFFFAOYSA-N 2-N-[2-methoxy-4-(4-methylpiperazin-1-yl)phenyl]-5-methyl-4-N-(2-propan-2-ylsulfonylphenyl)pyrrolo[3,2-d]pyrimidine-2,4-diamine Chemical compound CN1C=CC=2N=C(N=C(C=21)NC1=C(C=CC=C1)S(=O)(=O)C(C)C)NC1=C(C=C(C=C1)N1CCN(CC1)C)OC QCOQZAPQWLCFQO-UHFFFAOYSA-N 0.000 claims 2
- RWRXCVMXKHACNW-UHFFFAOYSA-N 2-N-[2-methoxy-4-(4-methylpiperazin-1-yl)phenyl]-5-methyl-4-N-[(2-methylsulfanylphenyl)methyl]pyrrolo[3,2-d]pyrimidine-2,4-diamine Chemical compound CN1C=CC=2N=C(N=C(C=21)NCC1=C(C=CC=C1)SC)NC1=C(C=C(C=C1)N1CCN(CC1)C)OC RWRXCVMXKHACNW-UHFFFAOYSA-N 0.000 claims 2
- RCNHDKNZINFLGQ-UHFFFAOYSA-N 2-N-[2-methoxy-4-(4-methylpiperazin-1-yl)phenyl]-5-methyl-4-N-[(2-methylsulfonylphenyl)methyl]pyrrolo[3,2-d]pyrimidine-2,4-diamine Chemical compound CN1C=CC=2N=C(N=C(C=21)NCC1=C(C=CC=C1)S(=O)(=O)C)NC1=C(C=C(C=C1)N1CCN(CC1)C)OC RCNHDKNZINFLGQ-UHFFFAOYSA-N 0.000 claims 2
- AGWNTGOXXFFDJL-UHFFFAOYSA-N 2-N-[2-methoxy-4-(4-methylpiperazin-1-yl)phenyl]-5-methyl-4-N-[(2-propan-2-ylsulfanylphenyl)methyl]pyrrolo[3,2-d]pyrimidine-2,4-diamine Chemical compound CN1C=CC=2N=C(N=C(C=21)NCC1=C(C=CC=C1)SC(C)C)NC1=C(C=C(C=C1)N1CCN(CC1)C)OC AGWNTGOXXFFDJL-UHFFFAOYSA-N 0.000 claims 2
- ICDZXWPCCZKOPA-UHFFFAOYSA-N 2-N-[2-methoxy-4-(4-methylpiperazin-1-yl)phenyl]-5-methyl-4-N-[(2-propan-2-ylsulfonylphenyl)methyl]pyrrolo[3,2-d]pyrimidine-2,4-diamine Chemical compound CN1C=CC=2N=C(N=C(C=21)NCC1=C(C=CC=C1)S(=O)(=O)C(C)C)NC1=C(C=C(C=C1)N1CCN(CC1)C)OC ICDZXWPCCZKOPA-UHFFFAOYSA-N 0.000 claims 2
- BGXVLARCSILQDQ-UHFFFAOYSA-N 2-N-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]-5-methyl-4-N-(2-methylsulfanylphenyl)pyrrolo[3,2-d]pyrimidine-2,4-diamine Chemical compound CN1C=CC=2N=C(N=C(C=21)NC1=C(C=CC=C1)SC)NC1=C(C=C(C=C1)N1CCC(CC1)N1CCN(CC1)C)OC BGXVLARCSILQDQ-UHFFFAOYSA-N 0.000 claims 2
- NWOHIYFJRWCENX-UHFFFAOYSA-N 2-N-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]-5-methyl-4-N-(2-methylsulfonylphenyl)pyrrolo[3,2-d]pyrimidine-2,4-diamine Chemical compound CN1C=CC=2N=C(N=C(C=21)NC1=C(C=CC=C1)S(=O)(=O)C)NC1=C(C=C(C=C1)N1CCC(CC1)N1CCN(CC1)C)OC NWOHIYFJRWCENX-UHFFFAOYSA-N 0.000 claims 2
- CPHRBBBBCULACO-UHFFFAOYSA-N 2-N-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]-5-methyl-4-N-(2-propan-2-ylsulfanylphenyl)pyrrolo[3,2-d]pyrimidine-2,4-diamine Chemical compound CN1C=CC=2N=C(N=C(C=21)NC1=C(C=CC=C1)SC(C)C)NC1=C(C=C(C=C1)N1CCC(CC1)N1CCN(CC1)C)OC CPHRBBBBCULACO-UHFFFAOYSA-N 0.000 claims 2
- CDIBLPUKLJETTR-UHFFFAOYSA-N 2-N-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]-5-methyl-4-N-(2-propan-2-ylsulfonylphenyl)pyrrolo[3,2-d]pyrimidine-2,4-diamine Chemical compound CN1C=CC=2N=C(N=C(C=21)NC1=C(C=CC=C1)S(=O)(=O)C(C)C)NC1=C(C=C(C=C1)N1CCC(CC1)N1CCN(CC1)C)OC CDIBLPUKLJETTR-UHFFFAOYSA-N 0.000 claims 2
- SGUBAGIPVQCPOA-UHFFFAOYSA-N 2-N-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]-5-methyl-4-N-[(2-methylsulfonylphenyl)methyl]pyrrolo[3,2-d]pyrimidine-2,4-diamine Chemical compound CN1C=CC=2N=C(N=C(C=21)NCC1=C(C=CC=C1)S(=O)(=O)C)NC1=C(C=C(C=C1)N1CCC(CC1)N1CCN(CC1)C)OC SGUBAGIPVQCPOA-UHFFFAOYSA-N 0.000 claims 2
- ZLIBDPKPTSNISY-UHFFFAOYSA-N 4-[[5-methyl-4-(2-methylsulfonylanilino)pyrrolo[3,2-d]pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound CN1C=CC=2N=C(N=C(C=21)NC1=C(C=CC=C1)S(=O)(=O)C)NC1=CC=C(C=C1)S(=O)(=O)N ZLIBDPKPTSNISY-UHFFFAOYSA-N 0.000 claims 2
- PULNMBGJTNMFFO-UHFFFAOYSA-N 4-[[5-methyl-4-(2-propan-2-ylsulfonylanilino)pyrrolo[3,2-d]pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound CN1C=CC=2N=C(N=C(C=21)NC1=C(C=CC=C1)S(=O)(=O)C(C)C)NC1=CC=C(C=C1)S(=O)(=O)N PULNMBGJTNMFFO-UHFFFAOYSA-N 0.000 claims 2
- YEPUTUDOEXVEKD-UHFFFAOYSA-N 4-[[5-methyl-4-[(2-methylsulfanylphenyl)methylamino]pyrrolo[3,2-d]pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound CN1C=CC=2N=C(N=C(C=21)NCC1=C(C=CC=C1)SC)NC1=CC=C(C=C1)S(=O)(=O)N YEPUTUDOEXVEKD-UHFFFAOYSA-N 0.000 claims 2
- ZUFJNTXETPREOX-UHFFFAOYSA-N 4-[[5-methyl-4-[(2-methylsulfonylphenyl)methylamino]pyrrolo[3,2-d]pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound CN1C=CC=2N=C(N=C(C=21)NCC1=C(C=CC=C1)S(=O)(=O)C)NC1=CC=C(C=C1)S(=O)(=O)N ZUFJNTXETPREOX-UHFFFAOYSA-N 0.000 claims 2
- NQWFFMLKULRNTB-UHFFFAOYSA-N 4-[[5-methyl-4-[(2-propan-2-ylsulfanylphenyl)methylamino]pyrrolo[3,2-d]pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound CN1C=CC=2N=C(N=C(C=21)NCC1=C(C=CC=C1)SC(C)C)NC1=CC=C(C=C1)S(=O)(=O)N NQWFFMLKULRNTB-UHFFFAOYSA-N 0.000 claims 2
- PJWRXHONOFNODJ-UHFFFAOYSA-N 4-[[5-methyl-4-[(2-propan-2-ylsulfonylphenyl)methylamino]pyrrolo[3,2-d]pyrimidin-2-yl]amino]benzenesulfonamide Chemical compound CN1C=CC=2N=C(N=C(C=21)NCC1=C(C=CC=C1)S(=O)(=O)C(C)C)NC1=CC=C(C=C1)S(=O)(=O)N PJWRXHONOFNODJ-UHFFFAOYSA-N 0.000 claims 2
- OEWHUIQJHLCJRT-UHFFFAOYSA-N 5-methyl-2-N-[4-(4-methylpiperazin-1-yl)phenyl]-4-N-(2-methylsulfonylphenyl)pyrrolo[3,2-d]pyrimidine-2,4-diamine Chemical compound CN1C=CC=2N=C(N=C(C=21)NC1=C(C=CC=C1)S(=O)(=O)C)NC1=CC=C(C=C1)N1CCN(CC1)C OEWHUIQJHLCJRT-UHFFFAOYSA-N 0.000 claims 2
- FPSCMJJYANGRQK-UHFFFAOYSA-N 5-methyl-2-N-[4-(4-methylpiperazin-1-yl)phenyl]-4-N-(2-propan-2-ylsulfonylphenyl)pyrrolo[3,2-d]pyrimidine-2,4-diamine Chemical compound CN1C=CC=2N=C(N=C(C=21)NC1=C(C=CC=C1)S(=O)(=O)C(C)C)NC1=CC=C(C=C1)N1CCN(CC1)C FPSCMJJYANGRQK-UHFFFAOYSA-N 0.000 claims 2
- UUMZVDOCMPQZQL-UHFFFAOYSA-N 5-methyl-2-N-[4-(4-methylpiperazin-1-yl)phenyl]-4-N-[(2-propan-2-ylsulfonylphenyl)methyl]pyrrolo[3,2-d]pyrimidine-2,4-diamine Chemical compound CN1C=CC=2N=C(N=C(C=21)NCC1=C(C=CC=C1)S(=O)(=O)C(C)C)NC1=CC=C(C=C1)N1CCN(CC1)C UUMZVDOCMPQZQL-UHFFFAOYSA-N 0.000 claims 2
- XOFKSYSHUFXORQ-UHFFFAOYSA-N C(C)(C)OC1=C(C=CC(=C1)N1CCC(CC1)O)C1(N=C(C2=C(N1)C=CN2)NC2=C(C=CC=C2)C(=O)OC)N Chemical compound C(C)(C)OC1=C(C=CC(=C1)N1CCC(CC1)O)C1(N=C(C2=C(N1)C=CN2)NC2=C(C=CC=C2)C(=O)OC)N XOFKSYSHUFXORQ-UHFFFAOYSA-N 0.000 claims 2
- CMFGHRBGSAQDJC-UHFFFAOYSA-N C(C)OC1=C(C=CC(=C1)N1CCC(CC1)O)C1(N=C(C2=C(N1)C=CN2)NC2=C(C=CC=C2)C(=O)OC)N Chemical compound C(C)OC1=C(C=CC(=C1)N1CCC(CC1)O)C1(N=C(C2=C(N1)C=CN2)NC2=C(C=CC=C2)C(=O)OC)N CMFGHRBGSAQDJC-UHFFFAOYSA-N 0.000 claims 2
- NOAWIQFAAVVSRR-UHFFFAOYSA-N CN1CCN(CC1)C1=CC=C(C=C1)C1(N=C(C2=C(N1)C=CN2)NC2=C(C=CC=C2)S(=O)(=O)C(C)C)N Chemical compound CN1CCN(CC1)C1=CC=C(C=C1)C1(N=C(C2=C(N1)C=CN2)NC2=C(C=CC=C2)S(=O)(=O)C(C)C)N NOAWIQFAAVVSRR-UHFFFAOYSA-N 0.000 claims 2
- HHMDKFSMPAXCMI-UHFFFAOYSA-N CN1CCN(CC1)C1=CC=C(C=C1)C1(N=C(C2=C(N1)C=CN2)NC2=C(C=CC=C2)S(=O)(=O)C)N Chemical compound CN1CCN(CC1)C1=CC=C(C=C1)C1(N=C(C2=C(N1)C=CN2)NC2=C(C=CC=C2)S(=O)(=O)C)N HHMDKFSMPAXCMI-UHFFFAOYSA-N 0.000 claims 2
- WSUDQVGIBRLJRE-UHFFFAOYSA-N CN1CCN(CC1)C1=CC=C(C=C1)C1(N=C(C2=C(N1)C=CN2)NC2=CC(=CC=C2)C(=O)OC)N Chemical compound CN1CCN(CC1)C1=CC=C(C=C1)C1(N=C(C2=C(N1)C=CN2)NC2=CC(=CC=C2)C(=O)OC)N WSUDQVGIBRLJRE-UHFFFAOYSA-N 0.000 claims 2
- DHUMOBXBXPFVOJ-UHFFFAOYSA-N CN1CCN(CC1)C1=CC=C(C=C1)C1(N=C(C2=C(N1)C=CN2)NCC2=C(C=CC=C2)S(=O)(=O)C(C)C)N Chemical compound CN1CCN(CC1)C1=CC=C(C=C1)C1(N=C(C2=C(N1)C=CN2)NCC2=C(C=CC=C2)S(=O)(=O)C(C)C)N DHUMOBXBXPFVOJ-UHFFFAOYSA-N 0.000 claims 2
- NLPKYFBLLRWYIR-UHFFFAOYSA-N CN1CCN(CC1)C1=CC=C(C=C1)C1(N=C(C2=C(N1)C=CN2)NCC2=C(C=CC=C2)S(=O)(=O)C)N Chemical compound CN1CCN(CC1)C1=CC=C(C=C1)C1(N=C(C2=C(N1)C=CN2)NCC2=C(C=CC=C2)S(=O)(=O)C)N NLPKYFBLLRWYIR-UHFFFAOYSA-N 0.000 claims 2
- QNUKDZCXXWPBNI-UHFFFAOYSA-N CN1CCN(CC1)C=1C=CC(=NC1)C1(N=C(C2=C(N1)C=CN2)NC2=C(C=CC=C2)C(=O)OC)N Chemical compound CN1CCN(CC1)C=1C=CC(=NC1)C1(N=C(C2=C(N1)C=CN2)NC2=C(C=CC=C2)C(=O)OC)N QNUKDZCXXWPBNI-UHFFFAOYSA-N 0.000 claims 2
- OMSQPHIQAXXYBW-UHFFFAOYSA-N COC(=O)C1=CC=CC=C1NC2=NC(NC3=C2NC=C3)(C4=CC=C(C=C4)OCC5=CC=CC=N5)N Chemical compound COC(=O)C1=CC=CC=C1NC2=NC(NC3=C2NC=C3)(C4=CC=C(C=C4)OCC5=CC=CC=N5)N OMSQPHIQAXXYBW-UHFFFAOYSA-N 0.000 claims 2
- GXFGKVYINCCPHL-UHFFFAOYSA-N COC1=C(C=CC(=C1)C(=O)N1CCN(CC1)C)C1(N=C(C2=C(N1)C=CN2)NC)N Chemical compound COC1=C(C=CC(=C1)C(=O)N1CCN(CC1)C)C1(N=C(C2=C(N1)C=CN2)NC)N GXFGKVYINCCPHL-UHFFFAOYSA-N 0.000 claims 2
- BOBVXYSYYVZIHF-UHFFFAOYSA-N COC1=C(C=CC(=C1)C(=O)N1CCN(CC1)C)C1(N=C(C2=C(N1)C=CN2)NC2CC2)N Chemical compound COC1=C(C=CC(=C1)C(=O)N1CCN(CC1)C)C1(N=C(C2=C(N1)C=CN2)NC2CC2)N BOBVXYSYYVZIHF-UHFFFAOYSA-N 0.000 claims 2
- OPYOYPMZQLFKLN-UHFFFAOYSA-N COC1=C(C=CC(=C1)C(=O)N1CCN(CC1)C)C1(N=C(C2=C(N1)C=CN2)NCC)N Chemical compound COC1=C(C=CC(=C1)C(=O)N1CCN(CC1)C)C1(N=C(C2=C(N1)C=CN2)NCC)N OPYOYPMZQLFKLN-UHFFFAOYSA-N 0.000 claims 2
- COTGXPKDZRUMCL-UHFFFAOYSA-N COC1=C(C=CC(=C1)N1CCC(CC1)N1CCCC1)C1(N=C(C2=C(N1)C=CN2)NC2=C(C=CC=C2)C(=O)OC)N Chemical compound COC1=C(C=CC(=C1)N1CCC(CC1)N1CCCC1)C1(N=C(C2=C(N1)C=CN2)NC2=C(C=CC=C2)C(=O)OC)N COTGXPKDZRUMCL-UHFFFAOYSA-N 0.000 claims 2
- RRWBKPFYQJTKRJ-UHFFFAOYSA-N COC1=C(C=CC(=C1)N1CCC(CC1)N1CCCC1)C1(N=C(C2=C(N1)C=CN2)NC2=CC(=CC=C2)C(=O)OC)N Chemical compound COC1=C(C=CC(=C1)N1CCC(CC1)N1CCCC1)C1(N=C(C2=C(N1)C=CN2)NC2=CC(=CC=C2)C(=O)OC)N RRWBKPFYQJTKRJ-UHFFFAOYSA-N 0.000 claims 2
- BHZRHFMXZRTNCE-UHFFFAOYSA-N COC1=C(C=CC(=C1)N1CCC(CC1)N1CCN(CC1)C)C1(N=C(C2=C(N1)C=CN2)NC2=C(C=CC=C2)C(=O)OC)N Chemical compound COC1=C(C=CC(=C1)N1CCC(CC1)N1CCN(CC1)C)C1(N=C(C2=C(N1)C=CN2)NC2=C(C=CC=C2)C(=O)OC)N BHZRHFMXZRTNCE-UHFFFAOYSA-N 0.000 claims 2
- JPQOOSNUSWFIAF-UHFFFAOYSA-N COC1=C(C=CC(=C1)N1CCC(CC1)N1CCN(CC1)C)C1(N=C(C2=C(N1)C=CN2)NC2=C(C=CC=C2)S(=O)(=O)C(C)C)N Chemical compound COC1=C(C=CC(=C1)N1CCC(CC1)N1CCN(CC1)C)C1(N=C(C2=C(N1)C=CN2)NC2=C(C=CC=C2)S(=O)(=O)C(C)C)N JPQOOSNUSWFIAF-UHFFFAOYSA-N 0.000 claims 2
- LFHHJHHEKPQBKZ-UHFFFAOYSA-N COC1=C(C=CC(=C1)N1CCC(CC1)N1CCN(CC1)C)C1(N=C(C2=C(N1)C=CN2)NC2=C(C=CC=C2)S(=O)(=O)C)N Chemical compound COC1=C(C=CC(=C1)N1CCC(CC1)N1CCN(CC1)C)C1(N=C(C2=C(N1)C=CN2)NC2=C(C=CC=C2)S(=O)(=O)C)N LFHHJHHEKPQBKZ-UHFFFAOYSA-N 0.000 claims 2
- WTNRNUITPLSZRY-UHFFFAOYSA-N COC1=C(C=CC(=C1)N1CCC(CC1)N1CCN(CC1)C)C1(N=C(C2=C(N1)C=CN2)NC2=CC(=CC=C2)C(=O)OC)N Chemical compound COC1=C(C=CC(=C1)N1CCC(CC1)N1CCN(CC1)C)C1(N=C(C2=C(N1)C=CN2)NC2=CC(=CC=C2)C(=O)OC)N WTNRNUITPLSZRY-UHFFFAOYSA-N 0.000 claims 2
- XBKQOXCFBXUSPX-UHFFFAOYSA-N COC1=C(C=CC(=C1)N1CCC(CC1)N1CCN(CC1)C)C1(N=C(C2=C(N1)C=CN2)NC2CC2)N Chemical compound COC1=C(C=CC(=C1)N1CCC(CC1)N1CCN(CC1)C)C1(N=C(C2=C(N1)C=CN2)NC2CC2)N XBKQOXCFBXUSPX-UHFFFAOYSA-N 0.000 claims 2
- KTGHGDLYNAQAJR-UHFFFAOYSA-N COC1=C(C=CC(=C1)N1CCC(CC1)N1CCN(CC1)C)C1(N=C(C2=C(N1)C=CN2)NCC2=C(C=CC=C2)S(=O)(=O)C(C)C)N Chemical compound COC1=C(C=CC(=C1)N1CCC(CC1)N1CCN(CC1)C)C1(N=C(C2=C(N1)C=CN2)NCC2=C(C=CC=C2)S(=O)(=O)C(C)C)N KTGHGDLYNAQAJR-UHFFFAOYSA-N 0.000 claims 2
- QHUIPPYIDFKKII-UHFFFAOYSA-N COC1=C(C=CC(=C1)N1CCC(CC1)N1CCN(CC1)C)C1(N=C(C2=C(N1)C=CN2)NCC2=C(C=CC=C2)S(=O)(=O)C)N Chemical compound COC1=C(C=CC(=C1)N1CCC(CC1)N1CCN(CC1)C)C1(N=C(C2=C(N1)C=CN2)NCC2=C(C=CC=C2)S(=O)(=O)C)N QHUIPPYIDFKKII-UHFFFAOYSA-N 0.000 claims 2
- DLVKNPHUPHPUIK-UHFFFAOYSA-N COC1=C(C=CC(=C1)N1CCN(CC1)C)C1(N=C(C2=C(N1)C=CN2)NC2=C(C=CC=C2)C(=O)OCC(C)C)N Chemical compound COC1=C(C=CC(=C1)N1CCN(CC1)C)C1(N=C(C2=C(N1)C=CN2)NC2=C(C=CC=C2)C(=O)OCC(C)C)N DLVKNPHUPHPUIK-UHFFFAOYSA-N 0.000 claims 2
- DMNFSCIWLHRCST-UHFFFAOYSA-N COC1=C(C=CC(=C1)N1CCN(CC1)C)C1(N=C(C2=C(N1)C=CN2)NC2=C(C=CC=C2)S(=O)(=O)C(C)C)N Chemical compound COC1=C(C=CC(=C1)N1CCN(CC1)C)C1(N=C(C2=C(N1)C=CN2)NC2=C(C=CC=C2)S(=O)(=O)C(C)C)N DMNFSCIWLHRCST-UHFFFAOYSA-N 0.000 claims 2
- IVMSOXOLRFPDDG-UHFFFAOYSA-N COC1=C(C=CC(=C1)N1CCN(CC1)C)C1(N=C(C2=C(N1)C=CN2)NC2=C(C=CC=C2)S(=O)(=O)C)N Chemical compound COC1=C(C=CC(=C1)N1CCN(CC1)C)C1(N=C(C2=C(N1)C=CN2)NC2=C(C=CC=C2)S(=O)(=O)C)N IVMSOXOLRFPDDG-UHFFFAOYSA-N 0.000 claims 2
- GVRBOIUSWABJLL-UHFFFAOYSA-N COC1=C(C=CC(=C1)N1CCN(CC1)C)C1(N=C(C2=C(N1)C=CN2)NC2=C(C=CC=C2)SC)N Chemical compound COC1=C(C=CC(=C1)N1CCN(CC1)C)C1(N=C(C2=C(N1)C=CN2)NC2=C(C=CC=C2)SC)N GVRBOIUSWABJLL-UHFFFAOYSA-N 0.000 claims 2
- DZPWSAJFEXKCSG-UHFFFAOYSA-N COC1=C(C=CC(=C1)N1CCN(CC1)C)C1(N=C(C2=C(N1)C=CN2)NC2=CC(=CC=C2)C(=O)OC)N Chemical compound COC1=C(C=CC(=C1)N1CCN(CC1)C)C1(N=C(C2=C(N1)C=CN2)NC2=CC(=CC=C2)C(=O)OC)N DZPWSAJFEXKCSG-UHFFFAOYSA-N 0.000 claims 2
- BRTRNBZVWLASQG-UHFFFAOYSA-N COC1=C(C=CC(=C1)N1CCN(CC1)C)C1(N=C(C2=C(N1)C=CN2)NCC2=C(C=CC=C2)S(=O)(=O)C(C)C)N Chemical compound COC1=C(C=CC(=C1)N1CCN(CC1)C)C1(N=C(C2=C(N1)C=CN2)NCC2=C(C=CC=C2)S(=O)(=O)C(C)C)N BRTRNBZVWLASQG-UHFFFAOYSA-N 0.000 claims 2
- QCQZLMZIFBKNTK-UHFFFAOYSA-N COC1=C(C=CC(=C1)N1CCN(CC1)C)C1(N=C(C2=C(N1)C=CN2)NCC2=C(C=CC=C2)S(=O)(=O)C)N Chemical compound COC1=C(C=CC(=C1)N1CCN(CC1)C)C1(N=C(C2=C(N1)C=CN2)NCC2=C(C=CC=C2)S(=O)(=O)C)N QCQZLMZIFBKNTK-UHFFFAOYSA-N 0.000 claims 2
- OECQNVLNGPIVHW-UHFFFAOYSA-N COC1=C(C=CC(=C1)N1CCN(CC1)C)C1(N=C(C2=C(N1)C=CN2)NCC2=C(C=CC=C2)SC(C)C)N Chemical compound COC1=C(C=CC(=C1)N1CCN(CC1)C)C1(N=C(C2=C(N1)C=CN2)NCC2=C(C=CC=C2)SC(C)C)N OECQNVLNGPIVHW-UHFFFAOYSA-N 0.000 claims 2
- SYABWMBJIZTBIY-UHFFFAOYSA-N COC1=C(C=CC(=C1)N1CCOCC1)C1(N=C(C2=C(N1)C=CN2)NC2=C(C=CC=C2)C(=O)OC)N Chemical compound COC1=C(C=CC(=C1)N1CCOCC1)C1(N=C(C2=C(N1)C=CN2)NC2=C(C=CC=C2)C(=O)OC)N SYABWMBJIZTBIY-UHFFFAOYSA-N 0.000 claims 2
- OUYSCUXVOONTBH-UHFFFAOYSA-N NS(=O)(=O)C1=CC=C(C=C1)C1(N=C(C2=C(N1)C=CN2)NC)N Chemical compound NS(=O)(=O)C1=CC=C(C=C1)C1(N=C(C2=C(N1)C=CN2)NC)N OUYSCUXVOONTBH-UHFFFAOYSA-N 0.000 claims 2
- VZGCOSUFWHLPNJ-UHFFFAOYSA-N NS(=O)(=O)C1=CC=C(C=C1)C1(N=C(C2=C(N1)C=CN2)NC2=C(C=CC=C2)C(=O)OC)N Chemical compound NS(=O)(=O)C1=CC=C(C=C1)C1(N=C(C2=C(N1)C=CN2)NC2=C(C=CC=C2)C(=O)OC)N VZGCOSUFWHLPNJ-UHFFFAOYSA-N 0.000 claims 2
- MWRXPIYIDOLRDX-UHFFFAOYSA-N NS(=O)(=O)C1=CC=C(C=C1)C1(N=C(C2=C(N1)C=CN2)NC2=C(C=CC=C2)S(=O)(=O)C(C)C)N Chemical compound NS(=O)(=O)C1=CC=C(C=C1)C1(N=C(C2=C(N1)C=CN2)NC2=C(C=CC=C2)S(=O)(=O)C(C)C)N MWRXPIYIDOLRDX-UHFFFAOYSA-N 0.000 claims 2
- BDTJEUAVHKMGRV-UHFFFAOYSA-N NS(=O)(=O)C1=CC=C(C=C1)C1(N=C(C2=C(N1)C=CN2)NC2=C(C=CC=C2)S(=O)(=O)C)N Chemical compound NS(=O)(=O)C1=CC=C(C=C1)C1(N=C(C2=C(N1)C=CN2)NC2=C(C=CC=C2)S(=O)(=O)C)N BDTJEUAVHKMGRV-UHFFFAOYSA-N 0.000 claims 2
- QCQIWLZJCRCUDD-UHFFFAOYSA-N NS(=O)(=O)C1=CC=C(C=C1)C1(N=C(C2=C(N1)C=CN2)NC2=C(C=CC=C2)SC(C)C)N Chemical compound NS(=O)(=O)C1=CC=C(C=C1)C1(N=C(C2=C(N1)C=CN2)NC2=C(C=CC=C2)SC(C)C)N QCQIWLZJCRCUDD-UHFFFAOYSA-N 0.000 claims 2
- XGLSKXBOVBVIPX-UHFFFAOYSA-N NS(=O)(=O)C1=CC=C(C=C1)C1(N=C(C2=C(N1)C=CN2)NC2=C(C=CC=C2)SC)N Chemical compound NS(=O)(=O)C1=CC=C(C=C1)C1(N=C(C2=C(N1)C=CN2)NC2=C(C=CC=C2)SC)N XGLSKXBOVBVIPX-UHFFFAOYSA-N 0.000 claims 2
- BOSPPLSHUJAAAV-UHFFFAOYSA-N NS(=O)(=O)C1=CC=C(C=C1)C1(N=C(C2=C(N1)C=CN2)NC2CC2)N Chemical compound NS(=O)(=O)C1=CC=C(C=C1)C1(N=C(C2=C(N1)C=CN2)NC2CC2)N BOSPPLSHUJAAAV-UHFFFAOYSA-N 0.000 claims 2
- LPJFIJLDUOBIEU-UHFFFAOYSA-N NS(=O)(=O)C1=CC=C(C=C1)C1(N=C(C2=C(N1)C=CN2)NCC2=C(C=CC=C2)S(=O)(=O)C(C)C)N Chemical compound NS(=O)(=O)C1=CC=C(C=C1)C1(N=C(C2=C(N1)C=CN2)NCC2=C(C=CC=C2)S(=O)(=O)C(C)C)N LPJFIJLDUOBIEU-UHFFFAOYSA-N 0.000 claims 2
- UOEPZDRSWQUROS-UHFFFAOYSA-N NS(=O)(=O)C1=CC=C(C=C1)C1(N=C(C2=C(N1)C=CN2)NCC2=C(C=CC=C2)S(=O)(=O)C)N Chemical compound NS(=O)(=O)C1=CC=C(C=C1)C1(N=C(C2=C(N1)C=CN2)NCC2=C(C=CC=C2)S(=O)(=O)C)N UOEPZDRSWQUROS-UHFFFAOYSA-N 0.000 claims 2
- IOMMMHUQBBOEFX-UHFFFAOYSA-N NS(=O)(=O)C1=CC=C(C=C1)C1(N=C(C2=C(N1)C=CN2)NCC2=C(C=CC=C2)SC(C)C)N Chemical compound NS(=O)(=O)C1=CC=C(C=C1)C1(N=C(C2=C(N1)C=CN2)NCC2=C(C=CC=C2)SC(C)C)N IOMMMHUQBBOEFX-UHFFFAOYSA-N 0.000 claims 2
- XPKZTIKTFMGYPJ-UHFFFAOYSA-N O1CCN(CC1)C1=CC=C(C=C1)C1(N=C(C2=C(N1)C=CN2)NC2=C(C=CC=C2)C(=O)OC)N Chemical compound O1CCN(CC1)C1=CC=C(C=C1)C1(N=C(C2=C(N1)C=CN2)NC2=C(C=CC=C2)C(=O)OC)N XPKZTIKTFMGYPJ-UHFFFAOYSA-N 0.000 claims 2
- FYGYXYLLRWNPTO-UHFFFAOYSA-N O1CCN(CC1)C1=CC=C(C=C1)C1(N=C(C2=C(N1)C=CN2)NC2=CC(=CC=C2)C(=O)OC)N Chemical compound O1CCN(CC1)C1=CC=C(C=C1)C1(N=C(C2=C(N1)C=CN2)NC2=CC(=CC=C2)C(=O)OC)N FYGYXYLLRWNPTO-UHFFFAOYSA-N 0.000 claims 2
- JUKDILHLSCKKDS-UHFFFAOYSA-N OC1CCN(CC1)C1=CC=C(C=C1)C1(N=C(C2=C(N1)C=CN2)NC)N Chemical compound OC1CCN(CC1)C1=CC=C(C=C1)C1(N=C(C2=C(N1)C=CN2)NC)N JUKDILHLSCKKDS-UHFFFAOYSA-N 0.000 claims 2
- IKEZVSLXWJXKBS-UHFFFAOYSA-N OC1CCN(CC1)C1=CC=C(C=C1)C1(N=C(C2=C(N1)C=CN2)NC2=C(C=CC=C2)S(=O)(=O)C)N Chemical compound OC1CCN(CC1)C1=CC=C(C=C1)C1(N=C(C2=C(N1)C=CN2)NC2=C(C=CC=C2)S(=O)(=O)C)N IKEZVSLXWJXKBS-UHFFFAOYSA-N 0.000 claims 2
- QDIXQYYWUMUYOE-UHFFFAOYSA-N OC1CCN(CC1)C1=CC=C(C=C1)C1(N=C(C2=C(N1)C=CN2)NC2=C(C=CC=C2)SC(C)C)N Chemical compound OC1CCN(CC1)C1=CC=C(C=C1)C1(N=C(C2=C(N1)C=CN2)NC2=C(C=CC=C2)SC(C)C)N QDIXQYYWUMUYOE-UHFFFAOYSA-N 0.000 claims 2
- QBICJLJPZIQTAH-UHFFFAOYSA-N OC1CCN(CC1)C1=CC=C(C=C1)C1(N=C(C2=C(N1)C=CN2)NC2=C(C=CC=C2)SC)N Chemical compound OC1CCN(CC1)C1=CC=C(C=C1)C1(N=C(C2=C(N1)C=CN2)NC2=C(C=CC=C2)SC)N QBICJLJPZIQTAH-UHFFFAOYSA-N 0.000 claims 2
- GHSMJHFPROONKN-UHFFFAOYSA-N OC1CCN(CC1)C1=CC=C(C=C1)C1(N=C(C2=C(N1)C=CN2)NC2CC2)N Chemical compound OC1CCN(CC1)C1=CC=C(C=C1)C1(N=C(C2=C(N1)C=CN2)NC2CC2)N GHSMJHFPROONKN-UHFFFAOYSA-N 0.000 claims 2
- GMTZCZGVAKFAME-UHFFFAOYSA-N OC1CCN(CC1)C1=CC=C(C=C1)C1(N=C(C2=C(N1)C=CN2)NCC)N Chemical compound OC1CCN(CC1)C1=CC=C(C=C1)C1(N=C(C2=C(N1)C=CN2)NCC)N GMTZCZGVAKFAME-UHFFFAOYSA-N 0.000 claims 2
- VEASGIIPRJIKOQ-UHFFFAOYSA-N OC1CCN(CC1)C1=CC=C(C=C1)C1(N=C(C2=C(N1)C=CN2)NCC2=C(C=CC=C2)S(=O)(=O)C)N Chemical compound OC1CCN(CC1)C1=CC=C(C=C1)C1(N=C(C2=C(N1)C=CN2)NCC2=C(C=CC=C2)S(=O)(=O)C)N VEASGIIPRJIKOQ-UHFFFAOYSA-N 0.000 claims 2
- DNVUJSCIVNZGFV-UHFFFAOYSA-N OC1CCN(CC1)C1=CC=C(C=C1)C1(N=C(C2=C(N1)C=CN2)NCC2=C(C=CC=C2)SC(C)C)N Chemical compound OC1CCN(CC1)C1=CC=C(C=C1)C1(N=C(C2=C(N1)C=CN2)NCC2=C(C=CC=C2)SC(C)C)N DNVUJSCIVNZGFV-UHFFFAOYSA-N 0.000 claims 2
- MAHMXHSLNQAVSC-UHFFFAOYSA-N OC1CCN(CC1)C1=CC=C(C=N1)C1(N=C(C2=C(N1)C=CN2)NC2=C(C=CC=C2)C(=O)OC)N Chemical compound OC1CCN(CC1)C1=CC=C(C=N1)C1(N=C(C2=C(N1)C=CN2)NC2=C(C=CC=C2)C(=O)OC)N MAHMXHSLNQAVSC-UHFFFAOYSA-N 0.000 claims 2
- IAUSHALUTSWYRP-UHFFFAOYSA-N OC1CCN(CC1)S(=O)(=O)C1=CC=C(C=C1)C1(N=C(C2=C(N1)C=CN2)NC2=C(C=CC=C2)C(=O)OC)N Chemical compound OC1CCN(CC1)S(=O)(=O)C1=CC=C(C=C1)C1(N=C(C2=C(N1)C=CN2)NC2=C(C=CC=C2)C(=O)OC)N IAUSHALUTSWYRP-UHFFFAOYSA-N 0.000 claims 2
- SZTJVPXLHBBGTL-UHFFFAOYSA-N [3-methoxy-4-[[5-methyl-4-[(2-methylsulfonylphenyl)methylamino]pyrrolo[3,2-d]pyrimidin-2-yl]amino]phenyl]-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]methanone Chemical compound CN1C=CC=2N=C(N=C(C=21)NCC1=C(C=CC=C1)S(=O)(=O)C)NC1=C(C=C(C=C1)C(=O)N1CCC(CC1)N1CCN(CC1)C)OC SZTJVPXLHBBGTL-UHFFFAOYSA-N 0.000 claims 2
- PYVCKNZGYDBNFK-UHFFFAOYSA-N methyl 2-[2-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]anilino]-5-methylpyrrolo[3,2-d]pyrimidin-4-yl]oxybenzoate Chemical compound COC(=O)C1=C(C=CC=C1)OC=1C2=C(N=C(N=1)NC1=C(C=C(C=C1)N1CCC(CC1)N1CCN(CC1)C)OC)C=CN2C PYVCKNZGYDBNFK-UHFFFAOYSA-N 0.000 claims 2
- NKFMWLYTDOHVGS-UHFFFAOYSA-N methyl 2-[2-[4-(4-hydroxypiperidin-1-yl)anilino]-5-methylpyrrolo[3,2-d]pyrimidin-4-yl]oxybenzoate Chemical compound COC(=O)C1=C(C=CC=C1)OC=1C2=C(N=C(N=1)NC1=CC=C(C=C1)N1CCC(CC1)O)C=CN2C NKFMWLYTDOHVGS-UHFFFAOYSA-N 0.000 claims 2
- YIATYEQFBAAVHN-UHFFFAOYSA-N methyl 2-[[2-(4-sulfamoylanilino)-5H-pyrrolo[3,2-d]pyrimidin-4-yl]sulfanyl]benzoate Chemical compound COC(=O)C1=C(C=CC=C1)SC=1C2=C(N=C(N=1)NC1=CC=C(C=C1)S(=O)(=O)N)C=CN2 YIATYEQFBAAVHN-UHFFFAOYSA-N 0.000 claims 2
- BVUOQSKXONFELN-UHFFFAOYSA-N methyl 2-[[2-[2-methoxy-4-(4-methylpiperazin-1-yl)anilino]-5-methylpyrrolo[3,2-d]pyrimidin-4-yl]amino]benzoate Chemical compound COC(=O)c1ccccc1Nc1nc(Nc2ccc(cc2OC)N2CCN(C)CC2)nc2ccn(C)c12 BVUOQSKXONFELN-UHFFFAOYSA-N 0.000 claims 2
- DHMXAAGAOQDMPO-UHFFFAOYSA-N methyl 2-[[2-[2-methoxy-4-(4-methylpiperazin-1-yl)anilino]-5H-pyrrolo[3,2-d]pyrimidin-4-yl]oxy]benzoate Chemical compound COC(=O)C1=C(C=CC=C1)OC=1C2=C(N=C(N=1)NC1=C(C=C(C=C1)N1CCN(CC1)C)OC)C=CN2 DHMXAAGAOQDMPO-UHFFFAOYSA-N 0.000 claims 2
- PVJCOZUEUHOPAL-UHFFFAOYSA-N methyl 2-[[2-[2-methoxy-4-(4-methylpiperazin-1-yl)anilino]-5H-pyrrolo[3,2-d]pyrimidin-4-yl]sulfanyl]benzoate Chemical compound COC(=O)C1=C(C=CC=C1)SC=1C2=C(N=C(N=1)NC1=C(C=C(C=C1)N1CCN(CC1)C)OC)C=CN2 PVJCOZUEUHOPAL-UHFFFAOYSA-N 0.000 claims 2
- MZUZKJSMELHBHS-UHFFFAOYSA-N methyl 2-[[2-[2-methoxy-4-(4-pyrrolidin-1-ylpiperidin-1-yl)anilino]-5H-pyrrolo[3,2-d]pyrimidin-4-yl]sulfanyl]benzoate Chemical compound COC(=O)C1=C(C=CC=C1)SC=1C2=C(N=C(N=1)NC1=C(C=C(C=C1)N1CCC(CC1)N1CCCC1)OC)C=CN2 MZUZKJSMELHBHS-UHFFFAOYSA-N 0.000 claims 2
- KGBSYSXHPQGGJL-UHFFFAOYSA-N methyl 2-[[2-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]anilino]-5H-pyrrolo[3,2-d]pyrimidin-4-yl]oxy]benzoate Chemical compound COC(=O)C1=C(C=CC=C1)OC=1C2=C(N=C(N=1)NC1=C(C=C(C=C1)N1CCC(CC1)N1CCN(CC1)C)OC)C=CN2 KGBSYSXHPQGGJL-UHFFFAOYSA-N 0.000 claims 2
- WIXYOISPXUYPSR-UHFFFAOYSA-N methyl 2-[[2-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]anilino]-5H-pyrrolo[3,2-d]pyrimidin-4-yl]sulfanyl]benzoate Chemical compound COC(=O)C1=C(C=CC=C1)SC=1C2=C(N=C(N=1)NC1=C(C=C(C=C1)N1CCC(CC1)N1CCN(CC1)C)OC)C=CN2 WIXYOISPXUYPSR-UHFFFAOYSA-N 0.000 claims 2
- KZVSZESVHLOGJF-UHFFFAOYSA-N methyl 2-[[2-[4-(4-hydroxypiperidin-1-yl)anilino]-5H-pyrrolo[3,2-d]pyrimidin-4-yl]sulfanyl]benzoate Chemical compound COC(=O)C1=C(C=CC=C1)SC=1C2=C(N=C(N=1)NC1=CC=C(C=C1)N1CCC(CC1)O)C=CN2 KZVSZESVHLOGJF-UHFFFAOYSA-N 0.000 claims 2
- KXAMZGGTQFNLHR-UHFFFAOYSA-N methyl 3-[[2-[2-methoxy-4-(4-methylpiperazin-1-yl)anilino]-5-methylpyrrolo[3,2-d]pyrimidin-4-yl]amino]benzoate Chemical compound COC(=O)c1cccc(Nc2nc(Nc3ccc(cc3OC)N3CCN(C)CC3)nc3ccn(C)c23)c1 KXAMZGGTQFNLHR-UHFFFAOYSA-N 0.000 claims 2
- 238000011321 prophylaxis Methods 0.000 claims 2
- LJXQPZWIHJMPQQ-UHFFFAOYSA-N pyrimidin-2-amine Chemical compound NC1=NC=CC=N1 LJXQPZWIHJMPQQ-UHFFFAOYSA-N 0.000 claims 2
- XZRBLIYHAXTYAT-QFIPXVFZSA-N (2S)-2-amino-3-methyl-N-[3-[[4-(2-propan-2-ylsulfonylanilino)-5H-pyrrolo[3,2-d]pyrimidin-2-yl]amino]phenyl]butanamide Chemical compound C(C)(C)[C@@H](C(=O)NC=1C=C(C=CC=1)NC=1N=C(C2=C(N=1)C=CN2)NC1=C(C=CC=C1)S(=O)(=O)C(C)C)N XZRBLIYHAXTYAT-QFIPXVFZSA-N 0.000 claims 1
- KWNVFGWQQDKBAW-HNNXBMFYSA-N (2S)-2-amino-N-[3-[[4-(2-propan-2-ylsulfonylanilino)-5H-pyrrolo[3,2-d]pyrimidin-2-yl]amino]phenyl]propanamide Chemical compound C[C@@H](C(=O)NC=1C=C(C=CC=1)NC=1N=C(C2=C(N=1)C=CN2)NC1=C(C=CC=C1)S(=O)(=O)C(C)C)N KWNVFGWQQDKBAW-HNNXBMFYSA-N 0.000 claims 1
- YXYRVMFAKIIXGN-UHFFFAOYSA-N 1-[3-ethoxy-4-[[5-methyl-4-(2-propan-2-ylsulfonylanilino)pyrrolo[3,2-d]pyrimidin-2-yl]amino]phenyl]piperidin-4-ol Chemical compound CN1C=CC=2N=C(N=C(C=21)NC1=C(C=CC=C1)S(=O)(=O)C(C)C)NC1=C(C=C(C=C1)N1CCC(CC1)O)OCC YXYRVMFAKIIXGN-UHFFFAOYSA-N 0.000 claims 1
- KZEFJBMYEUNKGY-UHFFFAOYSA-N 1-[4-[[4-(2-dimethylphosphorylanilino)-5-methylpyrrolo[3,2-d]pyrimidin-2-yl]amino]phenyl]piperidin-4-ol Chemical compound CN1C=CC=2N=C(N=C(C=21)NC1=C(C=CC=C1)P(=O)(C)C)NC1=CC=C(C=C1)N1CCC(CC1)O KZEFJBMYEUNKGY-UHFFFAOYSA-N 0.000 claims 1
- DTOUFNKXWRNXAS-UHFFFAOYSA-N 1-[4-[[4-[(2,6-dichlorophenyl)methylamino]-5-methylpyrrolo[3,2-d]pyrimidin-2-yl]amino]phenyl]piperidin-4-ol Chemical compound CN1C=CC=2N=C(N=C(C=21)NCC1=C(C=CC=C1Cl)Cl)NC1=CC=C(C=C1)N1CCC(CC1)O DTOUFNKXWRNXAS-UHFFFAOYSA-N 0.000 claims 1
- LSRXYBUOLIRCHW-UHFFFAOYSA-N 1-[4-[[5-methyl-4-[(2-propan-2-ylsulfonylphenyl)methylamino]pyrrolo[3,2-d]pyrimidin-2-yl]amino]phenyl]piperidin-4-ol Chemical compound CN1C=CC=2N=C(N=C(C=21)NCC1=C(C=CC=C1)S(=O)(=O)C(C)C)NC1=CC=C(C=C1)N1CCC(CC1)O LSRXYBUOLIRCHW-UHFFFAOYSA-N 0.000 claims 1
- XHVJJKIYEQIXRU-UHFFFAOYSA-N 1-[4-[[7-bromo-4-(cyclopropylamino)-5H-pyrrolo[3,2-d]pyrimidin-2-yl]amino]phenyl]piperidin-4-ol Chemical compound BrC1=CNC2=C1N=C(N=C2NC1CC1)NC1=CC=C(C=C1)N1CCC(CC1)O XHVJJKIYEQIXRU-UHFFFAOYSA-N 0.000 claims 1
- CLAZVGSAOAAXFW-UHFFFAOYSA-N 1-[4-[[7-bromo-4-(ethylamino)-5H-pyrrolo[3,2-d]pyrimidin-2-yl]amino]phenyl]piperidin-4-ol Chemical compound BrC1=CNC2=C1N=C(N=C2NCC)NC1=CC=C(C=C1)N1CCC(CC1)O CLAZVGSAOAAXFW-UHFFFAOYSA-N 0.000 claims 1
- NICIDVBHTYHXCQ-UHFFFAOYSA-N 1-[4-[[7-chloro-4-(cyclopropylamino)-5H-pyrrolo[3,2-d]pyrimidin-2-yl]amino]phenyl]piperidin-4-ol Chemical compound ClC1=CNC2=C1N=C(N=C2NC1CC1)NC1=CC=C(C=C1)N1CCC(CC1)O NICIDVBHTYHXCQ-UHFFFAOYSA-N 0.000 claims 1
- FIRVRHXGDMQZJP-UHFFFAOYSA-N 1-[4-[[7-chloro-4-(ethylamino)-5H-pyrrolo[3,2-d]pyrimidin-2-yl]amino]phenyl]piperidin-4-ol Chemical compound ClC1=CNC2=C1N=C(N=C2NCC)NC1=CC=C(C=C1)N1CCC(CC1)O FIRVRHXGDMQZJP-UHFFFAOYSA-N 0.000 claims 1
- KKSMJRUZPRMXKJ-UHFFFAOYSA-N 2-N-[2-methoxy-4-(4-methylpiperazin-1-yl)phenyl]-5-methyl-4-N-(2-propan-2-ylsulfanylphenyl)pyrrolo[3,2-d]pyrimidine-2,4-diamine Chemical compound CN1C=CC=2N=C(N=C(C=21)NC1=C(C=CC=C1)SC(C)C)NC1=C(C=C(C=C1)N1CCN(CC1)C)OC KKSMJRUZPRMXKJ-UHFFFAOYSA-N 0.000 claims 1
- MPJPIQBUOKVJIL-UHFFFAOYSA-N 2-N-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]-5-methyl-4-N-[(2-propan-2-ylsulfonylphenyl)methyl]pyrrolo[3,2-d]pyrimidine-2,4-diamine Chemical compound CN1C=CC=2N=C(N=C(C=21)NCC1=C(C=CC=C1)S(=O)(=O)C(C)C)NC1=C(C=C(C=C1)N1CCC(CC1)N1CCN(CC1)C)OC MPJPIQBUOKVJIL-UHFFFAOYSA-N 0.000 claims 1
- SPDJTAIJVORZRX-UHFFFAOYSA-N 2-N-[2-methoxy-5-methyl-4-(1-methylpiperidin-4-yl)phenyl]-5-methyl-4-N-(2-propan-2-ylsulfonylphenyl)pyrrolo[3,2-d]pyrimidine-2,4-diamine Chemical compound CN1C=CC=2N=C(N=C(C=21)NC1=C(C=CC=C1)S(=O)(=O)C(C)C)NC1=C(C=C(C(=C1)C)C1CCN(CC1)C)OC SPDJTAIJVORZRX-UHFFFAOYSA-N 0.000 claims 1
- IOCFWAUSDJDYFF-UHFFFAOYSA-N 2-[4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]-2-(trifluoromethoxy)phenyl]-4-N-(2-propan-2-ylsulfonylphenyl)-1,5-dihydropyrrolo[3,2-d]pyrimidine-2,4-diamine Chemical compound FC(OC1=C(C=CC(=C1)N1CCC(CC1)N1CCN(CC1)C)C1(N=C(C2=C(N1)C=CN2)NC2=C(C=CC=C2)S(=O)(=O)C(C)C)N)(F)F IOCFWAUSDJDYFF-UHFFFAOYSA-N 0.000 claims 1
- AITQWYPFAZERRQ-UHFFFAOYSA-N 4-(2-propan-2-ylsulfonylphenyl)-5H-pyrrolo[3,2-d]pyrimidine Chemical compound C(C)(C)S(=O)(=O)C1=C(C=CC=C1)C=1C2=C(N=CN=1)C=CN2 AITQWYPFAZERRQ-UHFFFAOYSA-N 0.000 claims 1
- NYFWQGWYHSXFSG-UHFFFAOYSA-N 4-N-(2-dimethylphosphorylphenyl)-2-N-[2-methoxy-4-(4-methylpiperazin-1-yl)phenyl]-5-methylpyrrolo[3,2-d]pyrimidine-2,4-diamine Chemical compound CN1C=CC=2N=C(N=C(C=21)NC1=C(C=CC=C1)P(=O)(C)C)NC1=C(C=C(C=C1)N1CCN(CC1)C)OC NYFWQGWYHSXFSG-UHFFFAOYSA-N 0.000 claims 1
- AFPKSJIYERRNCP-UHFFFAOYSA-N 4-N-(2-dimethylphosphorylphenyl)-2-N-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]-5-methylpyrrolo[3,2-d]pyrimidine-2,4-diamine Chemical compound CN1C=CC=2N=C(N=C(C=21)NC1=C(C=CC=C1)P(=O)(C)C)NC1=C(C=C(C=C1)N1CCC(CC1)N1CCN(CC1)C)OC AFPKSJIYERRNCP-UHFFFAOYSA-N 0.000 claims 1
- KGNLAABSHZMDPA-UHFFFAOYSA-N 4-N-(2-dimethylphosphorylphenyl)-5-methyl-2-N-[1-(1-methylpiperidin-4-yl)pyrazol-4-yl]pyrrolo[3,2-d]pyrimidine-2,4-diamine Chemical compound CN1C=CC=2N=C(N=C(C=21)NC1=C(C=CC=C1)P(=O)(C)C)NC=1C=NN(C=1)C1CCN(CC1)C KGNLAABSHZMDPA-UHFFFAOYSA-N 0.000 claims 1
- SQJYKMGYIYIMCM-UHFFFAOYSA-N 4-N-(2-dimethylphosphorylphenyl)-5-methyl-2-N-[4-(4-methylpiperazin-1-yl)phenyl]pyrrolo[3,2-d]pyrimidine-2,4-diamine Chemical compound CN1C=CC=2N=C(N=C(C=21)NC1=C(C=CC=C1)P(=O)(C)C)NC1=CC=C(C=C1)N1CCN(CC1)C SQJYKMGYIYIMCM-UHFFFAOYSA-N 0.000 claims 1
- KVJOBJBILZNOOO-UHFFFAOYSA-N 4-N-[(2,6-dichlorophenyl)methyl]-2-N-[2-methoxy-4-(4-methylpiperazin-1-yl)phenyl]-5-methylpyrrolo[3,2-d]pyrimidine-2,4-diamine Chemical compound CN1C=CC=2N=C(N=C(C=21)NCC1=C(C=CC=C1Cl)Cl)NC1=C(C=C(C=C1)N1CCN(CC1)C)OC KVJOBJBILZNOOO-UHFFFAOYSA-N 0.000 claims 1
- POURABNIOVRUBK-UHFFFAOYSA-N 4-N-[(2,6-dichlorophenyl)methyl]-2-N-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]-5-methylpyrrolo[3,2-d]pyrimidine-2,4-diamine Chemical compound CN1C=CC=2N=C(N=C(C=21)NCC1=C(C=CC=C1Cl)Cl)NC1=C(C=C(C=C1)N1CCC(CC1)N1CCN(CC1)C)OC POURABNIOVRUBK-UHFFFAOYSA-N 0.000 claims 1
- WLLPURHANGYXDO-UHFFFAOYSA-N 4-N-[(2,6-dichlorophenyl)methyl]-5-methyl-2-N-[4-(4-methylpiperazin-1-yl)phenyl]pyrrolo[3,2-d]pyrimidine-2,4-diamine Chemical compound CN1C=CC=2N=C(N=C(C=21)NCC1=C(C=CC=C1Cl)Cl)NC1=CC=C(C=C1)N1CCN(CC1)C WLLPURHANGYXDO-UHFFFAOYSA-N 0.000 claims 1
- 125000004195 4-methylpiperazin-1-yl group Chemical group [H]C([H])([H])N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims 1
- DDWOUDNQESFNAK-UHFFFAOYSA-N 5-methyl-2-N-[4-(4-methylpiperazin-1-yl)phenyl]-4-N-(2-methylsulfanylphenyl)pyrrolo[3,2-d]pyrimidine-2,4-diamine Chemical compound CN1C=CC=2N=C(N=C(C=21)NC1=C(C=CC=C1)SC)NC1=CC=C(C=C1)N1CCN(CC1)C DDWOUDNQESFNAK-UHFFFAOYSA-N 0.000 claims 1
- ZTSRSMCTPCODCO-UHFFFAOYSA-N 5-methyl-2-N-[4-(4-methylpiperazin-1-yl)phenyl]-4-N-[(2-methylsulfonylphenyl)methyl]pyrrolo[3,2-d]pyrimidine-2,4-diamine Chemical compound CN1C=CC=2N=C(N=C(C=21)NCC1=C(C=CC=C1)S(=O)(=O)C)NC1=CC=C(C=C1)N1CCN(CC1)C ZTSRSMCTPCODCO-UHFFFAOYSA-N 0.000 claims 1
- KVNQHXVOVNMLKT-UHFFFAOYSA-N 5-methyl-2-N-[5-methyl-4-(1-methylpiperidin-4-yl)-2-propan-2-yloxyphenyl]-4-N-(2-propan-2-ylsulfonylphenyl)pyrrolo[3,2-d]pyrimidine-2,4-diamine Chemical compound CN1C=CC=2N=C(N=C(C=21)NC1=C(C=CC=C1)S(=O)(=O)C(C)C)NC1=C(C=C(C(=C1)C)C1CCN(CC1)C)OC(C)C KVNQHXVOVNMLKT-UHFFFAOYSA-N 0.000 claims 1
- WPHQMSAPTMZEIQ-UHFFFAOYSA-N 7-bromo-4-N-cyclopropyl-2-N-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]-5H-pyrrolo[3,2-d]pyrimidine-2,4-diamine Chemical compound BrC1=CNC2=C1N=C(N=C2NC1CC1)NC1=C(C=C(C=C1)N1CCC(CC1)N1CCN(CC1)C)OC WPHQMSAPTMZEIQ-UHFFFAOYSA-N 0.000 claims 1
- QCSFAGDRCPSLOU-UHFFFAOYSA-N 7-chloro-2-N-[2-methoxy-4-(4-methylpiperazin-1-yl)phenyl]-4-N-methyl-5H-pyrrolo[3,2-d]pyrimidine-2,4-diamine Chemical compound ClC1=CNC2=C1N=C(N=C2NC)NC1=C(C=C(C=C1)N1CCN(CC1)C)OC QCSFAGDRCPSLOU-UHFFFAOYSA-N 0.000 claims 1
- NMKUZRUADJXXDW-UHFFFAOYSA-N 7-chloro-4-N-cyclopropyl-2-N-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]-5H-pyrrolo[3,2-d]pyrimidine-2,4-diamine Chemical compound ClC1=CNC2=C1N=C(N=C2NC1CC1)NC1=C(C=C(C=C1)N1CCC(CC1)N1CCN(CC1)C)OC NMKUZRUADJXXDW-UHFFFAOYSA-N 0.000 claims 1
- QWAQBOFKSMFNGR-UHFFFAOYSA-N 7-chloro-4-N-ethyl-2-N-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]-5H-pyrrolo[3,2-d]pyrimidine-2,4-diamine Chemical compound ClC1=CNC2=C1N=C(N=C2NCC)NC1=C(C=C(C=C1)N1CCC(CC1)N1CCN(CC1)C)OC QWAQBOFKSMFNGR-UHFFFAOYSA-N 0.000 claims 1
- HRBZOPCOHFXHRL-UHFFFAOYSA-N BrC1=CNC2=C1N=C(N=C2NCC)NC1=C(C=C(C=C1)N1CCC(CC1)N1CCN(CC1)C)OC Chemical compound BrC1=CNC2=C1N=C(N=C2NCC)NC1=C(C=C(C=C1)N1CCC(CC1)N1CCN(CC1)C)OC HRBZOPCOHFXHRL-UHFFFAOYSA-N 0.000 claims 1
- UCXZSVOJHXRELQ-UHFFFAOYSA-N C(C)(=O)NCC(=O)NC=1C=C(C=CC1)C1(N=C(C2=C(N1)C=CN2)NC2=C(C=CC=C2)S(=O)(=O)C(C)C)N Chemical compound C(C)(=O)NCC(=O)NC=1C=C(C=CC1)C1(N=C(C2=C(N1)C=CN2)NC2=C(C=CC=C2)S(=O)(=O)C(C)C)N UCXZSVOJHXRELQ-UHFFFAOYSA-N 0.000 claims 1
- MRJVVEDGNLRWLL-UHFFFAOYSA-N C(C)(C)(C)OC(=O)NCC(=O)NC=1C=C(C=CC1)C1(N=C(C2=C(N1)C=CN2)NC2=C(C=CC=C2)S(=O)(=O)C(C)C)N Chemical compound C(C)(C)(C)OC(=O)NCC(=O)NC=1C=C(C=CC1)C1(N=C(C2=C(N1)C=CN2)NC2=C(C=CC=C2)S(=O)(=O)C(C)C)N MRJVVEDGNLRWLL-UHFFFAOYSA-N 0.000 claims 1
- ZMWMJFVLDMBLIV-UHFFFAOYSA-N C(C)C1(C2=C(N=C(N1)N)C=CN2)N Chemical compound C(C)C1(C2=C(N=C(N1)N)C=CN2)N ZMWMJFVLDMBLIV-UHFFFAOYSA-N 0.000 claims 1
- MSFGWXXCIJYMGA-UHFFFAOYSA-N C(C)OC1=C(C=CC(=C1)N1CCN(CC1)C)C1(N=C(C2=C(N1)C=CN2)NC2=C(C=CC=C2)C(=O)OC)N Chemical compound C(C)OC1=C(C=CC(=C1)N1CCN(CC1)C)C1(N=C(C2=C(N1)C=CN2)NC2=C(C=CC=C2)C(=O)OC)N MSFGWXXCIJYMGA-UHFFFAOYSA-N 0.000 claims 1
- LBPQNDNNKLPPJH-NRFANRHFSA-N C(C1=CC=CC=C1)OC(=O)N[C@H](C(=O)NC=1C=C(C=CC=1)NC=1N=C(C2=C(N=1)C=CN2)NC1=C(C=CC=C1)S(=O)(=O)C(C)C)C Chemical compound C(C1=CC=CC=C1)OC(=O)N[C@H](C(=O)NC=1C=C(C=CC=1)NC=1N=C(C2=C(N=1)C=CN2)NC1=C(C=CC=C1)S(=O)(=O)C(C)C)C LBPQNDNNKLPPJH-NRFANRHFSA-N 0.000 claims 1
- RPAPUSGCGGCVLH-UHFFFAOYSA-N C(C=C)(=O)NC=1C=C(C=CC1)C1(N=C(C2=C(N1)C=CN2)NC2=C(C=CC=C2)S(=O)(=O)C(C)C)N Chemical compound C(C=C)(=O)NC=1C=C(C=CC1)C1(N=C(C2=C(N1)C=CN2)NC2=C(C=CC=C2)S(=O)(=O)C(C)C)N RPAPUSGCGGCVLH-UHFFFAOYSA-N 0.000 claims 1
- MEAATBOWCASIKA-UHFFFAOYSA-N CC(C)S(=O)(=O)C1=CC=CC=C1CC2=NC=NC3=C2NC=C3 Chemical compound CC(C)S(=O)(=O)C1=CC=CC=C1CC2=NC=NC3=C2NC=C3 MEAATBOWCASIKA-UHFFFAOYSA-N 0.000 claims 1
- YMTFRHLASSBSRT-UHFFFAOYSA-N CN(C)C1CCN(CC1)CC(=O)NC=1C=C(C=CC1)C1(N=C(C2=C(N1)C=CN2)NC2=C(C=CC=C2)S(=O)(=O)C(C)C)N Chemical compound CN(C)C1CCN(CC1)CC(=O)NC=1C=C(C=CC1)C1(N=C(C2=C(N1)C=CN2)NC2=C(C=CC=C2)S(=O)(=O)C(C)C)N YMTFRHLASSBSRT-UHFFFAOYSA-N 0.000 claims 1
- KHAPOJCSUDAORX-UHFFFAOYSA-N CN1C=CC=2N=C(N=C(C=21)NC1=C(C=CC=C1)SC(C)C)NC1=CC=C(C=C1)N1CCC(CC1)O Chemical compound CN1C=CC=2N=C(N=C(C=21)NC1=C(C=CC=C1)SC(C)C)NC1=CC=C(C=C1)N1CCC(CC1)O KHAPOJCSUDAORX-UHFFFAOYSA-N 0.000 claims 1
- FNMMEEISDZCUHG-UHFFFAOYSA-N CN1CCC(CC1)N1N=CC(=C1)C1(N=C(C2=C(N1)C=CN2)NC2=C(C=CC=C2)NS(=O)(=O)C)N Chemical compound CN1CCC(CC1)N1N=CC(=C1)C1(N=C(C2=C(N1)C=CN2)NC2=C(C=CC=C2)NS(=O)(=O)C)N FNMMEEISDZCUHG-UHFFFAOYSA-N 0.000 claims 1
- RTTUIFKOXLGSAL-UHFFFAOYSA-N CN1CCC(CC1)N1N=CC(=C1)C1(N=C(C2=C(N1)C=CN2)NC2=C(C=CC=C2)P(=O)(C)C)N Chemical compound CN1CCC(CC1)N1N=CC(=C1)C1(N=C(C2=C(N1)C=CN2)NC2=C(C=CC=C2)P(=O)(C)C)N RTTUIFKOXLGSAL-UHFFFAOYSA-N 0.000 claims 1
- VBQGKENAISTINJ-UHFFFAOYSA-N CN1CCN(CC1)C1=CC=C(C=C1)C1(N=C(C2=C(N1)C=CN2)NC2=C(C=CC=C2)C(=O)OC)N Chemical compound CN1CCN(CC1)C1=CC=C(C=C1)C1(N=C(C2=C(N1)C=CN2)NC2=C(C=CC=C2)C(=O)OC)N VBQGKENAISTINJ-UHFFFAOYSA-N 0.000 claims 1
- JAJABDMNLGZRRS-UHFFFAOYSA-N CN1CCN(CC1)C1=CC=C(C=C1)C1(N=C(C2=C(N1)C=CN2)NC2=C(C=CC=C2)NS(=O)(=O)C)N Chemical compound CN1CCN(CC1)C1=CC=C(C=C1)C1(N=C(C2=C(N1)C=CN2)NC2=C(C=CC=C2)NS(=O)(=O)C)N JAJABDMNLGZRRS-UHFFFAOYSA-N 0.000 claims 1
- REYJPDHYRRWCKD-UHFFFAOYSA-N CN1CCN(CC1)C1=CC=C(C=C1)C1(N=C(C2=C(N1)C=CN2)NC2=C(C=CC=C2)P(=O)(C)C)N Chemical compound CN1CCN(CC1)C1=CC=C(C=C1)C1(N=C(C2=C(N1)C=CN2)NC2=C(C=CC=C2)P(=O)(C)C)N REYJPDHYRRWCKD-UHFFFAOYSA-N 0.000 claims 1
- NQQLHCKXRAFDIX-UHFFFAOYSA-N CN1CCN(CC1)C1=CC=C(C=C1)C1(N=C(C2=C(N1)C=CN2)NCC2=C(C=CC=C2Cl)Cl)N Chemical compound CN1CCN(CC1)C1=CC=C(C=C1)C1(N=C(C2=C(N1)C=CN2)NCC2=C(C=CC=C2Cl)Cl)N NQQLHCKXRAFDIX-UHFFFAOYSA-N 0.000 claims 1
- RLIPEHQRTQNZIP-UHFFFAOYSA-N CN1CCN(CC1)C1CCN(CC1)CC(=O)NC=1C=C(C=CC1)C1(N=C(C2=C(N1)C=CN2)NC2=C(C=CC=C2)S(=O)(=O)C(C)C)N Chemical compound CN1CCN(CC1)C1CCN(CC1)CC(=O)NC=1C=C(C=CC1)C1(N=C(C2=C(N1)C=CN2)NC2=C(C=CC=C2)S(=O)(=O)C(C)C)N RLIPEHQRTQNZIP-UHFFFAOYSA-N 0.000 claims 1
- WVNYNHIHBMIFDX-UHFFFAOYSA-N CN1CCN(CC1)C2CCN(CC2)C(=O)C3=CC(=C(C=C3)C4(NC5=C(C(=N4)NC6=CC=CC=C6C(=O)OC)NC=C5)N)OC Chemical compound CN1CCN(CC1)C2CCN(CC2)C(=O)C3=CC(=C(C=C3)C4(NC5=C(C(=N4)NC6=CC=CC=C6C(=O)OC)NC=C5)N)OC WVNYNHIHBMIFDX-UHFFFAOYSA-N 0.000 claims 1
- GVEHMSDHZDGCLT-UHFFFAOYSA-N CN1CCN(CC1)CC(=O)NC=1C=C(C=CC1)C1(N=C(C2=C(N1)C=CN2)NC2=C(C=CC=C2)S(=O)(=O)C(C)C)N Chemical compound CN1CCN(CC1)CC(=O)NC=1C=C(C=CC1)C1(N=C(C2=C(N1)C=CN2)NC2=C(C=CC=C2)S(=O)(=O)C(C)C)N GVEHMSDHZDGCLT-UHFFFAOYSA-N 0.000 claims 1
- OUHVZNSBTPQELQ-UHFFFAOYSA-N COC(=O)C1=C(C=CC=C1)N1C=CC=2N=C(N=C(C=21)N)N Chemical compound COC(=O)C1=C(C=CC=C1)N1C=CC=2N=C(N=C(C=21)N)N OUHVZNSBTPQELQ-UHFFFAOYSA-N 0.000 claims 1
- KMWSAFKZLADBJC-UHFFFAOYSA-N COC1=C(C=CC(=C1)C(=O)N1CCOCC1)C1(N=C(C2=C(N1)C=CN2)NC)N Chemical compound COC1=C(C=CC(=C1)C(=O)N1CCOCC1)C1(N=C(C2=C(N1)C=CN2)NC)N KMWSAFKZLADBJC-UHFFFAOYSA-N 0.000 claims 1
- CIJCZDXLKKRERF-UHFFFAOYSA-N COC1=C(C=CC(=C1)C(=O)N1CCOCC1)C1(N=C(C2=C(N1)C=CN2)NC2=C(C=CC=C2)C(=O)OC)N Chemical compound COC1=C(C=CC(=C1)C(=O)N1CCOCC1)C1(N=C(C2=C(N1)C=CN2)NC2=C(C=CC=C2)C(=O)OC)N CIJCZDXLKKRERF-UHFFFAOYSA-N 0.000 claims 1
- UQMSCUVWKRWZQW-UHFFFAOYSA-N COC1=C(C=CC(=C1)N1CCC(CC1)N(C)C)C1(N=C(C2=C(N1)C=CN2)NC2=C(C=CC=C2)S(=O)(=O)C(C)C)N Chemical compound COC1=C(C=CC(=C1)N1CCC(CC1)N(C)C)C1(N=C(C2=C(N1)C=CN2)NC2=C(C=CC=C2)S(=O)(=O)C(C)C)N UQMSCUVWKRWZQW-UHFFFAOYSA-N 0.000 claims 1
- TXMVFHRIYJPEOG-UHFFFAOYSA-N COC1=C(C=CC(=C1)N1CCC(CC1)N1CCN(CC1)C)C1(N=C(C2=C(N1)C=CN2)NC2=C(C=CC=C2)NS(=O)(=O)C)N Chemical compound COC1=C(C=CC(=C1)N1CCC(CC1)N1CCN(CC1)C)C1(N=C(C2=C(N1)C=CN2)NC2=C(C=CC=C2)NS(=O)(=O)C)N TXMVFHRIYJPEOG-UHFFFAOYSA-N 0.000 claims 1
- WIVUGBDBBFXIBF-UHFFFAOYSA-N COC1=C(C=CC(=C1)N1CCC(CC1)N1CCN(CC1)C)C1(N=C(C2=C(N1)C=CN2)NC2=C(C=CC=C2)P(=O)(C)C)N Chemical compound COC1=C(C=CC(=C1)N1CCC(CC1)N1CCN(CC1)C)C1(N=C(C2=C(N1)C=CN2)NC2=C(C=CC=C2)P(=O)(C)C)N WIVUGBDBBFXIBF-UHFFFAOYSA-N 0.000 claims 1
- CSDYNTQQUBYXSQ-UHFFFAOYSA-N COC1=C(C=CC(=C1)N1CCC(CC1)N1CCN(CC1)C)C1(N=C(C2=C(N1)C=CN2)NCC)N Chemical compound COC1=C(C=CC(=C1)N1CCC(CC1)N1CCN(CC1)C)C1(N=C(C2=C(N1)C=CN2)NCC)N CSDYNTQQUBYXSQ-UHFFFAOYSA-N 0.000 claims 1
- QJMAQRKGPBGINL-UHFFFAOYSA-N COC1=C(C=CC(=C1)N1CCC(CC1)N1CCN(CC1)C)C1(N=C(C2=C(N1)C=CN2)NCC2=C(C=CC=C2)SC)N Chemical compound COC1=C(C=CC(=C1)N1CCC(CC1)N1CCN(CC1)C)C1(N=C(C2=C(N1)C=CN2)NCC2=C(C=CC=C2)SC)N QJMAQRKGPBGINL-UHFFFAOYSA-N 0.000 claims 1
- RGRYDNHNNXPZJX-UHFFFAOYSA-N COC1=C(C=CC(=C1)N1CCC(CC1)N1CCN(CC1)C)C1(N=C(C2=C(N1)C=CN2)NCC2=C(C=CC=C2Cl)Cl)N Chemical compound COC1=C(C=CC(=C1)N1CCC(CC1)N1CCN(CC1)C)C1(N=C(C2=C(N1)C=CN2)NCC2=C(C=CC=C2Cl)Cl)N RGRYDNHNNXPZJX-UHFFFAOYSA-N 0.000 claims 1
- PHMUOKUBDJSFLQ-UHFFFAOYSA-N COC1=C(C=CC(=C1)N1CCN(CC1)C)C1(N=C(C2=C(N1)C=CN2)NC2=C(C=CC=C2)P(=O)(C)C)N Chemical compound COC1=C(C=CC(=C1)N1CCN(CC1)C)C1(N=C(C2=C(N1)C=CN2)NC2=C(C=CC=C2)P(=O)(C)C)N PHMUOKUBDJSFLQ-UHFFFAOYSA-N 0.000 claims 1
- CHBHFBZFYLSMMP-UHFFFAOYSA-N COC1=C(C=CC(=C1)N1CCN(CC1)C)C1(N=C(C2=C(N1)C=CN2)NC2=C(C=CC=C2)SC(C)C)N Chemical compound COC1=C(C=CC(=C1)N1CCN(CC1)C)C1(N=C(C2=C(N1)C=CN2)NC2=C(C=CC=C2)SC(C)C)N CHBHFBZFYLSMMP-UHFFFAOYSA-N 0.000 claims 1
- BBKAEXOQDKASIL-UHFFFAOYSA-N COC1=C(C=CC(=C1)N1CCN(CC1)C)C1(N=C(C2=C(N1)C=CN2)NCC2=C(C=CC=C2Cl)Cl)N Chemical compound COC1=C(C=CC(=C1)N1CCN(CC1)C)C1(N=C(C2=C(N1)C=CN2)NCC2=C(C=CC=C2Cl)Cl)N BBKAEXOQDKASIL-UHFFFAOYSA-N 0.000 claims 1
- VZJNOGIUDNRDEH-UHFFFAOYSA-N COC1=C(C=CC(=C1)N1CCOCC1)C1(N=C(C2=C(N1)C=CN2)NC2=C(C=CC=C2)NS(=O)(=O)C)N Chemical compound COC1=C(C=CC(=C1)N1CCOCC1)C1(N=C(C2=C(N1)C=CN2)NC2=C(C=CC=C2)NS(=O)(=O)C)N VZJNOGIUDNRDEH-UHFFFAOYSA-N 0.000 claims 1
- BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical group OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M Methanesulfonate Chemical group CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 claims 1
- HYMWVHCVBDNOCQ-UHFFFAOYSA-N N-[2-[[2-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]anilino]-5-methylpyrrolo[3,2-d]pyrimidin-4-yl]amino]phenyl]methanesulfonamide Chemical compound CN1C=CC=2N=C(N=C(C=21)NC1=C(C=CC=C1)NS(=O)(=O)C)NC1=C(C=C(C=C1)N1CCC(CC1)N1CCN(CC1)C)OC HYMWVHCVBDNOCQ-UHFFFAOYSA-N 0.000 claims 1
- PPTSKIHCQSILED-UHFFFAOYSA-N N1(CCCC1)C1CCN(CC1)CC(=O)NC=1C=C(C=CC1)C1(N=C(C2=C(N1)C=CN2)NC2=C(C=CC=C2)S(=O)(=O)C(C)C)N Chemical compound N1(CCCC1)C1CCN(CC1)CC(=O)NC=1C=C(C=CC1)C1(N=C(C2=C(N1)C=CN2)NC2=C(C=CC=C2)S(=O)(=O)C(C)C)N PPTSKIHCQSILED-UHFFFAOYSA-N 0.000 claims 1
- ATEICBBOGZAIJY-UHFFFAOYSA-N N1(CCOCC1)C1=CC=C(C=C1)C1(N=C(C2=C(N1)C=CN2)NC2=C(C=CC=C2)NS(=O)(=O)C)N Chemical compound N1(CCOCC1)C1=CC=C(C=C1)C1(N=C(C2=C(N1)C=CN2)NC2=C(C=CC=C2)NS(=O)(=O)C)N ATEICBBOGZAIJY-UHFFFAOYSA-N 0.000 claims 1
- VGVOUXLHUSWWRR-UHFFFAOYSA-N N1(CCOCC1)C1=NC=C(C=C1)C1(N=C(C2=C(N1)C=CN2)NC2=CC(=CC=C2)C(=O)OC)N Chemical compound N1(CCOCC1)C1=NC=C(C=C1)C1(N=C(C2=C(N1)C=CN2)NC2=CC(=CC=C2)C(=O)OC)N VGVOUXLHUSWWRR-UHFFFAOYSA-N 0.000 claims 1
- RLTBEEUSEDNHLG-UHFFFAOYSA-N N1(CCOCC1)CC(=O)NC=1C=C(C=CC1)C1(N=C(C2=C(N1)C=CN2)NC2=C(C=CC=C2)S(=O)(=O)C(C)C)N Chemical compound N1(CCOCC1)CC(=O)NC=1C=C(C=CC1)C1(N=C(C2=C(N1)C=CN2)NC2=C(C=CC=C2)S(=O)(=O)C(C)C)N RLTBEEUSEDNHLG-UHFFFAOYSA-N 0.000 claims 1
- GRIAQFJQBICFQX-UHFFFAOYSA-N NC=1C=C(C=CC1)C1(N=C(C2=C(N1)C=CN2)NC2=C(C=CC=C2)S(=O)(=O)C(C)C)N Chemical compound NC=1C=C(C=CC1)C1(N=C(C2=C(N1)C=CN2)NC2=C(C=CC=C2)S(=O)(=O)C(C)C)N GRIAQFJQBICFQX-UHFFFAOYSA-N 0.000 claims 1
- XNBDMWYYOOUOOT-UHFFFAOYSA-N NCC(=O)NC=1C=C(C=CC1)C1(N=C(C2=C(N1)C=CN2)NC2=C(C=CC=C2)S(=O)(=O)C(C)C)N Chemical compound NCC(=O)NC=1C=C(C=CC1)C1(N=C(C2=C(N1)C=CN2)NC2=C(C=CC=C2)S(=O)(=O)C(C)C)N XNBDMWYYOOUOOT-UHFFFAOYSA-N 0.000 claims 1
- UGQNIAJAWLSBDM-UHFFFAOYSA-N O1CCN(CC1)C1=CC=C(C=N1)C1(N=C(C2=C(N1)C=CN2)NC2=C(C=CC=C2)S(=O)(=O)C(C)C)N Chemical compound O1CCN(CC1)C1=CC=C(C=N1)C1(N=C(C2=C(N1)C=CN2)NC2=C(C=CC=C2)S(=O)(=O)C(C)C)N UGQNIAJAWLSBDM-UHFFFAOYSA-N 0.000 claims 1
- BQXDURPLGVKHHQ-UHFFFAOYSA-N OC1CCN(CC1)C1=CC=C(C=C1)C1(N=C(C2=C(N1)C=CN2)N2CCOCC2)N Chemical compound OC1CCN(CC1)C1=CC=C(C=C1)C1(N=C(C2=C(N1)C=CN2)N2CCOCC2)N BQXDURPLGVKHHQ-UHFFFAOYSA-N 0.000 claims 1
- LBWNQSLYAWWBFM-UHFFFAOYSA-N OC1CCN(CC1)C1=CC=C(C=C1)C1(N=C(C2=C(N1)C=CN2)NC2=C(C=CC=C2)C(=O)OC)N Chemical compound OC1CCN(CC1)C1=CC=C(C=C1)C1(N=C(C2=C(N1)C=CN2)NC2=C(C=CC=C2)C(=O)OC)N LBWNQSLYAWWBFM-UHFFFAOYSA-N 0.000 claims 1
- TXGKFMNMUZVELV-UHFFFAOYSA-N OC1CCN(CC1)C1=CC=C(C=C1)C1(N=C(C2=C(N1)C=CN2)NC2=C(C=CC=C2)NS(=O)(=O)C)N Chemical compound OC1CCN(CC1)C1=CC=C(C=C1)C1(N=C(C2=C(N1)C=CN2)NC2=C(C=CC=C2)NS(=O)(=O)C)N TXGKFMNMUZVELV-UHFFFAOYSA-N 0.000 claims 1
- CDEWIVKEVSMYBA-UHFFFAOYSA-N OC1CCN(CC1)C1=CC=C(C=C1)C1(N=C(C2=C(N1)C=CN2)NC2=C(C=CC=C2)P(=O)(C)C)N Chemical compound OC1CCN(CC1)C1=CC=C(C=C1)C1(N=C(C2=C(N1)C=CN2)NC2=C(C=CC=C2)P(=O)(C)C)N CDEWIVKEVSMYBA-UHFFFAOYSA-N 0.000 claims 1
- SACJQVQVWYRNCS-UHFFFAOYSA-N OC1CCN(CC1)C1=CC=C(C=C1)C1(N=C(C2=C(N1)C=CN2)NC2=C(C=CC=C2)S(=O)(=O)C(C)C)N Chemical compound OC1CCN(CC1)C1=CC=C(C=C1)C1(N=C(C2=C(N1)C=CN2)NC2=C(C=CC=C2)S(=O)(=O)C(C)C)N SACJQVQVWYRNCS-UHFFFAOYSA-N 0.000 claims 1
- ZOQVWBMKFMZCDL-UHFFFAOYSA-N OC1CCN(CC1)C1=CC=C(C=C1)C1(N=C(C2=C(N1)C=CN2)NC2=CC(=CC=C2)C(=O)OC)N Chemical compound OC1CCN(CC1)C1=CC=C(C=C1)C1(N=C(C2=C(N1)C=CN2)NC2=CC(=CC=C2)C(=O)OC)N ZOQVWBMKFMZCDL-UHFFFAOYSA-N 0.000 claims 1
- LVRZRUDDSVLOQN-UHFFFAOYSA-N OC1CCN(CC1)C1=CC=C(C=C1)C1(N=C(C2=C(N1)C=CN2)NCC2=C(C=CC=C2)S(=O)(=O)C(C)C)N Chemical compound OC1CCN(CC1)C1=CC=C(C=C1)C1(N=C(C2=C(N1)C=CN2)NCC2=C(C=CC=C2)S(=O)(=O)C(C)C)N LVRZRUDDSVLOQN-UHFFFAOYSA-N 0.000 claims 1
- AJPIFLRMWCEMTO-UHFFFAOYSA-N OC1CCN(CC1)C1=CC=C(C=C1)C1(N=C(C2=C(N1)C=CN2)NCC2=C(C=CC=C2Cl)Cl)N Chemical compound OC1CCN(CC1)C1=CC=C(C=C1)C1(N=C(C2=C(N1)C=CN2)NCC2=C(C=CC=C2Cl)Cl)N AJPIFLRMWCEMTO-UHFFFAOYSA-N 0.000 claims 1
- SMVLMWBNXCCFIN-UHFFFAOYSA-N OC1CCN(CC1)C1=CC=C(C=C1)N1C=CC=2N=C(N=C(C=21)NCC1=C(C=CC=C1)SC)N Chemical compound OC1CCN(CC1)C1=CC=C(C=C1)N1C=CC=2N=C(N=C(C=21)NCC1=C(C=CC=C1)SC)N SMVLMWBNXCCFIN-UHFFFAOYSA-N 0.000 claims 1
- BIVGPQJGVAPUFE-UHFFFAOYSA-N OC1CCN(CC1)C1=CC=C(C=N1)C1(N=C(C2=C(N1)C=CN2)NC2=C(C=CC=C2)S(=O)(=O)C(C)C)N Chemical compound OC1CCN(CC1)C1=CC=C(C=N1)C1(N=C(C2=C(N1)C=CN2)NC2=C(C=CC=C2)S(=O)(=O)C(C)C)N BIVGPQJGVAPUFE-UHFFFAOYSA-N 0.000 claims 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims 1
- 241000209140 Triticum Species 0.000 claims 1
- 235000021307 Triticum Nutrition 0.000 claims 1
- NTTOXLATBGBXNL-UHFFFAOYSA-N [1-[3-ethoxy-4-[[5-methyl-4-(2-methylsulfanylanilino)pyrrolo[3,2-d]pyrimidin-2-yl]amino]phenyl]piperidin-4-yl]-(4-methylpiperazin-1-yl)methanone Chemical compound CN1C=CC=2N=C(N=C(C=21)NC1=C(C=CC=C1)SC)NC1=C(C=C(C=C1)N1CCC(CC1)C(=O)N1CCN(CC1)C)OCC NTTOXLATBGBXNL-UHFFFAOYSA-N 0.000 claims 1
- QCURVAWTNYNOLQ-UHFFFAOYSA-N [1-[3-ethoxy-4-[[5-methyl-4-(2-propan-2-ylsulfonylanilino)pyrrolo[3,2-d]pyrimidin-2-yl]amino]phenyl]piperidin-4-yl]-(4-methylpiperazin-1-yl)methanone Chemical compound CN1C=CC=2N=C(N=C(C=21)NC1=C(C=CC=C1)S(=O)(=O)C(C)C)NC1=C(C=C(C=C1)N1CCC(CC1)C(=O)N1CCN(CC1)C)OCC QCURVAWTNYNOLQ-UHFFFAOYSA-N 0.000 claims 1
- XOZYBXSJKUSOGE-UHFFFAOYSA-N [3-ethoxy-4-[[5-methyl-4-(2-methylsulfanylanilino)pyrrolo[3,2-d]pyrimidin-2-yl]amino]phenyl]-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]methanone Chemical compound CN1C=CC=2N=C(N=C(C=21)NC1=C(C=CC=C1)SC)NC1=C(C=C(C=C1)C(=O)N1CCC(CC1)N1CCN(CC1)C)OCC XOZYBXSJKUSOGE-UHFFFAOYSA-N 0.000 claims 1
- JCHCRHXJAOQWQJ-UHFFFAOYSA-N [4-[[7-bromo-4-(cyclopropylamino)-5H-pyrrolo[3,2-d]pyrimidin-2-yl]amino]-3-methoxyphenyl]-(4-methylpiperazin-1-yl)methanone Chemical compound BrC1=CNC2=C1N=C(N=C2NC1CC1)NC1=C(C=C(C=C1)C(=O)N1CCN(CC1)C)OC JCHCRHXJAOQWQJ-UHFFFAOYSA-N 0.000 claims 1
- DNANTBFFZAIPIJ-UHFFFAOYSA-N [4-[[7-chloro-4-(cyclopropylamino)-5H-pyrrolo[3,2-d]pyrimidin-2-yl]amino]-3-methoxyphenyl]-(4-methylpiperazin-1-yl)methanone Chemical compound ClC1=CNC2=C1N=C(N=C2NC1CC1)NC1=C(C=C(C=C1)C(=O)N1CCN(CC1)C)OC DNANTBFFZAIPIJ-UHFFFAOYSA-N 0.000 claims 1
- HQDDAQVQIAJDNU-UHFFFAOYSA-N [4-[[7-chloro-4-(ethylamino)-5H-pyrrolo[3,2-d]pyrimidin-2-yl]amino]-3-methoxyphenyl]-(4-methylpiperazin-1-yl)methanone Chemical compound ClC1=CNC2=C1N=C(N=C2NCC)NC1=C(C=C(C=C1)C(=O)N1CCN(CC1)C)OC HQDDAQVQIAJDNU-UHFFFAOYSA-N 0.000 claims 1
- HOTLCPVGYOHLDU-UHFFFAOYSA-N [4-[[7-chloro-4-(methylamino)-5H-pyrrolo[3,2-d]pyrimidin-2-yl]amino]-3-methoxyphenyl]-morpholin-4-ylmethanone Chemical compound CNc1nc(Nc2ccc(cc2OC)C(=O)N2CCOCC2)nc2c(Cl)c[nH]c12 HOTLCPVGYOHLDU-UHFFFAOYSA-N 0.000 claims 1
- 150000001242 acetic acid derivatives Chemical class 0.000 claims 1
- 229940045714 alkyl sulfonate alkylating agent Drugs 0.000 claims 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 claims 1
- 150000001860 citric acid derivatives Chemical class 0.000 claims 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 claims 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 claims 1
- 150000002688 maleic acid derivatives Chemical class 0.000 claims 1
- IUVCOSBVEVHHHN-UHFFFAOYSA-N methyl 2-[2-[2-methoxy-4-(4-methylpiperazin-1-yl)anilino]-5-methylpyrrolo[3,2-d]pyrimidin-4-yl]oxybenzoate Chemical compound COC(=O)C1=C(C=CC=C1)OC=1C2=C(N=C(N=1)NC1=C(C=C(C=C1)N1CCN(CC1)C)OC)C=CN2C IUVCOSBVEVHHHN-UHFFFAOYSA-N 0.000 claims 1
- HQAXFHBZLBQPQK-UHFFFAOYSA-N methyl 2-[[2-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]anilino]-5-methylpyrrolo[3,2-d]pyrimidin-4-yl]amino]benzoate Chemical compound CN1C=CC=2N=C(N=C(C=21)NC1=C(C=CC=C1)C(=O)OC)NC1=C(C=C(C=C1)N1CCC(CC1)N1CCN(CC1)C)OC HQAXFHBZLBQPQK-UHFFFAOYSA-N 0.000 claims 1
- MAMWYLRZKKWKTM-UHFFFAOYSA-N methyl 2-[[2-[2-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidine-1-carbonyl]anilino]-5-methylpyrrolo[3,2-d]pyrimidin-4-yl]amino]benzoate Chemical compound CN1C=CC=2N=C(N=C(C=21)NC1=C(C=CC=C1)C(=O)OC)NC1=C(C=C(C=C1)C(=O)N1CCC(CC1)N1CCN(CC1)C)OC MAMWYLRZKKWKTM-UHFFFAOYSA-N 0.000 claims 1
- BOMIEOMAVVFREZ-UHFFFAOYSA-N methyl 2-[[2-[4-(4-hydroxypiperazin-1-yl)anilino]-5H-pyrrolo[3,2-d]pyrimidin-4-yl]oxy]benzoate Chemical compound COC(=O)C1=C(C=CC=C1)OC=1C2=C(N=C(N=1)NC1=CC=C(C=C1)N1CCN(CC1)O)C=CN2 BOMIEOMAVVFREZ-UHFFFAOYSA-N 0.000 claims 1
- CAPQKZSIKPCYMD-UHFFFAOYSA-N methyl 2-[[2-[4-(4-hydroxypiperidin-1-yl)anilino]-5-methylpyrrolo[3,2-d]pyrimidin-4-yl]amino]benzoate Chemical compound CN1C=CC=2N=C(N=C(C=21)NC1=C(C=CC=C1)C(=O)OC)NC1=CC=C(C=C1)N1CCC(CC1)O CAPQKZSIKPCYMD-UHFFFAOYSA-N 0.000 claims 1
- GIWXEUWVSLEACX-UHFFFAOYSA-N methyl 3-(2,4-diamino-1,5-dihydropyrrolo[3,2-d]pyrimidin-4-yl)benzoate Chemical compound COC(=O)C=1C=C(C=CC=1)C1(C2=C(N=C(N1)N)C=CN2)N GIWXEUWVSLEACX-UHFFFAOYSA-N 0.000 claims 1
- AUYCCFLNKUBYOZ-UHFFFAOYSA-N methyl 3-[[2-[4-(4-hydroxypiperidin-1-yl)anilino]-5-methylpyrrolo[3,2-d]pyrimidin-4-yl]amino]benzoate Chemical compound CN1C=CC=2N=C(N=C(C=21)NC1=CC(=CC=C1)C(=O)OC)NC1=CC=C(C=C1)N1CCC(CC1)O AUYCCFLNKUBYOZ-UHFFFAOYSA-N 0.000 claims 1
- CXHHBNMLPJOKQD-UHFFFAOYSA-M methyl carbonate Chemical compound COC([O-])=O CXHHBNMLPJOKQD-UHFFFAOYSA-M 0.000 claims 1
- 150000003890 succinate salts Chemical class 0.000 claims 1
- 239000000651 prodrug Substances 0.000 abstract description 9
- 229940002612 prodrug Drugs 0.000 abstract description 9
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 238000005481 NMR spectroscopy Methods 0.000 description 135
- 239000000243 solution Substances 0.000 description 117
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 92
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 81
- 238000005160 1H NMR spectroscopy Methods 0.000 description 76
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 66
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 64
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 46
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 30
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 23
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 23
- 238000002360 preparation method Methods 0.000 description 23
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 21
- 239000012071 phase Substances 0.000 description 20
- 238000010898 silica gel chromatography Methods 0.000 description 19
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 18
- 239000007788 liquid Substances 0.000 description 18
- 239000012074 organic phase Substances 0.000 description 18
- 230000000694 effects Effects 0.000 description 13
- 239000007787 solid Substances 0.000 description 12
- 239000002146 L01XE16 - Crizotinib Substances 0.000 description 11
- 239000007864 aqueous solution Substances 0.000 description 11
- 229940125904 compound 1 Drugs 0.000 description 11
- 229960005061 crizotinib Drugs 0.000 description 11
- KTEIFNKAUNYNJU-GFCCVEGCSA-N crizotinib Chemical compound O([C@H](C)C=1C(=C(F)C=CC=1Cl)Cl)C(C(=NC=1)N)=CC=1C(=C1)C=NN1C1CCNCC1 KTEIFNKAUNYNJU-GFCCVEGCSA-N 0.000 description 11
- 238000000746 purification Methods 0.000 description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 10
- 238000004949 mass spectrometry Methods 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- 229940125773 compound 10 Drugs 0.000 description 9
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 7
- 238000002953 preparative HPLC Methods 0.000 description 7
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 6
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 6
- 229940125898 compound 5 Drugs 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 239000003208 petroleum Substances 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 4
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 4
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 4
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 description 4
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 4
- 102100027100 Echinoderm microtubule-associated protein-like 4 Human genes 0.000 description 4
- 101001057929 Homo sapiens Echinoderm microtubule-associated protein-like 4 Proteins 0.000 description 4
- 206010027476 Metastases Diseases 0.000 description 4
- 229940125797 compound 12 Drugs 0.000 description 4
- 229940126543 compound 14 Drugs 0.000 description 4
- 229940126214 compound 3 Drugs 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 230000009401 metastasis Effects 0.000 description 4
- VAMXMNNIEUEQDV-UHFFFAOYSA-N methyl anthranilate Chemical compound COC(=O)C1=CC=CC=C1N VAMXMNNIEUEQDV-UHFFFAOYSA-N 0.000 description 4
- 238000005457 optimization Methods 0.000 description 4
- 229910000104 sodium hydride Inorganic materials 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- JENANTGGBLOTIB-UHFFFAOYSA-N 1,5-diphenylpentan-3-one Chemical compound C=1C=CC=CC=1CCC(=O)CCC1=CC=CC=C1 JENANTGGBLOTIB-UHFFFAOYSA-N 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- CSCPPACGZOOCGX-WFGJKAKNSA-N acetone d6 Chemical compound [2H]C([2H])([2H])C(=O)C([2H])([2H])[2H] CSCPPACGZOOCGX-WFGJKAKNSA-N 0.000 description 3
- 229940125890 compound Ia Drugs 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 230000009036 growth inhibition Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000012299 nitrogen atmosphere Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- YVEJLBIEESKJLG-UHFFFAOYSA-N (2-methylsulfanylphenyl)methanamine Chemical compound CSC1=CC=CC=C1CN YVEJLBIEESKJLG-UHFFFAOYSA-N 0.000 description 2
- HTSGKJQDMSTCGS-UHFFFAOYSA-N 1,4-bis(4-chlorophenyl)-2-(4-methylphenyl)sulfonylbutane-1,4-dione Chemical compound C1=CC(C)=CC=C1S(=O)(=O)C(C(=O)C=1C=CC(Cl)=CC=1)CC(=O)C1=CC=C(Cl)C=C1 HTSGKJQDMSTCGS-UHFFFAOYSA-N 0.000 description 2
- 101150023956 ALK gene Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 108010002386 Interleukin-3 Proteins 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 2
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000001464 adherent effect Effects 0.000 description 2
- 229960001611 alectinib Drugs 0.000 description 2
- KDGFLJKFZUIJMX-UHFFFAOYSA-N alectinib Chemical compound CCC1=CC=2C(=O)C(C3=CC=C(C=C3N3)C#N)=C3C(C)(C)C=2C=C1N(CC1)CCC1N1CCOCC1 KDGFLJKFZUIJMX-UHFFFAOYSA-N 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
- 229910000024 caesium carbonate Inorganic materials 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 229960001602 ceritinib Drugs 0.000 description 2
- VERWOWGGCGHDQE-UHFFFAOYSA-N ceritinib Chemical compound CC=1C=C(NC=2N=C(NC=3C(=CC=CC=3)S(=O)(=O)C(C)C)C(Cl)=CN=2)C(OC(C)C)=CC=1C1CCNCC1 VERWOWGGCGHDQE-UHFFFAOYSA-N 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- LFLVWJRUOWNNAC-UHFFFAOYSA-N dicyclohexyl-[2-phenyl-1,3,5-tri(propan-2-yl)cyclohexa-2,4-dien-1-yl]phosphane Chemical group C1CCCCC1P(C1CCCCC1)C1(C(C)C)CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1 LFLVWJRUOWNNAC-UHFFFAOYSA-N 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000012312 sodium hydride Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- UGOMMVLRQDMAQQ-UHFFFAOYSA-N xphos Chemical group CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C1=CC=CC=C1P(C1CCCCC1)C1CCCCC1 UGOMMVLRQDMAQQ-UHFFFAOYSA-N 0.000 description 2
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 1
- VLVLNNQMURDGPM-UHFFFAOYSA-N (2,6-dichlorophenyl)methanamine Chemical compound NCC1=C(Cl)C=CC=C1Cl VLVLNNQMURDGPM-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- WBRPQQSADOCKCH-UHFFFAOYSA-N 2-methylsulfanylaniline Chemical compound CSC1=CC=CC=C1N WBRPQQSADOCKCH-UHFFFAOYSA-N 0.000 description 1
- 125000000972 4,5-dimethylthiazol-2-yl group Chemical group [H]C([H])([H])C1=C(N=C(*)S1)C([H])([H])[H] 0.000 description 1
- RXGJTUSBYWCRBK-UHFFFAOYSA-M 5-methylphenazinium methyl sulfate Chemical compound COS([O-])(=O)=O.C1=CC=C2[N+](C)=C(C=CC=C3)C3=NC2=C1 RXGJTUSBYWCRBK-UHFFFAOYSA-M 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 description 1
- 101000850794 Homo sapiens Tropomyosin alpha-3 chain Proteins 0.000 description 1
- 102000003746 Insulin Receptor Human genes 0.000 description 1
- 108010001127 Insulin Receptor Proteins 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical group CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 108091022875 Microtubule Proteins 0.000 description 1
- 102000029749 Microtubule Human genes 0.000 description 1
- 206010061296 Motor dysfunction Diseases 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 102100033080 Tropomyosin alpha-3 chain Human genes 0.000 description 1
- 108091005906 Type I transmembrane proteins Proteins 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 230000004641 brain development Effects 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 101150068690 eml4 gene Proteins 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical class CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 210000000777 hematopoietic system Anatomy 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- BAQGCWNPCFABAY-UHFFFAOYSA-N methyl 2-sulfanylbenzoate Chemical compound COC(=O)C1=CC=CC=C1S BAQGCWNPCFABAY-UHFFFAOYSA-N 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 210000004688 microtubule Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000003147 molecular marker Substances 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- 230000017066 negative regulation of growth Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Description
본 발명은 약학 영역에 관한 것이며, 구체적으로, ALK 및/또는 c-MET 선택적 억제 활성을 갖는 화합물, 그 제조 방법, 그 화합물을 포함하는 약학 조성물, 및 생체 내 역형성 림프종 키나아제와 관련된 질병을 예방하거나 치료하는 약제 제조 용도, 및 혈관신생 또는 암 전이와 관련된 질병을 예방하거나 치료하는 약제 제조 용도, 특히 종양 성장 및 전이를 예방하거나 치료하는 약제 제조 용도의 그 화합물에 관한 것이다.
역형성 림프종 키나아제(ALK)는 일종의 수용체 티로신 카나아제로서, 인슐린 수용체 슈퍼 패밀리에 속한다. 단백질 구조는 N말단에서 C말단까지 순서대로 세포 외 수용체 도메인, 막 횡단 도메인과 세포 내 티로신 키나아제 도메인이다. 정상적 ALK 단백질은 주로 중추 신경계와 말초 신경계에서 발현되고, 인체에서 ALK 유전자의 발현은 뇌의 발달 정도에 따라 감소하는 경향을 나타내고 있으며, 특히 성숙한 뇌 조직에서는 매우 적다. 그러나 기타 시스템, 특히 조혈계에서 ALK가 아직 발현되지 않은 것은 그 발현 및 분포가 특정한 지역성을 가지고 있음을 증명한다.
정상적 상황 하에서, 인간의 ALK 유전자는 1602개의 아미노산, 200kDa의 I형 트랜스 멤브레인 단백질 ALK를 코딩할 수 있지만, 그 유전자는 보통 휴면 상태에 있다. 다른 유전자와 융합하는 상황 하에서, ALK유전자는 매우 강력한 종양 유전자가 될 수 있다. 현재 이미 발견된 ALK유전자와 융합할 수 있는 유전자로는 핵 인산환 단백질 유전자(NPM, 역형성 대세포 림프종 ALCL), 극피동물 미세소관 관련 단백질 유사 4유전자(EML4,비소세포 폐암 NSCLC),트로포미오신 3유전자(TPM3,염증성 근섬유 모세포종 IMT) 등이 있다(Nat. Rev. Cancer, 2008, 8, 11-23.;Nat. Rev. Cancer, 2013, 13, 685-700.;Expert Opin . Ther . Pat., 2014. 24(4): p. 417-42.)
비소세포 폐암 중에서, 주로 EML4유전자와 융합이 발생하며, 그 융합 유전자(EML4-ALK)의 NSCLC 중 발병율은 4%-7%이다. 분자 생물학에서 비소세포 폐암(NSCLC)에 대한 연구가 부단히 심화됨에 따라, 분자 표지자(biomarker)를 기반으로 하는 맞춤 치료는 이미 실험실에서 임상으로 나아가고 있으며, 말기 비소세포 폐암 환자의 치료에서 임상적으로도 비교적 큰 진전을 이루었다. 이는 NSCLC에 대해 전통적인 병리학적 분류 이외에도, 구체적 환자의 다른 분자 표지자의 서로 다른 발현 수준에 근거해서 분자 표현형 분류가 가능하다는 의미이다. NSCLC환자는 치료를 받기 전에 관련 분자 표지자 검사를 진행한다. 임상에서 의사가 그 종양 분자의 표현형 특성에 근거하여 표적 치료를 진행함에 따라, 치료 효과를 향상시킬 수 있다. 이러한 배경 하에서, 종양의 형성, 발달과 밀접하게 관련된 구동 유전자 또는 그 단백질 코딩은 신약의 연구 개발을 타겟으로 하는 종양 억제 약물 연구에서 이미 뜨거운 이슈가 되었다.
현재, 미국 식품의약국은 이미 파이저(Pfizer)가 개발한 소분자 억제제 CrizotInib(J. Thorac . Oncol ., 2010. 5(12): p. 2044-6.), 노바티스(Novartis)가 개발한 Ceritinib(J. Med . Chem ., 2013. 56(14): p. 5675-90.)의 출시를 승인했으며, Chugai PharmaceutICal이 개발한 Alectinib(Cancer Lett ., 2014. 351(2): p. 215-21.)역시 일본에서 출시를 승인받았다. 그러나, 임상 연구에서 일부 환자가 Crizotinib에 대해 내성을 보이는 것 역시 밝혀졌으며, 동시에 Crizotinib의 생체 이용률도 개선될 것으로 기대된다. Ceritinib는 Crizotinib에 대해 내성이나 불내성을 보이는 환자를 표적으로 할 수 있지만, Alectinib는 일본에서만 출시 승인을 받았으며, 유럽과 미국 지역에서는 아직 임상 시험 단계 중이다. 따라서, 임상 실습 중에서 그 대체 화합물이 매우 필요하다.
본 발명자는 ALK 억제제를 찾기 위해 심도있는 광범위한 연구를 거쳐, 일련의 새로운 구조의 안전성이 높고, 다양한 티로신 키나아제(EGFR, PDGFR, c-Met등), 특히 ALK에 대해 비교적 높은 활성을 가진 다중치환 피로미도피롤(피롤(3,2-d) 유도체를 설계, 합성하였고, 그 새로운 유도체의 종양 억제 활성를 연구하였다.
화합물의 화학식 :
I
그 중 치환기 및 기호의 정의는 아래에서 상세하게 설명한다.
본 발명의 목적은 ALK 및/또는 c-Met 선택적 억제 활성을 갖는 화합물 및 그 약학적으로 허용 가능한 염 또는 그 약학적으로 허용 가능한 용매 화합물을 제공하는 데에 있다.
본 발명의 또 다른 목적은 일종의 상기 화합물의 제조 방법을 제공하는 데에 있다.
본 발명의 또 다른 목적은 일종의 상기 화합물을 포함하는 약제학적 조성물을 제공하는 데에 있다.
본 발명의 또 다른 목적은 생체 내 역형성 림프종 키나아제와 관련된 비정상적 세포 증식, 형태 변화 및 운동 기능 항진 등을 동반하는 질병을 예방하거나 치료하는 약제의 제조 용도, 및 혈관신생이나 암 전이와 관련된 질병을 예방하거나 치료하는 약제의 제조 용도, 특히 종양의 성장과 전이를 예방하거나 치료하는 약제 제조 용도의 상기 화합물을 제공하는 데에 있다.
본 발명은 아래의 기술배경을 통해 구현된다.
한편으로, 본 발명은 아래 화학식 I로 표시되는 화합물, 그 입체 이성질체, 그 프로드러그, 그 약학적으로 허용 가능한 염 또는 그 약학적으로 허용 가능한 용매 화합물을 제공한다.
I
그 중,
R'은 수소, 염소 또는 브롬이다.
R1은 다음에서 선택한다.
1) C1-C6 알킬, 2-N,N-디메틸아미노에틸, 2-히드록시에틸, 2-N,N-디메틸아미노에틸, 2-N,N-디이소프로필아미노에틸, 2-모르폴리노에틸, 2-(4-N-메틸피페라진)에틸, 3-N,N-디메틸아미노프로필, 3-N,N-디에틸아미노프로필, 3-N,N-디이소프로필아미노프로필, 3-모르폴리노프로필, 3-(4-N-메틸피페라진)프로필, 4-N,N-디메틸아미노시클로헥실, 4-N,N-디에틸아미노시클로헥실, N-메틸-4-피페리딜, N-에틸-4-피페리딜, N-이소프로필-4-피페리딜, 1,3-디메틸-5-피라졸일, 1-메틸-4-피라졸일, 3-메틸-5-이소옥사졸리닐, 1-(N-메틸-4-피페리딜)-4-피라졸일, 1-(N-tert-부톡시포르밀-4-피페리딜)-4-피라졸일.
(1) 수소, 불소, 염소, 브롬, 요오드, 니트로, 시아노.
(2) C1-C6알킬, C1-C6알콕시, C1-C6옥시알킬, C1-C6플루오로알킬, C1-C6플루오로알콕시, N-메틸-4-피페리딜.
(3) N,N-디메틸아미노, N,N-디에틸아미노, N,N-디이소프로필아미노, 2-N,N-디메틸아미노 에틸아미노, 2-모르폴리노에틸아미노, 2-(4-N-메틸피페라지닐)에틸아미노, 3-N,N-디메틸아미노프로필아미노, 3-N,N-디에틸아미노프로필아미노, 3-N,N-디이소프로필아미노프로필아미노, 3-모르폴리노프로필아미노, 3-(4-N-메틸피페라지닐)프로필아미노, N-메틸피페리딘-4-일아미노, N-에틸피페리딘-4-일아미노, N-이소프로필피페리딘-4-일아미노.
(4) 2-N,N-디메틸아미노에톡시, 2-N,N-디에틸아미노에톡시, 2-N,N-디이소프로필아미노에톡시, 2-(N-메틸피페라지닐)에톡시, 2-(N-아세틸피페라지닐)에톡시, 2-모르폴리노에톡시, 2-티오모르폴리노에톡시, 2-피페리딜에톡시, 3-N,N-디메틸아미노프로폭시, 3-N,N-디에틸아미노프로폭시, 3-N,N-디이소프로필아미노프로폭시, 3-(N-메틸피페라지닐)프로폭시, 3-(N-아세틸피페라지닐)프로폭시, 3-모르폴리노프로폭시, 3-티오모르폴리노에톡시, 3-피페리딜프로폭시, 2-피리딜프로폭시, 3-피리딜메톡시, 4-피리딜메톡시, 페닐메톡시, 모노할로겐-치환페닐메톡시, 젬-디할로겐 치환 페닐 메톡시, 헤테로-디할로겐 치환 페닐 메톡시.
(5) 피페리딜, 4-N,N-디메틸아미노피페리딜, 4-N,N-디에틸아미노피페리딜, 4-N,N-디이소프로필아미노피페리딜, 4-히드록시피페리딜, 모르폴리노, 3,5-디메틸모르폴리노,티오모르폴리노, 피롤리딘일, 3-N,N-디메틸피롤리딘일, 3-N,N-디에틸피롤리딘일, N-메틸피페라지닐, N-에틸피페라지닐, N-이소프로필피페라지닐, N-아세틸피페라지닐, N-tert-부톡시포르밀피페라지닐, N-메틸설포닐피페라지닐, N-(2-히드록시에틸)피페라지닐, N-(2-시아노에틸)피페라지닐, N-(3-히드록시프로필)피페라지닐, N-(2-N,N-디메틸에틸)피페라지닐, N-(2-N,N-디에틸에틸)피페라지닐, N-(3-N,N-디메틸프로필)피페라지닐, N-(3-N,N-디에틸프로필)피페라지닐, 2-옥소-피페라진-4-일, 이미다졸릴, 4-메틸이미다졸릴.
(6) 4-(N-메틸피페라지닐)피페리딜, 4-(N-에틸피페라지닐)피페리딜, 4-(N-이소프로필피페라지닐)피페리딜, 4-(N-아세틸피페라지닐)피페리딜, 4-(N-tert-부톡시포르밀)피페라지닐)피페리딜, 4-(N-메틸설포닐피페라지닐)피페리딜, 4-(N-(2-히드록시에틸)피페라지닐)피페리딜, 4-(N-(2-시아노에틸)피페라지닐)피페리딜, 4-(N-(3-히드록시프로필) 피페라지닐)피페리딜, 4-(N-(2-N,N-디메틸에틸) 피페라지닐)피페리딜, 4-(N-(2-N,N-디에틸에틸)피페라지닐)피페리딜, 4-(N-(3-N,N-디메틸 프로필)피페라지닐)피페리딜, 4-(N-(3-N,N-디에틸프로필)피페라지닐)피페리딜, 4-(피롤리딘일)피페리딜, 4-(3-N,N-디메틸피롤리딘일)피페리딜, N-(N-메틸-4-피페리딜)피페라지닐, N-(N-에틸-4-피페리딜)피페라지닐.
(7) 히드록시설포닐, 아미노설포닐, 메틸아미노설포닐, 에틸아미노설포닐, 프로필아미노설포닐, 이소프로필아미노설포닐, 시클로프로필아미노설포닐, 시클로부틸아미노설포닐, 시클로펜틸아미노설포닐, 피페리딘-1-일설포닐, 4-히드록시피페리딘-1-일설포닐, 4-N,N-디메틸피페리딘-1-일설포닐, 4-N,N-디에틸피페리딘-1-일설포닐, 피롤리딘-1-일설포닐, 3-N,N-디메틸피롤리딘-1-일설포닐, 3-N,N-디에틸피롤리딘-1-일설포닐, N-메틸피페라진-1-일설포닐, N-에틸피페라진-1-일설포닐, N-아세틸피페라진-1-일설포닐, N-tert-부톡시포르밀피페라진-1-일설포닐, N-(2-히드록시에틸)피페라진-1-일설포닐, N-(2-시아노에틸)피페라진-1-일설포닐, N-(2-N,N-디메틸에틸)피페라진-1-일설포닐, N-(2-N,N-디에틸에틸)피페라진-1-일설포닐, N-(3-히드록시프로필)피페라진-1-일설포닐, N-(3-N,N-디메틸프로필)피페라진-1-일설포닐, N-(3-N,N-디에틸프로필)피페라진-1-일설포닐, 모르폴리노-1-설포닐, 3,5-디메틸모르폴리노-1-설포닐,4-(N-메틸-1-피페라지닐)피페리딘-1-일설포닐, 4-(N-에틸-1-피페라지닐)피페리딘-1-일설포닐, 4-(N-아세틸-1-피페라지닐)피페리딘-1-일설포닐, N-(N-메틸-4-피페리딜)피페라진-1-일설포닐.
(8) 히드록시카르보닐, 아미노카르보닐, 메틸아미노카르보닐, 에틸아미노카르보닐, 프로필아미노카르보닐, 이소프로필아미노카르보닐, 시클로프로필아미노카르보닐, 시클로부틸아미노카르보닐, 시클로펜틸아미노카르보닐, 피페리딘-1-일카르보닐, 4-히드록시피페리딘-1-일카르보닐, 4-N,N-디메틸피페리딘-1-일카르보닐, 4-N,N-디에틸피페리딘-1-일카르보닐, 피롤리딘-1-일카르보닐, 3-N,N-디메틸피롤리딘-1-일카르보닐, 3-N,N-디에틸피롤리딘-1-일카르보닐, N-메틸피페라진-1-일카르보닐, N-에틸피페라진-1-일카르보닐, N-아세틸피페라진-1-일카르보닐, N-tert-부톡시카르보닐피페라진-1-일카르보닐, N-(2-히드록시에틸)피페라진-1-일카르보닐, N-(2-시아노에틸)피페라진-1-일카르보닐, N-(2-N,N-디메틸에틸)피페라진-1-일카르보닐, N-(2-N,N-디에틸에틸)피페라진-1-일카르보닐, N-(3-히드록시프로필)피페라진-1-일카르보닐, N-(3-N,N-디메틸프로필)피페라진-1-일카르보닐, N-(3-N,N-디에틸프로필)피페라진-1-일카르보닐, 모르폴리노-1-카르보닐, 3,5-디메틸모르폴리노-1-카르보닐,4-(N-메틸-1-피페라지닐)피페리딘-1-일카르보닐, 4-(N-에틸-1-피페라지닐)피페리딘-1-일카르보닐, 4-(N-아세틸-1-피페라지닐)피페리딘-1-일카르보닐, N-(N-메틸-4-피페리딜)피페라진-1-일카르보닐.
(9) 메톡시카르보닐, 에톡시카르보닐, 프로폭시카르보닐, 이소프로폭시카르보닐, n-부톡시카르보닐, 이소부톡시카르보닐, tert-부톡시카르보닐.
(10) 아미노포름아미도, 메틸아미노포름아미도, 에틸아미노포름아미도, 프로필아미노포름아미도, 이소프로필아미노포름아미도, 시클로프로필아미노포름아미도, 시클로부틸아미노포름아미도, 시클로펜틸아미노포름아미도, 피페리딘-1-일포름아미도, 4-히드록시피페리딘-1-일포름아미도, 4-N,N-디메틸피페리딘-1-일포름아미도, 4-N,N-디에틸피레리딘-1-일포름아미도, 피롤리딘-1-일포름아미도, 3-N,N-디메틸피롤리딘-1-일포름아미도, 3-N,N-디에틸피롤리딘-1-일포름아미도, N-메틸피페라진-1-일포름아미도, N-에틸피페라진-1-일포름아미도, N-아세틸 피페라진-1-일포름아미도, N-tert-부톡시카르보닐피페라진-1-일포름아미도, N-(2-히드록시에틸)피페라진-1-일포름아미도, N-(2-시아노에틸)피페라진-1-일포름아미도, N-(2-N,N-디메틸에틸)피페라진-1-일포름아미도, N-(2-N,N-디에틸에틸)피페라진-1-일포름아미도, N-(3-히드록시프로필)피페라진-1-일포름아미도, N-(3-N,N-디메틸프로필)피페라진-1-일포름아미도, N-(3-N,N-디에틸프로필)피페라진-1-일포름아미도, 모르폴리노-1-포름아미도, 3,5-디메틸모르폴리노-1-포름아미도4-(N-메틸-1-피페라지닐)피페리딘-1-일포름아미도, 4-(N-에틸-1-피페라지닐)피페리딘-1-일포름아미도, 4-(N-아세틸-1-피페라지닐)피페리딘-1-일포름아미도, N-(N-메틸-4-피페리딜)피페라진-1-일포름아미도, 또는,
(11) 아미노아세트아미도, N-tert-부톡시카르보닐아세트아미도, N-아세틸아미노아세트아미도, 아크릴아미도, 시클로프로피온아미도, 클로로아세트아미도, 피페리딜아세트아미도, 4-히드록시 피페리딜아세트아미도, 4-N,N-디메틸피페리딜아세트아미도, 4-N,N-디에틸피페리딜아세트아미도, 피롤리딘일아세트아미도, 3-N,N-디메틸피롤리딘일아세트아미도, 3-N,N-디에틸피롤리딘일아세트아미도, N-메틸피페라지닐아세트아미도, N-에틸피페라지닐아세트아미도, N-아세틸피페라지닐아세트아미도, N-tert-부톡시카르보닐피페라지닐아세트아미도, N-(2-히드록시에틸)피페라지닐아세트아미도, N-(2-시아노에틸)피페라지닐아세트아미도, N-(2-N,N-디메틸에틸)피페라지닐아세트아미도, N-(2-N,N-디에틸에틸)피페라지닐아세트아미도, N-(3-히드록시프로필)피페라지닐 아세트아미도, N-(3-N,N-디메틸프로필)피페라지닐아세트아미도, N-(3-N,N-디에틸프로필)피페라지닐아세트아미도, 모르폴리노-1-아세트아미도, 3,5-디메틸모르폴리노아세트아미도,4-(N-메틸-1-피페라지닐)피페리딜아세트아미도, 4-(N-에틸-1-피페라지닐)피페리딜아세트아미도, 4-(N-아세틸-1-피페라지닐)피페리딜아세트아미도, N-(N-메틸-4-피페리딜)피페라지닐아세트아미도; 4-(피롤리딘-1-일)피페리딜아세트아미도, 2-메틸아미노아세트아미도, 2-(1-메틸에틸)아미노아세트아미도, N-벤질옥시카르보닐-2-메틸아미노아세트아미도.
(12) Z2와 Z3은 산소를 함유한 치환 또는 비치환된 5원자 고리 또는 6원자 고리를 형성할 수 있다. 치환기는 Z1과 동일한 상기 치환기에서 선택될 수 있다.
(13) Z2와 Z3은 질소를 함유한 치환 또는 비치환된 5원자 고리 또는 6원자 고리를 형성할 수 있다. 치환기는 Z1과 동일한 치환기에서 선택될 수 있다.
A는 직접 결합 또는 메틸렌이다.
X는 직접 결합, NH, S 또는 O원자이다.
R2는 다음에서 임의적으로 선택한다.
1)C1-C6알킬,C2-C6알케닐, C2-C6알키닐,C3-C6시클로 알킬.
(1) 수소, 불소, 염소, 브롬, 요오도, 시아노, 트리플루오로 메틸, 트리플루오로 메톡시, 니트로.
(2) 메틸티오, 에틸티오, 이소프로필티오, 메틸설피닐, 에틸설피닐, 이소프로필설피닐, 메틸설포닐, 에틸설포닐, 이소프로필설포닐, 메틸설포닐아미노, 메톡시카르보닐, 에톡시카르보닐, 프로폭시카르보닐, 이소프로폭시카르보닐, n-부톡시카르보닐, 이소부톡시카르보닐, tert-부톡시카르보닐, 메틸아미노카르보닐, 에틸아미노카르보닐, 프로필아미노카르보닐, 이소프로필아미노카르보닐, 시클로프로필아미노카르보닐, 시클로부틸아미노카르보닐, 시클로펜틸아미노카르보닐, 디메틸포스피닐, 디에틸포스피닐, 디이소프로필포스피닐.
그 중, Y는 NH,S 또는 O원자이다.
A6,A7,A8,A9,A10,A11는 다음에서 독립적으로 선택한다.
(1) 수소, 불소,염소, 브롬, 요오드, 시아노, 트리플루오로 메틸, 트리플루오로 메톡시, 니트로.
(2) 메톡시카르보닐, 에톡시카르보닐, 프로폭시카르보닐, 이소프로폭시카르보닐, n-부톡시카르보닐, 이소부톡시카르보닐, tert-부톡시카르보닐, 메틸아미노카르보닐, 에틸아미노카르보닐, 프로필아미노카르보닐, 이소프로필아미노카르보닐, 시클로프로필아미노카르보닐, 시클로부틸아미노카르보닐, 시클로펜틸아미노카르보닐.
그 중 A12는 다음에서 선택한다.
(1) 수소, 불소, 염소, 브롬, 요오드, 시아노, 트리플루오로 메틸, 트리플루오로 메톡시, 니트로.
(2) 메톡시카르보닐, 에톡시카르보닐, 프로폭시카르보닐, 이소프로폭시카르보닐, n-부톡시카르보닐, 이소부톡시카르보닐, tert-부톡시카르보닐, 메틸아미노카르보닐, 에틸아미노카르보닐, 프로필아미노카르보닐, 이소프로필아미노카르보닐, 시클로프로필아미노카르보닐, 시클로부틸아미노카르보닐, 시클로펜틸아미노카르보닐, 메틸설피닐, 에틸설피닐, 이소프로필설피닐, 메틸설포닐, 에틸설포닐, 이소프로필설포닐.
Y2, Y3, Y4는 다음의 조합에서 선택한다.
Y2는 N,Y3은 N-A13,Y4는 CH 또는 N이다.
Y2는 N,Y3는 C-A13,Y4는 N,O 또는 S이다.
Y2는 O 또는 S,Y3는 N-A13,Y4는 CH이다.
Y2는 O 또는 S,Y3는 C-A13,Y4는 N이다. 및
Y2는 C,Y3는 N-A13,Y4는 O 또는 S이다.
그 중, A13은 수소,C1-C6 알킬,C2-C6 알케닐,C2-C6 알키닐,C3-C6 시클로알킬이다.
(5) 피페리딜, 4-N,N-디메틸아미노피페리딜, 4-N,N-디에틸아미노피페리딜, 4-N,N-디이소프로필아미노피페리딜, 4-히드록시피페리딜, 모르폴리노, 3,5-디메틸모르폴리노, 티오모르폴리노, 피롤리딘일, 3-N,N-디메틸피롤리딜, 3-N,N-디에틸피롤리딜, N-메틸피페라지닐, N-에틸피페라지닐, N-이소프로필피페라지닐, N-아세틸피페라지닐, N-tert-부톡시카르보닐피페라지닐, N-메틸설포닐피페라지닐, N-(2-히드록시에틸)피페라지닐, N-(2-시아노에틸)피페라지닐, N-(3-히드록시프로필)피페라지닐, N-(2-N,N-디메틸에틸)피페라지닐, 4-(2-N,N-디에틸에틸)피페라지닐, N-(3-N,N-디메틸프로필)피페라지닐, N-(3-N,N-디에틸프로필)피페라지닐.
R3은 수소,C1-C6 알킬,C2-C6 알케닐,C2-C6 알키닐,또는 C3-C6 시클로알킬이다.
특별한 설명이 없는 한, 상기 그룹과 치환기는 약학 분야의 일반적인 의미를 갖는다. 설명해야 할 점은, 산소 함유 알킬기는 메톡시에틸, 메톡시에톡시메틸과 같이 알킬기 골격 중간에 한 개 또는 다수의 산소 치환기가 있는 것을 의미한다.
본 발명의 일종의 구체적 기술배경에 따라, 상기 화합물, 그 입체 이성질체, 그 프로드러그, 또는 그 약학적으로 허용 가능한 염 또는 그 약학적으로 허용 가능한 용매 화합물은 화학식 II구조를 갖는다.
II
그 중,
W는 옥소, 티오, 또는 수소이다.
n = 0, 또는 1이다.
R4,R5,R6는 다음에서 독립적으로 선택한다.
(1) 수소, 불소, 염소, 브롬, 요오드. 니트로, 시아노.
(2) C1-C6 알킬, C1-C6 알콕시, C1-C6 옥시알킬, C1-C6 플루오로알킬, C1-C6 플루오로알콕시.
R7은 다음에서 선택한다.
(1) 수소, C1-C6 알킬, 아세틸, 프로피오닐, 부티릴, 이소부티릴.
(2) 글리실, 2-N,N-디메틸아세틸, 2-N,N-디에틸아세틸, 2-N,N-디이소프로필아세틸, 피페리딜아세틸, 4-히드록시피페리딜아세틸, 4-N,N-디메틸피페리딜아세틸, 4-N,N-디에틸피페리딜아세틸, 피롤리딘일아세틸, 3-N,N-디메틸피롤리딘일아세틸, 3-N,N-디에틸피롤리딘일아세틸, N-메틸피페라지닐아세틸, N-에틸피페라지닐아세틸, N-아세틸피페라지닐아세틸, N-tert-부톡시카르보닐피페라지닐아세틸, N-(2-히드록시에틸)피페라지닐아세틸, N-(2-시아노에틸)피페라지닐아세틸, N-(2-N,N-디메틸에틸)피페라지닐아세틸, N-(2-N,N-디에틸에틸)피페라지닐아세틸, N-(3-히드록시프로필)피페라지닐아세틸, N-(3-N,N-디메틸프로필)피페라지닐아세틸, N-(3-N,N-디에틸프로필)피페라지닐아세틸, 모르폴리노아세틸, 3,5-디메틸모르폴리노아세틸,4-(N-메틸-1-피페라지닐)피페리딜아세틸, 4-(N-에틸-1-피페라지닐)피페리딜아세틸, 4-(N-아세틸-1-피페라지닐)피페리딜아세틸, N-(N-메틸-4-피페리딜)피페라지닐아세틸.
A,X,R2,R3는 상기 기술배경 중의 정의와 동일하다.
본 발명의 일종의 구체적 기술배경에 따라, 상기 화합물, 그 입체 이성질체, 그 프로드러그, 또는 그 약학적으로 허용 가능한 염 또는 그 약학적으로 허용 가능한 용매 화합물은 화학식 III구조를 갖는다.
III
그 중,
X ,R1,R2,R3는 화학식 I구조의 화합물 중의 정의와 동일하다. 화학식 I구조 표시에 해당되는 화합물 중의 A는 직접 결합이고, R'은 수소이다.
본 발명의 일종의 구체적 기술배경에 따라, 상기 화합물, 그 입체 이성질체, 그 프로드러그, 또는 그 약학적으로 허용 가능한 염 또는 그 약학적으로 허용 가능한 용매 화합물은 화학식 IV구조를 갖는다.
IV
그 중,
R1,R3는 화학식 I구조의 화합물 중의 정의와 동일하다.
R2는 다음에서 선택한다.
C1-C6알킬,C2-C6알케닐,C2-C6알키닐, C3-C6시클로알킬.
(1) 수소, 불소,염소, 브롬, 요오드, 시아노, 트리플루오로 메틸, 트리플루오로 메톡시, 니트로.
(2) 메틸티오, 에틸티오, 이소프로필티오, 메틸설피닐, 에틸설피닐, 이소프로필설피닐, 메틸설포닐, 에틸설포닐, 이소프로필설포닐, 메틸설포닐아미노, 메톡시카르보닐, 에톡시카르보닐, 프로폭시카르보닐, 이소프로폭시카르보닐, n-부톡시카르보닐, 이소부톡시카르보닐, tert-부톡시카르보닐, 메틸아미노카르보닐, 에틸아미노카르보닐, 프로필아미노카르보닐, 이소프로필아미노카르보닐, 시클로프로필아미노카르보닐, 시클로부틸아미노카르보닐, 시클로펜틸아미노카르보닐, 디메틸포스피닐, 디에틸포스피닐, 디이소프로필포스피닐.
(1) 수소, 불소,염소, 브롬, 요오드, 시아노, 트리플루오로 메틸, 트리플루오로 메톡시, 니트로.
(2) 메톡시카르보닐, 에톡시카르보닐, 프로폭시카르보닐, 이소프로폭시카르보닐, n-부톡시카르보닐, 이소부톡시카르보닐, tert-부톡시카르보닐, 메틸아미노카르보닐, 에틸아미노카르보닐, 프로필아미노카르보닐, 이소프로필아미노카르보닐, 시클로프로필아미노카르보닐, 시클로부틸아미노카르보닐, 시클로펜틸아미노카르보닐.
본 발명의 일종의 구체적 기술배경에 따라, 상기 화합물, 그 입체 이성질체, 그 프로드러그, 또는 그 약학적으로 허용 가능한 염 또는 그 약학적으로 허용 가능한 용매 화합물에서,
그 중, 최적화는 아래의 적어도 하나이다.
(1) R1 중에서 Z1은 메톡시, 에톡시, 이소프로폭시 또는 트리플루오로메톡시에서 선택되고, 및/또는 Z3는 4-N,N-디메틸아미노피페리딜, 4-히드록시피페리딜, 모르폴리노, 피롤리딘일, 3-N,N-디메틸피롤리딘일, N-메틸피페라지닐, N-에틸피페라지닐, N-아세틸피페라지닐, N-(2-히드록시에틸)피페라지닐, N-(2-시아노에틸)피페라지닐, N-(3-히드록시프로필)피페라지닐, 4-(N-메틸피페라지닐)피페리딜, 4-(N-에틸피페라지닐)피페리딜, 4-(N-아세틸피페라지닐)피페리딜, 4-(N-tert-부톡시카르보닐피페라지닐)피페리딜,4-(N-(2-히드록시에틸)피페라지닐)피페리딜, 4-(N-(2-시아노에틸)피페라지닐)피페리딜, 4-피롤리딜피페리딜, N-(N-메틸-4-피페리딜)피페라지닐, N-(N-에틸-4-피페리딜)피페라지닐, 아미노설포닐, 메트아미노설포닐, 시클로프로아미노설포닐, 피페리딘-1-일설포닐, 4-히드록시피페리딘-1-일설포닐, 4-N,N-디메틸피페리딘-1-일설포닐, 피롤리딘-1-일설포닐, 3-N,N-디메틸피롤리딘-1-일설포닐, 4-메틸피페라진-1-일설포닐, 4-에틸피페라진-1-일설포닐, 모르폴리노-1-설포닐, 히드록시카르보닐, 아미노카르보닐, 메틸아미노카르보닐, 에틸아미노카르보닐, 이소프로필아미노카르보닐, 시클로프로필아미노카르보닐, 피페리딘-1-일카르보닐, 4-히드록시피페리딘-1-일카르보닐, 4-N,N-디메틸피페리딘-1-일카르보닐, 피롤리딘-1-일카르보닐, 3-N,N-디메틸피롤리딘-1-일카르보닐, N-메틸피페라진-1-일카르보닐, N-에틸피페라진-1-일카르보닐, N-아세틸피페라진-1-일카르보닐, 모르폴리노-1-카르보닐, 4-(N-메틸-1-피페라지닐)피페리딘-1-일카르보닐, 4-(N-에틸-1- 피페라지닐)피페리딘-1-일카르보닐, 4-(N-아세틸-1-피페라지닐)피페리딘-1-일카르보닐, N-(N-메틸-4-피페리딜)피페라진-1-일카르보닐.
(2) R2는 2-메틸설포닐펜질, 2-에틸설포닐펜질, 2-이소프로필설포닐펜질, 2-메틸설포아미도페닐 또는 2-디메틸포스피닐페닐에서 선택한다.
(3) R3는 수소 또는 메틸에서 선택한다.
(4) 화합물은 약학적으로 허용 가능한 염이며, 그 중 상기 약학적으로 허용 가능한 염은 무기산염 또는 유기산염이고, 그 중, 상기 무기산염은 염산염, 브롬산염, 질산염, 황산염 또는 인산염이며, 상기 유기산염은 포름산염, 아세트산염, 프로피온산염, 벤조산염, 말레산염, 푸마르산염, 석신산염, 타타르산염, 시트르산염, 알킬설폰산염 또는 아릴설폰산염이다. 최적화로서, 상기 알킬설폰산염은 메틸설폰산염 또는 에틸설폰산염이다. 상기 아릴설폰산염은 벤젠설폰산염 또는 p-메틸벤젠설폰산염이다.
본 발명의 일종의 구체적 기술배경에 따라, 상기 화합물, 그 입체 이성질체, 그 프로드러그, 또는 그 약학적으로 허용 가능한 염 또는 그 약학적으로 허용 가능한 용매 화합물에서, 그 중 상기 화합물은 아래 실시예 중 상기 화합물의 하나이다.
또 다른 측면에서, 본 발명이 제공하는 일종의 약학 조성물은 상기 임의의 기술배경에서 설명한 화합물, 그 입체 이성질체, 그 프로드러그, 또는 그 약학적으로 허용 가능한 염 또는 그 약학적으로 허용 가능한 용매 화합물, 및 약학적으로 허용 가능한 담체, 희석제 또는 부형제를 포함한다.
또 다른 측면에서, 본 발명이 또 제공하는 일종의 상기 임의의 기술배경에서 설명하는 화합물의 제조 방법은 다음 단계를 포함한다.
그 반응의 시재료는 시중에서 구할 수 있다.
반응 조건 : (a) 알칼리성 조건(디이소프로필에틸아민, 트리메틸아민, 포타슘 카르보네이트, 등) 또는 산성 조건(트리플루오로 아세트산, 염산 등)의 치환 반응. (b) 산성 조건(트리플루오로 아세트산, 염산 등) 또는 팔라듐 촉매화된 아민화 반응, 또는,
반응 조건 : (a) 할로겐화 알킬, 알칼리성 조건(NaH 등) 치환 반응 또는 디메틸 설페이트의 메틸화. (b) 알칼리성 조건(디이소프로필에틸아민, 트리메틸아민, 포타슘 카르보네이트 등) 또는 산성 조건(트리플루오로 아세트산, 염산 등)의 치환 반응. (c) 산성 조건(트리플루오로 아세트산, 염산 등) 또는 팔라듐 촉매화된 아민화 반응.
또 다른 측면에서, 본 발명은 또 종양을 예방하고 치료하는 약제의 제조에 사용되는 일종의 상기 임의의 기술배경에서 설명하는 화합물, 그 입체 이성질체, 그 프로드러그, 또는 그 약학적으로 허용 가능한 염 또는 그 약학적으로 허용 가능한 용매 화합물을 제공한다. 최적화로서, 그 중 상기 종양은 역형성 대세포 림프종, 염증성 근섬유 모세포종, 비소세포 폐암, 신경모세포종, 소세포 폐암, 폐선암, 췌장암, 유선암, 전립선암, 간암, 피부암, 상피세포암, 위장 간질 종양, 백혈병, 조직세포 림프종, 비인두암 중 임의의 일종이다. 더욱 최적화로서, 그 중 상기 종양은 역형성 대세포 림프종, 염증성 근섬유 모세포종, 비소세포 폐암이나 신경모세포종이다.
아래는 구체적 실시예를 통한 본 발명의 실시방식에 대한 상세한 설명이지만, 본 발명에 대한 제한으로 해석될 수는 없다.
상기 화학식 화합물은 몇가지 합성 공정으로 분류된다.
화합물 I의 화학식.
실시예 1
화합물 IA의 합성 화학식.
화합물 3의 제조.
화합물 1(200mg, 1.06mmol), 화합물 2(163mg, 1.17mmol)을 10 mL의 tert-부탄올에 용해시킨 후, 그 용액 속에 트리플루오로 아세트산(0.393mL, 5.3mmol)을 첨가한다. 생성된 반응액을 100℃로 예열된 오일 배스에 놓고 화합물 1이 완전히 반응할 때까지(LC-MS와 TLC 추적) 가열 교반한다. 반응이 중지되면, 반응액에 포화 중탄산 나트륨 용액을 넣고 액체를 분리하며, 유기상은 포화 염화나트륨 용액으로 2회 세척, 무수 황산나트륨 건조, 실리카 겔 칼럼 크로마토그래피 농축(석유 에테르/에틸 아세테이트 = 1/2)으로 화합물 3(백색 고체, 147.3mg, 수득률 47.8%)을 얻어서 다음 반응에 직접 사용한다.
MS (ESI) m/z: 291 [M+H]+.
화합물 IA의 제조.
방법 A.
화합물 3(18.3mg, 0.063mmol), 아닐린(0.044mmol)을 1mL의 tert-부탄올에 용해시킨 후, 그 용액 속에 트리플루오로 아세트산(23.4μL, 0.32mmol)을 첨가한다. 생성된 반응액을 아닐린이 완전히 반응할 때까지(LC-MS와 TLC 추적) 110℃로 예열된 오일 배스에 놓고 가열 교반한다. 반응이 중지되면, 반응액에 포화 중탄산 나트륨 용액을 넣고 액체를 분리하며, 유기상은 포화 염화나트륨 용액으로 2회 세척, 무수 황산나트륨 건조, 실리카 겔 칼럼 크로마토그래피 농축(디클로로메테인/메탄올)으로 화합물 IA를 얻는다.
방법 B.
화합물 3(18.3mg, 0.063mmol), 아닐린(0.044mmol)을 1mL의 tert-부탄올에 용해시킨 후에, 그 용액 속에 트리플루오로 아세트산(23.4μL, 0.32mmol)을 첨가한다. 생성된 반응액을 아닐린이 완전히 반응할 때까지(LC-MS와 TLC 추적) 110℃로 예열된 오일 배스에 놓고 가열 교반한다. 반응이 중지되면, 농축시켜 역상 제조형 HPLC 정제를 거치고(0.35% 트리플루오로 아세트산을 포함한 수용액과 메탄올이 이동상), 진공 농축시켜 화합물 IA를 얻는다.
화합물 IB, IC, ID, IE, IF는 모두 유사한 방법을 사용해 합성할 수 있다.
아래는 구체적 화합물 및 구조 확인 데이터이다.
번호 | 구조 | 핵 자기 공명 분광법 및/또는 질량 분석 데이터 |
IA-1 | TFA salt | 1H NMR (600 MHz, Methanol-d 4) δ 7.53 - 7.48 (m, 2H), 7.45 (dd, J = 8.0, 1.4 Hz, 1H), 7.41 - 7.3411 (m, 2H), 7.25 (td, J = 7.6, 1.4 Hz, 1H), 6.67 (d, J = 2.4 Hz, 1H), 6.40 - 6.34 (m, 1H), 6.32 (d, J = 3.0 Hz, 1H), 3.84 (s, 3H), 3.79 (d, J = 13.2 Hz, 2H), 3.62 (d, J = 11.3 Hz, 2H), 3.25 (t, J = 11.8 Hz, 2H), 3.07 (t, J = 13.4 Hz, 2H), 2.96 (s, 3H), 2.42 (s, 3H). MS (ESI) m/z: 476 [M+H]+. |
IA-2 | 1H NMR (600 MHz, Methanol-d 4) δ 7.83 (dd, J = 7.8, 1.5 Hz, 1H), 7.45 (dd, J = 7.7, 1.6 Hz, 1H), 7.40 - 7.34 (m, 2H), 7.34 (d, J = 3.0 Hz, 1H), 7.24 (td, J = 7.6, 1.6 Hz, 1H), 7.20 (td, J = 7.6, 1.6 Hz, 1H), 6.89 - 6.83 (m, 2H), 6.24 (d, J = 3.0 Hz, 1H), 3.71 (hept, J = 8.9, 4.1 Hz, 1H), 3.39 (dt, J = 12.1, 4.3 Hz, 2H), 2.77 (ddd, J = 12.6, 10.3, 2.9 Hz, 2H), 2.40 (s, 3H), 1.99 - 1.93 (m, 2H), 1.6727 (dtd, J = 13.2, 9.7, 3.8 Hz, 2H). MS (ESI) m/z: 447 [M+H]+. | |
IA-3 | 1H NMR (600 MHz, DMSO-d 6) δ 11.01 (d, J = 3.1 Hz, 1H), 9.09 (s, 1H), 8.6210 (s, 1H), 7.85 - 7.74 (m, 2H), 7.62 (dd, J = 7.8, 1.7 Hz, 1H), 7.53 (t, J = 2.9 Hz, 1H), 7.51 - 7.46 (m, 2H), 7.41 (dd, J = 7.7, 1.6 Hz, 1H), 7.34 - 7.25 (m, 2H), 7.04 (s, 2H), 6.27 (t, J = 2.4 Hz, 1H), 2.43 (s, 3H). MS (ESI) m/z: 427 [M+H]+. | |
IB -1 | TFA salt | 1H NMR (600 MHz, DMSO-d 6) δ 12.13 (s, 1H), 10.15 (s, 1H), 9.20 (s, 1H), 7.66 (t, J = 3.0 Hz, 1H), 7.57 (d, J = 2.1 Hz, 1H), 7.55 (d, J = 2.5 Hz, 1H), 7.37 - 7.31 (m, 2H), 7.28 (d, J = 8.4 Hz, 1H), 6.69 (d, J = 2.6 Hz, 1H), 6.37 - 6.32 (m, 2H), 3.82 (d, J = 13.0 Hz, 2H), 3.78 (s, 3H), 3.54 (s, 2H), 3.45 (hept, J = 6.6 Hz, 1H), 3.22 - 3.12 (m, 2H), 2.97 (s, 2H), 2.88 (s, 3H), 1.18 (d, J = 6.6 Hz, 6H). MS (ESI) m/z: 504 [M+H]+. |
IB -2 | 1H NMR (600 MHz, DMSO-d 6) δ 11.23 (s, 1H), 8.42 (s, 1H), 8.30 (s, 1H), 8.13 - 7.96 (m, 1H), 7.60 - 7.55 (m, 2H), 7.52 (dd, J = 7.7, 1.5 Hz, 1H), 7.48 - 7.44 (m, 1H), 7.34 (td, J = 7.6, 1.6 Hz, 1H), 7.15 (td, J = 7.5, 1.4 Hz, 1H), 6.79 - 6.74 (m, 2H), 6.23 - 6.18 (m, 1H), 4.64 (d, J = 3.9 Hz, 1H), 3.57 (dt, J = 8.8, 4.9 Hz, 1H), 3.17 (d, J = 3.9 Hz, 2H), 2.69 (ddd, J = 12.4, 10.4, 3.0 Hz, 2H), 1.82 (dt, J = 12.8, 4.0 Hz, 2H), 1.50 (dtd, J = 13.0, 9.5, 3.8 Hz, 2H), 1.19 (d, J = 6.8 Hz, 6H). MS (ESI) m/z: 475 [M+H]+. | |
IB -3 | 1H NMR (600 MHz, DMSO-d 6) δ 11.30 - 11.21 (m, 1H), 9.15 (s, 1H), 8.64 (s, 1H), 7.88 (dd, J = 8.0, 1.3 Hz, 1H), 7.86 - 7.82 (m, 2H), 7.57 - 7.54 (m, 2H), 7.54 - 7.51 (m, 2H), 7.37 (td, J = 7.7, 1.5 Hz, 1H), 7.24 (td, J = 7.6, 1.4 Hz, 1H), 7.05 (s, 2H), 6.29 (dd, J = 2.9, 2.0 Hz, 1H), 3.42 - 3.35 (m, 1H), 1.18 (d, J = 6.6 Hz, 6H). MS (ESI) m/z: 455 [M+H]+. | |
IC-1 | 1H NMR (600 MHz, DMSO-d 6) δ 11.32 (s, 1H), 8.75 (s, 1H), 8.07 (d, J = 8.8 Hz, 1H), 7.99 - 7.92 (m, 2H), 7.81 - 7.72 (m, 1H), 7.51 (s, 1H), 7.44 (t, J = 7.7 Hz, 1H), 7.04 (s, 1H), 6.59 (d, J = 2.6 Hz, 1H), 6.36 (dd, J = 8.8, 2.5 Hz, 1H), 6.25 (d, J = 2.9 Hz, 1H), 3.80 (s, 3H), 3.15 (s, 3H), 3.08 (t, J = 5.0 Hz, 4H), 2.56 - 2.53 (m, 4H), 2.29 (s, 3H). MS (ESI) m/z: 508 [M+H]+. | |
IC-2 | TFA salt | 1H NMR (600 MHz, Methanol-d 4) δ 8.10 (dd, J = 8.0, 1.5 Hz, 1H), 7.92 (d, J = 8.0 Hz, 1H), 7.80 (td, J = 7.8, 1.6 Hz, 1H), 7.65 - 7.57 (m, 2H), 7.42 - 7.36 (m, 1H), 6.91 (d, J = 2.1 Hz, 1H), 6.63 (dd, J = 8.7, 2.5 Hz, 1H), 6.40 (d, J = 3.0 Hz, 1H), 3.87 (s, 3H), 3.81 (d, J = 12.6 Hz, 2H), 3.40 (s, 4H), 3.22 (s, 4H), 3.12 (d, J = 13.6 Hz, 2H), 3.08 (s, 3H), 3.07 - 3.02 (m, 1H), 2.90 (s, 3H), 2.66 (s, 1H), 2.22 - 2.13 (m, 2H), 1.91 (qd, J = 12.2, 3.9 Hz, 2H). MS (ESI) m/z: 591 [M+H]+. |
IC-3 | 1H NMR (600 MHz, Methanol-d 4) δ 8.08 (dd, J = 8.0, 1.5 Hz, 1H), 7.88 (d, J = 8.0 Hz, 1H), 7.78 (td, J = 7.7, 1.5 Hz, 1H), 7.63 - 7.57 (m, 2H), 7.23 (d, J = 9.0 Hz, 2H), 6.98 (d, J = 8.4 Hz, 2H), 6.41 (d, J = 2.9 Hz, 1H), 3.83 (tt, J = 8.0, 3.7 Hz, 1H), 3.56 (dt, J = 11.0, 4.7 Hz, 2H), 3.06 (s, 3H), 2.99 (td, J = 10.5, 9.5, 4.5 Hz, 2H), 2.01 (dq, J = 13.1, 4.1 Hz, 2H), 1.72 (ddt, J = 14.0, 9.3, 4.6 Hz, 2H). MS (ESI) m/z: 479 [M+H]+. | |
IC-4 | 1H NMR (600 MHz, DMSO-d 6) δ 11.43 (s, 1H), 9.24 (s, 1H), 8.85 (s, 1H), 8.02 - 7.92 (m, 2H), 7.80 (ddd, J = 11.3, 6.9, 1.8 Hz, 3H), 7.60 (q, J = 2.4 Hz, 1H), 7.52 (dd, J = 9.0, 7.2 Hz, 3H), 7.07 (s, 2H), 6.34 (dt, J = 2.9, 1.8 Hz, 1H), 3.15 (d, J = 1.8 Hz, 3H). MS (ESI) m/z: 459 [M+H]+. | |
IC-5 | 1H NMR (600 MHz, DMSO-d 6) δ 11.26 (s, 1H), 8.67 (s, 1H), 8.40 (s, 1H), 8.02 (d, J = 8.2 Hz, 1H), 7.95 (dd, J = 7.9, 1.6 Hz, 1H), 7.76 (ddd, J = 8.5, 7.5, 1.6 Hz, 1H), 7.57 - 7.52 (m, 2H), 7.50 (t, J = 3.0 Hz, 1H), 7.42 (t, J = 7.4 Hz, 1H), 6.76 - 6.74 (m, 2H), 6.24 (dd, J = 2.8, 1.6 Hz, 1H), 3.15 (s, 3H), 3.01 - 2.99 (m, 4H), 2.44 (t, J = 4.9 Hz, 4H), 2.21 (s, 3H). MS (ESI) m/z: 478 [M+H]+. | |
ID-1 | TFA salt | 1H NMR (600 MHz, DMSO-d 6) δ 12.23 (s, 1H), 10.26 (s, 1H), 9.23 (s, 1H), 7.92 (dd, J = 8.0, 1.6 Hz, 1H), 7.80 (td, J = 7.7, 1.6 Hz, 1H), 7.71 (d, J = 8.0 Hz, 1H), 7.66 (t, J = 3.0 Hz, 1H), 7.60 (td, J = 7.7, 1.3 Hz, 1H), 7.11 (d, J = 8.7 Hz, 1H), 6.62 (d, J = 2.6 Hz, 1H), 6.35 - 6.29 (m, 1H), 6.22 (s, 1H), 3.78 (d, J = 12.5 Hz, 2H), 3.74 (s, 3H), 3.51 (d, J = 11.9 Hz, 2H), 3.30 (hept, J = 13.9, 7.0 Hz, 1H), 3.12 (d, J = 8.1 Hz, 2H), 2.91 (s, 2H), 2.84 (s, 3H), 1.00 (d, J = 6.7 Hz, 6H). MS (ESI) m/z: 536 [M+H]+. |
ID-2 | 1H NMR (600 MHz, Methanol-d 4) δ 8.24 (d, J = 8.3 Hz, 1H), 7.88 (dd, J = 8.0, 1.6 Hz, 1H), 7.69 - 7.61 (m, 1H), 7.41 - 7.40 (m, 1H), 7.39 - 7.35 (m, 2H), 7.35 - 7.31 (m, 1H), 6.83 (d, J = 9.0 Hz, 2H), 6.28 (d, J = 3.0 Hz, 1H), 3.24 (hept, J = 6.9 Hz, 1H), 3.12 - 3.07 (m, 4H), 2.66 - 2.59 (m, 4H), 2.34 (s, 3H), 1.16 (d, J = 6.8 Hz, 6H). MS (ESI) m/z: 506 [M+H]+. | |
ID-3 | TFA salt | 1H NMR (600 MHz, DMSO-d 6) δ 12.27 (s, 1H), 10.31 (s, 1H), 9.25 (s, 1H), 7.97 (d, J = 7.9 Hz, 1H), 7.84 (t, J = 7.8 Hz, 1H), 7.76 (d, J = 8.0 Hz, 1H), 7.70 (d, J = 3.9 Hz, 1H), 7.65 (t, J = 7.7 Hz, 1H), 7.15 (d, J = 8.7 Hz, 1H), 6.71 (s, 1H), 6.36 (s, 1H), 6.31 (d, J = 8.7 Hz, 1H), 3.82 (d, J = 12.2 Hz, 2H), 3.78 (s, 3H), 3.60 (s, 4H), 3.45 - 3.32 (m, 5H), 2.90 (s, 3H), 2.77 (t, J = 12.2 Hz, 2H), 2.59 - 2.51 (m, 1H), 2.16 (d, J = 11.6 Hz, 2H), 1.78 - 1.69 (m, 2H), 1.05 (d, J = 6.8 Hz, 6H). MS (ESI) m/z: 619 [M+H]+. |
ID-4 | TFA salt | 1H NMR (600 MHz, Methanol-d 4) δ 8.04 (dd, J = 8.0, 1.5 Hz, 1H), 7.90 (d, J = 7.9 Hz, 1H), 7.85 (td, J = 7.7, 1.5 Hz, 1H), 7.69 - 7.63 (m, 2H), 7.46 (d, J = 8.9 Hz, 2H), 7.33 - 7.27 (m, 2H), 6.48 (d, J = 3.0 Hz, 1H), 4.01 (hept, J = 7.3, 3.5 Hz, 1H), 3.70 (ddd, J = 11.8, 7.6, 3.6 Hz, 2H), 3.38 (ddd, J = 12.0, 8.0, 3.6 Hz, 2H), 3.24 (hept, J = 6.9 Hz, 1H), 2.17 (ddt, J = 14.5, 7.5, 3.6 Hz, 2H), 1.92 (dtd, J = 14.9, 7.7, 3.6 Hz, 2H), 1.12 (d, J = 6.8 Hz, 6H). MS (ESI) m/z: 507 [M+H]+. |
ID-5 | 1H NMR (600 MHz, DMSO-d 6) δ 12.05 (s, 1H), 10.56 (s, 1H), 10.21 (s, 1H), 8.03 (dd, J = 7.9, 1.5 Hz, 1H), 7.92 (td, J = 7.7, 1.6 Hz, 1H), 7.87 (dd, J = 8.1, 1.3 Hz, 1H), 7.78 (t, J = 3.0 Hz, 1H), 7.74 - 7.68 (m, 1H), 7.51 - 7.43 (m, 4H), 7.22 (s, 2H), 6.43 (dd, J = 3.0, 1.9 Hz, 1H), 3.30 (hept, J = 6.7 Hz, 1H), 1.03 (d, J = 6.8 Hz, 6H). MS (ESI) m/z: 487 [M+H]+. | |
ID-6 | 1H NMR (600 MHz, Methanol-d 4) δ 8.02 (dd, J = 8.0, 1.6 Hz, 1H), 7.94 (d, J = 8.0 Hz, 1H), 7.78 (td, J = 7.8, 1.6 Hz, 1H), 7.63 (d, J = 3.0 Hz, 1H), 7.59 (td, J = 7.7, 1.2 Hz, 1H), 7.34 (s, 1H), 6.85 (s, 1H), 6.40 (d, J = 3.0 Hz, 1H), 4.62 (hept, J = 5.9 Hz, 1H), 3.61 (d, J = 12.8 Hz, 2H), 3.32 - 3.24 (m, 1H), 3.17 (td, J = 12.1, 4.6 Hz, 2H), 3.05 (hept, J = 10.5, 5.0 Hz, 1H), 2.91 (s, 3H), 2.0718 (s, 3H), 2.02 - 1.94 (m, 4H), 1.27 (d, J = 6.0 Hz, 6H), 1.15 (d, J = 6.8 Hz, 6H). MS (ESI) m/z: 577 [M+H]+. | |
ID-7 | 1H NMR (600 MHz, Methanol-d 4) δ 8.02 (dd, J = 7.9, 1.5 Hz, 1H), 7.92 (d, J = 8.0 Hz, 1H), 7.77 (td, J = 7.8, 1.6 Hz, 1H), 7.63 (d, J = 2.9 Hz, 1H), 7.59 (td, J = 7.7, 1.2 Hz, 1H), 7.32 (s, 1H), 6.84 (s, 1H), 6.41 (d, J = 3.0 Hz, 1H), 3.85 (s, 3H), 3.63 (dq, J = 10.5, 1.9 Hz, 2H), 3.27 (q, J = 6.8 Hz, 1H), 3.18 (td, J = 12.5, 3.4 Hz, 2H), 3.07 (tt, J = 11.8, 4.1 Hz, 1H), 2.93 (s, 3H), 2.08 (s, 3H), 2.06 - 1.95 (m, 4H), 1.15 (d, J = 6.8 Hz, 6H). MS (ESI) m/z: 549 [M+H]+. | |
ID-8 | 1H NMR (600 MHz, Methanol-d 4) δ 8.16 (d, J = 8.3 Hz, 1H), 7.95 (dd, J = 7.9, 1.6 Hz, 1H), 7.79 - 7.72 (m, 1H), 7.70 (s, 1H), 7.45 (s, 1H), 7.44 - 7.38 (m, 2H), 6.28 (d, J = 3.0 Hz, 1H), 4.03 (dq, J = 10.8, 5.6, 4.5 Hz, 1H), 3.32 - 3.24 (m, 1H), 3.10 (d, J = 12.1 Hz, 2H), 2.45 (s, 3H), 2.42 - 2.37 (m, 2H), 2.09 - 1.97 (m, 4H), 1.19 (d, J = 6.8 Hz, 6H). MS (ESI) m/z: 495 [M+H]+. | |
ID-9 | 1H NMR (600 MHz, DMSO-d 6) δ 11.35 (s, 1H), 8.97 - 8.67 (m, 1H), 8.02 (dd, J = 19.5, 8.5 Hz, 2H), 7.89 (dd, J = 8.0, 1.6 Hz, 1H), 7.79 - 7.73 (m, 1H), 7.51 (d, J = 3.3 Hz, 1H), 7.43 (t, J = 7.7 Hz, 1H), 7.02 (s, 1H), 6.59 (d, J = 2.6 Hz, 1H), 6.31 (dd, J = 8.7, 2.6 Hz, 1H), 6.24 (d, J = 2.9 Hz, 1H), 4.58 (s, 2H), 3.80 (s, 3H), 3.57 - 3.52 (m, 2H), 3.34 - 3.28 (m, 1H), 2.75 - 2.66 (m, 2H), 2.61 (td, J = 12.2, 2.5 Hz, 2H), 1.96 (d, J = 12.2 Hz, 2H), 1.74 (s, 4H), 1.60 - 1.52 (m, 2H), 1.10 (d, J = 6.8 Hz, 6H). MS (ESI) m/z: 590 [M+H]+. | |
ID-10 | 1H NMR (600 MHz, DMSO-d 6) δ 11.39 (s, 1H), 8.95 (s, 1H), 8.66 (s, 1H), 8.58 (ddd, J = 4.8, 1.8, 0.9 Hz, 1H), 8.01 (d, J = 8.2 Hz, 1H), 7.88 (dd, J = 8.0, 1.6 Hz, 1H), 7.83 (td, J = 7.7, 1.8 Hz, 1H), 7.74 (ddd, J = 8.4, 7.3, 1.6 Hz, 1H), 7.56 - 7.51 (m, 3H), 7.49 (dt, J = 7.8, 1.0 Hz, 1H), 7.45 - 7.41 (m, 1H), 7.34 (ddd, J = 7.5, 4.8, 1.1 Hz, 1H), 6.81 - 6.76 (m, 2H), 6.25 (dd, J = 2.9, 1.7 Hz, 1H), 5.09 (s, 2H), 1.09 (d, J = 6.8 Hz, 6H). MS (ESI) m/z: 515 [M+H]+. | |
ID-11 | 1H NMR (600 MHz, DMSO-d 6) δ 11.34 (s, 1H), 8.85 (s, 1H), 8.01 (dd, J = 12.9, 8.4 Hz, 2H), 7.88 (dd, J = 8.0, 1.6 Hz, 1H), 7.81 - 7.69 (m, 1H), 7.51 (s, 1H), 7.43 (t, J = 7.7 Hz, 1H), 7.07 - 6.98 (m, 1H), 6.58 (d, J = 2.5 Hz, 1H), 6.31 (dd, J = 8.8, 2.6 Hz, 1H), 6.27 - 6.21 (m, 1H), 3.80 (s, 3H), 3.79 - 3.74 (m, 1H), 3.61 - 3.55 (m, 2H), 2.57 (td, J = 12.2, 2.5 Hz, 2H), 2.23 (s, 6H), 1.87 - 1.81 (m, 2H), 1.50 (qd, J = 12.0, 4.0 Hz, 2H), 1.10 (d, J = 6.8 Hz, 6H). MS (ESI) m/z: 564 [M+H]+. | |
ID-12 | 1H NMR (600 MHz, Methanol-d 4) δ 7.99 - 7.96 (m, 2H), 7.85 (d, J = 8.1 Hz, 1H), 7.77 (td, J = 7.7, 1.5 Hz, 1H), 7.62 (dd, J = 7.6, 2.8 Hz, 2H), 7.57 (td, J = 7.7, 1.2 Hz, 1H), 6.85 (d, J = 9.3 Hz, 1H), 6.43 (d, J = 3.0 Hz, 1H), 4.00 (dt, J = 13.7, 4.6 Hz, 2H), 3.90 (hept, J = 8.5, 4.0 Hz, 1H), 3.24 (ddd, J = 11.8, 4.9, 2.6 Hz, 2H), 1.98 - 1.92 (m, 2H), 1.55 (dtd, J = 13.1, 9.3, 3.8 Hz, 2H), 1.12 (d, J = 6.8 Hz, 6H). MS (ESI) m/z: 508 [M+H]+. | |
ID-13 | 1H NMR (600 MHz, DMSO-d 6) δ 11.34 (d, J = 3.1 Hz, 1H), 8.82 (s, 1H), 8.51 (s, 1H), 8.43 (d, J = 2.7 Hz, 1H), 8.06 (dd, J = 8.2, 1.1 Hz, 1H), 7.96 (dd, J = 9.1, 2.7 Hz, 1H), 7.87 (dd, J = 8.0, 1.6 Hz, 1H), 7.76 (ddd, J = 8.5, 7.3, 1.6 Hz, 1H), 7.50 (t, J = 2.8 Hz, 1H), 7.40 (ddd, J = 8.2, 7.3, 1.2 Hz, 1H), 6.66 (d, J = 9.1 Hz, 1H), 6.24 (dd, J = 3.0, 1.5 Hz, 1H), 3.72 - 3.68 (m, 4H), 3.30 - 3.26 (m, 4H), 1.11 (d, J = 6.8 Hz, 6H). MS (ESI) m/z: 494 [M+H]+. | |
ID-14 | 1H NMR (600 MHz, DMSO-d 6) δ 11.40 (s, 1H), 9.03 (s, 1H), 8.89 (s, 1H), 8.10 (d, J = 8.3 Hz, 1H), 7.85 (d, J = 7.9 Hz, 1H), 7.66 (t, J = 7.8 Hz, 1H), 7.55 - 7.52 (m, 1H), 7.36 (t, J = 7.6 Hz, 1H), 7.19 (s, 1H), 6.91 (s, 1H), 6.24 (d, J = 3.0 Hz, 1H), 4.15 (t, J = 8.3 Hz, 2H), 3.79 (s, 3H), 3.33 - 3.32 (m, 1H), 3.26 (s, 2H), 3.09 (t, J = 8.3 Hz, 2H), 2.32 (s, 6H), 1.15 (d, J = 6.8 Hz, 6H). MS (ESI) m/z: 564 [M+H]+. | |
ID-15 | 1H NMR (600 MHz, DMSO-d 6) δ 11.40 - 11.29 (m, 1H), 9.80 (s, 1H), 8.83 (s, 1H), 8.62 (s, 1H), 7.99 (dd, J = 8.3, 1.2 Hz, 1H), 7.89 (dd, J = 8.0, 1.6 Hz, 1H), 7.78 - 7.71 (m, 1H), 7.52 (t, J = 2.9 Hz, 1H), 7.48 (d, J = 2.4 Hz, 1H), 7.47 - 7.41 (m, 1H), 7.33 (dd, J = 8.6, 2.4 Hz, 1H), 6.60 (d, J = 8.6 Hz, 1H), 6.23 (dd, J = 2.9, 1.8 Hz, 1H), 3.32 (p, J = 6.8 Hz, 1H), 2.61 (t, J = 7.5 Hz, 2H), 2.36 (dd, J = 8.5, 6.5 Hz, 2H), 1.10 (d, J = 6.8 Hz, 6H). MS (ESI) m/z: 477 [M+H]+ | |
ID-16 | TFA Salt |
1H NMR (600 MHz, DMSO-d 6) δ 12.30 - 12.17 (m, 1H), 10.49 (s, 1H), 9.33 (s, 1H), 7.99 (dd, J = 7.9, 1.5 Hz, 1H), 7.89 (td, J = 7.7, 1.6 Hz, 1H), 7.81 - 7.77 (m, 2H), 7.70 (td, J = 7.6, 1.2 Hz, 1H), 7.44 (d, J = 8.2 Hz, 1H), 7.00 (d, J = 1.7 Hz, 1H), 6.51 (dd, J = 8.2, 1.7 Hz, 1H), 6.48 (dd, J = 2.9, 2.0 Hz, 1H), 4.53 (s, 2H), 3.84 (s, 3H), 3.53 (d, J = 49.5 Hz, 4H), 3.29 (p, J = 6.8 Hz, 1H), 3.11 (d, J = 70.3 Hz, 6H), 2.84 (s, 3H), 2.54 (s, 1H), 1.93 (d, J = 45.7 Hz, 2H), 1.51 (s, 2H), 1.00 (d, J = 6.7 Hz, 6H). MS (ESI) m/z: 647 [M+H]+. |
ID-17 | 1H NMR (600 MHz, DMSO-d 6) δ 11.46 (s, 1H), 8.96 (s, 1H), 8.38 (d, J = 9.0 Hz, 1H), 7.95 (d, J = 8.2 Hz, 1H), 7.92 (dd, J = 8.0, 1.6 Hz, 1H), 7.79 - 7.75 (m, 1H), 7.62 (s, 1H), 7.59 (d, J = 3.0 Hz, 1H), 7.47 (t, J = 7.9 Hz, 1H), 7.02 (d, J = 2.8 Hz, 1H), 6.90 - 6.87 (m, 1H), 6.34 (d, J = 3.0 Hz, 1H), 3.31 - 3.27 (m, 1H), 2.96 (d, J = 11.4 Hz, 2H), 2.64 (dd, J = 12.5, 10.3 Hz, 2H), 2.5517 (s, 1H), 2.48 (s, 4H), 2.4105 - 2.2923 (m, 4H), 2.19 (s, 3H), 1.83 (d, J = 12.2 Hz, 2H), 1.55 - 1.46 (m, 2H), 1.09 (d, J = 6.8 Hz, 6H). MS (ESI) m/z: 673 [M+H]+ | |
ID-18 | TFA Salt |
1H NMR (600 MHz, Methanol-d 4) δ 8.01 - 7.93 (m, 2H), 7.86 (s, 1H), 7.72 (t, J = 7.1 Hz, 1H), 7.67 (d, J = 2.8 Hz, 1H), 7.54 (t, J = 7.3 Hz, 1H), 7.24 (dd, J = 13.4, 5.6 Hz, 1H), 7.13 (d, J = 7.4 Hz, 1H), 6.47 (d, J = 2.9 Hz, 1H), 6.44 (d, J = 10.0 Hz, 1H), 6.39 (d, J = 1.6 Hz, 1H), 5.82 (dd, J = 10.0, 1.7 Hz, 1H), 3.28 - 3.21 (m, 1H), 1.28 (d, J = 6.8 Hz, 1H), 1.16 (d, J = 6.8 Hz, 6H). MS (ESI) m/z: 477 [M+H]+. |
ID-19 | 1H NMR (600 MHz, DMSO-d 6) δ 11.39 (s, 1H), 9.49 (s, 1H), 8.89 (s, 1H), 8.77 (s, 1H), 8.15 (d, J = 8.2 Hz, 1H), 7.89 (dd, J = 8.0, 1.6 Hz, 1H), 7.80 (t, J = 1.8 Hz, 1H), 7.78 - 7.73 (m, 1H), 7.56 - 7.50 (m, 2H), 7.43 - 7.39 (m, 1H), 7.12 (d, J = 8.8 Hz, 1H), 7.03 (t, J = 8.1 Hz, 1H), 6.29 (dd, J = 2.8, 1.7 Hz, 1H), 4.04 (q, J = 7.1 Hz, 1H), 3.67 - 3.61 (m, 4H), 3.12 (s, 2H), 2.00 (s, 2H), 1.18 (d, J = 7.1 Hz, 1H), 1.14 (d, J = 6.8 Hz, 6H). MS (ESI) m/z: 550 [M+H]+. | |
ID-20 | 1H NMR (600 MHz, DMSO-d 6) δ 9.52 (s, 1H), 8.78 (s, 1H), 8.13 (d, J = 8.1 Hz, 1H), 7.96 (s, 2H), 7.89 (dd, J = 8.0, 1.6 Hz, 1H), 7.79 (t, J = 1.8 Hz, 1H), 7.77 - 7.73 (m, 1H), 7.55 (s, 1H), 7.51 (dd, J = 8.2, 1.1 Hz, 1H), 7.44 - 7.39 (m, 1H), 7.15 - 7.11 (m, 1H), 7.03 (t, J = 8.1 Hz, 1H), 6.29 (d, J = 2.8 Hz, 1H), 3.16 (s, 2H), 2.89 (s, 4H), 2.74 (d, J = 0.5 Hz, 4H), 2.40 (s, 3H), 1.23 (s, 1H), 1.13 (d, J = 6.8 Hz, 6H). MS (ESI) m/z: 563 [M+H]+. | |
ID-21 | 1H NMR (600 MHz, DMSO-d 6) δ 11.41 (s, 1H), 9.42 (s, 1H), 8.90 (s, 1H), 8.75 (s, 1H), 8.13 (d, J = 8.2 Hz, 1H), 7.88 (dd, J = 8.0, 1.6 Hz, 1H), 7.79 - 7.70 (m, 2H), 7.54 (s, 1H), 7.51 (dd, J = 8.2, 1.0 Hz, 1H), 7.43 - 7.39 (m, 1H), 7.15 - 7.11 (m, 1H), 7.03 (t, J = 8.1 Hz, 1H), 6.28 (d, J = 2.9 Hz, 1H), 3.08 (s, 2H), 2.27 (s, 8H), 1.77 (s, 1H), 1.23 (s, 6H), 1.19 - 1.15 (m, 1H), 1.13 (d, J = 6.8 Hz, 6H). MS (ESI) m/z: 591 [M+H]+. | |
ID-22 | 1H NMR (600 MHz, DMSO-d 6) δ 11.44 (s, 1H), 9.53 (s, 1H), 8.94 (s, 1H), 8.74 (s, 1H), 8.12 (d, J = 8.2 Hz, 1H), 7.89 (dd, J = 8.0, 1.5 Hz, 1H), 7.78 (s, 1H), 7.77 - 7.72 (m, 1H), 7.54 (t, J = 2.6 Hz, 1H), 7.51 (d, J = 8.1 Hz, 1H), 7.42 (t, J = 7.7 Hz, 1H), 7.10 (d, J = 8.0 Hz, 1H), 7.02 (t, J = 8.1 Hz, 1H), 6.29 (s, 1H), 4.12 (s, 1H), 3.17 (d, J = 17.1 Hz, 8H), 2.55 (s, 1H), 2.21 (dd, J = 19.8, 8.5 Hz, 2H), 1.99 (d, J = 10.4 Hz, 2H), 1.91 (d, J = 18.0 Hz, 4H), 1.76 (d, J = 9.9 Hz, 2H), 1.14 (d, J = 6.8 Hz, 6H). MS (ESI) m/z: 617 [M+H]+. | |
ID-23 | 1H NMR (600 MHz, DMSO-d 6) δ 12.10 (s, 1H), 10.59 (s, 1H), 10.29 (s, 1H), 9.87 (s, 1H), 7.98 (d, J = 8.2 Hz, 1H), 7.91 - 7.82 (m, 2H), 7.77 (s, 1H), 7.68 (d, J = 7.6 Hz, 1H), 7.39 (s, 1H), 7.23 (d, J = 8.0 Hz, 2H), 6.93 (t, J = 8.0 Hz, 1H), 6.40 (s, 1H), 3.18 (s, 2H), 2.79 (s, 3H), 2.54 - 2.48 (m, 12H), 1.99 (d, J = 11.7 Hz, 2H), 1.75 (d, J = 12.2 Hz, 2H), 1.24 (s, 1H), 1.02 (d, J = 6.7 Hz, 6H). MS (ESI) m/z: 646 [M+H]+. | |
ID-24 | TFA Salt |
1H NMR (600 MHz, DMSO-d 6) δ 11.39 (s, 1H), 10.01 (s, 1H), 8.89 (s, 1H), 8.76 (s, 1H), 8.14 (d, J = 8.1 Hz, 1H), 7.88 (dd, J = 8.0, 1.5 Hz, 1H), 7.75 (dd, J = 12.0, 5.0 Hz, 2H), 7.55 (t, J = 2.9 Hz, 1H), 7.45 (d, J = 8.2 Hz, 1H), 7.43 - 7.38 (m, 1H), 7.11 (d, J = 8.0 Hz, 1H), 7.00 (t, J = 8.1 Hz, 1H), 6.30 (dd, J = 2.9, 1.9 Hz, 1H), 4.38 (d, J = 4.2 Hz, 1H), 3.78 (dtd, J = 12.2, 6.1, 4.2 Hz, 1H), 1.13 (d, J = 6.8 Hz, 6H), 0.81 - 0.74 (m, 4H). MS (ESI) m/z: 491 [M+H]+. |
ID-25 | 1H NMR (600 MHz, DMSO-d 6) δ 11.80 (s, 1H), 9.71 (s, 1H), 9.46 (s, 1H), 7.96 - 7.92 (m, 2H), 7.85 (td, J = 7.8, 1.5 Hz, 1H), 7.65 (s, 1H), 7.57 (t, J = 7.6 Hz, 1H), 6.75 (t, J = 7.9 Hz, 1H), 6.68 - 6.60 (m, 2H), 6.33 (d, J = 2.5 Hz, 1H), 6.21 (dd, J = 7.9, 1.1 Hz, 1H), 3.31 - 3.28 (m, 1H), 1.07 (d, J = 6.8 Hz, 6H). MS (ESI) m/z: 423 [M+H]+. | |
ID-26 | 1H NMR (600 MHz, DMSO-d 6) δ 11.36 (s, 1H), 9.72 (s, 1H), 8.84 (s, 1H), 8.77 (s, 1H), 8.11 (d, J = 8.3 Hz, 1H), 7.87 (d, J = 8.0 Hz, 1H), 7.75 (dd, J = 15.4, 7.0 Hz, 2H), 7.53 (t, J = 2.9 Hz, 1H), 7.45 (d, J = 0.6 Hz, 1H), 7.40 (t, J = 7.7 Hz, 1H), 7.08 (d, J = 8.8 Hz, 1H), 7.04 - 6.96 (m, 2H), 6.28 (s, 1H), 3.70 (d, J = 6.1 Hz, 2H), 3.31 (d, J = 6.3 Hz, 1H), 1.39 (s, 9H), 1.12 (d, J = 6.8 Hz, 6H). MS (ESI) m/z: 580 [M+H]+. | |
ID-27 | 1H NMR (600 MHz, DMSO-d 6) δ 11.37 (s, 1H), 9.78 (s, 1H), 8.86 (s, 1H), 8.76 (s, 1H), 8.17 (t, J = 5.7 Hz, 1H), 8.11 (d, J = 7.9 Hz, 1H), 7.87 (dd, J = 8.0, 1.4 Hz, 1H), 7.77 - 7.72 (m, 2H), 7.53 (t, J = 2.9 Hz, 1H), 7.46 (d, J = 7.4 Hz, 1H), 7.40 (t, J = 7.2 Hz, 1H), 7.10 (d, J = 7.9 Hz, 1H), 7.00 (t, J = 8.1 Hz, 1H), 6.30 - 6.26 (m, 1H), 4.36 (d, J = 4.2 Hz, 1H), 3.85 (d, J = 5.9 Hz, 2H), 1.88 (s, 3H), 1.12 (d, J = 6.8 Hz, 6H). MS (ESI) m/z: 522 [M+H]+. | |
ID-28 | 1H NMR (600 MHz, DMSO-d 6) δ 11.39 (s, 1H), 9.82 (s, 1H), 8.79 (s, 2H), 8.10 (d, J = 8.2 Hz, 1H), 7.88 (d, J = 7.9 Hz, 1H), 7.76 (dd, J = 17.6, 9.8 Hz, 2H), 7.54 (d, J = 2.8 Hz, 1H), 7.47 (d, J = 8.1 Hz, 1H), 7.41 (t, J = 7.6 Hz, 1H), 7.15 (d, J = 7.7 Hz, 1H), 7.02 (t, J = 8.1 Hz, 1H), 6.27 (d, J = 2.9 Hz, 1H), 3.41 (s, 2H), 3.32 - 3.31 (m, 1H), 1.12 (d, J = 6.8 Hz, 6H). MS (ESI) m/z: 480 [M+H]+. | |
ID-29 | 1H NMR (600 MHz, DMSO-d 6) δ 11.35 (s, 1H), 9.79 (s, 1H), 8.87 (s, 1H), 8.72 (s, 1H), 8.14 (d, J = 8.4 Hz, 1H), 7.88 - 7.84 (m, 1H), 7.76 (d, J = 15.1 Hz, 2H), 7.53 (dd, J = 6.7, 4.0 Hz, 2H), 7.47 (d, J = 8.3 Hz, 1H), 7.39 (t, J = 7.8 Hz, 1H), 7.36 (d, J = 4.3 Hz, 3H), 7.31 (dd, J = 8.8, 4.5 Hz, 1H), 7.11 (d, J = 8.1 Hz, 1H), 7.00 (t, J = 8.1 Hz, 1H), 6.28 (s, 1H), 5.06 - 4.97 (m, 2H), 4.38 (d, J = 4.2 Hz, 1H), 4.22 (t, J = 7.2 Hz, 1H), 3.33 - 3.28 (m, 1H), 1.28 (d, J = 7.1 Hz, 3H), 1.12 (d, J = 6.8 Hz, 6H). MS (ESI) m/z: 628 [M+H]+. | |
ID-30 | 1H NMR (600 MHz, DMSO-d 6) δ 11.38 (s, 1H), 9.63 (s, 1H), 8.79 (d, J = 79.9 Hz, 2H), 8.12 (d, J = 8.0 Hz, 1H), 7.88 (dd, J = 8.0, 1.6 Hz, 1H), 7.76 - 7.74 (m, 2H), 7.53 (d, J = 3.0 Hz, 1H), 7.47 (dd, J = 8.3, 1.2 Hz, 1H), 7.42 - 7.39 (m, 1H), 7.18 - 7.15 (m, 1H), 7.01 (t, J = 8.1 Hz, 1H), 6.28 (d, J = 2.9 Hz, 1H), 3.77 (dt, J = 12.2, 6.1 Hz, 1H), 3.46 - 3.43 (m, 1H), 1.22 (d, J = 6.9 Hz, 3H), 1.12 (d, J = 6.8 Hz, 6H). MS (ESI) m/z: 494 [M+H]+. | |
ID-31 | MS (ESI) m/z: 522 [M+H]+. | |
IE -1 | MS (ESI) m/z: 606 [M+H]+. | |
IE -2 | TFA salt | 1H-NMR (600 MHz; Methanol-d 4): δ 8.41 (d, J = 8.4 Hz, 1H), 7.87 (d, J = 7.9 Hz, 1H), 7.71 - 7.68 (m, 1H), 7.64 (tt, J = 4.2, 2.1 Hz, 2H), 7.56 (d, J = 9.0 Hz, 2H), 7.49 (td, J = 7.8, 1.5 Hz, 1H), 7.42-7.39 (m, 2H), 6.55 (d, J = 2.9 Hz, 1H), 6.47 (d, J = 3.0 Hz, 1H), 4.08 (t, J = 3.5 Hz, 1H), 3.78 - 3.74 (m, 2H), 3.52-3.49 (m, 2H), 2.95 (s, 3H), 2.25 - 2.21 (m, 2H), 2.02-1.99 (m, 2H). MS (ESI) m/z: 494 [M+H]+. |
IE -3 | MS (ESI) m/z: 482 [M+H]+. | |
IE -4 | 1H NMR (600 MHz, DMSO-d 6) δ 10.99 (d, J = 4.0 Hz, 1H), 8.61 (s, 1H), 8.37 (s, 1H), 7.85 (dd, J = 8.0, 1.5 Hz, 1H), 7.61 - 7.55 (m, 2H), 7.47 (d, J = 2.9 Hz, 1H), 7.44 (dd, J = 8.0, 1.5 Hz, 1H), 7.29 (td, J = 7.7, 1.6 Hz, 1H), 7.21 (td, J = 7.7, 1.5 Hz, 1H), 6.81 - 6.75 (m, 2H), 6.21 (d, J = 2.9 Hz, 1H), 3.17 (s, 1H), 3.04 - 2.99 (m, 4H), 2.93 (s, 3H), 2.47 (t, J = 5.0 Hz, 4H), 2.23 (s, 3H). MS (ESI) m/z: 493 [M+H]+. | |
IE -5 | TFA salt | 1H-NMR (600 MHz; Methanol-d 4): δ 7.72 (dd, J = 7.9, 1.4 Hz, 1H), 7.62 - 7.60 (m, 1H), 7.59-7.57 (m, 1H), 7.44 (td, J = 7.8, 1.5 Hz, 1H), 7.37 (ddt, J = 7.3, 4.1, 1.9 Hz, 3H), 7.15-7.13 (m, 1H), 7.12 (d, J = 4.8 Hz, 1H), 6.41 (d, J = 3.0 Hz, 1H), 3.94 (dd, J = 5.7, 3.9 Hz, 4H), 3.89 (t, J = 4.8 Hz, 2H), 3.27-3.25 (m, 2H), 2.95 (s, 3H). MS (ESI) m/z: 480 [M+H]+. |
IE -6 | TFA salt | 1H-NMR (600 MHz; Methanol-d 4): δ 7.76 (dd, J = 7.9, 1.4 Hz, 1H), 7.58 - 7.56 (m, 2H), 7.41 (td, J = 7.7, 1.6 Hz, 1H), 7.38-7.35 (m, 2H), 6.79 (d, J = 2.5 Hz, 1H), 6.56 (dd, J = 8.7, 2.5 Hz, 1H), 6.36 (d, J = 3.0 Hz, 1H), 3.91 (t, J = 4.8 Hz, 4H), 3.86 (s, 3H), 3.28-3.27 (m, 4H), 2.98 (s, 3H). MS (ESI) m/z: 510 [M+H]+. |
IF-1 | 1H NMR (600 MHz, DMSO-d 6) δ 10.80 (s, 1H), 10.73 (s, 1H), 8.35 (dd, J = 8.4, 4.0 Hz, 1H), 8.11 (d, J = 8.7 Hz, 1H), 7.62 (ddd, J = 13.9, 7.8, 1.7 Hz, 1H), 7.53 (t, J = 7.8 Hz, 1H), 7.41 - 7.37 (m, 1H), 7.16 (t, J = 7.2 Hz, 1H), 7.07 (s, 1H), 6.60 (d, J = 2.5 Hz, 1H), 6.44 (dd, J = 8.8, 2.5 Hz, 1H), 6.21 (d, J = 2.8 Hz, 1H), 3.82 (s, 3H), 3.76 (d, J = 6.3 Hz, 1H), 3.65 - 3.56 (m, 2H), 2.59 (td, J = 12.3, 2.5 Hz, 2H), 2.37 - 2.22 (m, 4H), 2.14 (s, 3H), 1.83 (d, J = 13.2 Hz, 2H), 1.80 (d, J = 13.5 Hz, 6H), 1.52 (qd, J = 12.0, 3.9 Hz, 2H), 1.27 - 1.12 (m, 2H), 1.04 (d, J = 6.1 Hz, 2H). MS (ESI) m/z: 589 [M+H]+ . | |
IF-2 | 1H NMR (600 MHz, DMSO-d 6) δ 10.91 (s, 1H), 10.61 (s, 1H), 8.52 (dd, J = 8.5, 4.0 Hz, 1H), 8.46 (s, 1H), 7.62 (dd, J = 22.4, 8.2 Hz, 3H), 7.55 (t, J = 7.9 Hz, 1H), 7.39 (t, J = 2.7 Hz, 1H), 7.16 (t, J = 7.5 Hz, 1H), 6.84 (d, J = 8.5 Hz, 2H), 6.24 - 6.20 (m, 1H), 3.59 (tt, J = 9.0, 4.2 Hz, 1H), 3.43 - 3.38 (m, 2H), 2.77 - 2.69 (m, 2H), 1.85 (d, J = 5.0 Hz, 2H), 1.82 (d, J = 13.4 Hz, 6H), 1.55 - 1.48 (m, 2H). MS (ESI) m/z: 477 [M+H]+ . | |
IF-3 | 1H NMR (600 MHz, DMSO-d 6) δ 10.61 (d, J = 62.9 Hz, 2H), 8.48 (s, 1H), 8.34 (s, 1H), 7.81 (d, J = 14.9 Hz, 1H), 7.70 - 7.63 (m, 1H), 7.56 (t, J = 7.8 Hz, 1H), 7.42 - 7.35 (m, 2H), 7.20 (t, J = 7.4 Hz, 1H), 6.19 (d, J = 2.9 Hz, 1H), 3.77 (p, J = 6.1 Hz, 1H), 2.90 (d, J = 11.4 Hz, 2H), 2.25 (s, 3H), 2.15 - 2.08 (m, 2H), 1.94 - 1.85 (m, 4H), 1.78 (d, J = 13.3 Hz, 6H). MS (ESI) m/z: 465 [M+H]+. | |
IF-4 | 1H NMR (600 MHz, DMSO-d 6) δ 10.90 (s, 1H), 10.59 (s, 1H), 8.56 - 8.50 (m, 1H), 8.45 (s, 1H), 7.66 - 7.57 (m, 3H), 7.54 (ddt, J = 8.6, 7.3, 1.2 Hz, 1H), 7.38 (dd, J = 2.9, 1.4 Hz, 1H), 7.18 - 7.12 (m, 1H), 6.85 - 6.79 (m, 2H), 6.21 (d, J = 2.9 Hz, 1H), 3.05 - 3.00 (m, 4H), 2.47 (t, J = 5.0 Hz, 4H), 2.23 (s, 3H), 1.81 (d, J = 13.4 Hz, 6H). MS (ESI) m/z: 476 [M+H]+ . | |
IF-5 | 1H NMR (600 MHz, DMSO-d 6) δ 10.84 (s, 1H), 10.71 (s, 1H), 8.34 (dd, J = 8.4, 4.0 Hz, 1H), 8.12 (d, J = 8.7 Hz, 1H), 7.68 - 7.57 (m, 1H), 7.54 (t, J = 7.9 Hz, 1H), 7.39 (t, J = 2.7 Hz, 1H), 7.19 - 7.13 (m, 1H), 7.09 (s, 1H), 6.62 (d, J = 2.6 Hz, 1H), 6.44 (dd, J = 8.7, 2.6 Hz, 1H), 6.21 (d, J = 2.9 Hz, 1H), 3.83 (s, 3H), 3.33 (s, 4H), 3.14 - 3.04 (m, 4H), 2.25 (s, 3H), 1.80 (d, J = 13.4 Hz, 6H). MS (ESI) m/z: 506 [M+H]+. | |
IF-6 | 1H NMR (600 MHz, DMSO-d 6) δ 10.82 (s, 1H), 10.70 (s, 1H), 8.34 (dd, J = 8.5, 4.1 Hz, 1H), 8.11 (d, J = 8.7 Hz, 1H), 7.65 - 7.60 (m, 1H), 7.54 (t, J = 7.8 Hz, 1H), 7.39 (t, J = 2.8 Hz, 1H), 7.16 (td, J = 7.7, 6.6, 1.9 Hz, 1H), 7.06 (s, 1H), 6.62 (d, J = 2.5 Hz, 1H), 6.45 (dd, J = 8.8, 2.5 Hz, 1H), 6.23 - 6.19 (m, 1H), 3.83 (s, 3H), 3.67 - 3.58 (m, 2H), 2.61 (td, J = 12.1, 2.4 Hz, 2H), 2.51 (s, 1H), 2.26 (s, 6H), 1.86 (d, J = 12.3 Hz, 2H), 1.80 (d, J = 13.4 Hz, 6H), 1.53 (qd, J = 12.2, 4.1 Hz, 2H). MS (ESI) m/z: 534 [M+H]+. |
실시예 2.
화합물 IG의 합성 화학식.
화합물 4의 제조.
화합물 1(435mg, 2.3mmol), 메틸 o-아미노벤조에이트(419mg, 2.7mmol)를 10mL의 tert-부탄올 속에 용해시킨 후, 그 용액 속에 트리플루오로 아세트산(0.256mL, 3.45mmol)을 첨가한다. 생성된 반응액을 화합물 1이 완전히 반을할 때까지(LC-MS 추적) 85℃로 예열된 오일 배스에 놓고 가열 교반한다. 반응이 증지되면, 반응액에 포화 중탄산 나트륨 용액 40mL를 넣고 액체를 분리하며, 유기상은 포화 염화나트륨 용액으로 2회 세척, 무수 황산나트륨 건조, 실리카 겔 칼럼 크로마토그래피 농축(디클로로메테인/메탄올=1/25)으로 화합물 4(백색 고체, 424mg, 수득률 61%)를 얻어서 다음 반응에 직접 사용한다.
MS (ESI) m/z: 303 [M+H]+.
화합물 IG의 제조.
방법 A.
화합물 4(30.3mg, 0.1mmol), 아닐린(0.1mmol)을 1mL의 tert-부탄올에 용해시킨 후, 그 용액 속에 트리플루오로 아세트산(45μL, 0.6mmol)을 첨가한다. 생성된 반응액을 아닐린이 완전히 반응할 때까지(LC-MS 추적) 110℃로 예열된 오일 배스에 놓고 가열 교반한다. 반응이 중지되면, 반응액에 포화 중탄산 나트륨 용액 10mL를 넣고 액체를 분리하며, 유기상은 포화 염화나트륨 용액으로 2회 세척, 무수 황산나트륨 건조, 실리카 겔 칼럼 크로마토 농축(디클로로메테인/메탄올)으로 화합물 IH를 얻는다.
방법 B.
화합물 4(10.0mg, 0.03mmol), 아닐린(0.03mmol)을 1mL의 tert-부탄올에 용해시킨 후, 그 용액 속에 4N HCL용액(16.5μL)을 첨가한다. 생성된 반응액을 아닐린이 완전히 반응할 때까지(LC-MS 추적) 110℃로 예열된 오일 배스에 놓고 가열 교반한다. 반응이 중지되면, 농축시켜 역상 제조형 HPLC 정제를 거치고(0.35% 트리플루오로 아세트산을 포함한 수용액과 메탄올이 이동상), 진공 농축시켜 화합물 IH를 얻는다.
방법 C.
화합물 4(25.0mg, 0.08mmol), 아닐린(0.08mmol)을 1mL의 tert-부탄올에 용해시킨 후에, 그 용액 속에 트리플루오로 아세트산(36.8μL, 0.24mmol)을 첨가한다. 생성된 반응액을 아닐린이 완전히 반응할 때까지(LC-MS 추적) 110℃로 예열된 오일 배스에 놓고 가열 교반한다. 반응이 중지되면, 농축시켜 역상 제조형 HPLC 정제를 거치고(0.35% 트리플루오로 아세트산을 포함한 수용액과 메탄올이 이동상), 진공 농축시켜 화합물 IH를 얻는다.
화합물 IH, II, IJ, IK는 모두 유사한 방법을 사용해 합성할 수 있다.
번호 | 구조 | 핵 자기 공명 분광법 및/또는 질량 분석 데이터 |
IG-1 | MS (ESI) m/z: 488 [M+H]+. | |
IG-2 | 1H-NMR (600 MHz; Methanol-d 4): δ 8.63 (d, J = 8.4 Hz, 1H), 8.05 - 8.04 (m, 1H), 7.90 (d, J = 8.6 Hz, 1H), 7.52 - 7.49 (m, 1H), 7.42 (d, J = 3.0 Hz, 1H), 7.10 - 7.07 (m, 1H), 6.64 (d, J = 2.3 Hz, 1H), 6.49 (dd, J = 8.8, 2.1 Hz, 1H), 6.29 (d, J = 3.0 Hz, 1H), 3.95 (s, 3H), 3.86 (d, J = 3.7 Hz, 3H), 3.63-3.61 (m, 2H), 3.46 - 3.42 (m, 1H), 2.65-2.61 (m, 10H), 2.33 (s, 3H), 1.96 (d, J = 12.1 Hz, 2H), 1.66 - 1.62 (m, 2H). MS (ESI) m/z: 571 [M+H]+. | |
IG-3 | 1H-NMR (600 MHz; Methanol-d 4): δ 8.76 (d, J = 8.5 Hz, 1H), 8.05 (dd, J = 8.0, 1.6 Hz, 1H), 7.50 (td, J = 7.9, 1.4 Hz, 1H), 7.45 (d, J = 8.8 Hz, 2H), 7.41 (d, J = 3.0 Hz, 1H), 7.09 - 7.06 (m, 1H), 6.98 (d, J = 8.5 Hz, 2H), 6.30 (d, J = 3.0 Hz, 1H), 3.97 (s, 3H), 3.76 (dt, J = 8.9, 4.6 Hz, 1H), 3.50 - 3.46 (m, 2H), 2.87 - 2.84 (m, 2H), 2.02 - 1.99 (m, 2H), 1.72 (dtd, J = 12.9, 9.7, 3.3 Hz, 2H). MS (ESI) m/z: 459 [M+H]+. | |
IG-4 | TFA salt | 1H-NMR (600 MHz; Methanol-d 4): δ 8.17 - 8.13 (m, 2H), 7.86 - 7.80 (m, 3H), 7.68 - 7.62 (m, 3H), 7.40 (dd, J = 8.2, 0.8 Hz, 1H), 6.49 - 6.48 (m, 1H), 3.91 (s, 3H). MS (ESI) m/z: 439 [M+H]+. |
IG-5 | 1H-NMR (600 MHz, Acetone-d 6): δ 8.99 (m, 1H), 8.06 - 8.00 (m, 2H), 7.77 - 7.75 (m, 2H), 7.53 (d, J = 41.2 Hz, 2H), 7.09 - 7.08 (m, 1H), 6.93 - 6.91 (m, 1H), 6.33 (m, 1H), 3.95 (s, 2H), 3.78 (s, 3H), 3.07 - 3.06 (m, 2H), 1.96 (s, 2H), 1.29 - 1.28 (m, 2H). MS (ESI) m/z: 445 [M+H]+. | |
IG-6 | MS (ESI) m/z: 458 [M+H]+. | |
IG-7 | 1H-NMR (600 MHz; Methanol-d 4): δ 8.65 (d, J = 8.5 Hz, 1H), 8.07 (dd, J = 8.0, 1.4 Hz, 1H), 7.98 (d, J = 8.7 Hz, 1H), 7.53 (d, J = 1.3 Hz, 1H), 7.43 (d, J = 3.0 Hz, 1H), 7.11-7.10 (m, 1H), 6.66 (d, J = 2.2 Hz, 1H), 6.51 - 6.50 (m, 1H), 6.30 (d, J = 3.0 Hz, 1H), 3.97 (s, 3H), 3.88 (s, 3H), 3.60 - 3.58 (m, 2H), 2.70 (d, J = 3.4 Hz, 3H), 2.05 - 2.03 (m, 2H), 1.84 (d, J = 2.9 Hz, 4H), 1.69-1.67 (m, 2H). MS (ESI) m/z: 542 [M+H]+. | |
IG-8 | 1H-NMR (600 MHz; Methanol-d 4): δ 8.73 (d, J = 8.5 Hz, 1H), 8.56 (d, J = 4.9 Hz, 1H), 8.02 (d, J = 8.0 Hz, 1H), 7.87 (d, J = 1.4 Hz, 1H), 7.62 (d, J = 7.8 Hz, 1H), 7.48 - 7.46 (m, 2H), 7.39-7.38 (m, 3H), 7.04 (d, J = 7.3 Hz, 1H), 6.95 - 6.93 (m, 2H), 6.29 (t, J = 2.6 Hz, 1H), 5.17 (s, 2H), 3.95 (s, 3H). MS (ESI) m/z: 467 [M+H]+. | |
IG-9 | 1H-NMR (600 MHz; Methanol-d 4): δ 8.25-8.24 (m, 1H), 8.14 (d, J = 7.8 Hz, 1H), 7.70 - 7.65 (m, 3H), 7.41 - 7.38 (m, 1H), 7.13 (t, J = 0.6 Hz, 1H), 6.92 - 6.90 (m, 1H), 6.44 (d, J = 2.8 Hz, 1H), 4.76 - 4.74 (m, 1H), 4.03 - 4.00 (m, 1H), 3.94 - 3.93 (m, 3H), 3.79 - 3.75 (m, 2H), 3.41 - 3.35 (m, 2H), 2.20 - 2.16 (m, 2H), 1.93 - 1.90 (m, 2H), 1.33 - 1.31 (m, 6H). MS (ESI) m/z: 517 [M+H]+. | |
IG-10 | 1H-NMR (600 MHz; Methanol-d 4): δ 8.26 - 8.25 (m, 1H), 8.14 (dd, J = 8.0, 1.5 Hz, 1H), 7.67 - 7.62 (m, 3H), 7.38 (t, J = 7.7 Hz, 1H), 7.06 (d, J = 0.5 Hz, 1H), 6.89 - 6.87 (m, 1H), 6.43 (d, J = 2.9 Hz, 1H), 4.16 (q, J = 7.0 Hz, 2H), 4.00 - 3.98 (m, 1H), 3.98 - 3.94 (m, 3H), 3.78 - 3.74 (m, 2H), 3.37 - 3.35 (m, 2H), 2.18 - 2.14 (m, 2H), 1.91 - 1.86 (m, 2H), 1.37 (t, J = 7.0 Hz, 3H). MS (ESI) m/z: 503 [M+H]+. | |
IG-11 | TFA salt | 1H-NMR (600 MHz; Methanol-d 4): δ 8.09 - 8.05 (m, 2H), 7.92 (d, J = 8.8 Hz, 1H), 7.80 (d, J = 8.8 Hz, 1H), 7.67 (t, J = 4.3 Hz, 2H), 7.60 (d, J = 8.7 Hz, 2H), 7.39 (d, J = 7.6 Hz, 1H), 6.50 (d, J = 2.9 Hz, 1H), 3.88 (s, 3H), 3.67 (d, J = 3.9 Hz, 1H), 3.35 (d, J = 3.6 Hz, 2H), 2.80 (dd, J = 9.9, 6.7 Hz, 2H), 1.90 (ddd, J = 9.6, 6.3, 3.3 Hz, 2H), 1.61 (dt, J = 8.6, 4.2 Hz, 2H). MS (ESI) m/z: 523 [M+H]+. |
IG-12 | TFA salt | 1H-NMR (600 MHz; Methanol-d 4): δ 8.16 - 8.11 (m, 2H), 7.78 (d, J = 8.1 Hz, 1H), 7.67 - 7.64 (m, 2H), 7.40 - 7.37 (m, 1H), 7.15 (d, J = 1.6 Hz, 1H), 6.91 (dd, J = 8.1, 1.6 Hz, 1H), 6.46 (d, J = 3.0 Hz, 1H), 3.93 (s, 3H), 3.91 (s, 3H), 3.37 - 3.35 (m, 2H), 3.13 - 2.98 (m, 7H), 2.90 (s, 3H), 2.12 - 1.96 (m, 2H), 1.62 (dtd, J = 3.0, 1.5, 0.9 Hz, 2H). MS (ESI) m/z: 599 [M+H]+. |
IG-13 | TFA salt | 1H-NMR (600 MHz; Methanol-d 4): δ 8.23 (dd, J = 8.3, 0.7 Hz, 1H), 8.15 (dd, J = 7.9, 1.6 Hz, 1H), 7.88 (dd, J = 9.7, 2.7 Hz, 1H), 7.83 (d, J = 3.1 Hz, 1H), 7.74 (ddd, J = 8.4, 7.2, 1.4 Hz, 1H), 7.33 - 7.30 (m, 2H), 6.97 (d, J = 9.8 Hz, 1H), 6.77 - 6.72 (m, 1H), 3.98 (t, J = 0.6 Hz, 2H), 3.98 - 3.95 (m, 3H), 3.91 (s, 1H), 3.69 - 3.66 (m, 1H), 3.57 (m, 3H), 3.16 - 3.14 (m, 2H), 3.00 - 2.97 (m, 1H), 2.71 (m, 1H). MS (ESI) m/z: 459 [M+H]+. |
IG-14 | TFA salt | 1H-NMR (600 MHz; Methanol-d 4): δ 8.24 (dd, J = 3.9, 3.2 Hz, 1H), 8.09 (d, J = 7.6 Hz, 1H), 7.60 - 7.54 (m, 2H), 7.41 (s, 1H), 7.33 - 7.30 (m, 1H), 6.91 (s, 1H), 6.40 (s, 1H), 3.92 (s, 3H), 3.87 (s, 3H), 3.67 (d, J = 11.8 Hz, 2H), 3.25-3.22 (m, 2H), 3.15 (s, 1H), 2.96 (s, 3H), 2.23 (s, 3H), 2.11-2.07 (m, 4H). MS (ESI) m/z: 501 [M+H]+. |
IG-15 | TFA salt | 1H-NMR (600 MHz; Methanol-d 4): δ 8.27 (d, J = 8.2 Hz, 1H), 8.11 (d, J = 7.9 Hz, 1H), 7.62 - 7.58 (m, 2H), 7.43 (s, 1H), 7.34 (t, J = 7.6 Hz, 1H), 6.92 (s, 1H), 6.41 (d, J = 2.8 Hz, 1H), 4.65 (t, J = 6.1 Hz, 1H), 3.93 (s, 3H), 3.67 (d, J = 12.2 Hz, 2H), 3.24 - 3.22 (m, 2H), 3.15 (s, 1H), 2.96 (s, 3H), 2.06 (d, J = 2.4 Hz, 4H), 2.03 (s, 3H), 1.28 (dd, J = 5.8, 2.0 Hz, 6H). MS (ESI) m/z: 528 [M+H]+. |
IG-16 | TFA salt | 1H-NMR (600 MHz; Methanol-d 4): δ 8.39 - 8.37 (m, 1H), 8.10 - 8.09 (m, 1H), 7.56 (d, J = 2.9 Hz, 2H), 7.30 (dt, J = 14.8, 7.7 Hz, 2H), 6.73 (d, J = 2.3 Hz, 1H), 6.60 - 6.58 (m, 1H), 6.37 (d, J = 2.9 Hz, 1H), 3.96 (s, 3H), 3.89 (s, 4H), 3.84 (s, 3H), 3.23 (d, J = 4.8 Hz, 4H). MS (ESI) m/z: 475 [M+H]+. |
IG-17 | TFA salt | 1H-NMR (600 MHz; Methanol-d 4): δ 8.12 (dd, J = 15.7, 8.0 Hz, 2H), 7.77 (d, J = 8.2 Hz, 1H), 7.66 - 7.63 (m, 2H), 7.39 (t, J = 7.7 Hz, 1H), 7.16 (s, 1H), 6.91 (d, J = 8.2 Hz, 1H), 6.45 (d, J = 2.9 Hz, 1H), 3.96 (s, 1H), 3.94 (s, 3H), 3.91 (s, 3H), 3.81-3.76 (m, 4H), 3.56 - 3.51 (m, 4H). MS (ESI) m/z: 503 [M+H]+. |
IG-18 | TFA salt | 1H-NMR (600 MHz; Methanol-d 4): δ 8.20 - 8.08 (m, 3H), 7.80 (ddd, J = 18.6, 9.3, 2.6 Hz, 1H), 7.62 (dd, J = 13.9, 3.0 Hz, 1H), 7.59 - 7.51 (m, 1H), 7.34-7.27 (m, 1H), 7.09 (dd, J = 18.2, 9.4 Hz, 1H), 6.44 (dd, J = 4.0, 3.0 Hz, 1H), 4.09 - 4.07 (m, 1H), 3.93 (s, 3H), 3.38 - 3.34 (m, 2H), 2.03 - 2.00 (m, 2H), 1.63 (dq, J = 12.7, 4.1 Hz, 2H). MS (ESI) m/z: 460 [M+H]+. |
IG-19 | TFA salt | 1H-NMR (600 MHz; Methanol-d 4): δ 8.34 - 8.33 (m, 1H), 8.11 (dd, J = 8.0, 1.5 Hz, 1H), 7.59 - 7.56 (m, 2H), 7.40 (d, J = 8.5 Hz, 1H), 7.32 - 7.29 (m, 1H), 6.76 (d, J = 2.5 Hz, 1H), 6.62 (dd, J = 8.6, 2.4 Hz, 1H), 6.39 (d, J = 2.9 Hz, 1H), 4.10 (q, J = 7.0 Hz, 2H), 3.96 (s, 3H), 3.92-3.89 (m, 2H), 3.68 - 3.65 (m, 2H), 3.32 - 3.30 (m, 2H), 3.16 - 3.13 (m, 2H), 3.01 (s, 3H), 1.30 (t, J = 7.0 Hz, 3H). MS (ESI) m/z: 502 [M+H]+. |
IH-1 | TFA salt | 1H-NMR (600 MHz; Methanol-d 4): δ 8.30 - 8.28 (m, 1H), 8.12 (d, J = 8.0 Hz, 1H), 7.58 (s, 2H), 7.40 - 7.39 (m, 1H), 7.34 (t, J = 7.6 Hz, 1H), 6.81 - 6.80 (m, 1H), 6.63 - 6.61 (m, 1H), 6.39 (d, J = 2.8 Hz, 1H), 5.14 (dq, J = 12.4, 6.3 Hz, 1H), 3.97 - 3.91 (m, 2H), 3.90 (s, 3H), 3.68 - 3.62 (m, 2H), 3.17 - 3.12 (m, 2H), 3.02 (s, 3H), 2.68 (s, 2H), 1.75 - 1.66 (m, 2H), 1.32 (d, J = 6.2 Hz, 3H), 0.97 (t, J = 7.4 Hz, 3H). MS (ESI) m/z: 530 [M+H]+. |
IH-2 | TFA salt | 1H-NMR (600 MHz; Methanol-d 4): δ 8.23 - 8.22 (m, 1H), 8.13 (d, J = 8.0 Hz, 1H), 7.64 - 7.60 (m, 2H), 7.50 (d, J = 8.6 Hz, 1H), 7.37 (m, 1H), 6.96 (s, 1H), 6.77 - 6.75 (m, 1H), 6.41 - 6.40 (m, 1H), 5.11 (m, 1H), 3.90 - 3.87 (m, 5H), 3.47 - 3.38 (m, 3H), 3.17 - 3.13 (m, 8H), 2.92 (s, 3H), 2.22 - 2.19 (m, 2H), 1.98 - 1.91 (m, 2H), 1.72 - 1.63 (m, 2H), 1.30 (d, J = 6.3 Hz, 3H), 0.95 (t, J = 7.4 Hz, 3H). MS (ESI) m/z: 501 [M+H]+. |
IH-3 | TFA salt | 1H-NMR (600 MHz; Methanol-d 4): δ 8.23 - 8.22 (m, 1H), 8.13 (d, J = 8.0 Hz, 1H), 7.64 - 7.60 (m, 2H), 7.50 (d, J = 8.6 Hz, 1H), 7.37 (m, 1H), 6.96 (s, 1H), 6.77 - 6.75 (m, 1H), 6.41 - 6.40 (m, 1H), 5.11 (qd, J = 6.2, 0.4 Hz, 1H), 3.90 - 3.87 (m, 5H), 3.47 - 3.38 (m, 3H), 3.17 - 3.13 (m, 8H), 2.92 (s, 3H), 2.22 - 2.19 (m, 2H), 1.98 - 1.91 (m, 2H), 1.72 - 1.63 (m, 2H), 1.30 (d, J = 6.3 Hz, 3H), 0.95 (t, J = 7.4 Hz, 3H). MS (ESI) m/z: 613 [M+H]+. |
IH-4 | TFA salt | 1H-NMR (600 MHz; Methanol-d 4): δ 8.13 - 8.12 (m, 1H), 7.68 - 7.57 (m, 4H), 7.34 - 7.32 (m, 2H), 6.77 (m, 1H), 6.63 - 6.62 (m, 1H), 6.38 (m, 1H), 5.16 - 5.13 (m, 1H), 3.98 (s, 1H), 3.95 - 3.92 (m, 2H), 3.86 (s, 3H), 3.74 - 3.71 (m, 2H), 3.21 (m, 2H), 2.91 - 2.86 (m, 2H), 2.32 - 2.29 (m, 2H), 2.22 - 2.20 (m, 2H), 2.08 - 2.04 (m, 2H), 1.92 - 1.85 (m, 2H), 1.76 - 1.67 (m, 2H), 1.33 (d, J = 6.3 Hz, 3H), 0.98 (t, J = 7.5 Hz, 3H). MS (ESI) m/z: 613 [M+H]+. |
II-1 | TFA salt | 1H-NMR (600 MHz; Methanol-d 4): δ 8.32 (s, 1H), 8.08 - 8.07 (m, 1H), 7.85 (d, J = 7.8 Hz, 1H), 7.57 (d, J = 3.0 Hz, 1H), 7.49 - 7.44 (m, 2H), 6.80 (d, J = 2.5 Hz, 1H), 6.61 - 6.59 (m, 1H), 6.36 (d, J = 2.9 Hz, 1H), 3.93 (s, 3H), 3.88 (s, 3H), 3.69 - 3.66 (m, 2H), 3.17 - 3.12 (m, 2H), 3.02 (s, 3H). MS (ESI) m/z: 488 [M+H]+. |
II-2 | TFA salt | 1H-NMR (600 MHz; Methanol-d 4): δ 8.29 (s, 1H), 8.03 (dd, J = 8.2, 1.0 Hz, 1H), 7.86 (d, J = 7.8 Hz, 1H), 7.62 (d, J = 8.6 Hz, 1H), 7.61 - 7.58 (m, 1H), 7.49 (t, J = 7.9 Hz, 1H), 7.02 (d, J = 2.0 Hz, 1H), 6.78 (dd, J = 8.7, 2.4 Hz, 1H), 6.38 (d, J = 3.0 Hz, 1H), 3.92 (s, 3H), 3.91 (s, 3H), 3.90 - 3.88 (m, 2H), 3.55 (d, J = 0.5 Hz, 4H), 3.41 - 3.37 (m, 4H), 3.23 (dd, J = 21.4, 9.6 Hz, 3H), 2.98 (s, 3H), 2.27 (dd, J = 12.3, 0.5 Hz, 2H), 2.03 (tt, J = 12.1, 6.1 Hz, 2H). MS (ESI) m/z: 571 [M+H]+. |
II-3 | TFA salt | 1H-NMR (600 MHz; Methanol-d 4): δ 8.31 (s, 1H), 7.97 (dd, J = 8.1, 0.4 Hz, 1H), 7.93 - 7.92 (m, 1H), 7.65 (t, J = 3.9 Hz, 3H), 7.55 (t, J = 7.9 Hz, 1H), 7.46 - 7.44 (m, 2H), 6.47 (d, J = 2.9 Hz, 1H), 4.07 - 4.06 (m, 1H), 3.93 (s, 3H), 3.79 - 3.78 (m, 2H), 3.48 - 3.44 (m, 2H), 2.23 - 2.18 (m, 2H), 1.99 - 1.95 (m, 2H). MS (ESI) m/z: 459 [M+H]+. |
II-4 | TFA salt | 1H-NMR (600 MHz; Methanol-d 4): δ 8.29 (s, 1H), 8.04 - 8.03 (m, 1H), 7.85 (d, J = 7.7 Hz, 1H), 7.58 (d, J = 3.0 Hz, 1H), 7.47 (t, J = 7.9 Hz, 1H), 7.41 - 7.39 (m, 2H), 7.05 (d, J = 8.9 Hz, 2H), 6.40 (d, J = 3.0 Hz, 1H), 3.91 - 3.87 (m, 5H), 3.67 - 3.64 (m, 2H), 3.13 - 3.11 (m, 2H), 3.01 (s, 3H). MS (ESI) m/z: 459 [M+H]+. |
II-5 | TFA salt | 1H-NMR (600 MHz; Methanol-d 4): δ 8.29 (s, 1H), 8.04 (dt, J = 8.1, 0.5 Hz, 1H), 7.84 (d, J = 7.7 Hz, 1H), 7.57 (d, J = 2.9 Hz, 1H), 7.46 (t, J = 7.9 Hz, 1H), 7.40 (d, J = 8.9 Hz, 2H), 7.10 (d, J = 8.8 Hz, 2H), 6.38 (d, J = 2.9 Hz, 1H), 3.91 (t, J = 4.7 Hz, 7H), 3.27 (t, J = 4.6 Hz, 4H). MS (ESI) m/z: 445 [M+H]+. |
II-6 | TFA salt | 1H-NMR (600 MHz; Methanol-d 4): δ 8.29 (s, 1H), 7.85 (dt, J = 7.8, 1.2 Hz, 1H), 7.58 (d, J = 3.0 Hz, 1H), 7.47 (t, J = 8.0 Hz, 1H), 7.41 - 7.39 (m, 1H), 7.05 (d, J = 8.9 Hz, 2H), 6.40 (d, J = 3.0 Hz, 1H), 3.91 (d, J = 20.2 Hz, 5H), 3.67 - 3.66 (m, 2H), 3.11 - 3.10 (m, 2H), 3.01 (s, 3H). MS (ESI) m/z: 542 [M+H]+. |
II-7 | TFA salt |
1H-NMR (600 MHz; Methanol-d4): δ 8.33 (d, J = 1.2 Hz, 1H), 8.20 (d, J = 2.5 Hz, 1H), 7.91-7.90 (m, 1H), 7.87-7.85 (m, 1H), 7.81-7.79 (m, 1H), 7.62 (d, J = 3.0 Hz, 1H), 7.49 (t, J = 7.9 Hz, 1H), 7.00 (d, J = 9.2 Hz, 1H), 6.42 (d, J = 3.0 Hz, 1H), 3.92 (s, 3H), 3.86 (t, J = 4.9 Hz, 4H), 3.57 (t, J = 4.9 Hz, 4H). MS (ESI) m/z: 446 [M+H]+. |
II-8 | TFA salt |
1H-NMR (600 MHz; Methanol-d4): δ 8.32 (d, J = 4.0 Hz, 1H), 8.11-8.10 (m, 1H), 7.83 (d, J = 7.7 Hz, 1H), 7.54 (d, J = 2.9 Hz, 1H), 7.47 (t, J = 8.0 Hz, 1H), 7.36-7.34 (m, 1H), 6.72 (s, 1H), 6.57-6.55 (m, 1H), 6.33 (d, J = 2.9 Hz, 1H), 3.93 (s, 3H), 3.88 (t, J = 4.8 Hz, 4H), 3.85 (s, 3H), 3.22 (t, J = 4.7 Hz, 4H). MS (ESI) m/z: 475 [M+H]+. |
IJ-1 | MS (ESI) m/z: 570 [M+H]+. | |
IJ-2 | 1H-NMR (600 MHz; Methanol-d 4): δ 8.51 (dd, J = 8.4, 0.6 Hz, 1H), 7.99 (d, J = 8.7 Hz, 1H), 7.67 (dd, J = 7.9, 1.4 Hz, 1H), 7.48 (ddd, J = 8.4, 7.3, 1.3 Hz, 1H), 7.41 (t, J = 1.5 Hz, 1H), 7.15-7.13 (m, 1H), 6.65 (d, J = 2.5 Hz, 1H), 6.47 (dd, J = 8.8, 2.5 Hz, 1H), 3.88 (s, 3H), 3.57 (d, J = 12.7 Hz, 2H), 2.94 (s, 3H), 2.74 (t, J = 5.5 Hz, 4H), 2.62 (td, J = 12.2, 1.7 Hz, 2H), 2.28 (s, 1H), 2.04-2.02 (m, 2H), 1.84 (dt, J = 6.6, 3.3 Hz, 4H), 1.67 (dt, J = 11.9, 6.0 Hz, 2H). MS (ESI) m/z: 541 [M+H]+. | |
IJ-3 | TFA salt |
1H-NMR (600 MHz; Methanol-d 4): δ 8.13 - 8.11 (m, 1H), 7.82 - 7.80 (m, 2H), 7.75 (d, J = 7.7 Hz, 1H), 7.68 - 7.65 (m, 3H), 7.57 (s, 1H), 7.39 (s, 1H), 6.49 (d, J = 2.7 Hz, 1H), 2.92 (s, 3H). MS (ESI) m/z: 438 [M+H]+. |
IK -1 | TFA salt |
1H-NMR (600 MHz; Aceton-d 6): δ 7.64-7.56 (m, 3H), 7.35 (d, J = 8.6 Hz, 1H), 6.78 (d, J = 2.4 Hz, 1H), 6.61 (dd, J = 8.6, 2.5 Hz, 1H), 6.37 (d, J = 2.9 Hz, 1H), 3.98 - 3.90 (m, 2H), 3.86 (s, 3H), 3.75 (s, 3H), 3.74 - 3.68 (m, 2H), 3.39-3.33 (m, 4H), 3.00 (s, 3H). MS (ESI) m/z: 494 [M+H]+. |
IK -2 | TFA salt |
1H-NMR (600 MHz; Aceton-d6): δ 7.78 - 7.76 (m, 1H), 7.69 (d, J = 2.9 Hz, 1H), 7.61 (d, J = 5.3 Hz, 1H), 7.36 (t, J = 4.3 Hz, 1H), 6.87 (s, 1H), 6.68 (dd, J = 8.6, 2.3 Hz, 1H), 6.41 (d, J = 2.8 Hz, 1H), 4.01 (d, J = 12.7 Hz, 2H), 3.92 - 3.89 (m, 4H), 3.89 - 3.81 (m, 9H), 3.80 (s, 3H), 3.54 - 3.50 (m, 1H), 3.03 (d, J = 5.9 Hz, 3H), 2.99 - 2.95 (m, 2H), 2.36 (dd, J = 11.4, 0.5 Hz, 2H). MS (ESI) m/z: 577 [M+H]+. |
IK -3 | TFA salt |
1H-NMR (600 MHz; Methanol-d 4): δ 7.88 (d, J = 5.4 Hz, 1H), 7.71 (d, J = 5.4 Hz, 1H), 7.65 (dd, J = 6.0, 3.0 Hz, 3H), 7.58-7.57 (m, 2H), 6.48 (d, J = 3.0 Hz, 1H), 4.08 (qt, J = 7.1, 3.5 Hz, 1H), 3.94 (s, 3H), 3.83 (ddd, J = 11.9, 8.0, 3.6 Hz, 2H), 3.53 (ddd, J = 12.0, 8.0, 3.7 Hz, 2H), 2.24 (ddt, J = 13.9, 7.6, 3.5 Hz, 2H), 2.00 (dtd, J = 14.3, 7.3, 3.6 Hz, 2H). MS (ESI) m/z: 465 [M+H]+. |
IK -4 | TFA salt |
1H-NMR (600 MHz; Methanol-d 4): δ 7.79-7.76 (m, 1H), 7.65-7.64 (m, 1H), 7.60 (d, J = 2.9 Hz, 1H), 7.35-7.33 (m, 2H), 7.10 (d, J = 8.9 Hz, 2H), 6.41-6.40 (m, 1H), 3.96 (s, 3H), 3.89 (t, J = 4.8 Hz, 5H), 3.22 (t, J = 4.8 Hz, 4H).MS (ESI) m/z: 451 [M+H]+. |
IK -5 | TFA salt |
MS (ESI) m/z: 481 [M+H]+. |
IK -6 | TFA salt |
1H-NMR (600 MHz; Methanol-d 4): δ 7.96 (d, J = 5.2 Hz, 1H), 7.65 (d, J = 5.5 Hz, 1H), 7.61 (d, J = 2.9 Hz, 1H), 7.47 (d, J = 8.9 Hz, 2H), 7.31 (d, J = 9.0 Hz, 2H), 6.44 (d, J = 2.9 Hz, 1H), 3.94 (s, 3H), 3.87 (d, J = 12.7 Hz, 2H), 3.49-3.46 (m, 4H), 3.19-3.14 (m, 3H), 2.94 (d, J = 8.0 Hz, 3H), 2.67 (s, 6H), 2.24-2.22 (m, 2H), 2.02-1.95 (m, 2H).MS (ESI) m/z: 547 [M+H]+. |
IK -7 | TFA salt |
1H-NMR (600 MHz; Methanol-d 4): δ 8.07-8.06 (m, 1H), 7.61 (dd, J = 29.9, 4.1 Hz, 2H), 7.37 (d, J = 8.5 Hz, 1H), 6.79 (d, J = 2.5 Hz, 1H), 6.68 (dd, J = 8.6, 2.5 Hz, 1H), 6.40 (d, J = 2.9 Hz, 1H), 4.10 (q, J = 7.0 Hz, 2H), 3.95 (s, 3H), 3.01 (s, 3H), 1.26 (t, J = 7.0 Hz, 3H).MS (ESI) m/z: 508 [M+H]+. |
IK -8 | TFA salt |
MS (ESI) m/z: 548 [M+H]+. |
IK -9 | TFA salt |
1H-NMR (600 MHz; Methanol-d 4): δ 8.10-8.08 (m, 1H), 7.63 (d, J = 5.1 Hz, 1H), 7.57 (d, J = 2.9 Hz, 1H), 7.31-7.30 (m, 1H), 6.77 (d, J = 2.5 Hz, 1H), 6.67 (dd, J = 8.7, 2.5 Hz, 1H), 6.38 (d, J = 2.9 Hz, 1H), 3.98 (dd, J = 10.9, 1.9 Hz, 2H), 3.95 (s, 3H), 3.84 (s, 3H), 3.41 (tt, J = 8.1, 4.0 Hz, 1H), 2.94 (s, 6H), 2.90 (td, J = 12.5, 1.8 Hz, 2H), 2.25-2.23 (m, 2H), 1.94-1.87 (m, 2H).MS (ESI) m/z: 522 [M+H]+. |
IK -10 | TFA salt |
MS (ESI) m/z: 507 [M+H]+. |
IK -11 | TFA salt |
MS (ESI) m/z: 535 [M+H]+. |
IK -12 | TFA salt |
1H-NMR (600 MHz; Methanol-d 4): δ 8.26 (s, 1H), 8.05-8.04 (m, 1H), 7.62 (d, J = 3.0 Hz, 2H), 7.19 (s, 1H), 6.42 (d, J = 3.0 Hz, 1H), 4.35 (s, 2H), 4.18 (t, J = 8.4 Hz, 2H), 3.96 (s, 3H), 3.85 (s, 3H), 3.40 (t, J = 8.3 Hz, 2H), 3.01 (s, 6H).MS (ESI) m/z: 522 [M+H]+. |
IW -1 | 1H-NMR (600 MHz, DMSO-d6) δ 11.50 (s, 1H), 8.82 (s, 1H), 8.55 (s, 1H), 8.20 (s, 1H), 7.45 (dd, J = 6.0, 3.1 Hz, 2H), 6.95 (s, 1H), 6.24 - 6.08 (m, 1H), 4.16 (t, J = 8.3 Hz, 2H), 3.88 (s, 3H), 3.79 (s, 3H), 3.46 - 3.40 (m, 1H), 3.20 (s, 2H), 3.11 (t, J = 8.4 Hz, 2H), 2.26 (s, 6H), 1.23 (d, J = 6.7 Hz, 6H). MS (ESI) m/z: 568 [M+H]+. | |
IW -2 | 1H-NMR (600 MHz, DMSO-d6) δ 11.4520 (s, 1H), 8.51 (s, 1H), 8.21 (s, 1H), 7.89 (d, J = 8.7 Hz, 1H), 7.42 (d, J = 2.9 Hz, 1H), 7.34 (s, 1H), 6.62 (d, J = 2.5 Hz, 1H), 6.50 (dd, J = 8.7, 2.5 Hz, 1H), 6.18 (d, J = 2.9 Hz, 1H), 3.95 (s, 3H), 3.80 (s, 3H), 3.78 - 3.75 (m, 1H), 3.67 (d, J = 12.6 Hz, 2H), 3.49 (t, J = 5.3 Hz, 2H), 2.63 (td, J = 12.3, 2.4 Hz, 8H), 2.38 (s, 1H), 2.30 (s, 3H), 1.86 (d, J = 11.5 Hz, 2H), 1.53 (qd, J = 12.0, 3.9 Hz, 2H), 1.23 (d, J = 6.7 Hz, 6H). MS (ESI) m/z: 623 [M+H]+. | |
IW -3 | MS (ESI) m/z: 540 [M+H]+ | |
IW -4 | MS (ESI) m/z: 511 [M+H]+ |
실시예 3.
화합물 IL의 합성 화학식.
화합물 5의 제조.
화합물 1(170mg, 1.11mmol), 2-메틸티오벤질아민(224mg, 1.11mmol)을 10mL의 tert-부탄올에 용해시킨 후에, 그 용액 속에 N,N-디이소프로필에틸아민(0.55mL, 3.33mmol)을 첨가한다. 생성된 반응액을 화합물 1이 완전히 반응할 때까지(LC-MS 추적) 120℃로 예열된 오일 배스에 놓고 가열 교반한다. 반응이 중지되면, 반응액을 농축, 실리카 겔 칼럼 크로마토그래피(에틸 아세테이트/석유 에테르=2/5)로 화합물 5(백색 고체, 238mg, 수득률 70%)를 얻어서 다음 반응에 직접 사용한다.
MS (ESI) m/z: 305 [M+H]+.
화합물 IL의 제조.
방법 A.
화합물 5(45mg, 0.15mmol), 아닐린(0.12mmol)을 2mL의 sec-부탄올에 용해시킨 후에, 그 용액 속에 트리플루오로 아세트산(56μL, 0.75mmol)을 첨가한다. 생성된 반응액을 화합물 5가 완전히 반응할 때까지(LC-MS 추적) 120℃로 예열된 오일 배스에 놓고 가열 교반한다. 반응이 중지되면, 반응액에 포화 중탄산 나트륨 용액 10mL, 디클로로메테인 50ml를 넣고 액체를 분리하며, 유기상은 포화 염화나트륨 용액으로 2회 세척, 무수 황산나트륨 건조, 농축시켜 실리카 겔 칼럼 크로마토그래피(디클로로메테인/메탄올=5/2)로 화합물 IL을 얻는다.
방법 B.
화합물 5(59mg, 0.19mmol), 아닐린(0.15mmol)을 2mL의 sec-부탄올에 용해시킨 후에, 그 용액 속에 트리플루오로 아세트산(70μL, 0.95mmol)을 첨가한다. 생성된 반응액을 마이크로파 반응기에 넣고 120℃에서 2시간 반응시킨다. 반응이 중지되면, 반응액 속에 포화 중탄산 나트륨 용액 10mL, 디클로로메테인 50mL를 넣고 액체를 분리하며, 유기상은 포화 염화나트륨 용액으로 2회 세척, 무수 황산나트륨 건조, 농축시켜 역상 제조형 HPLC 정제를 거치고(0.35% 트리플루오로 아세트산을 포함한 수용액과 메탄올이 이동상), 진공 농축시켜 화합물 IL을 얻는다.
방법 C.
화합물 5(45mg, 0.15mmol), 아닐린(0.12mmol)을 2mL의 sec-부탄올에 용해시킨 후에, 그 용액 속에 트리플루오로 아세트산(56μL, 0.75mmol)을 첨가한다. 생성된 반응액을 화합물 2가 완전히 반응할 때까지(LC-MS 추적) 120℃로 예열된 오일 배스에 놓고 가열 교반한다. 반응이 중지되면, 반응액 속에 포화 중탄산 나트륨 용액 10mL, 디클로로메테인 50mL를 넣고 액체를 분리하며, 유기상은 포화 염화나트륨 용액으로 2회 세척, 무수 황산나트륨 건조, 농축시켜 역상 제조형 HLPC 정제를 거치고(0.35% 트리플루오로 아세트산을 포함한 수용액과 메탄올이 이동상), 진공 농축시켜 화합물 IL을 얻는다.
화합물 IM, IN, IO, IP는 모두 유사한 방법을 사용해 합성할 수 있다.
번호 | 구조 | 핵 자기 공명 분광법 및/또는 질량 분석 데이터 |
IL-1 | 1H NMR (600 MHz, DMSO-d 6) δ 10.66 (s, 1H), 8.28 (s, 1H), 7.38 - 7.27 (m, 5H), 7.16 (t, J = 7.4 Hz, 1H), 7.06 - 6.87 (m, 1H), 6.60 (d, J = 2.7 Hz, 1H), 6.40 (dd, J = 8.7, 2.6 Hz, 1H), 6.16 - 6.11 (m, 1H), 4.70 (d, J = 5.3 Hz, 2H), 3.84 (s, 3H), 3.05 (d, J = 4.9 Hz, 4H), 2.52 (s, 3H), 2.47 (s, 4H), 2.23 (s, 3H). MS (ESI) m/z: 490 [M+H]+. | |
IL-2 | TFA salt |
MS (ESI) m/z: 573 [M+H]+. |
IL-3 | 1H NMR (600 MHz, DMSO-d 6) δ 10.62 (s, 1H), 8.25 (s, 1H), 7.60 (d, J = 9.0 Hz, 2H), 7.40 - 7.37 (m, 1H), 7.36 - 7.29 (m, 3H), 7.21 (t, J = 5.4 Hz, 1H), 7.15 (td, J = 7.3, 1.6 Hz, 1H), 6.77 (d, J = 9.0 Hz, 2H), 6.12 (dd, J = 2.7, 2.2 Hz, 1H), 4.74 (d, J = 5.4 Hz, 2H), 4.64 (d, J = 2.8 Hz, 1H), 3.57 (s, 1H), 3.34 (s, 2H), 2.72 - 2.65 (m, 2H), 2.51 (s, 3H), 1.85 - 1.78 (m, 2H), 1.53 - 1.45 (m, 2H). MS (ESI) m/z: 461 [M+H]+. | |
IL-4 | TFA salt |
1H NMR (600 MHz, DMSO-d 6) δ 11.78 (s, 1H), 10.76 (s, 1H), 9.17 (s, 1H), 7.69 (d, J = 8.8 Hz, 2H), 7.63 (d, J = 8.5 Hz, 3H), 7.41 - 7.32 (m, 3H), 7.27 (s, 2H), 7.19 - 7.15 (m, 1H), 6.35 (t, J = 2.3 Hz, 1H), 4.80 (d, J = 5.3 Hz, 2H), 2.53 (s, 3H). MS (ESI) m/z: 441 [M+H]+. |
IM -1 | 1H NMR (600 MHz, Methanol-d 4) δ 8.07 (d, J = 8.8 Hz, 1H), 7.51 (dd, J = 7.7, 1.3 Hz, 1H), 7.41 (dd, J = 7.5, 1.5 Hz, 1H), 7.28 - 7.22 (m, 2H), 7.21 (td, J = 7.5, 1.5 Hz, 1H), 6.62 (d, J = 2.5 Hz, 1H), 6.43 (dd, J = 8.8, 2.6 Hz, 1H), 6.17 (d, J = 3.0 Hz, 1H), 4.93 (s, 2H), 3.86 (s, 3H), 3.42 (hept, J = 6.7 Hz, 1H), 3.11 (t, J = 5.1 Hz, 4H), 2.60 (t, J = 5.0 Hz, 4H), 2.32 (s, 3H), 1.28 (d, J = 6.7 Hz, 6H). MS (ESI) m/z: 518 [M+H]+. | |
IM -2 | 1H NMR (600 MHz, Methanol-d 4) δ 7.51 (dd, J = 7.7, 1.3 Hz, 1H), 7.39 (dd, J = 7.6, 1.5 Hz, 1H), 7.38 - 7.34 (m, 2H), 7.28 - 7.25 (m, 2H), 7.21 (td, J = 7.5, 1.4 Hz, 1H), 6.90 (d, J = 8.4 Hz, 2H), 6.19 (d, J = 3.0 Hz, 1H), 4.91 (s, 2H), 3.72 (hept, J = 8.9, 4.1 Hz, 1H), 3.42 (dq, J = 13.3, 6.5 Hz, 3H), 2.83 - 2.77 (m, 2H), 1.95 (ddd, J = 12.5, 6.2, 2.9 Hz, 2H), 1.66 (dtd, J = 13.1, 9.8, 3.8 Hz, 2H), 1.28 (s, 3H), 1.27 (s, 3H). MS (ESI) m/z: 489 [M+H]+ | |
IM -3 | 1H NMR (600 MHz, Methanol-d 4) δ 7.75 - 7.72 (m, 1H), 7.70 - 7.67 (m, 1H), 7.51 (dd, J = 7.7, 1.3 Hz, 0H), 7.44 - 7.41 (m, 0H), 7.30 (d, J = 3.0 Hz, 0H), 7.25 (td, J = 7.5, 1.6 Hz, 1H), 7.21 (td, J = 7.4, 1.4 Hz, 1H), 6.26 (d, J = 3.0 Hz, 0H), 4.94 (s, 1H), 3.43 (hept, J = 7.2 Hz, 1H), 1.28 (d, J = 6.7 Hz, 3H). MS (ESI) m/z: 469 [M+H]+ | |
IN-1 | 1H NMR (600 MHz, CDCl3) δ 7.93 (dd, J = 7.6, 1.7 Hz, 1H), 7.79 (d, J = 8.7 Hz, 1H), 7.55 - 7.51 (m, 1H), 7.37 - 7.30 (m, 2H), 7.04 - 7.02 (m, 1H), 6.91 (d, J = 14.0 Hz, 1H), 6.41 (d, J = 2.5 Hz, 1H), 6.24 (dd, J = 8.7, 2.3 Hz, 1H), 6.15 (d, J = 3.0 Hz, 1H), 4.97 (s, 2H), 3.69 (s, 3H), 3.02 (d, J = 13.5 Hz, 7H), 2.56 - 2.52 (m, 4H), 2.31 (s, 3H). MS (ESI) m/z: 522 [M+H]+. | |
IN-2 | TFA salt |
1H NMR (600 MHz, DMSO-d 6) δ 11.98 (s, 1H), 9.25 (s, 1H), 9.11 (t, J = 5.8 Hz, 1H), 7.99 (dd, J = 7.9, 1.3 Hz, 1H), 7.69 (td, J = 7.6, 1.4 Hz, 1H), 7.59 (td, J = 7.7, 1.3 Hz, 1H), 7.56 (dd, J = 6.6, 3.5 Hz, 2H), 7.23 (d, J = 8.6 Hz, 1H), 6.73 (d, J = 2.5 Hz, 1H), 6.48 (q, J = 2.4 Hz, 1H), 6.26 (t, J = 2.4 Hz, 1H), 5.14 (d, J = 5.7 Hz, 2H), 3.91 - 3.85 (m, 2H), 3.77 (d, J = 4.4 Hz, 3H), 3.71 - 3.34 (m, 8H), 3.22 (s, 3H), 2.89 (s, 3H), 2.77 (t, J = 12.2 Hz, 2H), 2.18 - 2.11 (m, 2H), 1.77 - 1.68 (m, 2H). MS (ESI) m/z: 605[M+H]+. |
IN-3 | TFA salt |
1H NMR (600 MHz, DMSO-d 6) δ 11.80 (s, 1H), 10.25 (s, 1H), 9.08 (s, 1H), 8.03 (dd, J = 7.9, 1.2 Hz, 1H), 7.71 (dd, J = 10.8, 4.4 Hz, 1H), 7.64 - 7.57 (m, 3H), 7.35 (d, J = 8.4 Hz, 2H), 7.19 (d, J = 8.5 Hz, 2H), 6.34 - 6.29 (m, 1H), 5.19 (d, J = 5.5 Hz, 2H), 3.56 - 3.51 (m, 2H), 3.23 (s, 3H), 3.16 (d, J = 6.9 Hz, 2H), 1.93 (s, 2H), 1.65 (s, 2H). MS (ESI) m/z: 493 [M+H]+. |
IN-4 | 1H NMR (600 MHz, DMSO-d 6) δ 11.76 (s, 1H), 10.46 (s, 1H), 9.07 (s, 1H), 8.04 (dd, J = 8.2, 1.3 Hz, 1H), 7.75 - 7.70 (m, 1H), 7.68 (s, 1H), 7.67 - 7.65 (m, 2H), 7.63 (t, J = 7.0 Hz, 2H), 7.60 (d, J = 8.8 Hz, 2H), 7.27 (s, 2H), 6.41 - 6.36 (m, 1H), 5.23 (d, J = 5.5 Hz, 2H), 3.23 (s, 3H). MS (ESI) m/z: 473[M+H]+. | |
IN-5 | 1H NMR (600 MHz, CDCl3) δ 7.95 (dd, J = 7.8, 1.4 Hz, 1H), 7.49 (dd, J = 4.8, 3.9 Hz, 1H), 7.44 (td, J = 7.5, 1.4 Hz, 1H), 7.40 (td, J = 7.6, 1.4 Hz, 1H), 7.18 - 7.13 (m, 2H), 7.04 (d, J = 2.9 Hz, 1H), 6.69 - 6.64 (m, 2H), 6.08 (d, J = 2.9 Hz, 1H), 4.99 (s, 2H), 3.06 - 3.00 (m, 4H), 2.96 (s, 3H), 2.57 - 2.51 (m, 4H), 2.32 (s, 3H). MS (ESI) m/z: 492 [M+H]+. | |
IO -1 | 1H NMR (600 MHz, Methanol-d 4) δ 7.97 (dd, J = 7.9, 1.3 Hz, 1H), 7.92 (d, J = 8.7 Hz, 1H), 7.72 - 7.67 (m, 1H), 7.61 (td, J = 7.6, 1.4 Hz, 1H), 7.51 (td, J = 7.5, 1.3 Hz, 1H), 7.28 (d, J = 2.9 Hz, 1H), 6.62 (d, J = 2.5 Hz, 1H), 6.43 (dd, J = 8.9, 2.5 Hz, 1H), 6.19 (d, J = 3.0 Hz, 1H), 5.1921 (s, 2H), 3.85 (s, 3H), 3.49 (hept, J = 6.7 Hz, 1H), 3.12 (t, 4H), 2.60 (t, J = 5.0 Hz, 4H), 2.33 (s, 3H), 1.27 (s, 3H), 1.26 (s, 3H). MS (ESI) m/z: 550 [M+H]+ . | |
IO -2 | 1H NMR (600 MHz, DMSO-d 6) δ 10.75 (s, 1H), 8.30 (d, J = 8.8 Hz, 1H), 7.91 (dd, J = 7.9, 1.3 Hz, 1H), 7.71 (dd, J = 7.8, 1.3 Hz, 1H), 7.67 (dd, J = 7.9, 1.5 Hz, 1H), 7.58 (t, J = 5.9 Hz, 1H), 7.55 (ddd, J = 8.2, 7.2, 1.7 Hz, 1H), 7.36 (t, J = 2.9 Hz, 1H), 6.77 (s, 1H), 6.58 (d, J = 2.5 Hz, 1H), 6.40 (dd, J = 8.9, 2.5 Hz, 1H), 6.19 - 6.15 (m, 1H), 5.06 (d, J = 5.8 Hz, 2H), 3.81 (s, 3H), 3.75 (hept, J = 7.7, 7.0 Hz, 1H), 3.57 (d, J = 12.2 Hz, 2H), 2.60 - 2.52 (m, 4H), 2.54 - 2.50 (m, 1H), 2.35 - 2.30 (m, 2H), 2.28 - 2.22 (m, 2H), 2.15 (s, 3H), 1.82 (d, J = 11.3 Hz, 2H), 1.50 (qd, J = 12.4, 4.3 Hz, 2H), 1.27 (d, J = 6.8 Hz, 6H), 1.04 (d, J = 6.1 Hz, 2H). MS (ESI) m/z: 633 [M+H]+ . | |
IO -3 | 1H NMR (600 MHz, DMSO-d 6) δ 10.73 (s, 1H), 8.20 (s, 1H), 7.95 - 7.88 (m, 1H), 7.74 - 7.67 (m, 2H), 7.56 (ddd, J = 8.3, 6.2, 2.5 Hz, 1H), 7.52 (d, J = 9.0 Hz, 2H), 7.38 (s, 1H), 7.34 (t, J = 2.9 Hz, 1H), 6.79 - 6.73 (m, 2H), 6.13 (t, J = 2.4 Hz, 1H), 5.13 (d, J = 5.7 Hz, 2H), 3.60 - 3.49 (m, 3H), 2.68 (ddd, J = 12.7, 10.3, 2.9 Hz, 2H), 2.54 - 2.50 (m, 1H), 1.80 (dq, J = 13.2, 3.7 Hz, 2H), 1.48 (dtd, J = 12.9, 9.6, 3.7 Hz, 2H), 1.20 (d, J = 6.7 Hz, 6H). MS (ESI) m/z: 521 [M+H]+ . | |
IO -4 | 1H NMR (600 MHz, Methanol-d 4) δ 7.98 (dd, J = 7.9, 1.3 Hz, 1H), 7.75 (dd, J = 7.8, 1.2 Hz, 1H), 7.66 (s, 4H), 7.64 (dd, J = 7.6, 1.4 Hz, 1H), 7.52 (td, J = 7.7, 1.3 Hz, 1H), 7.33 (d, J = 3.0 Hz, 1H), 6.2715 (d, J = 3.0 Hz, 1H), 5.23 (s, 2H), 3.49 - 3.39 (m, 1H), 1.24 (d, J = 6.8 Hz, 6H). MS (ESI) m/z: 501 [M+H]+ . | |
IO -5 | 1H NMR (600 MHz, Methanol-d 4) δ 7.95 (dd, J = 7.9, 1.4 Hz, 1H), 7.69 (dd, J = 7.8, 1.2 Hz, 1H), 7.60 (td, J = 7.6, 1.4 Hz, 1H), 7.50 (td, J = 7.6, 1.3 Hz, 1H), 7.38 - 7.32 (m, 2H), 7.26 (d, J = 3.0 Hz, 1H), 6.87 - 6.80 (m, 2H), 6.19 (d, J = 3.0 Hz, 1H), 5.17 (s, 2H), 3.41 (hept, J = 6.8 Hz, 1H), 3.08 (t, J = 4.9 Hz, 4H), 2.59 (t, J = 4.9 Hz, 4H), 2.32 (s, 3H), 1.23 (d, J = 6.8 Hz, 6H). MS (ESI) m/z: 520 [M+H]+ . | |
IP-1 | 1H NMR (600 MHz, DMSO-d 6) δ 11.63 (s, 1H), 9.43 (s, 1H), 8.62 (s, 1H), 7.59 (d, J = 8.1 Hz, 3H), 7.51 (s, 1H), 7.47 (t, J = 8.1 Hz, 1H), 6.78 (s, 1H), 6.65 (d, J = 8.5 Hz, 1H), 6.24 (s, 1H), 4.94 (d, J = 3.8 Hz, 2H), 3.83 (s, 3H), 2.87 (s, 3H). MS (ESI) m/z: 513 [M+H]+. | |
IP-2 | 1H NMR (600 MHz, DMSO-d 6) δ 10.60 (s, 1H), 8.44 (d, J = 8.8 Hz, 1H), 7.57 (d, J = 8.1 Hz, 2H), 7.43 (dd, J = 8.4, 7.8 Hz, 1H), 7.31 (t, J = 2.9 Hz, 1H), 7.14 (t, J = 4.4 Hz, 1H), 7.09 (s, 1H), 6.63 (d, J = 2.5 Hz, 1H), 6.50 (dd, J = 8.9, 2.5 Hz, 1H), 6.16 (dd, J = 2.8, 2.1 Hz, 1H), 4.87 (d, J = 4.6 Hz, 2H), 4.60 (s, 1H), 3.88 (s, 3H), 3.61 (d, J = 12.3 Hz, 2H), 3.50 (d, J = 5.4 Hz, 2H), 3.43 (dd, J = 7.8, 2.9 Hz,2H), 2.58 (dd, J = 12.0, 10.1 Hz, 2H), 2.35 (s, 2H), 2.27 (ddd, J = 11.2, 7.8, 3.5 Hz, 2H), 2.17 (s, 3H), 1.84 (d, J = 11.8 Hz, 2H), 1.52 (qd, J = 12.2, 3.8 Hz, 2H). MS (ESI) m/z: 596 [M+H]+ . | |
IP-3 | 1H NMR (600 MHz, DMSO-d 6) δ 10.50 (s, 1H), 8.32 (s, 1H), 7.70 (d, J = 9.0 Hz, 2H), 7.60 (d, J = 8.1 Hz, 2H), 7.46 (t, J = 8.1 Hz, 1H), 7.29 (t, J = 2.8 Hz, 1H), 6.95 (s, 1H), 6.85 (d, J = 9.0 Hz, 2H), 6.13 (t, J = 2.4 Hz, 1H), 4.91 (d, J = 4.2 Hz, 2H), 4.68 (d, J = 2.9 Hz, 1H), 3.57 (s, 2H), 2.75 - 2.66 (m, 2H), 1.88 - 1.76 (m, 2H), 1.56 - 1.43 (m, 2H). MS (ESI) m/z: 484 [M+H]+ . | |
IP-4 | 1H NMR (600 MHz, DMSO-d 6) δ 10.03 (s, 1H), 7.87 (s, 1H), 7.53 (t, J = 7.3 Hz, 2H), 7.47 (d, J = 2.8 Hz, 1H), 7.45 - 7.40 (m, 1H), 7.36 (d, J = 7.9 Hz, 1H), 7.29 (s, 1H), 7.20 (s, 1H), 7.12 (s, 1H), 7.01 (d, J = 7.9 Hz, 1H), 6.16 (t, J = 39.9 Hz, 1H), 5.01 (d, J = 4.6 Hz, 2H), 3.89 (d, J = 75.0 Hz, 3H), 2.86 (d, J = 13.7 Hz, 2H), 1.83 (d, J = 9.2 Hz, 2H), 1.58 - 1.38 (m, 2H). MS (ESI) m/z: 483 [M+H]+ . |
실시예 4.
화합물 IQ의 합성 화학식.
화합물 6의 제조.
화합물 1(200mg, 1.06mmol), 메틸아민(33% wt IN EtoH, 2.34mmol)을 4mL의 tert-부탄올에 용해시킨다. 생성된 반응액을 화합물 1이 완전히 반응할 때까지(LC-MS 추적) 45℃로 예열된 오일 배스에 놓고 가열 교반하며, 농축, 실리카 겔 칼럼 크로마토그래피(디클로로메테인/메탄올=50/1)로 화합물 6(황색 고체, 165mg, 수득률 85.2%)을 얻어서 다음 반응에 직접 사용한다.
MS (ESI) m/z: 183 [M+H]+.
화합물 IQ의 제조.
화합물 6(15.0mg, 0.08mmol), 아닐린(0.08mmol)을 1 mL의 tert-부탄올에 용해시킨 후에, 그 용액 속에 트리플루오로 아세트산(36.7μL, 0.49mmol)을 첨가한다. 생성된 반응액을 아닐린이 완전 반응할 때까지(LC-MS 추적) 110℃로 예열된 오일 배스에 놓고 가열 교반한다. 반응이 중지되면, 반응액에 포화 중탄산 나트륨 용액 10mL, 디클로로메테인 50mL를 넣고 액체를 분리하며, 유기상은 포화 염화나트륨 용액으로 2회 세척, 무수 황산나트륨 건조, 실리카 겔 칼럼 크로마토그래피 농축(디클로로메테인/메탄올)으로 화합물 IQ를 얻는다.
화합물 IR, IS, IT는 모두 유사한 방법을 사용하여 합성할 수 있다.
번호 | 구조 | 핵 자기 공명 분광법 및/또는 질량 분석 데이터 |
IQ-1 | 1H-NMR (600 MHz; Methanol-d 4): δ 8.02 (dd, J = 8.7, 2.1 Hz, 1H), 7.28 (t, J = 1.5 Hz, 1H), 6.69 (d, J = 2.5 Hz, 1H), 6.60 (dd, J = 8.8, 2.4 Hz, 1H), 6.19 (d, J = 3.0 Hz, 1H), 3.90 (s, 3H), 3.20 (d, J = 3.9 Hz, 4H), 3.15 (s, 3H), 2.66 (t, J = 4.9 Hz, 4H), 2.38 (s, 3H). MS (ESI) m/z: 368 [M+H]+. | |
IQ-2 | 1H-NMR (600 MHz; Methanol-d 4): δ 8.19 (d, J = 8.7 Hz, 1H), 7.26 (s, 1H), 6.66 (s, 1H), 6.57 - 6.56 (m, 1H), 6.19 - 6.18 (m, 1H), 3.89 (s, 3H), 3.61 (d, J = 11.6 Hz, 2H), 3.14 (s, 3H), 2.64 - 2.61 (m, 6H), 2.29 (s, 5H), 1.96 (d, J = 12.1 Hz, 2H), 1.62 (dd, J = 11.9, 2.8 Hz, 2H). MS (ESI) m/z: 451 [M+H]+. | |
IQ-3 | 1H-NMR (600 MHz; Methanol-d 4): δ 7.44 (d, J = 8.5 Hz, 2H), 7.37 (d, J = 2.5 Hz, 1H), 7.13 (d, J = 8.7 Hz, 2H), 6.27 (d, J = 2.5 Hz, 1H), 3.83 (t, J = 4.2 Hz, 1H), 3.64 - 3.60 (m, 2H), 3.16 (s, 3H), 3.02 - 2.98 (m, 2H), 2.04 - 2.02 (m, 2H), 1.73 (td, J = 8.8, 4.9 Hz, 2H). MS (ESI) m/z: 339 [M+H]+. | |
IQ-4 | 1H-NMR (600 MHz; Methanol-d 4): δ 7.88 (q, J = 11.4 Hz, 4H), 7.44 (d, J = 3.0 Hz, 1H), 6.35 (d, J = 3.0 Hz, 1H), 3.21 (s, 3H). MS (ESI) m/z: 319 [M+H]+. | |
IQ-5 | MS (ESI) m/z: 383 [M+H]+. | |
IQ-6 | 1H-NMR (600 MHz; Methanol-d 4): δ 8.71 (d, J = 8.1 Hz, 1H), 7.32 - 7.31 (m, 1H), 7.07 - 7.06 (m, 2H), 6.25 (d, J = 3.0 Hz, 1H), 4.00 (s, 3H), 3.73 - 3.66 (m, 4H), 3.18 (s, 3H), 2.52 (dd, J = 1.4, 0.9 Hz, 4H), 2.36 (s, 4H). MS (ESI) m/z: 396 [M+H]+. | |
IQ-7 | 1H-NMR (600 MHz; Methanol-d4): δ 8.12 (d, J = 8.6 Hz, 1H), 7.42 (s, 1H), 6.67 (d, J = 0.2 Hz, 1H), 6.58-6.57 (m, 1H), 3.93 (s, 3H), 3.16 (s, 3H), 3.00 (s, 3H). MS (ESI) m/z: 402 [M+H]+. | |
IQ-8 | 1H-NMR (600 MHz; Methanol-d4): δ 8.50 (d, J = 8.2 Hz, 1H), 7.49 (s, 1H), 7.14 (s, 1H), 7.10 (d, J = 8.2 Hz, 1H), 4.00 (s, 3H), 3.21 (s, 3H). MS (ESI) m/z: 417 [M+H]+. | |
IR-1 | 1H-NMR (600 MHz; Methanol-d 4): δ 7.60 (d, J = 3.1 Hz, 1H), 7.39 (d, J = 2.8 Hz, 1H), 6.77 (d, J = 2.4 Hz, 1H), 6.56 (d, J = 3.1 Hz, 1H), 6.23 (d, J = 2.9 Hz, 1H), 3.90 (d, J = 34.2 Hz, 5H), 3.68 (dd, J = 12.9, 7.2 Hz, 3H), 3.55 (s, 2H), 3.24 - 3.22 (m, 2H), 1.39 (t, J = 7.3 Hz, 3H). MS (ESI) m/z: 382 [M+H]+. | |
IR-2 | 1H-NMR (600 MHz; Methanol-d 4): δ 7.55 - 7.53 (m, 1H), 7.37 (d, J = 2.8 Hz, 1H), 6.72 (d, J = 2.3 Hz, 1H), 6.63 (dd, J = 8.7, 2.4 Hz, 1H), 6.23 (d, J = 2.9 Hz, 1H), 3.88 (s, 3H), 3.83 (d, J = 12.4 Hz, 2H), 3.66 (d, J = 7.3 Hz, 2H), 3.18 - 3.16 (m, 5H), 2.78 (td, J = 25.0, 9.8 Hz, 6H), 2.07 (d, J = 11.2 Hz, 2H), 1.74 (dd, J = 11.8, 2.8 Hz, 2H), 1.34 (t, J = 7.3 Hz, 3H). MS (ESI) m/z: 465 [M+H]+. | |
IR-3 | 1H-NMR (600 MHz; Methanol-d 4): δ 7.38-7.35 (m, 3H), 7.04 (d, J = 8.9 Hz, 2H), 6.25 (d, J = 3.0 Hz, 1H), 3.78 (dd, J = 8.9, 4.6 Hz, 1H), 3.65 (q, J = 7.3 Hz, 2H), 3.58 - 3.55 (m, 2H), 2.92-2.88 (m, 2H), 2.01 - 1.97 (m, 2H), 1.71 - 1.66 (m, 2H), 1.33 (t, J = 7.3 Hz, 3H). MS (ESI) m/z: 353 [M+H]+. | |
IR-4 | MS (ESI) m/z: 460 [M+H]+. | |
IR-5 | 1H NMR (600 MHz, DMSO-d 6) δ 12.44 (d, J = 3.2 Hz, 1H), 9.11 (t, J = 5.3 Hz, 1H), 8.96 (s, 1H), 8.03 (d, J = 8.8 Hz, 1H), 7.73 (d, J = 3.1 Hz, 1H), 6.78 (d, J = 2.6 Hz, 1H), 6.64 (dd, J = 9.0, 2.5 Hz, 1H), 3.90 (s, 3H), 3.89 - 3.84 (m, 2H), 3.65 - 3.33 (m, 8H), 3.61 - 3.51 (m, 2H), 3.42 - 3.31 (m, 1H), 2.88 (s, 3H), 2.78 (t, J = 12.2 Hz, 2H), 2.14 (d, J = 11.8 Hz, 2H), 1.79 - 1.70 (m, 2H), 1.25 (t, J = 7.3 Hz, 3H). MS (ESI) m/z: 543 [M+H]+. | |
IR-6 | MS (ESI) m/z: 431 [M+H]+. | |
IR-7 | MS (ESI) m/z: 417 [M+H]+. | |
IR-8 | 1H NMR (600 MHz, DMSO-d 6) δ 10.84 - 10.79 (m, 1H), 8.48 (d, J = 8.7 Hz, 1H), 7.44 (d, J = 2.2 Hz, 1H), 7.04 (d, J = 5.6 Hz, 2H), 6.62 (d, J = 2.5 Hz, 1H), 6.48 (dd, J = 8.9, 2.5 Hz, 1H), 3.87 (s, 3H), 3.65 - 3.58 (m, 2H), 3.53 - 3.46 (m, 2H), 2.58 (td, J = 12.1, 2.3 Hz, 2H), 2.53 - 2.47 (m, 4H), 2.40 - 2.21 (m, 5H), 2.15 (s, 3H), 1.83 (d, J = 11.8 Hz, 2H), 1.52 (qd, J = 12.1, 3.9 Hz, 2H), 1.24 (t, J = 7.2 Hz, 3H). MS (ESI) m/z: 499 [M+H]+. | |
IR-9 | MS (ESI) m/z: 388 [M+H]+. | |
IS-1 | TFA salt |
1H-NMR (600 MHz; Methanol-d 4): δ 7.94 - 7.93 (m, 1H), 7.39 (s, 1H), 6.75 (d, J = 2.4 Hz, 1H), 6.64 (dd, J = 8.7, 2.4 Hz, 1H), 6.24 (d, J = 0.5 Hz, 1H), 3.91 (s, 5H), 3.55 - 3.42 (m, 4H), 3.11 (s, 2H), 3.00 (s, 4H), 2.68 (s, 2H), 0.95 (d, J = 5.9 Hz, 2H), 0.74 (s, 2H). MS (ESI) m/z: 394 [M+H]+. |
IS-2 | TFA salt |
1H-NMR (600 MHz; Methanol-d 4): δ 8.27 - 8.26 (m, 1H), 7.44 (s, 1H), 7.06 (s, 1H), 6.98-6.97 (m, 1H), 6.29 (s, 1H), 3.97 (s, 3H), 3.85 (d, J = 12.3 Hz, 2H), 3.45 - 3.44 (m, 2H), 3.28 - 3.24 (m, 3H), 3.11-3.09 (m, 2H), 2.93 (s, 3H), 2.68 (s, 3H), 2.22 (d, J = 12.4 Hz, 2H), 2.02 - 2.00 (m, 2H), 0.98 (d, J = 6.4 Hz, 2H), 0.76 (s, 2H). MS (ESI) m/z: 477 [M+H]+. |
IS-3 | TFA salt |
1H-NMR (600 MHz; Methanol-d 4): δ 7.99 (d, J = 8.6 Hz, 2H), 7.60 - 7.58 (m, 2H), 7.46 (d, J = 2.4 Hz, 1H), 6.36 (d, J = 2.5 Hz, 1H), 4.08 (t, J = 3.5 Hz, 1H), 3.80 (dd, J = 13.9, 5.7 Hz, 2H), 3.55 - 3.52 (m, 2H), 3.10 (ddd, J = 11.2, 7.3, 3.7 Hz, 1H), 2.24 (dq, J = 10.3, 3.8 Hz, 2H), 2.01 (dq, J = 10.6, 3.6 Hz, 2H), 1.00 (d, J = 6.2 Hz, 2H), 0.77 (s, 2H). MS (ESI) m/z: 365 [M+H]+. |
IS-4 | MS (ESI) m/z: 345 [M+H]+. | |
IS-5 | MS (ESI) m/z: 472 [M+H]+. | |
IS-6 | 1H NMR (600 MHz, DMSO-d 6) δ 10.95 (s, 1H), 8.63 (d, J = 8.8 Hz, 1H), 7.48 (s, 1H), 7.41 (d, J = 3.1 Hz, 1H), 7.10 (s, 1H), 6.64 (d, J = 2.5 Hz, 1H), 6.50 (dd, J = 8.9, 2.5 Hz, 1H), 3.89 (s, 3H), 3.65 (d, J = 12.0 Hz, 2H), 3.40 - 3.21 (m, 4H), 2.93 (dq, J = 7.0, 3.4 Hz, 1H), 2.87 - 2.67 (m, 5H), 2.61 (td, J = 12.2, 2.3 Hz, 2H), 2.46 (s, 3H), 1.92 - 1.84 (m, 2H), 1.56 (d, J = 11.8 Hz, 2H), 0.86 - 0.81 (m, 2H), 0.58 - 0.53 (m, 2H). MS (ESI) m/z: 555 [M+H]+. | |
IS-7 | MS (ESI) m/z: 443 [M+H]+. | |
IS-8 | MS (ESI) m/z: 429 [M+H]+. | |
IS-9 | 1H NMR (600 MHz, DMSO-d 6) δ 10.69 (d, J = 3.0 Hz, 1H), 8.59 (d, J = 8.8 Hz, 1H), 7.45 (d, J = 2.4 Hz, 1H), 7.30 (d, J = 3.2 Hz, 1H), 7.07 (s, 1H), 6.63 (d, J = 2.5 Hz, 1H), 6.49 (dd, J = 8.9, 2.5 Hz, 1H), 3.88 (s, 3H), 3.64 - 3.58 (m, 2H), 2.93 (dq, J = 7.0, 3.5 Hz, 1H), 2.59 (td, J = 12.1, 2.3 Hz, 2H), 2.55 - 2.43 (m, 4H), 2.38 - 2.21 (m, 5H), 2.15 (s, 3H), 1.83 (d, J = 12.2 Hz, 2H), 1.52 (qd, J = 12.1, 3.9 Hz, 2H), 0.84 (td, J = 6.7, 4.8 Hz, 2H), 0.58 - 0.51 (m, 2H). MS (ESI) m/z: 511 [M+H]+. | |
IS-10 | MS (ESI) m/z: 400 [M+H]+. | |
IT-1 | MS (ESI) m/z: 395 [M+H]+. |
실시예 5.
화합물 IU의 합성 화학식.
화합물 7의 제조.
화합물 1(200mg, 1.06mmol), 메틸 티오살리실레이트(179 mg, 1.06mmol)를 4mL의 1,4- 다이옥산에 용해시킨 후에, 그 용액 속에 N,N-디이소프로필에틸아민(0.35mL, 2.12mmol)을 첨가한다. 생성된 반응액을 50℃로 예열된 오일 배스에 놓고 가열 교반하며, 10h 반응시킨 후 반응을 중지한다. 반응액에 포화 염화나트륨 용액 40mL를 넣고 액체를 분리하며, 유기상은 포화 염화나트륨 용액으로 2회 세척, 무수 황산나트륨 건조, 실리카 겔 칼럼 크로마토그래피 농축(디클로로메테인/메탄올=5/1)으로 화합물 7(황색 고체, 299.6mg, 수득률 88.4%)을 얻어서 다음 반응에 직접 사용한다.
MS (ESI) m/z: 320[M+H]+.
화합물 IU의 제조.
방법 A.
화합물 7(20.0mg, 0.06mmol), 아닐린(0.06mmol)을 1mL의 tert-부탄올에 용해시킨 후에, 그 용액 속에 트리플루오로 아세트산(14μL, 0.18mmol)을 첨가한다. 생성된 반응액을 110℃로 예열된 오일 배스에 놓고 가열 교반하며, 36h 반응시킨 후 반응을 중지한다. 반응액에 포화 염화나트륨 용액 10mL를 넣고 액체를 분리하며, 유기상은 포화 염화나트륨 용액으로 2회 세척, 무수 황산나트륨 건조, 실리카 겔 칼럼 크로마토그래피 농축(디클로로메테인/메탄올)으로 화합물 IU를 얻는다.
방법 B.
화합물 7(20.0mg, 0.06mmol), 아닐린(0.06mmol)을 1mL의 tert-부탄올에 용해시킨 후에, 그 용액 속에 트리플루오로 아세트산(14μL, 0.18mmol)을 첨가한다. 생성된 반응액을 110℃로 예열된 오일 배스에 놓고 가열 교반하며 36h 반응시키고, 반응이 중지되면, 농축, 역상 제조형 HLPC 정제를 거치고(0.35% 트리플루오로 아세트산을 포함한 수용액과 메탄올이 이동상), 진공 농축시켜 화합물 IU를 얻는다.
번호 | 구조 | 핵 자기 공명 분광법 및/또는 질량 분석 데이터 |
IU -1 | TFA salt |
1H-NMR (600 MHz; Methanol-d 4): δ 8.03 - 8.01 (m, 1H), 7.78 (s, 1H), 7.74 (d, J = 2.9 Hz, 1H), 7.67 - 7.66 (m, 2H), 7.07 - 7.06 (m, 1H), 6.68 - 6.67 (m, 1H), 6.43 (d, J = 2.9 Hz, 1H), 3.93 - 3.85 (m, 2H), 3.81 (s, 3H), 3.78 (s, 3H), 3.66 - 3.64 (m, 2H), 3.24 (dd, J = 1.2, 0.4 Hz, 2H), 3.12 - 3.06 (m, 2H), 3.00 (s, 3H). MS (ESI) m/z: 505 [M+H]+. |
IU -2 | 1H-NMR (600 MHz; Methanol-d 4): δ 8.01 - 8.00 (m, 1H), 7.67 - 7.66 (m, 1H), 7.61-7.58 (m, 3H), 7.55 - 7.54 (m, 1H), 6.62 (d, J = 2.5 Hz, 1H), 6.34 (d, J = 3.1 Hz, 1H), 6.25 (dd, J = 8.8, 2.5 Hz, 1H), 3.87 (d, J = 5.8 Hz, 3H), 3.76 (s, 3H), 3.59 (d, J = 12.4 Hz, 2H), 2.67 - 2.62 (m, 9H), 2.33 - 2.32 (m, 5H), 2.02 - 2.00 (m, 2H), 1.68 - 1.66 (m, 2H). MS (ESI) m/z: 588 [M+H]+. | |
IU -3 | TFA salt |
1H-NMR (600 MHz; Methanol-d 4): δ 8.07 (dd, J = 7.7, 1.5 Hz, 1H), 7.82 - 7.70 (m, 4H), 7.33 (d, J = 8.9 Hz, 2H), 7.24 (d, J = 9.0 Hz, 2H), 6.53 (d, J = 3.0 Hz, 1H), 4.07 - 4.06 (m, 1H), 3.77 (s, 3H), 3.76 - 3.73 (m, 2H), 3.46 - 3.42 (m, 2H), 2.23 - 2.19 (m, 2H), 1.99 - 1.96 (m, 2H). MS (ESI) m/z: 476 [M+H]+. |
IU -4 | TFA salt |
1H-NMR (600 MHz; Methanol-d 4): δ 8.06 - 8.04 (m, 1H), 7.92 - 7.90 (m, 1H), 7.79 - 7.76 (m, 3H), 7.71 - 7.69 (m, 1H), 7.59 - 7.58 (m, 1H), 7.35 - 7.33 (m, 1H), 7.11 - 7.10 (m, 1H), 6.53 (dd, J = 1.7, 1.2 Hz, 1H), 3.75 (s, 3H). MS (ESI) m/z: 456 [M+H]+. |
IU -5 | 1H-NMR (600 MHz; Methanol-d 4): δ 8.02 - 8.00 (m, 1H), 7.67 - 7.66 (m, 1H), 7.63 (d, J = 8.8 Hz, 1H), 7.60 - 7.59 (m, 2H), 7.56 (d, J = 3.1 Hz, 1H), 6.62 (d, J = 2.5 Hz, 1H), 6.35 (d, J = 3.0 Hz, 1H), 6.26 (dd, J = 8.8, 2.5 Hz, 1H), 3.88 (s, 4H), 3.76 (s, 3H), 3.63 - 3.60 (m, 2H), 3.11 - 3.07 (m, 4H), 2.71-2.67 (m, 2H), 2.18 - 2.15 (m, 2H), 2.00 - 1.97 (m, 4H), 1.79 - 1.76 (m, 2H). MS (ESI) m/z: 559 [M+H]+. |
실시예 6.
화합물 IV의 합성 화학식.
화합물 8의 제조.
아이스 배스 하에서, NaH(480mg, 20mmol, 60%), 화합물 1(940mg, 5mmol)을 10 mL의 건조된 디클로로메테인에 넣고, 아이스 배스에서 30분간 교반한다. 다시 생성된 반응액 속에 (Boc)2O(1.29mL, 6mmol)를 첨가한다. 생성된 반응액을 아이스 배스에 놓고 교반하고, 서서히 온도를 실온까지 상승시키며 4시간 반응시킨 후 반응을 중지한다. 반응액 속에 포화 염화암모늄 40mL, 디클로로메테인 20mL를 넣고 액체를 분리하며, 유기상은 포화 염화나트륨 용액으로 2회 세척, 무수 황산나트륨 건조, 농축으로 화합물 8(황색 고체, 1.41mg, 수득률 97.9%)을 얻어서 다음 반응에 직접 사용한다.
MS (ESI) m/z: 289[M+H]+.
화합물 9의 제조.
화합물 8(300mg, 1.04mmol), 메틸 살리실레이트(237.6mg, 1.56mmol)를 5ml의 DMF에 용해시킨 후에, 그 용액 속에 탄산세슘(1.02g, 3.12mmol)을 첨가한다. 생성된 반응액을 60℃로 예열된 오일 배스에 놓고 가열 교반하며, 16h 반응시킨 후 반응을 중지한다. 반응액에 포화 염화나트륨 용액 40mL, 에틸 아세테이트 20mL를 넣고 액체를 분리하며, 유기상은 포화 염화나트륨 용액으로 2회 세척, 무수 황산나트륨 건조, 실리카 겔 칼럼 크로마토그래피 농축(디클로로메테인/메탄올=50/1)으로 화합물 9(황색 고체, 65mg, 수득률 20.5%)를 얻어서 다음 반응에 직접 사용한다.
MS (ESI) m/z: 304[M+H]+.
화합물 IV의 제조.
화합물 9(15.0mg, 0.05mmol), 아닐린(0.05mmol)을 1ml의 tert-부탄올에 용해시킨 후에, 그 용액 속에 트리플루오로 아세트산(11μL, 0.15mmol)을 첨가한다. 생성된 반응액을 110℃로 예열된 오일 배스에 놓고 가열 교반하며, 24h 반응시키고 반응이 중지되면, 농축시켜 역상 제조형 HPLC 정제를 거치고 (0.35% 트리플루오로 아세트산을 포함한 수용액과 메탄올이 이동상), 진공 농축시켜 화합물 IV를 얻는다.
번호 | 구조 | 핵 자기 공명 분광법 및/또는 질량 분석 데이터 |
IV-1 | TFA salt |
1H-NMR (600 MHz; Methanol-d 4): δ 8.12 (dd, J = 7.8, 1.4 Hz, 1H), 7.79-7.77 (m, 1H), 7.73 (d, J = 2.7 Hz, 1H), 7.53 (dd, J = 7.6, 0.9 Hz, 1H), 7.47 - 7.45 (m, 1H), 7.15 (d, J = 8.7 Hz, 1H), 6.72 (s, 1H), 6.46 (d, J = 2.6 Hz, 2H), 3.95 - 3.88 (m, 2H), 3.84 (s, 3H), 3.72 (s, 3H), 3.66 - 3.59 (m, 2H), 3.31 - 3.27 (m, 2H), 3.15 - 3.11 (m, 2H), 3.00 (s, 3H). MS (ESI) m/z: 489 [M+H]+. |
IV-2 | TFA salt |
1H-NMR (600 MHz; Methanol-d 4): δ 8.13 (dd, J = 7.8, 1.4 Hz, 1H), 7.80 - 7.75 (m, 2H), 7.55 (d, J = 6.9 Hz, 1H), 7.53 - 7.47 (m, 1H), 7.19 (t, J = 4.3 Hz, 1H), 6.86 (s, 1H), 6.61 - 6.59 (m, 1H), 6.48 (d, J = 2.5 Hz, 1H), 3.96 - 3.86 (m, 6H), 3.72 (s, 3H), 3.44 - 3.43 (m, 4H), 3.11 - 3.04 (m, 4H), 2.92 (d, J = 3.5 Hz, 5H), 2.19 (d, J = 12.4 Hz, 2H), 1.91 - 1.89 (m, 2H). MS (ESI) m/z: 572 [M+H]+. |
IV-3 | TFA salt |
1H-NMR (600 MHz; Methanol-d 4): δ 8.16 - 8.15 (m, 1H), 7.82 (t, J = 5.4 Hz, 2H), 7.60 - 7.57 (m, 1H), 7.49 (d, J = 8.1 Hz, 1H), 7.34 - 7.33 (m, 2H), 7.25 (d, J = 8.7 Hz, 2H), 6.58 (d, J = 2.1 Hz, 1H), 4.02 (s, 1H), 3.70 (d, J = 16.1 Hz, 5H), 3.38-3.35 (m, 2H), 2.19 - 2.16 (m, 2H), 1.93 - 1.92 (m, 2H). MS (ESI) m/z: 460 [M+H]+. |
IV-4 | TFA salt |
1H-NMR (600 MHz; Methanol-d 4): δ 8.18-8.17 (m, 1H), 7.85 (s, 2H), 7.62-7.61 (m, 3H), 7.50 - 7.49 (m, 1H), 7.37 (d, J = 5.7 Hz, 2H), 6.61 (s, 1H), 3.68 (s, 3H). MS (ESI) m/z: 440 [M+H]+. |
2. 화합물 II의 화학식.
실시예 7.
화합물 IIA의 합성 화학식.
화합물 10의 제조.
화합물 1(100mg, 0.53mmol), 탄산세슘(350mg, 1.06mmol)을 1ml의 DMF에 용해시킨 후에, 질소 분위기에서 그 용액 속에 디메틸 설페이트(1mL)를 첨가한다. 생성된 반응액을 실온에서 5h동안 교반한다. 반응이 중지되면, 반응액에 물 50mL를 천천히 첨가하고, 시스템이 냉각되면 에틸 아세테이트를 첨가하고 액체를 분리하며, 유기상은 포화 염화나트륨 용액으로 2회 세척, 무수 황산나트륨 건조, 실리카 겔 칼럼 크로마토그래피 농축(석유 에테르/에틸 아세테이트=2/1)으로 화합물 10(백색 고체, 76.3mg, 수득률 70%)을 얻어서 다음 반응에 직접 사용한다.
MS (ESI) m/z: 203 [M+H]+.
화합물 11의 제조.
화합물 10(101mg. 0.5mmol)을 N,N-디메틸포름아미드(4mL)에 용해시키고, 아이스 배스 조건 하에서 수소화나트륨(60mg, 2.5mmol)을 넣고 5-10min동안 교반한 후, 2-메틸티오아닐린(69.6mg, 0.5mmol)을 첨가하여 실온 하에서 교반하며, 밤새 반응시킨다. 화합물 10이 완전히 반응하면(LC-MS 추적) 반응을 중지한다. 시스템에 얼음을 첨가하여 수소화나트륨을 담금질하며, 에틸 아세테이트를 넣고 액체를 분리한다. 유기상은 포화 염화나트륨 용액으로 2회 세척, 무수 황산나트륨 건조, 실리카 겔 칼럼 크로마토그래피 농축(석유 에테르/에틸 아세테이트=2/1)으로 화합물 11(고체, 64.7 mg, 수득률 42.5%)를 얻어서 다음 반응에 직접 사용한다.
MS (ESI) m/z: 305 [M+H]+.
화합물 IIA의 제조.
방법 A.
화합물 11(30.0mg, 0.09mmol), 아닐린(0.072mmol)을 1mL의 tert-부탄올에 용해시킨 후에, 그 용액 속에 2-디시클로헥실포스피노-2,4,6-트리이소프로필비페닐(7.7mg, 0.016mmol), 트리스(디벤질리덴아세톤)디팔라듐(9.9mg, 0.011mmol), 탄산칼륨(37mg, 0.27mmol)을 첨가하고, 질소 분위기에서, 생성된 반응액을 120℃로 예열된 오일 배스에 놓고 가열 교반하며, 아닐린이 완전히 반응하면(LC-MS 및 TLC 추적) 반응을 중지한다. 반응액에 메탄올과 디클로로메테인을 첨가하고, 시스템을 여과하며, 직접 실리카 겔 칼럼 크로마토그래피 농축(디클로로메테인/메탄올)으로 화합물 IIA를 얻는다.
방법 B.
화합물 11(30.0mg, 0.09mmol), 아닐린(0.072mmol)을 1ml의 tert-부탄올에 용해시킨 후에, 그 용액 속에 2-디시클로헥실포스피노-2,4,6-트리이소프로필비페닐(7.7mg, 0.016mmol), 트리스(디벤질아세톤)디팔라듐(9.9mg, 0.011mmol), 탄산칼륨(37mg, 0.27mmol)을 첨가하고, 질소 분위기에서, 생성된 반응액을 120℃로 예열된 오일 배스에 놓고 가열 교반하며, 아닐린이 완전히 반응하면(LC-MS 및 TLC 추적) 반응을 중지한다. 반응액에 메탄올과 디클로로메테인을 첨가하고, 시스템을 여과, 직접 농축시키며, 역상 제조형. HPLC 정제를 거치고(0.35% 트리플루오로 아세트산을 포함한 수용액과 메탄올이 이동상), 진공 농축시켜 화합물 IIA를 얻는다.
화합물 IIB , IIC, IID , IIE , IIF는 모두 유사한 방법을 사용해 합성한다.
번호 | 구조 | 핵 자기 공명 분광법 및/또는 질량 분석 데이터 |
IIA -1 | 1H NMR (600 MHz, Chloroform-d) δ 8.58 (dd, J = 8.3, 1.3 Hz, 1H), 8.31 (d, J = 8.6 Hz, 1H), 8.18 (s, 1H), 7.53 (dd, J = 7.7, 1.5 Hz, 1H), 7.32 (ddd, J = 8.5, 7.3, 1.6 Hz, 1H), 7.17 (s, 1H), 7.03 (td, J = 7.5, 1.4 Hz, 1H), 7.01 (d, J = 3.0 Hz, 1H), 6.58 - 6.51 (m, 2H), 6.29 (d, J = 3.0 Hz, 1H), 4.13 (s, 3H), 3.86 (s, 3H), 3.19 - 3.13 (m, 4H), 2.61 (t, J = 4.9 Hz, 4H), 2.40 (s, 3H), 2.37 (s, 3H). MS (ESI) m/z: 490 [M+H]+. | |
IIA -2 | 1H NMR (600 MHz, Chloroform-d) δ 8.57 (dd, J = 8.3, 1.3 Hz, 1H), 8.28 (d, J = 8.7 Hz, 1H), 8.18 (s, 1H), 7.53 (dd, J = 7.7, 1.5 Hz, 1H), 7.31 (ddd, J = 8.5, 7.4, 1.6 Hz, 1H), 7.21 (s, 1H), 7.03 (td, J = 7.5, 1.3 Hz, 1H), 7.00 (d, J = 3.0 Hz, 1H), 6.55 (d, J = 2.5 Hz, 1H), 6.52 (dd, J = 8.8, 2.5 Hz, 1H), 6.29 (d, J = 3.0 Hz, 1H), 4.13 (s, 3H), 3.86 (s, 3H), 3.65 - 3.59 (m, 2H), 2.68 (td, J = 12.3, 2.5 Hz, 6H), 2.56 (s, 2H), 2.45 - 2.41 (m, 1H), 2.39 (s, 3H), 2.34 (s, 3H), 1.98 - 1.92 (m, 2H), 1.78 - 1.68 (m, 2H), 1.25 (d, J = 1.4 Hz, 2H). MS (ESI) m/z: 573 [M+H]+. | |
IIA -3 | 1H NMR (600 MHz, DMSO-d 6) δ 8.36 (s, 1H), 8.2454 (s, 1H), 8.12 (d, J = 8.0 Hz, 1H), 7.51 - 7.44 (m, 3H), 7.3433 (d, J = 3.0 Hz, 1H), 7.29 (td, J = 7.7, 1.6 Hz, 1H), 7.20 (td, J = 7.5, 1.4 Hz, 1H), 6.73 (d, J = 9.0 Hz, 2H), 6.12 (d, J = 2.9 Hz, 1H), 4.12 (s, 3H), 3.57 (tq, J = 8.6, 4.0 Hz, 1H), 3.37 (s, 2H), 2.69 (ddd, J = 12.6, 10.2, 2.9 Hz, 2H), 2.40 (s, 3H), 1.85 - 1.78 (m, 2H), 1.49 (dtd, J = 13.0, 9.6, 3.8 Hz, 2H). MS (ESI) m/z: 461 [M+H]+. | |
IIA -4 | 1H NMR (600 MHz, DMSO-d 6) δ 9.16 (s, 1H), 8.37 (s, 1H), 7.84 (d, J = 7.3 Hz, 1H), 7.72 - 7.65 (m, 2H), 7.47 (dt, J = 7.9, 2.4 Hz, 3H), 7.42 (dd, J = 3.2, 1.6 Hz, 1H), 7.31 (tt, J = 5.2, 1.9 Hz, 2H), 7.06 (s, 2H), 6.20 (dd, J = 3.0, 1.6 Hz, 1H), 4.13 (d, J = 1.8 Hz, 3H), 2.39 (d, J = 1.6 Hz, 3H). MS (ESI) m/z: 441 [M+H]+. | |
IIA -5 | MS (ESI) m/z: 615 [M+H]+. | |
IIA -6 | 1H NMR (600 MHz, Chloroform-d) δ 8.53 (d, J = 8.4 Hz, 1H), 8.27 (s, 1H), 7.53 (dt, J = 7.8, 1.5 Hz, 1H), 7.49 (dd, J = 8.8, 1.4 Hz, 2H), 7.30 - 7.25 (m, 1H), 7.24 (s, 1H), 7.06 - 6.99 (m, 2H), 6.93 - 6.88 (m, 2H), 6.29 (dd, J = 3.1, 1.3 Hz, 1H), 4.15 (d, J = 1.3 Hz, 3H), 3.18 (t, J = 4.9 Hz, 4H), 2.63 (t, J = 4.8 Hz, 4H), 2.40 (d, J = 1.3 Hz, 3H), 2.38 (d, J = 1.2 Hz, 3H). MS (ESI) m/z: 460 [M+H]+. | |
IIB -1 | 1H NMR (600 MHz, Chloroform-d) δ 8.65 (dd, J = 8.4, 1.3 Hz, 1H), 8.61 (s, 1H), 8.20 (d, J = 8.5 Hz, 1H), 7.58 (s, 1H), 7.54 (dd, J = 7.7, 1.6 Hz, 1H), 7.31 (ddd, J = 8.6, 7.3, 1.6 Hz, 1H), 7.03 - 6.97 (m, 2H), 6.58 - 6.51 (m, 2H), 6.30 (d, J = 3.0 Hz, 1H), 4.17 (s, 3H), 3.85 (s, 3H), 3.19 (q, J = 6.2, 5.6 Hz, 4H), 3.20 - 3.13 (m, 1H), 2.71 - 2.66 (m, 4H), 2.40 (s, 3H), 1.24 (d, J = 6.7 Hz, 6H). MS (ESI) m/z: 518 [M+H]+. | |
IIB -2 | 1H NMR (600 MHz, Chloroform-d) δ 8.69 (dd, J = 8.5, 1.3 Hz, 1H), 8.57 (s, 1H), 8.28 (d, J = 8.6 Hz, 1H), 7.55 (dd, J = 7.6, 1.6 Hz, 1H), 7.35 (td, J = 8.3, 7.9, 1.6 Hz, 1H), 7.24 (s, 1H), 7.03 - 6.99 (m, 2H), 6.57 - 6.52 (m, 2H), 6.30 (dd, J = 3.0, 0.9 Hz, 1H), 4.17 (s, 3H), 3.86 (s, 3H), 3.63 (d, J = 11.9 Hz, 2H), 3.18 (hept, J = 6.8 Hz, 1H), 2.78 - 2.59 (m, 10H), 2.48 - 2.41 (m, 1H), 2.37 (s, 3H), 1.97 (d, J = 11.8 Hz, 2H), 1.74 (qd, J = 12.1, 3.9 Hz, 2H), 1.25 (d, J = 6.7, 0.9 Hz, 6H). MS (ESI) m/z: 601 [M+H]+. | |
IIB -3 | 1H NMR (600 MHz, Chloroform-d) δ 8.66 - 8.61 (m, 2H), 7.53 (dd, J = 7.5, 1.7 Hz, 1H), 7.46 (d, J = 8.3 Hz, 2H), 7.31 - 7.24 (m, 2H), 7.03 - 6.97 (m, 2H), 6.90 (d, J = 8.4 Hz, 2H), 6.28 (dd, J = 3.1, 1.3 Hz, 1H), 4.16 (s, 3H), 3.82 (dt, J = 9.1, 4.7 Hz, 1H), 3.47 (dt, J = 10.2, 4.6 Hz, 2H), 3.16 (hept, J = 6.6 Hz, 1H), 2.84 (ddd, J = 12.6, 10.1, 3.3 Hz, 2H), 2.01 (dq, J = 11.9, 3.7 Hz, 2H), 1.76 - 1.68 (m, 2H), 1.24 (d, J = 6.7 Hz, 6H). MS (ESI) m/z: 489 [M+H]+. | |
IIB -4 | TFA salt | 1H NMR (600 MHz, DMSO-d 6) δ 10.45 (s, 1H), 9.52 (s, 1H), 7.73 (s, 1H), 7.65 (dd, J = 8.1, 3.3 Hz, 2H), 7.50 (d, J = 8.8 Hz, 2H), 7.48 - 7.40 (m, 4H), 7.23 (s, 2H), 6.34 (d, J = 2.9 Hz, 1H), 4.18 (s, 3H), 3.46 (s, 1H), 1.16 (d, J = 6.6 Hz, 6H). MS (ESI) m/z: 469 [M+H]+. |
IIB -5 | 1H NMR (600 MHz, Chloroform-d) δ 8.33 (dd, J = 8.3, 1.3 Hz, 1H), 8.28 (d, J = 8.1 Hz, 1H), 8.24 (s, 1H), 7.24 (dd, J = 7.7, 1.5 Hz, 1H), 7.07 - 7.03 (m, 1H), 6.94 (s, 1H), 6.74 (d, J = 3.0 Hz, 1H), 6.71 (td, J = 7.4, 1.3 Hz, 1H), 6.65 - 6.62 (m, 2H), 6.02 (d, J = 2.9 Hz, 1H), 3.87 (s, 3H), 3.81 (q, J = 7.0 Hz, 2H), 2.87 (hept, J = 6.6 Hz, 1H), 2.56 (dd, J = 39.1, 28.5 Hz, 2H), 2.31 (s, 4H), 2.23 - 2.12 (m, 5H), 1.99 (s, 3H), 1.74 (d, J = 13.7 Hz, 4H), 1.56 (s, 2H), 1.17 (t, J = 6.9 Hz, 3H), 0.93 (d, J = 6.7 Hz, 6H). MS (ESI) m/z: 643 [M+H]+. | |
IIC-1 | 1H NMR (600 MHz, Chloroform-d) δ 9.04 (s, 1H), 8.42 (d, J = 8.4 Hz, 1H), 8.27 (d, J = 8.7 Hz, 1H), 7.95 (dd, J = 8.0, 1.6 Hz, 1H), 7.63 (td, J = 7.9, 1.6 Hz, 1H), 7.25 - 7.21 (m, 2H), 7.07 (d, J = 2.9 Hz, 1H), 6.54 (d, J = 2.5 Hz, 1H), 6.45 (dd, J = 8.7, 2.5 Hz, 1H), 6.31 (d, J = 2.9 Hz, 1H), 4.05 (s, 3H), 3.85 (s, 3H), 3.15 (t, J = 5.0 Hz, 4H), 3.08 (s, 3H), 2.62 (t, J = 4.8 Hz, 4H), 2.37 (s, 3H). MS (ESI) m/z: 522 [M+H]+. | |
IIC-2 | 1H NMR (600 MHz, Chloroform-d) δ 9.03 (s, 1H), 8.42 (dd, J = 8.4, 1.1 Hz, 1H), 8.26 (d, J = 8.8 Hz, 1H), 7.96 (dd, J = 8.1, 1.6 Hz, 1H), 7.63 (ddd, J = 8.7, 7.3, 1.6 Hz, 1H), 7.25 - 7.21 (m, 2H), 7.07 (d, J = 3.0 Hz, 1H), 6.54 (d, J = 2.5 Hz, 1H), 6.44 (dd, J = 8.8, 2.5 Hz, 1H), 6.31 (d, J = 3.0 Hz, 1H), 4.06 (s, 3H), 3.85 (s, 3H), 3.64 - 3.56 (m, 2H), 3.08 (s, 3H), 2.74 - 2.63 (m, 8H), 2.59 (s, 3H), 2.42 (ddd, J = 11.5, 7.9, 3.6 Hz, 1H), 2.35 (s, 3H), 1.97 - 1.94 (m, 2H), 1.72 (qd, J = 12.1, 3.9 Hz, 2H). MS (ESI) m/z: 605 [M+H]+. | |
IIC-3 | 1H NMR (600 MHz, Chloroform-d) δ 9.07 (s, 1H), 8.41 (dd, J = 8.4, 1.1 Hz, 1H), 7.94 (dd, J = 8.0, 1.6 Hz, 1H), 7.59 (ddd, J = 8.6, 7.3, 1.7 Hz, 1H), 7.49 - 7.40 (m, 2H), 7.25 - 7.18 (m, 1H), 7.07 (d, J = 3.0 Hz, 1H), 6.91 - 6.80 (m, 3H), 6.29 (d, J = 3.0 Hz, 1H), 4.05 (s, 3H), 3.80 (hept, J = 8.8, 4.1 Hz, 1H), 3.47 - 3.38 (m, 2H), 3.07 (s, 3H), 2.82 (ddd, J = 12.6, 9.1, 3.0 Hz, 2H), 2.03 - 1.95 (m, 2H), 1.70 (dtd, J = 13.1, 9.5, 3.8 Hz, 2H). MS (ESI) m/z: 493 [M+H]+. | |
IIC-4 | 1H NMR (600 MHz, DMSO-d 6) δ 9.33 (s, 1H), 9.03 (s, 1H), 8.48 (d, J = 8.3 Hz, 1H), 7.93 (dd, J = 8.1, 1.6 Hz, 1H), 7.88 (d, J = 8.7 Hz, 2H), 7.79 - 7.75 (m, 1H), 7.63 - 7.59 (m, 2H), 7.52 (d, J = 3.0 Hz, 1H), 7.38 (t, J = 7.4 Hz, 1H), 7.10 (s, 2H), 6.30 (d, J = 3.0 Hz, 1H), 4.09 (s, 3H), 3.29 (s, 3H). MS (ESI) m/z: 473 [M+H]+. | |
IIC-5 | 1H NMR (600 MHz, Chloroform-d) δ 9.06 (s, 1H), 8.44 - 8.37 (m, 1H), 7.96 - 7.90 (m, 1H), 7.57 (t, J = 8.6 Hz, 1H), 7.45 (dd, J = 8.9, 2.8 Hz, 2H), 7.20 (td, J = 7.7, 2.7 Hz, 1H), 7.06 (d, J = 3.1 Hz, 1H), 6.94 - 6.82 (m, 3H), 6.28 (t, J = 2.9 Hz, 1H), 4.05 - 4.01 (m, 3H), 3.13 (dd, J = 6.0, 3.1 Hz, 4H), 3.08 - 3.00 (m, 3H), 2.59 (dd, J = 7.1, 3.4 Hz, 4H), 2.42 - 2.30 (m, 3H). MS (ESI) m/z: 492 [M+H]+. | |
IIC-6 | 1H NMR (600 MHz, Chloroform-d) δ 9.06 (s, 1H), 8.43 (dd, J = 8.4, 1.1 Hz, 1H), 8.22 (d, J = 8.7 Hz, 1H), 7.96 (dd, J = 8.0, 1.6 Hz, 1H), 7.62 (ddd, J = 8.6, 7.3, 1.6 Hz, 1H), 7.34 (s, 1H), 7.26 - 7.21 (m, 1H), 7.08 (d, J = 3.0 Hz, 1H), 6.56 (d, J = 2.5 Hz, 1H), 6.43 (dd, J = 8.8, 2.6 Hz, 1H), 6.32 (d, J = 3.0 Hz, 1H), 4.09 (t, J = 6.9 Hz, 2H), 4.06 (s, 3H), 3.82 (hept, J = 8.7, 4.1 Hz, 1H), 3.41 (dt, J = 10.6, 4.7 Hz, 2H), 3.09 (s, 3H), 2.87 - 2.79 (m, 2H), 2.04 - 1.98 (m, 2H), 1.73 (dtd, J = 13.0, 9.3, 3.7 Hz, 2H), 1.44 (t, J = 6.9 Hz, 3H). MS (ESI) m/z: 537 [M+H]+. | |
IID -1 | 1H NMR (600 MHz, Chloroform-d) δ 9.27 (s, 1H), 8.42 (dd, J = 8.5, 1.1 Hz, 1H), 8.26 (d, J = 8.8 Hz, 1H), 7.88 (dd, J = 8.0, 1.6 Hz, 1H), 7.61 (ddd, J = 8.6, 7.3, 1.6 Hz, 1H), 7.27 - 7.19 (m, 2H), 7.07 (d, J = 3.0 Hz, 1H), 6.54 (d, J = 2.5 Hz, 1H), 6.43 (dd, J = 8.8, 2.5 Hz, 1H), 6.31 (d, J = 3.0 Hz, 1H), 4.07 (s, 3H), 3.86 (s, 3H), 3.24 (hept, J = 7.0 Hz, 1H), 3.20 - 3.15 (m, 4H), 2.68 - 2.63 (m, 4H), 2.40 (s, 3H), 1.29 (d, J = 6.8 Hz, 6H). MS (ESI) m/z: 550 [M+H]+. | |
IID -2 | 1H NMR (600 MHz, Chloroform-d) δ 9.27 (s, 1H), 8.42 (dd, J = 8.4, 1.1 Hz, 1H), 8.25 (d, J = 8.8 Hz, 1H), 7.87 (dd, J = 8.0, 1.6 Hz, 1H), 7.62 (ddd, J = 8.6, 7.3, 1.7 Hz, 1H), 7.23 - 7.20 (m, 2H), 7.06 (d, J = 3.0 Hz, 1H), 6.55 (d, J = 2.5 Hz, 1H), 6.43 (dd, J = 8.8, 2.6 Hz, 1H), 6.30 (d, J = 3.0 Hz, 1H), 4.07 (s, 3H), 3.86 (s, 3H), 3.62 - 3.58 (m, 2H), 3.24 (h, 1H), 2.73 - 2.62 (m, 6H), 2.54 (s, 2H), 2.43 - 2.36 (m, 1H), 2.32 (s, 3H), 2.20 (s, 2H), 1.95 (d, J = 12.3 Hz, 2H), 1.72 (qd, J = 12.1, 3.9 Hz, 2H), 1.28 (d, J = 6.8 Hz, 6H). MS (ESI) m/z: 633 [M+H]+. | |
IID -3 | 1H NMR (600 MHz, Chloroform-d) δ 9.31 (s, 1H), 8.41 (d, J = 8.4 Hz, 1H), 7.87 (dd, J = 8.0, 1.6 Hz, 1H), 7.61 - 7.55 (m, 1H), 7.45 (d, J = 8.9 Hz, 2H), 7.21 (t, J = 7.6 Hz, 1H), 7.07 (d, J = 3.0 Hz, 1H), 6.90 - 6.84 (m, 2H), 6.82 (d, J = 9.6 Hz, 1H), 6.29 (d, J = 2.9 Hz, 1H), 4.07 (s, 3H), 3.81 (hept, J = 8.7, 4.0 Hz, 1H), 3.46 - 3.42 (m, 2H), 3.23 (hept, J = 6.9 Hz, 1H), 2.83 (td, J = 10.9, 9.7, 2.9 Hz, 2H), 2.01 (dd, J = 12.9, 4.3 Hz, 2H), 1.72 (dtd, J = 13.0, 9.4, 3.7 Hz, 2H), 1.28 (d, J = 6.8 Hz, 6H). MS (ESI) m/z: 521 [M+H]+. | |
IID -4 | 1H NMR (600 MHz, DMSO-d 6) δ 9.35 (s, 1H), 9.16 (s, 1H), 8.45 (dd, J = 8.4, 1.1 Hz, 1H), 7.90 (d, J = 1.9 Hz, 1H), 7.88 (d, J = 2.0 Hz, 1H), 7.86 (dd, J = 8.0, 1.6 Hz, 1H), 7.78 (ddd, J = 8.6, 7.3, 1.6 Hz, 1H), 7.61 - 7.58 (m, 2H), 7.53 (d, J = 3.0 Hz, 1H), 7.38 (ddd, J = 8.2, 7.3, 1.1 Hz, 1H), 7.10 (s, 2H), 6.30 (d, J = 3.0 Hz, 1H), 4.10 (s, 3H), 3.51 (hept, J = 7.0 Hz, 1H), 1.17 (d, J = 6.7 Hz, 6H). MS (ESI) m/z: 501 [M+H]+. | |
IID -5 | 1H NMR (600 MHz, Chloroform-d) δ 9.30 (s, 1H), 8.41 (dd, J = 8.5, 1.1 Hz, 1H), 7.86 (dd, J = 8.0, 1.6 Hz, 1H), 7.60 - 7.52 (m, 1H), 7.49 - 7.43 (m, 2H), 7.20 (ddt, J = 8.2, 7.2, 1.0 Hz, 1H), 7.06 (d, J = 3.0 Hz, 1H), 6.90 - 6.79 (m, 3H), 6.28 (dd, J = 3.1, 0.8 Hz, 1H), 4.06 (s, 3H), 3.23 (hept, J = 6.9 Hz, 1H), 3.16 - 3.11 (m, 4H), 2.61 - 2.58 (m, 4H), 2.35 (s, 3H), 1.28 (d, J = 6.9 Hz, 6H). MS (ESI) m/z: 520 [M+H]+. | |
IID -6 | 1H NMR (600 MHz, Chloroform-d) δ 9.29 (s, 1H), 8.42 (d, J = 8.4 Hz, 1H), 8.20 (d, J = 8.7 Hz, 1H), 7.88 (d, J = 7.9, 1.7 Hz, 1H), 7.60 (t, 1H), 7.34 (s, 1H), 7.23 (t, J = 7.6 Hz, 1H), 7.07 (d, J = 3.0 Hz, 1H), 6.56 (s, 1H), 6.4369 - 6.37 (m, 1H), 6.31 (d, J = 3.0 Hz, 1H), 4.08 - 4.07 (m, 5H), 3.83 (dq, J = 8.9, 4.7 Hz, 1H), 3.46 - 3.39 (m, 2H), 3.24 (hept, J = 6.8 Hz, 1H), 2.82 (d, J = 12.1 Hz, 2H), 2.04 - 2.01 (m, 2H), 1.77 - 1.70 (m, 2H), 1.45 (t, J = 7.0 Hz, 3H), 1.28 (d, J = 7.0 Hz, 6H). MS (ESI) m/z: 565 [M+H]+. | |
IID -7 | 1H NMR (600 MHz, Chloroform-d) δ 9.35 (s, 1H), 8.50 (d, J = 8.3 Hz, 1H), 8.39 (dd, J = 8.5, 1.1 Hz, 1H), 7.90 (dd, J = 8.0, 1.6 Hz, 1H), 7.67 - 7.57 (m, 2H), 7.25 - 7.23 (m, 1H), 7.12 (d, J = 3.1 Hz, 1H), 6.94 (d, J = 1.8 Hz, 1H), 6.86 (dd, J = 8.3, 1.8 Hz, 1H), 6.36 (d, J = 3.0 Hz, 1H), 4.16 - 4.11 (m, 2H), 4.11 (s, 3H), 3.24 (h, J = 6.9 Hz, 1H), 2.96 - 2.81 (m, 2H), 2.68 (s, 6H), 2.54 - 2.49 (m, 1H), 2.38 (s, 3H), 2.09 - 1.97 (m, 6H), 1.90 (s, 2H), 1.47 (t, J = 6.9 Hz, 3H), 1.29 (d, J = 6.8 Hz, 6H). MS (ESI) m/z: 675 [M+H]+. | |
IID -8 | TFA salt | 1H NMR (600 MHz, Methanol-d 4) δ 8.22 (d, J = 8.2 Hz, 1H), 7.98 (dd, J = 7.9, 1.6 Hz, 1H), 7.73 - 7.67 (m, 1H), 7.53 (d, J = 2.9 Hz, 1H), 7.54 - 7.48 (m, 1H), 7.35 (s, 1H), 6.90 (s, 1H), 6.32 (d, J = 3.0 Hz, 1H), 4.63 (hept, J = 6.1 Hz, 1H), 4.22 (s, 3H), 3.90 - 3.85 (m, 2H), 3.64 (d, J = 12.3 Hz, 2H), 3.37 (hept, J = 13.8, 6.9 Hz, 1H), 3.10 (q, J = 7.8, 6.4 Hz, 1H), 2.93 (s, 3H), 2.17 (s, 3H), 2.01 (td, J = 11.1, 10.0, 3.4 Hz, 4H), 1.26 (d, J = 6.0 Hz, 6H), 1.24 (d, J = 6.8 Hz, 6H). MS (ESI) m/z: 591 [M+H]+. |
IID -9 | TFA salt | 1H NMR (600 MHz, Methanol-d 4) δ 8.22 - 8.17 (m, 1H), 7.98 (dd, J = 7.9, 1.5 Hz, 1H), 7.69 (dd, J = 9.0, 7.3 Hz, 1H), 7.53 (d, J = 3.0 Hz, 1H), 7.50 (t, J = 7.8 Hz, 1H), 7.32 (s, 1H), 6.91 (s, 1H), 6.32 (d, J = 2.9 Hz, 1H), 4.22 (s, 3H), 3.86 (s, 3H), 3.65 (d, J = 12.4 Hz, 2H), 3.41 - 3.33 (m, 1H), 3.21 (ddd, J = 15.8, 10.1, 3.3 Hz, 2H), 3.17 - 3.10 (m, 1H), 2.94 (s, 3H), 2.18 (s, 3H), 2.05 (dt, J = 15.5, 11.6 Hz, 4H), 1.23 (d, J = 6.8 Hz, 6H). MS (ESI) m/z: 563 [M+H]+. |
IIE -1 | MS (ESI) m/z: 620[M+H]+. | |
IIF -1 | 1H NMR (600 MHz, DMSO-d 6) δ 10.82 (s, 1H), 8.31 (dd, J = 8.6, 4.0 Hz, 1H), 8.10 (d, J = 8.7 Hz, 1H), 7.56 (ddd, J = 14.0, 7.6, 1.6 Hz, 1H), 7.51 (td, J = 7.4, 1.4 Hz, 1H), 7.36 (d, J = 2.9 Hz, 1H), 7.15 - 7.09 (m, 1H), 7.08 (s, 1H), 6.62 (d, J = 2.5 Hz, 1H), 6.43 (dd, J = 8.8, 2.5 Hz, 1H), 6.15 (d, J = 2.9 Hz, 1H), 4.07 (s, 3H), 3.82 (s, 3H), 3.55 - 3.27 (m, 2H), 3.16 - 2.99 (m, 4H), 2.48 (s, 2H), 2.25 (s, 3H), 1.80 (d, J = 13.5 Hz, 6H). MS (ESI) m/z: 520[M+H]+. | |
IIF -2 | 1H NMR (600 MHz, DMSO-d 6) δ 10.87 (s, 1H), 8.29 (dd, J = 8.4, 4.1 Hz, 1H), 8.02 (s, 1H), 7.57 (ddd, J = 14.0, 7.8, 1.6 Hz, 1H), 7.50 (td, J = 8.0, 1.6 Hz, 1H), 7.39 (d, J = 3.0 Hz, 1H), 7.23 (s, 1H), 7.13 (td, J = 7.9, 7.3, 1.8 Hz, 1H), 6.62 (d, J = 2.5 Hz, 1H), 6.45 (dd, J = 8.8, 2.6 Hz, 1H), 6.15 (d, J = 2.9 Hz, 1H), 4.07 (s, 3H), 3.81 (s, 3H), 3.77 (td, J = 6.1, 3.2 Hz, 1H), 3.67 (d, J = 12.5 Hz, 2H), 2.88 (s, 6H), 2.62 (td, J = 12.1, 2.4 Hz, 3H), 1.91 (s, 2H), 1.80 (d, J = 13.4 Hz, 6H), 1.59 (s, 2H), 1.04 (d, J = 6.1 Hz, 4H). MS (ESI) m/z: 603[M+H]+. | |
IIF -3 | 1H NMR (600 MHz, DMSO-d 6) δ 10.78 (s, 1H), 8.42 (d, J = 9.3 Hz, 2H), 7.61 - 7.48 (m, 4H), 7.35 (d, J = 3.0 Hz, 1H), 7.16 - 7.08 (m, 1H), 6.85 - 6.79 (m, 2H), 6.15 (d, J = 3.0 Hz, 1H), 4.07 (s, 3H), 3.57 (dt, J = 9.0, 4.8 Hz, 1H), 3.38 (dq, J = 11.5, 7.1, 5.8 Hz, 4H), 2.72 (ddd, J = 12.6, 10.3, 3.0 Hz, 2H), 1.80 (d, J = 13.5 Hz, 6H), 1.51 (dtd, J = 13.0, 9.6, 3.8 Hz, 2H). MS (ESI) m/z: 491[M+H]+. | |
IIF -4 | 1H NMR (600 MHz, DMSO-d 6) δ 10.77 (s, 1H), 8.42 (d, J = 5.4 Hz, 2H), 7.63 - 7.58 (m, 2H), 7.58 - 7.49 (m, 2H), 7.35 (d, J = 3.0 Hz, 1H), 7.12 (tdd, J = 7.4, 2.1, 1.0 Hz, 1H), 6.84 - 6.79 (m, 2H), 6.14 (d, J = 3.0 Hz, 1H), 4.07 (s, 3H), 3.12 - 2.97 (m, 4H), 2.47 (t, J = 5.0 Hz, 4H), 2.23 (s, 3H), 1.80 (d, J = 13.5 Hz, 6H). MS (ESI) m/z: 490[M+H]+. | |
IIF -5 | 1H NMR (600 MHz, DMSO-d 6) δ 10.69 (s, 1H), 8.46 (s, 1H), 8.34(s, 1H), 7.87 (s, 1H), 7.61 - 7.49 (m, 2H), 7.42 (s, 1H), 7.34 (d, J = 3.0 Hz, 1H), 7.13 (tt, J = 7.6, 1.3 Hz, 1H), 6.13 (d, J = 2.9 Hz, 1H), 4.05 (s, 3H), 3.98 (s, 1H), 2.88 (d, J = 11.3 Hz, 2H), 2.24 (s, 3H), 2.09 (d, J = 9.2 Hz, 2H), 1.94 - 1.87 (m, 4H), 1.79 (d, J = 13.5 Hz, 6H). MS (ESI) m/z: 479[M+H]+. |
실시예 8.
화합물 IIG의 합성 화학식.
화합물 12의 제조.
화합물 10(76.3mg, 0.38mmol), 메틸 o-아미노벤조에이트(62.7mg, 0.42mmol)를 3ml의 tert-부탄올에 용해시킨 후에, 그 용액 속에 트리플루오로 아세트산(0.085mL, 1.14mmol)을 첨가한다. 생성된 반응액을 85℃로 예열된 오일 배스에 놓고 화합물 10이 완전히 반응할 때까지(LC-MS 추적) 가열 교반한다. 반응이 중지되면, 반응액에 포화 중탄산나트륨 용액 40mL를 넣고 액체를 분리하며, 유기상은 포화 염화나트륨 용액으로 2회 세척, 무수 황산나트륨 건조, 실리카 겔 칼럼 크로마토그래피 농축(디클로로메테인/메탄올=1/25)으로 화합물 12(백색 고체, 43.2mg, 수득률 56.2%)를 얻어서 다음 반응에 직접 사용한다.
MS (ESI) m/z: 317 [M+H]+.
화합물 IIG의 제조.
방법 A.
화합물 12(20.0mg, 0.06mmol), 아닐린(0.06mmol)을 1mL의 tert-부탄올에 용해시킨 후에, 그 용액 속에 트리플루오로 아세트산(28μL, 0.36mmol)을 첨가한다. 생성된 반응액을 110℃로 예열된 오일 배스에 놓고 아닐린이 완전히 반응할 때까지(LC-MS 추적) 가열 교반한다. 반응이 중지되면, 반응액에 포화 중탄산나트륨 용액 10mL를 넣고 액체를 분리하며, 유기상은 포화 염화나트륨 용액으로 2회 세척, 무수 황산나트륨 건조, 실리카 겔 칼럼 크로마토그래피 농축(디클로로메테인/메탄올)으로 화합물 IIG를 얻는다.
방법 B.
화합물 12(20.0mg, 0.06mmol), 아닐린(0.06mmol)을 1mL의 tert-부탄올에 용해시킨 후에, 그 용액 속에 트리플루오로 아세트산(28μL, 0.36mmol)을 첨가한다. 생성된 반응액을 110℃로 예열된 오일 배스에 놓고 아닐린이 완전히 반응할 때까지(LC-MS 추적) 가열 교반한다. 반응이 중지되면, 농축시켜 역상 제조형 HPLC 정제를 거치고(0.35% 트리플루오로 아세트산을 포함한 수용액과 메탄올이 이동상), 진공 농축시켜 화합물 IIG를 얻는다.
화합물 IIH는 유사한 방법을 사용해 합성한다.
번호 | 구조 | 핵 자기 공명 분광법 및/또는 질량 분석 데이터 |
IIG -1 | 1H-NMR (600 MHz; Methanol-d 4): δ 8.74 - 8.73 (m, 1H), 8.10 - 8.08 (m, 1H), 7.89 (d, J = 8.7 Hz, 1H), 7.50 (td, J = 7.8, 1.6 Hz, 1H), 7.30 (d, J = 3.1 Hz, 1H), 7.10 (td, J = 7.6, 0.8 Hz, 1H), 6.71 (d, J = 2.5 Hz, 1H), 6.55 (dd, J = 8.8, 2.5 Hz, 1H), 6.21 (d, J = 3.0 Hz, 1H), 4.24 (s, 3H), 3.98 (s, 3H), 3.90 (s, 3H), 3.37 (s, 3H), 3.24 - 3.23 (m, 2H), 2.72 - 2.71 (m, 2H), 2.42 (s, 2H). MS (ESI) m/z: 502 [M+H]+. | |
IIG -2 | 1H-NMR (600 MHz; Methanol-d 4): δ 8.75 - 8.74 (m, 1H), 8.10 - 8.09 (m, 1H), 7.79 - 7.78 (m, 1H), 7.52 - 7.49 (m, 1H), 7.33 - 7.32 (m, 1H), 7.13 - 7.10 (m, 1H), 6.72 - 6.71 (m, 1H), 6.58 - 6.56 (m, 1H), 6.22 (d, J = 2.7 Hz, 1H), 4.24 (s, 3H), 3.98 (s, 3H), 3.89 - 3.88 (m, 3H), 3.76 - 3.73 (m, 2H), 2.78 - 2.75 (m, 8H), 2.49 (d, J = 4.0 Hz, 4H), 2.07 - 2.04 (m, 6H). MS (ESI) m/z: 585 [M+H]+. | |
IIG -3 | 1H-NMR (600 MHz; Methanol-d 4): δ 8.88 (dd, J = 8.6, 0.8 Hz, 1H), 8.09 (dd, J = 8.0, 1.5 Hz, 1H), 7.50 (ddd, J = 8.7, 7.1, 1.6 Hz, 1H), 7.45 - 7.44 (m, 1H), 7.26 (dd, J = 26.7, 2.7 Hz, 1H), 7.09 (td, J = 7.6, 1.0 Hz, 1H), 7.01 - 7.00 (m, 2H), 6.21 (d, J = 3.0 Hz, 1H), 4.24 (s, 3H), 3.98 (s, 3H), 3.78 (dd, J = 4.5, 0.5 Hz, 1H), 3.52-3.49 (m, 2H), 2.90 - 2.86 (m, 2H), 2.04 - 2.00 (m, 2H), 1.74 - 1.71 (m, 2H). MS (ESI) m/z: 473 [M+H]+. | |
IIG -4 | TFA salt |
1H-NMR (600 MHz; Methanol-d 4): δ 8.49 (d, J = 8.3 Hz, 1H), 8.13 (dd, J = 8.0, 1.5 Hz, 1H), 7.74 (d, J = 8.0 Hz, 1H), 7.58 - 7.54 (m, 2H), 7.30 - 7.27 (m, 1H), 7.19 (d, J = 1.5 Hz, 1H), 7.00 (dd, J = 8.0, 1.7 Hz, 1H), 6.36 (d, J = 3.0 Hz, 1H), 4.32 (s, 3H), 3.98 (s, 3H), 3.92 (s, 3H), 3.38-3.35 (m, 2H), 3.24 - 3.21 (m, 2H), 3.12 - 3.10 (m, 2H), 2.99 (d, J = 3.1 Hz, 2H), 2.90 (s, 3H), 2.10 - 1.95 (m, 2H), 1.63 - 1.62 (m, 2H). MS (ESI) m/z: 613 [M+H]+. |
IIH -1 | TFA salt |
1H-NMR (600 MHz; Methanol-d 4): δ 8.18 (t, J = 0.3 Hz, 1H), 7.95 - 7.94 (m, 1H), 7.83 - 7.81 (m, 1H), 7.55 - 7.52 (m, 1H), 7.47 (d, J = 1.0 Hz, 1H), 7.32 - 7.30 (m, 1H), 6.71 (s, 1H), 6.38 - 6.36 (m, 1H), 6.29 (t, J = 1.3 Hz, 1H), 4.21 (s, 3H), 3.92 (d, J = 1.1 Hz, 3H), 3.85 (s, 3H), 3.68 - 3.63 (m, 2H), 3.13 - 3.07 (m, 2H), 3.01 (s, 3H). MS (ESI) m/z: 502 [M+H]+. |
IIH -2 | TFA salt |
1H-NMR (600 MHz; Methanol-d 4): δ 8.17 (t, J = 1.6 Hz, 1H), 8.06-8.04 (m, 1H), 7.80-7.79 (m, 1H), 7.63 (t, J = 7.9 Hz, 1H), 7.55 (d, J = 2.9 Hz, 1H), 7.50 (d, J = 9.0 Hz, 2H), 7.31 (d, J = 9.0 Hz, 2H), 6.40 (d, J = 3.0 Hz, 1H), 4.24 (s, 3H), 4.09-4.08 (m, 1H), 3.93 (s, 3H), 3.77-3.73 (m, 2H), 3.49-3.45 (m, 2H), 2.24-2.20 (m, 2H), 2.01-1.98 (m, 2H). MS (ESI) m/z: 473 [M+H]+. |
실시예 9.
화합물 III의 합성 화학식.
화합물 13의 제조.
화합물 10(66mg, 0.33mmol), 2-메틸티오벤질아민(50mg, 0.33mmol)을 2mL의 tert-부탄올에 용해시킨 후에, 그 용액 속에 N,N-디이소프로필에틸아민(0.74mL, 4.47mmol)을 첨가한다. 생성된 반응액을 120℃로 예열된 오일 배스에 놓고 화합물 10이 완전히 반응할 때까지(LC-MS 추적) 가열 교반한다. 반응이 중지되면, 반응액을 농축하고, 실리카 겔 칼럼 크로마토그래피(에틸 아세테이트/석유 에테르=1/1)로 화합물 13(백색 고체, 60mg, 수득률 57%)을 얻어서 다음 반응에 직접 사용한다.
MS (ESI) m/z: 319 [M+H]+.
화합물 III의 제조.
방법 A.
화합물 13(20mg, 0.06mmol), 아닐린(0.05mmol)을 2ml의 tert-부탄올에 용해시킨 후에, 그 용액 속에 2-디시클로헥실포스피노-2',4',6'-트리이소프로필비페닐(9.6mg, 0.05mmol), 트리스(디벤질아세톤)디팔라듐(5.1mg, 0.01mmol), 탄산칼륨(24.8mg, 0.18mmol)을 첨가하고, N2 보호 조건 하에서 생성된 반응액을 120℃로 예열된 오일 배스에 놓고 화합물 13이 완전히 반응할 때까지(LC-MS 추적) 가열 교반한다. 반응이 중지되면, 1섹션 실리카 겔 칼럼 여과, 농축, 실리카 겔 칼럼 크로마토그래피(디클로로메테인/메탄올=20/3)로 화합물 III을 얻는다.
방법 B.
화합물 13(20mg, 0.06mmol), 아닐린(0.05mmol)을 2mL의 tert-부탄올에 용해시킨 후에, 그 용액 속에 2-디시클로헥실포스피노-2',4',6'-트리이소프로필비페닐(9.6mg, 0.05mmol), 트리스(디벤질아세톤)디팔라듐(5.1mg, 0.01mmol), 탄산칼륨(24.8mg, 0.18mmol)을 첨가하고, N2 보호 조건 하에서 생성된 반응액을 120℃로 예열된 오일 배스에 놓고 화합물 13이 완전히 반응할 때까지(LC-MS 추적) 가열 교반한다. 반응이 중지되면, 1섹션 실리카 겔 칼럼 여과, 농축시켜 역상 제조형 HPLC 정제를 거치고(0.35% 트리플루오로 아세트산을 포함한 수용액과 메탄올이 이동상), 진공 농축을 거쳐 화합물 III를 얻는다.
화합물 IIJ , IIK , IIL은 모두 유사한 방법을 사용해 제조한다.
번호 | 구조 | 핵 자기 공명 분광법 및/또는 질량 분석 데이터 |
III-1 | 1H NMR (600 MHz, DMSO-d 6) δ 7.96 (d, J = 8.8 Hz, 1H), 7.36 - 7.29 (m, 3H), 7.28 - 7.26 (m, 1H), 7.26 - 7.23 (m, 1H), 7.22 - 7.13 (m, 1H), 7.12 - 7.08 (m, 1H), 6.58 (d, J = 2.5 Hz, 1H), 6.08 (t, J = 3.9 Hz, 1H), 4.68 (d, J = 5.6 Hz, 2H), 4.04 (s, 3H), 3.80 (d, J = 6.4 Hz, 3H), 3.10 (t, J = 4.8 Hz, 4H), 2.62 (t, J = 4.9 Hz, 4H), 2.55 (s, 3H), 2.34 (s, 3H). MS (ESI) m/z: 504 [M+H]+. | |
III-2 | TFA salt |
1H NMR (600 MHz, DMSO-d 6) δ 8.47 (t, J = 5.6 Hz, 1H), 8.47 (t, J = 5.6 Hz, 1H), 7.54 (d, J = 2.9 Hz, 1H), 7.40 - 7.36 (m, 1H), 7.31 (t, J = 7.6 Hz, 1H), 7.25 (d, J = 7.6 Hz, 1H), 7.17 (d, J = 8.5 Hz, 2H), 7.13 (td, J = 7.4, 1.3 Hz, 1H), 7.01 (s, 2H), 6.23 (d, J = 2.9 Hz, 1H), 4.70 (d, J = 5.6 Hz, 2H), 4.11 (s, 2H), 3.74 (s, 1H), 3.52 - 3.45 (m, 2H), 3.06 (s, 2H), 2.55 (d, J = 7.2 Hz, 6H), 1.92 (d, J = 13.1 Hz, 2H), 1.67 - 1.56 (m, 2H). MS (ESI) m/z: 475 [M+H]+. |
III-3 | 1H NMR (600 MHz, DMSO-d 6) δ 9.06 (s, 1H), 7.71 - 7.68 (m, 2H), 7.51 - 7.47 (m, 2H), 7.37 - 7.31 (m, 3H), 7.28 (dd, J = 11.1, 4.5 Hz, 1H), 7.24 (t, J = 6.0 Hz, 1H), 7.12 (td, J = 7.4, 1.2 Hz, 1H), 7.05 (s, 2H), 6.15 (d, J = 2.9 Hz, 1H), 4.74 (d, J = 5.7 Hz, 2H), 4.07 (s, 3H), 2.58 (s, 3H). MS (ESI) m/z: 455 [M+H]+. | |
III-4 | TFA salt |
1H NMR (600 MHz, DMSO-d 6) δ 9.09 (s, 1H), 8.33 (s, 1H), 7.51 (d, J = 3.0 Hz, 1H), 7.35 (dd, J = 8.0, 1.3 Hz, 1H), 7.30 (td, J = 7.6, 1.4 Hz, 1H), 7.25 - 7.21 (m, 1H), 7.19 - 7.15 (m, 1H), 7.12 (ddd, J = 7.4, 6.0, 1.3 Hz, 1H), 6.76 (s, 1H), 6.46 (d, J = 8.4 Hz, 1H), 6.22 (d, J = 2.9 Hz, 1H), 4.72 (d, J = 5.7 Hz, 2H), 4.09 (s, 3H), 4.03 (q, J = 7.0 Hz, 2H), 3.54 - 3.51 (m, 2H), 2.99 (s, 2H), 2.54 (s, 3H), 1.91 - 1.84 (m, 2H), 1.55 (d, J = 10.9 Hz, 2H), 1.21 (t, J = 6.9 Hz, 3H). MS (ESI) m/z: 519 [M+H]+. |
IIJ -1 | 1H NMR (600 MHz, Chloroform-d) δ 8.31 (d, J = 8.6 Hz, 1H), 7.43 (dd, J = 7.9, 1.3 Hz, 1H), 7.40 (dd, J = 7.7, 1.6 Hz, 1H), 7.32 (s, 1H), 7.23 (td, J = 7.6, 1.6 Hz, 1H), 7.19 - 7.13 (m, 1H), 6.84 (d, J = 3.0 Hz, 1H), 6.56 - 6.49 (m, 2H), 6.17 (d, J = 3.0 Hz, 1H), 5.67 - 5.62 (m, 1H), 4.90 (d, J = 5.8 Hz, 2H), 3.92 (s, 3H), 3.85 (s, 3H), 3.44 (hept, J = 6.7 Hz, 1H), 3.14 (t, J = 5.0 Hz, 4H), 2.60 (d, J = 4.9 Hz, 4H), 2.35 (s, 3H), 1.33 (s, 3H), 1.32 (s, 3H). MS (ESI) m/z: 532 [M+H]+ | |
IIJ -2 | 1H NMR (600 MHz, Chloroform-d) δ 7.5159 - 7.4561 (m, 2H), 7.4310 (dd, J = 7.8, 1.3 Hz, 1H), 7.3607 (dd, J = 7.6, 1.5 Hz, 1H), 7.2340 (td, J = 7.6, 1.5 Hz, 1H), 7.1533 (td, J = 7.5, 1.3 Hz, 1H), 6.9567 (s, H), 6.9303 - 6.8705 (m, 2H), 6.8482 (d, J = 2.9 Hz, 1H), 6.1661 (d, J = 3.0 Hz, 1H), 5.6661 (t, J = 5.7 Hz, 1H), 4.8590 (d, J = 5.8 Hz, 2H), 3.9275 (s, 3H), 3.7948 (hept, J = 8.8, 4.1 Hz, 1H), 3.4661 - 3.4135 (m, 3H), 2.8242 (ddd, J = 12.6, 10.1, 3.0 Hz, 2H), 1.9955 (dqd, J = 12.6, 3.7, 1.8 Hz, 2H), 1.7077 (dtd, J = 13.1, 9.4, 3.8 Hz, 2H), 1.3208 (d, J = 6.7 Hz, 6H). MS (ESI) m/z: 503 [M+H]+ | |
IIJ -3 | 1H NMR (600 MHz, DMSO-d 6) δ 10.42 (s, 1H), 8.45 (s, 1H), 7.59 - 7.55 (m, 3H), 7.52 (d, J = 7.8 Hz, 1H), 7.44 (d, J = 8.4 Hz, 2H), 7.35 - 7.28 (m, 2H), 7.23 (d, J = 6.6 Hz, 3H), 6.30 (d, J = 2.9 Hz, 1H), 4.85 (d, J = 5.6 Hz, 2H), 4.12 (s, 3H), 3.54 (h, J = 6.8 Hz, 1H), 1.29 (d, J = 6.6 Hz, 6H). MS (ESI) m/z: 483 [M+H]+ | |
IIK -1 | 1H NMR (600 MHz, DMSO-d 6) δ 7.98 (dd, J = 11.6, 10.3 Hz, 2H), 7.72 - 7.63 (m, 2H), 7.53 (t, J = 7.6 Hz, 1H), 7.26 (d, J = 2.8 Hz, 2H), 6.55 (d, J = 2.5 Hz, 1H), 6.28 (dd, J = 9.0, 2.5 Hz, 1H), 6.08 (d, J = 2.9 Hz, 1H), 5.02 (d, J = 5.7 Hz, 2H), 4.04 (s, 3H), 3.78 (s, 3H), 3.39 (s, 4H), 3.17 (d, J = 5.0 Hz, 3H), 3.05 - 3.01 (m, 4H), 2.23 (s, 3H). MS (ESI) m/z: 536 [M+H]+. | |
IIK -2 | 1H NMR (600 MHz, DMSO-d 6) δ 7.98 (dd, J = 17.1, 8.3 Hz, 2H), 7.71 - 7.63 (m, 2H), 7.53 (t, J = 7.6 Hz, 1H), 7.25 (dd, J = 12.2, 4.5 Hz, 2H), 6.76 (s, 1H), 6.54 (d, J = 2.5 Hz, 1H), 6.29 (d, J = 8.8 Hz, 1H), 6.08 (d, J = 2.9 Hz, 1H), 5.02 (d, J = 5.7 Hz, 2H), 4.11 (q, J = 5.3 Hz, 1H), 4.04 (s, 3H), 3.77 (s, 3H), 3.55 (d, J = 12.1 Hz, 2H), 3.39 (s, 3H), 3.17 (d, J = 4.6 Hz, 4H), 2.41 - 2.20 (m, 6H), 2.15 (s, 3H), 1.82 (d, J = 12.2 Hz, 2H), 1.49 (qd, J = 12.0, 3.9 Hz, 2H). MS (ESI) m/z: 619 [M+H]+. | |
IIK -3 | 1H NMR (600 MHz, DMSO-d 6) δ 8.26 (s, 1H), 7.97 (dd, J = 7.7, 1.2 Hz, 1H), 7.72 - 7.63 (m, 2H), 7.57 - 7.51 (m, 1H), 7.28 (t, J = 6.0 Hz, 3H), 7.21 (s, 1H), 6.71 - 6.62 (m, 2H), 6.07 (d, J = 3.0 Hz, 1H), 5.08 (d, J = 5.8 Hz, 2H), 4.65 (d, J = 4.2 Hz, 1H), 4.10 (q, J = 5.3 Hz, 1H), 4.02 (s, 3H), 3.24 (s, 3H), 3.17 (d, J = 4.9 Hz, 4H), 2.73 - 2.64 (m, 2H), 1.80 (dq, J = 13.1, 3.9 Hz, 2H). MS (ESI) m/z: 507 [M+H]+. | |
IIK -4 | 1H NMR (600 MHz, DMSO-d 6) δ 8.97 (s, 1H), 7.99 (d, J = 7.8 Hz, 1H), 7.72 - 7.66 (m, 4H), 7.55 (t, J = 6.8 Hz, 1H), 7.48 (d, J = 8.9 Hz, 2H), 7.34 (d, J = 3.0 Hz, 1H), 7.19 (s, 1H), 7.05 (s, 2H), 6.16 (d, J = 2.9 Hz, 1H), 5.15 (d, J = 5.6 Hz, 2H), 4.05 (s, 3H), 3.31 (s, 3H). MS (ESI) m/z: 487 [M+H]+. | |
IIK -5 | 1H NMR (600 MHz, DMSO-d 6) δ 8.16 (s, 1H), 7.97 (d, J = 8.0 Hz, 1H), 7.71 - 7.65 (m, 2H), 7.55 (t, J = 7.2 Hz, 1H), 7.35 (d, J = 9.0 Hz, 2H), 7.25 (d, J = 2.9 Hz, 1H), 7.10 (s, 1H), 6.67 (d, J = 8.9 Hz, 2H), 6.05 (d, J = 3.0 Hz, 1H), 5.08 (d, J = 5.5 Hz, 2H), 4.02 (s, 3H), 3.25 (s, 3H), 3.02 (s, 4H), 2.61 (s, 4H), 2.32 (s, 3H). MS (ESI) m/z: 506 [M+H]+. | |
IIK -6 | 1H NMR (600 MHz, DMSO-d 6) δ 8.37 (d, J = 8.3 Hz, 1H), 7.98 (dd, J = 7.9, 1.2 Hz, 1H), 7.72 (d, J = 7.6 Hz, 1H), 7.66 (td, J = 7.7, 1.2 Hz, 1H), 7.53 (t, J = 7.3 Hz, 1H), 7.40 (t, J = 5.9 Hz, 1H), 7.33 (d, J = 3.0 Hz, 1H), 7.15 (s, 1H), 6.92 (d, J = 1.7 Hz, 1H), 6.78 (dd, J = 8.3, 1.6 Hz, 1H), 6.16 (d, J = 3.0 Hz, 1H), 5.08 (d, J = 5.7 Hz, 2H), 4.08 (s, 3H), 3.84 (s, 3H), 3.42 (d, J = 10.1 Hz, 4H), 3.17 (s, 3H), 2.86 (s, 2H), 2.48 - 2.24 (m, 6H), 2.17 (s, 3H), 1.76 (s, 2H), 1.34 (qd, J = 12.3, 4.1 Hz, 2H). MS (ESI) m/z: 647 [M+H]+. | |
IIK -7 | 1H NMR (600 MHz, DMSO) δ 9.11 (s, 1H), 8.22 (d, J = 7.3 Hz, 1H), 7.99 (dd, J = 7.9, 1.4 Hz, 1H), 7.67 (tt, J = 5.0, 2.5 Hz, 1H), 7.58 (dd, J = 9.1, 6.6 Hz, 2H), 7.51 (d, J = 2.9 Hz, 1H), 7.07 (d, J = 8.7 Hz, 1H), 6.70 (s, 1H), 6.42 (s, 1H), 6.21 (d, J = 2.9 Hz, 1H), 5.15 (dd, J = 15.2, 5.7 Hz, 2H), 4.09 (s, 3H), 4.02 (p, J = 7.2 Hz, 2H), 3.52 (s, 2H), 3.24 (s, 3H), 2.95 (s, 2H), 1.85 (d, J = 12.6 Hz, 2H), 1.57 - 1.47 (m, 2H), 1.18 (t, J = 7.0 Hz, 3H). MS (ESI) m/z: 551 [M+H]+. | |
IIL -1 | 1H NMR (600 MHz, DMSO-d 6) δ 8.12 (d, J = 8.8 Hz, 1H), 7.90 (dd, J = 7.7, 1.1 Hz, 1H), 7.70 - 7.63 (m, 2H), 7.52 (ddd, J = 8.3, 6.4, 2.2 Hz, 1H), 7.32 - 7.25 (m, 2H), 6.86 (s, 1H), 6.57 (d, J = 2.5 Hz, 1H), 6.35 (dd, J = 8.9, 2.6 Hz, 1H), 6.10 (d, J = 2.9 Hz, 1H), 5.03 (d, J = 5.8 Hz, 2H), 4.05 (s, 3H), 3.78 (s, 3H), 3.69 (hept, J = 7.0 Hz, 1H), 3.11 - 3.02 (m, 4H), 2.61 - 2.56 (m, 4H), 2.31 (s, 3H), 1.29 (d, J = 6.8 Hz, 6H). MS (ESI) m/z: 564 [M+H]+ | |
IIL -2 | TFA salt |
1H NMR (600 MHz, Methanol-d 4) δ 8.01 (dd, J = 7.9, 1.3 Hz, 1H), 7.69 - 7.63 (m, 1H), 7.57 (ddd, J = 10.0, 7.7, 1.8 Hz, 2H), 7.48 (t, J = 4.4 Hz, 1H), 7.36 (d, J = 2.9 Hz, 1H), 6.98 (s, 1H), 6.78 (dd, J = 8.8, 2.5 Hz, 1H), 6.23 (d, J = 3.0 Hz, 1H), 5.21 (s, 2H), 4.12 (s, 3H), 4.08 (s, 1H), 3.89 (s, 3H), 3.86 (d, J = 13.3 Hz, 2H), 3.49 (h, J = 6.8 Hz, 5H), 3.31 (s, 2H), 3.17 (dtd, J = 26.3, 11.8, 11.2, 4.9 Hz, 4H), 2.95 (s, 3H), 2.26 - 2.20 (m, 2H), 1.99 (qd, J = 11.8, 3.8 Hz, 2H), 1.33 (d, J = 6.8 Hz, 6H). MS (ESI) m/z: 647 [M+H]+ |
IIL -3 | 1H NMR (600 MHz, Chloroform-d) δ 7.93 - 7.88 (m, 1H), 7.57 (dd, J = 7.4, 1.6 Hz, 1H), 7.53 - 7.47 (m, 2H), 7.47 - 7.38 (m, 2H), 6.98 - 6.92 (m, 3H), 6.83 (d, J = 2.9 Hz, 1H), 6.51 (t, J = 6.5 Hz, 1H), 6.12 (d, J = 3.0 Hz, 1H), 4.94 (d, J = 6.4 Hz, 2H), 3.89 (s, 3H), 3.80 (hept, J = 8.6, 4.0 Hz, 1H), 3.49 - 3.42 (m, 2H), 3.29 (hept, J = 6.8 Hz, 1H), 2.84 (ddd, J = 12.7, 10.0, 3.0 Hz, 2H), 1.99 (dtd, J = 11.2, 3.7, 1.9 Hz, 2H), 1.76 - 1.64 (m, 2H), 1.33 (d, J = 6.8 Hz, 6H). MS (ESI) m/z: 535 [M+H]+ | |
IIL -4 | TFA salt |
1H NMR (600 MHz, DMSO-d 6) δ 7.94 (d, J = 7.6 Hz, 1H), 7.70 (t, J = 7.6 Hz, 1H), 7.64 (d, J = 7.8 Hz, 1H), 7.59 (t, J = 7.6 Hz, 1H), 7.53 (t, J = 10.1 Hz, 4H), 7.18 (m, 3H), 6.29 (d, J = 2.9 Hz, 1H), 5.21 (d, J = 5.8 Hz, 2H), 4.10 (s, 2H), 2.52 (s, 3H), 1.17 (d, J = 6.7 Hz, 6H). MS (ESI) m/z: 515 [M+H]+ |
IIL -5 | 1H NMR (600 MHz, Methanol-d 4) δ 7.95 (dd, J = 7.9, 1.3 Hz, 1H), 7.61 (dd, J = 7.7, 1.7 Hz, 1H), 7.57 (td, J = 7.5, 1.4 Hz, 1H), 7.50 (td, J = 7.6, 1.5 Hz, 1H), 7.29 (d, J = 8.9 Hz, 2H), 7.13 (d, J = 3.0 Hz, 1H), 6.88 (d, J = 8.9 Hz, 2H), 6.08 (d, J = 3.0 Hz, 1H), 5.10 (s, 2H), 4.00 (s, 3H), 3.51 - 3.41 (m, 1H), 3.14 (t, J = 4.9 Hz, 4H), 2.64 (t, J = 5.1 Hz, 4H), 2.36 (s, 3H), 1.27 (s, 3H), 1.26 (s, 3H). MS (ESI) m/z: 534 [M+H]+ |
실시예 10.
화합물 IIM의 합성 화학식.
화합물 14의 제조
화합물 10(150mg, 0.74mmol), 2,6-디클로로벤질아민(130mg, 0.74mmol)을 5 mL의 DMF에 용해시킨 후에, 그 용액 속에 탄산칼륨(308mg, 2.23mmol)을 첨가한다. 생성된 반응액을 60℃로 예열된 오일 배스에 놓고 가열 교반하며, 16h 반응시킨 후 반응을 중지하고, 반응액 속에 포화 염화나트륨 용액 40mL, 에틸 아세테이트 20mL를 넣고 액체를 분리하며, 유기상은 포화 염화나트륨 용액으로 2회 세척, 무수 황산나트륨 건조, 농축하여 화합물 14(황색 고체, 175.3mg, 수득률 74.3%)를 얻어서 다음 반응에 직접 사용한다.
MS (ESI) m/z: 318 [M+H]+.
화합물 IIM의 제조.
방법 A.
화합물 14(25.0mg, 0.08mmol), 아닐린(0.08mmol)을 1mL의 tert-부탄올에 용해시킨 후에, 그 용액 속에 트리플루오로 아세트산(35μL, 0.47mmol)을 첨가한다. 생성된 반응액을 110℃로 예열된 오일 배스에 놓고 아닐린이 완전히 반응할 때까지(LC-MS 추적) 가열 교반한다. 반응이 중지되면, 반응액 속에 포화 염화나트룸 용액 40mL, 에틸 아세테이트 20mL를 넣고 액체를 분리하며, 유기상은 포화 염화나트륨 용액으로 2회 세척, 무수 황산나트륨 건조, 농축시켜 실리카 겔 칼럼 크로마토그래피(디클로로메테인/메탄올=40/1)로 화합물 IIM을 얻는다.
방법 B.
화합물 14(25.0mg, 0.08mmol), 아닐린(0.08mmol)을 1mL의 tert-부탄올에 용해시킨 후에, 그 용액 속에 트리플루오로 아세트산(35μL, 0.47mmol)을 첨가한다. 생성된 반응액을 110℃로 예열된 오일 배스에 놓고 아닐린이 완전히 반응할 때까지(LC-MS 추적) 가열 교반한다. 반응이 중지되면, 농축시켜 역상 제조형 HPLC 정화를 거치고(0.35% 트리플루오로 아세트산을 포함한 수용액과 메탄올이 이동상), 진공 농축시켜 화합물 IIM을 얻는다.
번호 | 구조 | 핵 자기 공명 분광법 및/또는 질량 분석 데이터 |
IIM -1 | 1H NMR (600 MHz, DMSO-d 6) δ 8.30 (d, J = 7.1 Hz, 1H), 7.48 (d, J = 8.1 Hz, 2H), 7.41 (s, 1H), 7.33 (t, J = 8.1 Hz, 1H), 7.24 (d, J = 2.7 Hz, 1H), 7.06 (s, 1H), 6.66 (d, J = 2.2 Hz, 1H), 6.50 (dd, J = 8.8, 2.2 Hz, 1H), 6.10 (d, J = 2.9 Hz, 1H), 4.85 (d, J = 4.7 Hz, 2H), 3.94 (s, 3H), 3.89 (s, 3H), 3.17 (s, 4H), 2.78 (s, 4H), 2.46 (s, 3H). MS (ESI) m/z: 527[M+H]+ | |
IIM -2 | 1H NMR (600 MHz, DMSO-d 6) δ 8.38 (d, J = 8.8 Hz, 1H), 7.47 (d, J = 8.1 Hz, 2H), 7.35 - 7.27 (m, 1H), 7.21 (d, J = 2.9 Hz, 1H), 7.15 (s, 1H), 6.94 (t, J = 5.0 Hz, 1H), 6.62 (d, J = 2.5 Hz, 1H), 6.47 (dd, J = 8.9, 2.5 Hz, 1H), 6.09 (d, J = 2.9 Hz, 1H), 4.82 (d, J = 4.9 Hz, 2H), 4.60 (s, 1H), 3.94 (s, 3H), 3.89 (s, 3H), 3.60 (d, J = 12.2 Hz, 2H), 3.50 (t, J = 5.2 Hz, 4H), 2.57 (dd, J = 11.9, 10.3 Hz, 4H), 2.29 (s, 2H), 1.84 (d, J = 12.3 Hz, 2H), 1.52 (qd, J = 12.0, 3.6 Hz, 2H). MS (ESI) m/z: 610[M+H]+ | |
IIM -3 | 1H NMR (600 MHz, DMSO-d 6) δ 10.62 (s, 1H), 8.45 (s, 1H), 7.73 (d, J = 9.1 Hz, 2H), 7.59 (d, J = 8.1 Hz, 2H), 7.54 - 7.39 (m, 1H), 7.31 (t, J = 2.8 Hz, 1H), 7.09 (t, J = 4.0 Hz, 1H), 6.87 (d, J = 9.1 Hz, 2H), 6.26 - 5.96 (m, 1H), 4.92 (d, J = 4.2 Hz, 2H), 3.13 - 2.96 (m, 4H), 2.58 - 2.54 (m, 4H), 2.29 (s,3H). MS (ESI) m/z: 498[M+H]+ | |
IIM -4 | 1H NMR (600 MHz, DMSO-d 6) δ 8.52 (s, 1H), 7.68 (d, J = 9.1 Hz, 2H), 7.52 (d, J = 8.1 Hz, 2H), 7.39 (dd, J = 8.5, 7.7 Hz, 1H), 7.25 (d, J = 2.9 Hz, 1H), 6.96 - 6.85 (m, 2H), 6.70 (s, 1H), 6.09 (d, J = 2.9 Hz, 1H), 4.95 (d, J = 4.7 Hz, 2H), 3.89 (s, 3H), 3.18 (d, J = 6.0 Hz, 4H), 2.91 (s, 4H), 2.55 (s, 3H). MS (ESI) m/z: 497[M+H]+ | |
IIN -1 | TFA salt |
1H-NMR (600 MHz; Methanol-d 4): δ 8.15 (dd, J = 7.9, 1.1 Hz, 1H), 7.80-7.77 (m, 1H), 7.67 (d, J = 2.7 Hz, 1H), 7.54-7.48 (m, 2H), 7.13-7.11 (m, 1H), 6.72-6.72 (m, 1H), 6.50-6.46 (m, 1H), 6.38 (d, J = 2.7 Hz, 1H), 4.18 (s, 3H), 3.89 (dd, J = 1.7, 0.6 Hz, 2H), 3.83-3.83 (m, 3H), 3.76-3.75 (m, 3H), 3.66-3.64 (m, 2H), 3.27-3.26 (m, 2H), 3.12-3.09 (m, 2H), 3.00 (s, 3H). MS (ESI) m/z: 503 [M+H]+. |
IIN -2 | TFA salt |
1H-NMR (600 MHz; Methanol-d 4): δ 8.15 (d, J = 7.8 Hz, 1H), 7.80 (s, 1H), 7.70 (d, J = 2.5 Hz, 1H), 7.55 (s, 1H), 7.49 (d, J = 8.1 Hz, 1H), 7.18 (d, J = 8.7 Hz, 1H), 6.90 (s, 1H), 6.63-6.62 (m, 1H), 6.42 (d, J = 2.5 Hz, 1H), 4.18 (s, 3H), 3.86 (s, 5H), 3.76 (s, 3H), 3.54 (td, J = 1.3, 0.6 Hz, 4H), 3.42-3.40 (m, 3H), 3.25 (s, 1H), 3.14 (d, J = 0.2 Hz, 2H), 2.97 (s, 3H), 2.25-2.23 (m, 2H), 1.99-1.96 (m, 2H). MS (ESI) m/z: 586 [M+H]+. |
IIN -3 | TFA salt |
1H-NMR (600 MHz; Methanol-d 4): δ 8.19-8.18 (m, 1H), 7.85-7.82 (m, 1H), 7.75 (d, J = 2.8 Hz, 1H), 7.60 (t, J = 7.7 Hz, 1H), 7.52 (d, J = 8.2 Hz, 1H), 7.34 (d, J = 9.0 Hz, 2H), 7.28 (d, J = 8.9 Hz, 2H), 6.51 (d, J = 2.9 Hz, 1H), 4.20 (s, 3H), 4.05 (s, 1H), 3.75-3.71 (m, 5H), 3.44-3.40 (m, 2H), 2.21-2.17 (m, 2H), 1.97-1.93 (m, 2H). MS (ESI) m/z: 474 [M+H]+. |
IIN -4 | TFA salt |
1H-NMR (600 MHz; Methanol-d 4): δ 8.19 (dd, J = 7.9, 1.7 Hz, 1H), 7.84 (td, J = 7.8, 1.7 Hz, 1H), 7.74 (d, J = 3.0 Hz, 1H), 7.63-7.60 (m, 3H), 7.51 (dd, J = 8.1, 0.7 Hz, 1H), 7.37-7.36 (m, 2H), 6.51 (d, J = 3.0 Hz, 1H), 4.21 (s, 3H), 3.72 (s, 3H). MS (ESI) m/z: 454 [M+H]+. |
시험예.
생체 활성 테스트.
키나아제 변형 세포주의 성장 억제에 대한 화합물의 활성
ALK 키나아제에 대한 화합물의 활성은 키나아제 변형 세포주 EML4-ALK-BaF3, EML4-ALK (L1196M)-BaF3, NPM-ALK-BaF3, 및 야생형 BaF3의 성장을 억제함으로써 평가를 진행한다(Proc. Natl. Acad. Sci. USA., 2006, 103, 3153-8.). 키나아제 변형 세포주 EML4-ALK-BaF3, EML4-ALK(L1196M)-BaF3과 NPM-ALK-BaF3의 성장은 그 키나아제의 활성에 의존하며, 화합물이 만약 키나아제 ALK 지체 활성을 억제할 수 있다면, ALK신호 경로의 활성이 그 형질전환된 BaF3 세포의 성장을 억제할 수 있다. 야생형 BaF3의 세포 성장은 ALK와 ALK 신호 경로의 활성에 의존하지 않으며, 야생형 BaF3 세포의 성장에 대한 화합물의 영향을 측정하면 그 광범위한 스펙트럼 독성을 평가할 수 있다. 따라서 화합물의 야생형 BaF3과 키나아제 형질전환된 EML4-ALK-BaF3, EML4-ALK (L1196M)-BaF3, NPM-ALK-BaF3 사이에 대한 IC50비율이 클수록 우수한 표적성을 갖는다.
구체적 시험 방법은 다음과 같다.
1) 배지 : DMEM(Dulbecco's modified eagle medium) 또는 RPMI1640(10% 소태아혈청, 100μg/mL 암피실린,100μg/mL 스트렙토마이신 포함).
2) 시약 : MTS 반응액(2 mg/mL의 MTS (3-(4,5-디메틸티아졸-2-일)-5-(3-카르복시메톡시페닐)-2-(4-설포페닐)-2H-테트라졸륨, 분자 내 염 포함). 100μg/mL의 PES (페나진 메토설페이트)).
3) 화합물 시험 : 형질전환된 키나아제 세포(EML4-ALK-BaF3 또는 EML4-ALK(L1196M)-BaF3 또는 NPM-ALK-BaF3) (2x104/well)를 세포액 체적 90μL로 96-웰 플레이트에 분주한 후, 각 구배 농도 화합물 10μL(최고 농도 10μM, 순서대로 1/3 단계에 따라 희석, 총 8개 농도점 설정, 시스템 중 0.1% DMSO(디메틸 설폭시드) 포함)을 첨가한다. 화합물의 세포를 골고루 혼합해서 세포 배양기(37℃, 5% CO2)에서 48h동안 배양한 후, 다시 20μL의 MTS 반응액을 첨가하여 골고루 혼합하고 세포 배양기(37℃, 5% CO2)에서 1-4h동안 배양한다. 마이크로플레이트 리더(VARIOSKAN FLASH, Thermo)로 490nm 파장에서의 OD값을 측정한다. 각 그룹에 3개 평행선을 설정하고, 최종 농도 0.1% DMSO를 음성 대조군, 세포 및 화합물을 함유하지 않은 배지를 무시약 대조군으로 사용한다. 세포 성장 억제율은 다음의 공식으로 계산한다.
세포 억제율%=1- (OD 실험 그룹-OD 무시약 그룹) / (OD 음성 그룹-OD 무시약 그룹) *100%.
4) IC50값 계산 : 측정된 세포 억제율에 따라 GradPad Prism 5 소프트웨어를 사용해 세포에 작용되는 화합물의 반 억제 농도를 계산한다.
Cmpd ID |
EML4
-
ALK
(IC 50 nM) |
EML4 - ALK (L1196M) (IC 50 nM) |
NPM
-
ALK
(IC 50 nM) |
BaF3
(IC 50 nM) |
IA-1 | 1369 | 1804 | 703.4 | ~ 2788 |
IA-2 | 648.7 | 760.6 | 1028 | 1523 |
IA-3 | 2423 | 6632 | 12882 | 7712 |
IB -1 | ~ 894.7 | ~ 2411 | 1447 | ~ 2799 |
IB -2 | 785.6 | 1738 | 1768 | 1925 |
IB -3 | 4220 | 8704 | 8833 | >10000 |
IC-1 | 3927 | ~ 7247 | ~ 4557 | >10000 |
IC-2 | 3678 | ~ 6859 | ~ 4913 | ~ 8766 |
IC-3 | >10000 | >10000 | >10000 | >10000 |
IC-4 | >10000 | >10000 | >10000 | >10000 |
IC-5 | 4082 | ~ 3345 | 5258 | 4592 |
ID-1 | 476.9 | 737.5 | 796 | ~ 8392 |
ID-2 | 1171 | 2032 | ~ 2848 | ~ 8307 |
ID-3 | 14.92 | 168 | 302.5 | 1013 |
ID-4 | 2856 | 6151 | ~ 8935 | >10000 |
ID-5 | >10000 | >10000 | >10000 | >10000 |
ID-6 | 1505 | ~ 2649 | 1024 | ~ 2841 |
ID-7 | 544.5 | ~ 1080 | ~ 1166 | ~ 2957 |
ID-8 | 5173 | 5675 | >10000 | >10000 |
IG-1 | 1467 | 1160 | 1797 | 2338 |
IG-10 | 9798 | >10000 | 19612 | >10000 |
IG-11 | 4674 | 5620 | >10000 | >10000 |
IG-11 | 1505 | 1341 | 1686 | ~ 2787 |
IG-12 | 6495 | 4128 | 4083 | ~ 7738 |
IG-13 | >10000 | >10000 | >10000 | >10000 |
IG-14 | ~ 1262 | 884.1 | 1393 | ~ 2548 |
IG-15 | ~ 1127 | ~ 937.1 | ~ 1044 | ~ 2489 |
IG-16 | 1371 | 1391 | 1738 | 2354 |
IG-17 | 7613 | ~ 9462 | 7675 | 9387 |
IG-18 | 4676 | 4366 | 8760 | >10000 |
IG-2 | 1201 | 1191 | 1430 | 1804 |
IG-3 | 2722 | 5043 | 6930 | 6866 |
IG-4 | 5112 | 4940 | 6103 | 8512 |
IG-5 | 7796 | >10000 | >10000 | >10000 |
IG-6 | 1366 | 1521 | 1737 | ~ 3145 |
IG-7 | 285.8 | 408.6 | 1206 | ~ 994.3 |
IG-8 | 1831 | 1534 | 1673 | 3865 |
IG-9 | >10000 | >10000 | >10000 | >10000 |
IH-1 | 1118 | 915.5 | 1556 | 2066 |
IH-2 | >10000 | 40377 | >10000 | >10000 |
IH-3 | ~ 446.2 | 502.2 | ~ 858.5 | ~ 949.4 |
IH-4 | ~ 1405 | ~ 974.5 | ~ 2762 | ~ 889.3 |
II-1 | 1488 | ~ 2631 | 1640 | ~ 2713 |
II-2 | 1813 | ~ 2563 | ~ 2598 | ~ 3033 |
II-3 | 7474 | 6164 | 4909 | 9613 |
II-4 | 1565 | 1675 | 1938 | ~ 2549 |
II-5 | 237.8 | 488.5 | 1291 | 1055 |
II-6 | 4959 | ~ 7403 | 6721 | ~ 8218 |
IJ-1 | 4272 | 3936 | 4661 | 5009 |
IJ-2 | ~ 8706 | 4112 | ~ 8358 | ~ 11667 |
IJ-3 | >10000 | >10000 | >10000 | >10000 |
IK -1 | ~ 2578 | 1548 | 1779 | 1825 |
IK -2 | 668.5 | 451.3 | ~ 822.5 | ~ 912.8 |
IL-1 | 1323 | 1615 | ~ 929.1 | ~ 2821 |
IL-2 | ~ 2567 | 2002 | ~ 7724 | ~ 7842 |
IL-3 | 3500 | 5024 | 5180 | 5184 |
IL-4 | 9508 | >10000 | >10000 | >10000 |
IM -1 | ~ 300.1 | 587.1 | 572.4 | ~ 866.7 |
IM -2 | 1244 | 1310 | 1624 | 2899 |
IM -3 | 7525 | >10000 | >10000 | >10000 |
IN-1 | >10000 | >10000 | >10000 | >10000 |
IN-2 | >10000 | >10000 | >10000 | >10000 |
IN-3 | >10000 | >10000 | >10000 | >10000 |
IN-4 | >10000 | >10000 | >10000 | >10000 |
IN-5 | >10000 | >10000 | >10000 | 1206000 |
IO -1 | 1719 | 3397 | 4828 | 4081 |
IO -2 | 4423 | 5075 | 6634 | ~ 7813 |
IO -3 | >10000 | >10000 | >10000 | >10000 |
IO -4 | >10000 | >10000 | >10000 | >10000 |
IO -5 | 4874 | 5205 | 5032 | 1912 |
IQ-1 | >10000 | >10000 | >10000 | >10000 |
IQ-2 | >10000 | >10000 | >10000 | >10000 |
IQ-3 | >10000 | >10000 | >10000 | >10000 |
IQ-4 | >10000 | >10000 | >10000 | >10000 |
IQ-5 | >10000 | >10000 | >10000 | >10000 |
IQ-6 | >10000 | >10000 | >10000 | >10000 |
IR-1 | >10000 | >10000 | >10000 | >10000 |
IR-2 | >10000 | >10000 | >10000 | >10000 |
IR-3 | >10000 | >10000 | >10000 | >10000 |
IS-1 | ~ 2552 | 1696 | 1790 | 5333 |
IS-2 | >10000 | 5034 | >10000 | >10000 |
IS-3 | 4485 | 9711 | >10000 | 11817 |
IS-4 | >10000 | >10000 | >10000 | >10000 |
IU -1 | >10000 | >10000 | >10000 | >10000 |
IU -2 | 4578 | 2666 | 4905 | ~ 8339 |
IU -3 | 4901 | 4183 | 8272 | 6518 |
IU -4 | 9111 | 5987 | >10000 | >10000 |
IU -5 | ~ 2877 | ~ 2512 | ~ 2850 | ~ 7724 |
IV-1 | 6900 | 7306 | >10000 | >10000 |
IV-2 | ~ 8984 | 3956 | ~ 9138 | ~ 8454 |
IV-3 | 4553 | 4339 | 8153 | 8915 |
IV-4 | >10000 | >10000 | >10000 | >10000 |
Crizotinib | 54.92 | 741.73 | ND | 1077.33 |
*Crizotinib(크리조티닙)은 양성 대조군이며, ND는 측정되지 않았음을 의미한다.
Cmpd ID |
EML4
-
ALK
(IC 50 nM) |
L1196M
(IC 50 nM) |
NPM
-
ALK
(IC 50 nM) |
BaF3
(IC 50 nM) |
IIA -1 | ~ 909.2 | ~ 2560 | 512.5 | 1547 |
IIA -2 | ~ 1113 | 1620 | 1398 | ~ 883.2 |
IIA -3 | 320.7 | 161.2 | 456.2 | 376.5 |
IIA -4 | 1298 | 1320 | 2696 | 2572 |
IIA -5 | ~ 876.8 | ~ 883.0 | 519.2 | ~ 336.5 |
IIA -6 | 643.9 | 977.7 | 536.2 | 1372 |
IIB -1 | 1719 | ~ 2796 | ~ 2509 | 1934 |
IIB -2 | ~ 949.0 | ~ 852.9 | ~ 939.5 | 605.9 |
IIB -3 | 488.9 | 916.8 | 653.4 | 1040 |
IIB -4 | 3018 | 4207 | 4568 | 4876 |
IIB -5 | ~ 2721 | ~ 2784 | ~ 1372 | ~ 2869 |
IIC-1 | 3530 | ~ 5890 | 5122 | ~ 8674 |
IIC-2 | 1510 | ~ 3512 | ~ 3462 | 5048 |
IIC-3 | 8292 | 8994 | 11814 | ~ 10639 |
IIC-4 | >10000 | 28193 | >10000 | >10000 |
IIC-5 | ~ 3240 | 4410 | 3785 | ~ 7727 |
IIC-6 | >10000 | >10000 | >10000 | >10000 |
IID -1 | 546.2 | ~ 2955 | 2264 | ~ 8176 |
IID -2 | 329.8 | 390.6 | 828.9 | 2907 |
IID -3 | 2156 | 6647 | 6988 | >10000 |
IID -4 | ~ 3286 | ~ 6442 | ~ 6354 | 7543 |
IID -5 | ~ 1127 | ~ 1116 | ~ 2578 | ~ 7935 |
IID -6 | 1599 | ~ 3004 | ~ 3130 | >10000 |
IID -7 | 782.8 | ~ 2781 | ~ 981.7 | ~ 2580 |
IID -8 | 1756 | 4770 | ~ 3464 | ~ 8378 |
IID -9 | 2241 | ~ 2882 | 4736 | ~ 8299 |
IIG -1 | 2372 | 3442 | 4871 | 5168 |
IIG -2 | ~ 3882 | 3726 | 4894 | ~ 7941 |
IIG -3 | 4255 | 2787 | 3180 | 5043 |
IIG -4 | ~ 1333 | 3950 | 4211 | 4871 |
IIH -1 | 1618 | 1844 | 1748 | 4941 |
IIH -2 | 1972 | 1809 | 4469 | 2832 |
III-1 | ~ 1359 | 1692 | ~ 2744 | ~ 2784 |
III-2 | >10000 | >10000 | >10000 | >10000 |
III-3 | 3202 | 4000 | 3711 | ~ 3335 |
III-4 | >10000 | >10000 | >10000 | >10000 |
IIJ -1 | ~ 865.4 | 544.4 | 626.6 | ~ 910.6 |
IIJ -2 | 1710 | 1610 | 1609 | ~ 2865 |
IIJ -3 | >10000 | 9697 | >10000 | >10000 |
IIK -1 | ~ 2702 | 2098 | 1978 | 3275 |
IIK -2 | ~ 3150 | ~ 2951 | ~ 3420 | ~ 2947 |
IIK -3 | >10000 | >10000 | >10000 | >10000 |
IIK -4 | >10000 | >10000 | 1777000 | >10000 |
IIK -5 | 1429 | ~ 2559 | 1878 | ~ 2870 |
IIK -6 | >10000 | >10000 | >10000 | >10000 |
IIK -7 | >10000 | >10000 | >10000 | >10000 |
IIL -1 | 1298 | 1595 | 1346 | ~ 2607 |
IIL -2 | 627.3 | 1420 | 1823 | 2616 |
IIL -3 | >10000 | >10000 | 7442 | >10000 |
IIL -4 | >10000 | >10000 | >10000 | >10000 |
IIL -5 | 1143 | 1531 | 847.6 | ~ 2761 |
IIN -1 | ~ 5746 | 6467 | >10000 | ~ 9964 |
IIN -2 | ~ 2593 | 2225 | 2327 | 5626 |
IIN -3 | >10000 | >10000 | >10000 | >10000 |
IIN -4 | >10000 | >10000 | >10000 | >10000 |
Crizotinib | 54.92 | 741.73 | ND | 1077.33 |
*Crizotinib(크리조티닙)은 양성 대조군이며, ND는 측정되지 않았음을 의미한다.
이상 활성 데이터를 통해, 활성이 비교적 우수한 ID-3, II-5, IID-2, IIL-2와 같은 화합물은 모두 비교적 우수한 표적 선택성을 가짐을 알 수 있다.
종양 세포의 성장 억제에 대한 화합물의 활성
테스트 하려는 종양 세포가 현탁 세포이면, 상기 (1)의 방법을 참조하여 측정을 진행한다.
테스트 하려는 종양 세포가 부착 세포이면, 1000-10000세포/웰을 96-웰 플레이트에 첨가하고, 부착 세포로 배양한 후 화합물을 첨가한다. 기타는 상기 (1)의 방법을 참조하여 진행한다.
화합물 ID-3은 폐암 세포 H3122, A549, DFCI076(크리조티닙 약물 내성 종양 세포주), 흑색종 A375, 간암 HepG2, 유선암 MCF7에 대해 모두 우수한 성장 억제 활성을 가지며, 그 중 키나아제 ALK 양성 폐암 세포주 H3122와 DFCI076에 대해 가장 민감하다.
Cmpd ID |
H3122
(IC 50 nM) |
A549
(IC 50 nM) |
DFCI076 (IC 50 nM) |
A375
(IC 50 nM) |
HepG2 (IC 50 nM) |
MCF7
(IC 50 nM) |
ID-3 | 61.14 | 2724 | 735 | 3758 | 3445 | 2835 |
Crizotinib | 185.23 | 2404 | 1655 | ND | ND | ND |
이상 상기 설명은 본 발명의 실시방식일 뿐이다. 본 영역의 일반적 기술자라면 본 발명의 개념을 벗어나지 않는 전제 하에서 약간의 변형과 수정을 가할 수 있으며, 이는 모두 본 발명의 보호 범위에 속한다.
Claims (20)
- 화학식 I:
I
의 화합물, 그 입체 이성질체, 그 약학적으로 허용 가능한 염 또는 그 약학적으로 허용 가능한 용매 화합물.
식 중,
R'은 수소, 염소 또는 브롬이며;
R1은 다음으로 이루어지는 군으로부터 임의적으로 선택하며,
1) C1-C6 알킬, 2-N,N-디메틸아미노에틸, 2-히드록시에틸, 2-N,N-디메틸아미노에틸, 2-N,N-디이소프로필아미노에틸, 2-모르폴리노에틸, 2-(4-N-메틸피페라진)에틸, 3-N,N-디메틸아미노프로필, 3-N,N-디에틸아미노프로필, 3-N,N-디이소프로필아미노프로필, 3-모르폴리노프로필, 3-(4-N-메틸피페라진)프로필, 4-N,N-디메틸아미노시클로헥실, 4-N,N-디에틸아미노시클로헥실, N-메틸-4-피페리딜, N-에틸-4-피페리딜, N-이소프로필-4-피페리딜, 1,3-디메틸-5-피라졸일, 1-메틸-4-피라졸일, 3-메틸-5-이소옥사졸리닐, 1-(N-메틸-4-피페리딜)-4-피라졸일, 1-(N-tert-부톡시포르밀-4-피페리딜)-4-피라졸일;
2) , 식 중, Z1,Z2,Z3,Z4,Z5는 다음으로 이루어지는 군으로부터 독립적으로 선택하며,
(1) 수소, 불소, 염소, 브롬, 요오드, 니트로, 시아노;
(2) C1-C6 알킬, C1-C6 알콕시, C1-C6 옥시알킬, C1-C6 플루오로알킬, C1-C6 플루오로알콕시, N-메틸-4-피페리딜;
(3) N,N-디메틸아미노, N,N-디에틸아미노, N,N-디이소프로필아미노, 2-N,N-디메틸아미노 에틸아미노, 2-모르폴리노에틸아미노, 2-(4-N-메틸피페라지닐)에틸아미노, 3-N,N-디메틸아미노프로필아미노, 3-N,N-디에틸아미노프로필아미노, 3-N,N-디이소프로필아미노프로필아미노, 3-모르폴리노프로필아미노, 3-(4-N-메틸피페라지닐)프로필아미노, N-메틸피페리딘-4-일아미노, N-에틸피페리딘-4-일아미노, N-이소프로필피페리딘-4-일아미노;
(4) 2-N,N-디메틸아미노에톡시, 2-N,N-디에틸아미노에톡시, 2-N,N-디이소프로필아미노에톡시, 2-(N-메틸피페라지닐)에톡시, 2-(N-아세틸피페라지닐)에톡시, 2-모르폴리노에톡시, 2-티오모르폴리노에톡시, 2-피페리딜에톡시, 3-N,N-디메틸아미노프로폭시, 3-N,N-디에틸아미노프로폭시, 3-N,N-디이소프로필아미노프로폭시, 3-(N-메틸피페라지닐)프로폭시, 3-(N-아세틸피페라지닐)프로폭시, 3-모르폴리노프로폭시, 3-티오모르폴리노에톡시, 3-피페리딜프로폭시, 2-피리딜프로폭시, 3-피리딜메톡시, 4-피리딜메톡시, 페닐메톡시, 모노할로겐-치환페닐메톡시, 젬-디할로겐 치환 페닐 메톡시, 헤테로-디할로겐 치환 페닐 메톡시;
(5) 피페리딜, 4-N,N-디메틸아미노피페리딜, 4-N,N-디에틸아미노피페리딜, 4-N,N-디이소프로필아미노피페리딜, 4-히드록시피페리딜, 모르폴리노, 3,5-디메틸모르폴리노,티오모르폴리노, 피롤리딘일, 3-N,N-디메틸피롤리딘일, 3-N,N-디에틸피롤리딘일, N-메틸피페라지닐, N-에틸피페라지닐, N-이소프로필피페라지닐, N-아세틸피페라지닐, N-tert-부톡시포르밀피페라지닐, N-메틸설포닐피페라지닐, N-(2-히드록시에틸)피페라지닐, N-(2-시아노에틸)피페라지닐, N-(3-히드록시프로필)피페라지닐, N-(2-N,N-디메틸에틸)피페라지닐, N-(2-N,N-디에틸에틸)피페라지닐, N-(3-N,N-디메틸프로필)피페라지닐, N-(3-N,N-디에틸프로필)피페라지닐, 2-옥소-피페라진-4-일, 이미다졸릴, 4-메틸이미다졸릴;
(6) 4-(N-메틸피페라지닐)피페리딜, 4-(N-에틸피페라지닐)피페리딜, 4-(N-이소프로필피페라지닐)피페리딜, 4-(N-아세틸피페라지닐)피페리딜, 4-(N-tert-부톡시포르밀)피페라지닐)피페리딜, 4-(N-메틸설포닐피페라지닐)피페리딜, 4-(N-(2-히드록시에틸)피페라지닐)피페리딜, 4-(N-(2-시아노에틸)피페라지닐)피페리딜, 4-(N-(3-히드록시프로필) 피페라지닐)피페리딜, 4-(N-(2-N,N-디메틸에틸) 피페라지닐)피페리딜, 4-(N-(2-N,N-디에틸에틸)피페라지닐)피페리딜, 4-(N-(3-N,N-디메틸 프로필)피페라지닐)피페리딜, 4-(N-(3-N,N-디에틸프로필)피페라지닐)피페리딜, 4-(피롤리딘일)피페리딜, 4-(3-N,N-디메틸피롤리딘일)피페리딜, N-(N-메틸-4-피페리딜)피페라지닐, N-(N-에틸-4-피페리딜)피페라지닐;
(7) 히드록시설포닐, 아미노설포닐, 메틸아미노설포닐, 에틸아미노설포닐, 프로필아미노설포닐, 이소프로필아미노설포닐, 시클로프로필아미노설포닐, 시클로부틸아미노설포닐, 시클로펜틸아미노설포닐, 피페리딘-1-일설포닐, 4-히드록시피페리딘-1-일설포닐, 4-N,N-디메틸피페리딘-1-일설포닐, 4-N,N-디에틸피페리딘-1-일설포닐, 피롤리딘-1-일설포닐, 3-N,N-디메틸피롤리딘-1-일설포닐, 3-N,N-디에틸피롤리딘-1-일설포닐, N-메틸피페라진-1-일설포닐, N-에틸피페라진-1-일설포닐, N-아세틸피페라진-1-일설포닐, N-tert-부톡시포르밀피페라진-1-일설포닐, N-(2-히드록시에틸)피페라진-1-일설포닐, N-(2-시아노에틸)피페라진-1-일설포닐, N-(2-N,N-디메틸에틸)피페라진-1-일설포닐, N-(2-N,N-디에틸에틸)피페라진-1-일설포닐, N-(3-히드록시프로필)피페라진-1-일설포닐, N-(3-N,N-디메틸프로필)피페라진-1-일설포닐, N-(3-N,N-디에틸프로필)피페라진-1-일설포닐, 모르폴리노-1-설포닐, 3,5-디메틸모르폴리노-1-설포닐,4-(N-메틸-1-피페라지닐)피페리딘-1-일설포닐, 4-(N-에틸-1-피페라지닐)피페리딘-1-일설포닐, 4-(N-아세틸-1-피페라지닐)피페리딘-1-일설포닐, N-(N-메틸-4-피페리딜)피페라진-1-일설포닐;
(8) 히드록시카르보닐, 아미노카르보닐, 메틸아미노카르보닐, 에틸아미노카르보닐, 프로필아미노카르보닐, 이소프로필아미노카르보닐, 시클로프로필아미노카르보닐, 시클로부틸아미노카르보닐, 시클로펜틸아미노카르보닐, 피페리딘-1-일카르보닐, 4-히드록시피페리딘-1-일카르보닐, 4-N,N-디메틸피페리딘-1-일카르보닐, 4-N,N-디에틸피페리딘-1-일카르보닐, 피롤리딘-1-일카르보닐, 3-N,N-디메틸피롤리딘-1-일카르보닐, 3-N,N-디에틸피롤리딘-1-일카르보닐, N-메틸피페라진-1-일카르보닐, N-에틸피페라진-1-일카르보닐, N-아세틸피페라진-1-일카르보닐, N-tert-부톡시카르보닐피페라진-1-일카르보닐, N-(2-히드록시에틸)피페라진-1-일카르보닐, N-(2-시아노에틸)피페라진-1-일카르보닐, N-(2-N,N-디메틸에틸)피페라진-1-일카르보닐, N-(2-N,N-디에틸에틸)피페라진-1-일카르보닐, N-(3-히드록시프로필)피페라진-1-일카르보닐, N-(3-N,N-디메틸프로필)피페라진-1-일카르보닐, N-(3-N,N-디에틸프로필)피페라진-1-일카르보닐, 모르폴리노-1-카르보닐, 3,5-디메틸모르폴리노-1-카르보닐,4-(N-메틸-1-피페라지닐)피페리딘-1-일카르보닐, 4-(N-에틸-1-피페라지닐)피페리딘-1-일카르보닐, 4-(N-아세틸-1-피페라지닐)피페리딘-1-일카르보닐, N-(N-메틸-4-피페리딜)피페라진-1-일카르보닐;
(9) 메톡시카르보닐, 에톡시카르보닐, 프로폭시카르보닐, 이소프로폭시카르보닐, n-부톡시카르보닐, 이소부톡시카르보닐, tert-부톡시카르보닐;
(10) 아미노포름아미도, 메틸아미노포름아미도, 에틸아미노포름아미도, 프로필아미노포름아미도, 이소프로필아미노포름아미도, 시클로프로필아미노포름아미도, 시클로부틸아미노포름아미도, 시클로펜틸아미노포름아미도, 피페리딘-1-일포름아미도, 4-히드록시피페리딘-1-일포름아미도, 4-N,N-디메틸피페리딘-1-일포름아미도, 4-N,N-디에틸피레리딘-1-일포름아미도, 피롤리딘-1-일포름아미도, 3-N,N-디메틸피롤리딘-1-일포름아미도, 3-N,N-디에틸피롤리딘-1-일포름아미도, N-메틸피페라진-1-일포름아미도, N-에틸피페라진-1-일포름아미도, N-아세틸 피페라진-1-일포름아미도, N-tert-부톡시카르보닐피페라진-1-일포름아미도, N-(2-히드록시에틸)피페라진-1-일포름아미도, N-(2-시아노에틸)피페라진-1-일포름아미도, N-(2-N,N-디메틸에틸)피페라진-1-일포름아미도, N-(2-N,N-디에틸에틸)피페라진-1-일포름아미도, N-(3-히드록시프로필)피페라진-1-일포름아미도, N-(3-N,N-디메틸프로필)피페라진-1-일포름아미도, N-(3-N,N-디에틸프로필)피페라진-1-일포름아미도, 모르폴리노-1-포름아미도, 3,5-디메틸모르폴리노-1-포름아미도4-(N-메틸-1-피페라지닐)피페리딘-1-일포름아미도, 4-(N-에틸-1-피페라지닐)피페리딘-1-일포름아미도, 4-(N-아세틸-1-피페라지닐)피페리딘-1-일포름아미도, N-(N-메틸-4-피페리딜)피페라진-1-일포름아미도;
(11) 아미노아세트아미도, N-tert-부톡시카르보닐아세트아미도, N-아세틸아미노아세트아미도, 아크릴아미도, 시클로프로피온아미도, 클로로아세트아미도, 피페리딜아세트아미도, 4-히드록시 피페리딜아세트아미도, 4-N,N-디메틸피페리딜아세트아미도, 4-N,N-디에틸피페리딜아세트아미도, 피롤리딘일아세트아미도, 3-N,N-디메틸피롤리딘일아세트아미도, 3-N,N-디에틸피롤리딘일아세트아미도, N-메틸피페라지닐아세트아미도, N-에틸피페라지닐아세트아미도, N-아세틸피페라지닐아세트아미도, N-tert-부톡시카르보닐피페라지닐아세트아미도, N-(2-히드록시에틸)피페라지닐아세트아미도, N-(2-시아노에틸)피페라지닐아세트아미도, N-(2-N,N-디메틸에틸)피페라지닐아세트아미도, N-(2-N,N-디에틸에틸)피페라지닐아세트아미도, N-(3-히드록시프로필)피페라지닐 아세트아미도, N-(3-N,N-디메틸프로필)피페라지닐아세트아미도, N-(3-N,N-디에틸프로필)피페라지닐아세트아미도, 모르폴리노-1-아세트아미도, 3,5-디메틸모르폴리노아세트아미도,4-(N-메틸-1-피페라지닐)피페리딜아세트아미도, 4-(N-에틸-1-피페라지닐)피페리딜아세트아미도, 4-(N-아세틸-1-피페라지닐)피페리딜아세트아미도, N-(N-메틸-4-피페리딜)피페라지닐아세트아미도, 4-(피롤리딘-1-일)피페리딜아세트아미도; 2-메틸아미노아세트아미도, 2-(1-메틸에틸)아미노아세트아미도; N-벤질옥시카르보닐-2-메틸아미노아세트아미도;
(12) Z2와 Z3은 산소를 함유한 치환 또는 비치환된 5원자 고리 또는 6원자 고리를 형성할 수 있으며; 치환기는 Z1과 동일한 상기 치환기에서 선택될 수 있으며;
(13) Z2와 Z3은 질소를 함유한 치환 또는 비치환된 5원자 고리 또는 6원자 고리를 형성할 수 있으며; 치환기는 Z1과 동일한 치환기에서 선택될 수 있으며;
3) ,식 중, Z2,Z3,Z4,Z5는 항목 2)에서 정의한 바와 같으며;
4), 식 중, Z1,Z3,Z4,Z5는 항목 2)에서 정의한 바와 같으며;
A는 직접 결합 또는 메틸렌이며;
X는 NH, S 또는 O원자이며;
R2는 R1과 상이하고, R2는 다음으로 이루어지는 군으로부터 임의적으로 선택하며;
1)C1-C6 알킬,C2-C6 알케닐, C2-C6 알키닐,C3-C6 시클로 알킬;
2),식 중, A1는 다음으로 이루어지는 군으로부터 독립적으로 선택하며,
(1) 불소, 염소, 브롬, 요오드, 시아노, 트리플루오로 메틸, 트리플루오로 메톡시, 니트로;
(2) 메틸티오, 에틸티오, 이소프로필티오, 메틸설피닐, 에틸설피닐, 이소프로필설피닐, 메틸설포닐, 에틸설포닐, 이소프로필설포닐, 메틸설포닐아미노, 메톡시카르보닐, 에톡시카르보닐, 프로폭시카르보닐, 이소프로폭시카르보닐, n-부톡시카르보닐, 이소부톡시카르보닐, tert-부톡시카르보닐, 메틸아미노카르보닐, 에틸아미노카르보닐, 프로필아미노카르보닐, 이소프로필아미노카르보닐, 시클로프로필아미노카르보닐, 시클로부틸아미노카르보닐, 시클로펜틸아미노카르보닐, 디메틸포스피닐, 디에틸포스피닐, 디이소프로필포스피닐;
식 중, A3는 다음으로 이루어지는 군으로부터 독립적으로 선택하며,
(1) 수소, 불소, 트리플루오로 메틸, 트리플루오로 메톡시, 니트로;
(2) 메틸티오, 에틸티오, 이소프로필티오, 메틸설피닐, 에틸설피닐, 이소프로필설피닐, 메틸설포닐, 에틸설포닐, 이소프로필설포닐, 메틸설포닐아미노, 메톡시카르보닐, 에톡시카르보닐, 프로폭시카르보닐, 이소프로폭시카르보닐, n-부톡시카르보닐, 이소부톡시카르보닐, tert-부톡시카르보닐, 메틸아미노카르보닐, 에틸아미노카르보닐, 프로필아미노카르보닐, 이소프로필아미노카르보닐, 시클로프로필아미노카르보닐, 시클로부틸아미노카르보닐, 시클로펜틸아미노카르보닐, 디메틸포스피닐, 디에틸포스피닐, 디이소프로필포스피닐;
식 중, A2,A4,A5는 다음으로 이루어지는 군으로부터 독립적으로 선택하며,
(1) 수소, 불소, 염소, 브롬, 요오드, 시아노, 트리플루오로 메틸, 트리플루오로 메톡시, 니트로;
(2) 메틸티오, 에틸티오, 이소프로필티오, 메틸설피닐, 에틸설피닐, 이소프로필설피닐, 메틸설포닐, 에틸설포닐, 이소프로필설포닐, 메틸설포닐아미노, 메톡시카르보닐, 에톡시카르보닐, 프로폭시카르보닐, 이소프로폭시카르보닐, n-부톡시카르보닐, 이소부톡시카르보닐, tert-부톡시카르보닐, 메틸아미노카르보닐, 에틸아미노카르보닐, 프로필아미노카르보닐, 이소프로필아미노카르보닐, 시클로프로필아미노카르보닐, 시클로부틸아미노카르보닐, 시클로펜틸아미노카르보닐, 디메틸포스피닐, 디에틸포스피닐, 디이소프로필포스피닐;
3) 또는 ,
식 중, Y는 NH,S 또는 O원자이며,
A6,A7,A8,A9,A10,A11는 다음으로 이루어지는 군으로부터 독립적으로 선택하며,
(1) 수소, 불소,염소, 브롬, 요오드, 시아노, 트리플루오로 메틸, 트리플루오로 메톡시, 니트로;
(2) 메톡시카르보닐, 에톡시카르보닐, 프로폭시카르보닐, 이소프로폭시카르보닐, n-부톡시카르보닐, 이소부톡시카르보닐, tert-부톡시카르보닐, 메틸아미노카르보닐, 에틸아미노카르보닐, 프로필아미노카르보닐, 이소프로필아미노카르보닐, 시클로프로필아미노카르보닐, 시클로부틸아미노카르보닐, 시클로펜틸아미노카르보닐;
4),
식 중, A12는 다음으로 이루어지는 군으로부터 임의적으로 선택하며,
(1) 수소, 불소,염소, 브롬, 요오드, 시아노, 트리플루오로 메틸, 트리플루오로 메톡시, 니트로;
(2) 메톡시카르보닐, 에톡시카르보닐, 프로폭시카르보닐, 이소프로폭시카르보닐, n-부톡시카르보닐, 이소부톡시카르보닐, tert-부톡시카르보닐, 메틸아미노카르보닐, 에틸아미노카르보닐, 프로필아미노카르보닐, 이소프로필아미노카르보닐, 시클로프로필아미노카르보닐, 시클로부틸아미노카르보닐, 시클로펜틸아미노카르보닐, 메틸설피닐, 에틸설피닐, 이소프로필설피닐, 메틸설포닐, 에틸설포닐, 이소프로필설포닐;
Y2, Y3, Y4는 다음으로 이루어지는 군으로부터 선택하며,
Y2는 N,Y3는 N-A13,Y4는 CH 또는 N이며;
Y2는 N,Y3는 C-A13,Y4는 N,O 또는 S이며;
Y2는 O 또는 S,Y3는 N-A13,Y4는 CH이며;
Y2는 O 또는 S,Y3는 C-A13,Y4는 N이며; 및
Y2는 C,Y3는 N-A13,Y4는 O 또는 S이며;
식 중, A13은 수소,C1-C6 알킬,C2-C6 알케닐,C2-C6 알키닐,C3-C6 시클로알킬이며;
5) 피페리딜, 4-N,N-디메틸아미노피페리딜, 4-N,N-디에틸아미노피페리딜, 4-N,N-디이소프로필아미노피페리딜, 4-히드록시피페리딜, 모르폴리노, 3,5-디메틸모르폴리노, 티오모르폴리노, 피롤리딘일, 3-N,N-디메틸피롤리딜, 3-N,N-디에틸피롤리딜, N-메틸피페라지닐, N-에틸피페라지닐, N-이소프로필피페라지닐, N-아세틸피페라지닐, N-tert-부톡시카르보닐피페라지닐, N-메틸설포닐피페라지닐, N-(2-히드록시에틸)피페라지닐, N-(2-시아노에틸)피페라지닐, N-(3-히드록시프로필)피페라지닐, N-(2-N,N-디메틸에틸)피페라지닐, 4-(2-N,N-디에틸에틸)피페라지닐, N-(3-N,N-디메틸프로필)피페라지닐, N-(3-N,N-디에틸프로필)피페라지닐;
R3은 수소,C1-C6 알킬,C2-C6 알케닐,C2-C6 알키닐,또는 C3-C6 시클로알킬이다. - 화학식 II:
II
의 화합물, 그 입체 이성질체, 그 약학적으로 허용 가능한 염 또는 그 약학적으로 허용 가능한 용매 화합물.
식 중,
W는 옥소, 티오, 또는 수소이며;
n = 0, 또는 1이며;
R4,R5,R6는 다음으로 이루어지는 군으로부터 독립적으로 선택하며,
(1) 수소, 불소, 염소, 브롬, 요오드. 니트로, 시아노;
(2) C1-C6 알킬, C1-C6 알콕시, C1-C6 옥시알킬, C1-C6 플루오로알킬, C1-C6 플루오로알콕시;
R7은 다음으로 이루어지는 군으로부터 독립적으로 선택하며,
(1) 수소, C1-C6 알킬, 아세틸, 프로피오닐, 부티릴, 이소부티릴;
(2) 글리실, 2-N,N-디메틸아세틸, 2-N,N-디에틸아세틸, 2-N,N-디이소프로필아세틸, 피페리딜아세틸, 4-히드록시피페리딜아세틸, 4-N,N-디메틸피페리딜아세틸, 4-N,N-디에틸피페리딜아세틸, 피롤리딘일아세틸, 3-N,N-디메틸피롤리딘일아세틸, 3-N,N-디에틸피롤리딘일아세틸, N-메틸피페라지닐아세틸, N-에틸피페라지닐아세틸, N-아세틸피페라지닐아세틸, N-tert-부톡시카르보닐피페라지닐아세틸, N-(2-히드록시에틸)피페라지닐아세틸, N-(2-시아노에틸)피페라지닐아세틸, N-(2-N,N-디메틸에틸)피페라지닐아세틸, N-(2-N,N-디에틸에틸)피페라지닐아세틸, N-(3-히드록시프로필)피페라지닐아세틸, N-(3-N,N-디메틸프로필)피페라지닐아세틸, N-(3-N,N-디에틸프로필)피페라지닐아세틸, 모르폴리노아세틸, 3,5-디메틸모르폴리노아세틸,4-(N-메틸-1-피페라지닐)피페리딜아세틸, 4-(N-에틸-1-피페라지닐)피페리딜아세틸, 4-(N-아세틸-1-피페라지닐)피페리딜아세틸, N-(N-메틸-4-피페리딜)피페라지닐아세틸;
A,X,R2,R3는 청구항 1에서 정의한 바와 같다. - 화학식 IV:
IV
의 화합물, 그 입체 이성질체, 그 약학적으로 허용 가능한 염 또는 그 약학적으로 허용 가능한 용매 화합물.
식 중,
R1,R3는 청구항 1에서 정의한 바와 같으며,
R2는 다음으로 이루어지는 군으로부터 임의적으로 선택하며,
1) C1-C6 알킬,C2-C6 알케닐,C2-C6 알키닐, C3-C6 시클로알킬,
2),식 중, A1은 다음으로 이루어지는 군으로부터 독립적으로 선택하며,
(1) 불소, 염소, 브롬, 요오드, 시아노, 트리플루오로 메틸, 트리플루오로 메톡시, 니트로;
(2) 메틸티오, 에틸티오, 이소프로필티오, 메틸설피닐, 에틸설피닐, 이소프로필설피닐, 메틸설포닐, 에틸설포닐, 이소프로필설포닐, 메틸설포닐아미노, 메톡시카르보닐, 에톡시카르보닐, 프로폭시카르보닐, 이소프로폭시카르보닐, n-부톡시카르보닐, 이소부톡시카르보닐, tert-부톡시카르보닐, 메틸아미노카르보닐, 에틸아미노카르보닐, 프로필아미노카르보닐, 이소프로필아미노카르보닐, 시클로프로필아미노카르보닐, 시클로부틸아미노카르보닐, 시클로펜틸아미노카르보닐, 디메틸포스피닐, 디에틸포스피닐, 디이소프로필포스피닐;
식 중,A2,A3,A4,A5는 다음으로 이루어지는 군으로부터 독립적으로 선택하며,
(1) 수소, 불소, 염소, 브롬, 요오드, 시아노, 트리플루오로 메틸, 트리플루오로 메톡시, 니트로;
(2) 메틸티오, 에틸티오, 이소프로필티오, 메틸설피닐, 에틸설피닐, 이소프로필설피닐, 메틸설포닐, 에틸설포닐, 이소프로필설포닐, 메틸설포닐아미노, 메톡시카르보닐, 에톡시카르보닐, 프로폭시카르보닐, 이소프로폭시카르보닐, n-부톡시카르보닐, 이소부톡시카르보닐, tert-부톡시카르보닐, 메틸아미노카르보닐, 에틸아미노카르보닐, 프로필아미노카르보닐, 이소프로필아미노카르보닐, 시클로프로필아미노카르보닐, 시클로부틸아미노카르보닐, 시클로펜틸아미노카르보닐, 디메틸포스피닐, 디에틸포스피닐, 디이소프로필포스피닐;
3) 또는 ,
식 중, Y는 NH, S 또는 O이고,
식 중, A6,A7,A8,A9,A10은 다음으로 이루어지는 군으로부터 독립적으로 선택한다.
(1) 수소, 불소, 염소, 브롬, 요오드, 시아노, 트리플루오로 메틸, 트리플루오로 메톡시, 니트로;
(2) 메톡시카르보닐, 에톡시카르보닐, 프로폭시카르보닐, 이소프로폭시카르보닐, n-부톡시카르보닐, 이소부톡시카르보닐, tert-부톡시카르보닐, 메틸아미노카르보닐, 에틸아미노카르보닐, 프로필아미노카르보닐, 이소프로필아미노카르보닐, 시클로프로필아미노카르보닐, 시클로부틸아미노카르보닐, 시클로펜틸아미노카르보닐. - 다음으로 이루어지는 군 중 적어도 하나로부터 선택하는 청구항 1 내지 청구항 4 중 어느 한 항에 기재된 화합물, 그 입체 이성질체, 그 약학적으로 허용 가능한 염 또는 그 약학적으로 허용 가능한 용매 화합물.
(1) R1 중에서 Z1은 메톡시, 에톡시, 이소프로폭시 또는 트리플루오로메톡시에서 선택되고, 및/또는 Z3는 4-N,N-디메틸아미노피페리딜, 4-히드록시피페리딜, 모르폴리노, 피롤리딘일, 3-N,N-디메틸피롤리딘일, N-메틸피페라지닐, N-에틸피페라지닐, N-아세틸피페라지닐, N-(2-히드록시에틸)피페라지닐, N-(2-시아노에틸)피페라지닐, N-(3-히드록시프로필)피페라지닐, 4-(N-메틸피페라지닐)피페리딜, 4-(N-에틸피페라지닐)피페리딜, 4-(N-아세틸피페라지닐)피페리딜, 4-(N-tert-부톡시카르보닐피페라지닐)피페리딜,4-(N-(2-히드록시에틸)피페라지닐)피페리딜, 4-(N-(2-시아노에틸)피페라지닐)피페리딜, 4-피롤리딜피페리딜, N-(N-메틸-4-피페리딜)피페라지닐, N-(N-에틸-4-피페리딜)피페라지닐, 아미노설포닐, 메트아미노설포닐, 시클로프로아미노설포닐, 피페리딘-1-일설포닐, 4-히드록시피페리딘-1-일설포닐, 4-N,N-디메틸피페리딘-1-일설포닐, 피롤리딘-1-일설포닐, 3-N,N-디메틸피롤리딘-1-일설포닐, N-메틸피페라진-1-일설포닐, N-에틸피페라진-1-일설포닐, 모르폴리노-1-설포닐, 히드록시카르보닐, 아미노카르보닐, 메틸아미노카르보닐, 에틸아미노카르보닐, 이소프로필아미노카르보닐, 시클로프로필아미노카르보닐, 피페리딘-1-일카르보닐, 4-히드록시피페리딘-1-일카르보닐, 4-N,N-디메틸피페리딘-1-일카르보닐, 피롤리딘-1-일카르보닐, 3-N,N-디메틸피롤리딘-1-일카르보닐, N-메틸피페라진-1-일카르보닐, N-에틸피페라진-1-일카르보닐, N-아세틸피페라진-1-일카르보닐, 모르폴리노-1-카르보닐, 4-(N-메틸-1-피페라지닐)피페리딘-1-일카르보닐, 4-(N-에틸-1- 피페라지닐)피페리딘-1-일카르보닐, 4-(N-아세틸-1-피페라지닐)피페리딘-1-일카르보닐, N-(N-메틸-4-피페리딜)피페라진-1-일카르보닐이며;
(2) R2는 2-메틸설포닐페닐, 2-에틸설포닐페닐, 2-이소프로필설포닐페닐, 2-메틸설포아미도페닐 또는 2-디메틸포스피닐페닐에서 선택하며;
(3) R3는 수소 또는 메틸에서 선택하며;
(4) 상기 화합물은 약학적으로 허용 가능한 염이며, 상기 약학적으로 허용 가능한 염은 무기산염 또는 유기산염이고, 상기 무기산염은 염산염, 브롬산염, 질산염, 황산염 또는 인산염이며, 상기 유기산염은 포름산염, 아세트산염, 프로피온산염, 벤조산염, 말레산염, 푸마르산염, 석신산염, 타타르산염, 시트르산염, 알킬설폰산염 또는 아릴설폰산염이다. - 이하의 화합물:
N2 -(2-메톡시-4-(4-메틸피페라진-1-일)페닐)-N4 -(2-(메틸티오)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N2 -(4-(4-히드록시피페리딘-1-일)페닐)-N4 -(2-(메틸티오)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N2 -(4-아미노설포닐페닐)-N4 -(2-(메틸티오)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N2 -(2-메톡시-4-(4-메틸피페라진-1-일)페닐)-N4 -(2-(이소프로필티오)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N2 -(4-(4-히드록시피페리딘-1-일)페닐)-N4 -(2-(이소프로필티오)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N2 -(4-아미노설포닐페닐)-N4 -(2-(이소프로필티오)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N2 -(2-메톡시-4-(4-메틸피페라진-1-일)페닐)-N4 -(2-(메틸설포닐)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N2 -(2-메톡시-4-(4-(4-메틸피페라진-1-일)피페리딘-1-일)페닐)-N4 -(2-(메틸설포닐)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N2 -(4-(4-히드록시피페리딘-1-일)페닐)-N4 -(2-(메틸설포닐)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N2 -(4-아미노설포닐페닐)-N4 -(2-(메틸설포닐)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N2 -(4-(4-메틸피페라진-1-일)페닐)-N4 -(2-(메틸설포닐)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N2 -(2-메톡시-4-(4-메틸피페라진-1-일)페닐)-N4 -(2-(이소프로필설포닐)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N2 -(4-(4-메틸피페라진-1-일)페닐)-N4 -(2-(이소프로필설포닐)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N2 -(2-메톡시-4-(4-(4-메틸피페라진-1-일)피페리딘-1-일)페닐)-N4 -(2-(이소프로필설포닐)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N2 -(4-(4-히드록시피페리딘-1-일)페닐)-N4 -(2-(이소프로필설포닐)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N2 -(4-아미노설포닐페닐)-N4 -(2-(이소프로필설포닐)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N2 -(2-이소프로폭시-5-메틸-(4-(1-메틸피페리딘-4-일)페닐-N4 -(2-(이소프로필설포닐)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N2 -(2-메톡시-5-메틸-(4-(1-메틸피페리딘-4-일)페닐-N4 -(2-(이소프로필설포닐)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N2 -(1-(1-메틸피페리딘-4-일)-1H-피라졸일-4-일-N4 -(2-(이소프로필설포닐)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N2 -(2-메톡시-4-(4-피롤리딘-1-일)피페리딘-1-일)페닐)-N4 -(2-(이소프로필설포닐)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N2 -(4-(피리딘-2-메톡시)페닐-N4 -(2-(이소프로필설포닐)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(2-메톡시-4-(4-(N,N-디메틸아미노)피페리딘-1-일)페닐)-N4 -(2-(이소프로필설포닐)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(6-(4-히드록시피페리딘-1-일)피리딘-3-일)-N4 -(2-(이소프로필설포닐)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(6-모르폴리노피리딘-3-일)-N4 -(2-(이소프로필설포닐)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(N-(2-N,N-디메틸아미노아세틸)-5-메톡시인돌린-6-일)-N4 -(2-(이소프로필설포닐)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N2 -(3,4-디히드로퀴놀린-2(1H)-one-6-일)-N4 -(2-(이소프로필설포닐)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(2-메톡시-4-(4-(4-메틸피페라진-1-일)피페리딘-1-일카르보닐)페닐)-N 4-(2-(이소프로필설포닐)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(2-트리플루오로메톡시-4-(4-(4-메틸피페라진-1-일)피페리딘-1-일)페닐)-N 4-(2-(이소프로필설포닐)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N2 -(3-아크릴아미도페닐)-N4 -(2-(이소프로필설포닐)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N2 -(3-(2-모르폴리노아세트아미도)페닐)-N4 -(2-(이소프로필설포닐)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N2 -(3-(2-(4-메틸피페라진-1-일)아세트아미도)페닐)-N4 -(2-(이소프로필설포닐)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N2 -(3-(2-(4-(N,N-디메틸아미노)피페리딘-1-일)아세트아미도)페닐)-N4 -(2-(이소프로필설포닐)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N2 -(3-(2-(4-(피롤리딘-1-일)피페리딘-1-일)아세트아미도)페닐)-N4 -(2-(이소프로필설포닐)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N2 -(3-(2-(4-(4-메틸피페라진-1-일)피페리딘-1-일)아세트아미도)페닐)-N4 -(2-(이소프로필설포닐)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N2 -(3-(시클로프로페인카르복사미도)페닐)-N4 -(2-(이소프로필설포닐)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N2 -(3-아미노페닐)-N4 -(2-(이소프로필설포닐)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N2 -(3-(2-tert-부톡시포름아미도아세트아미도)페닐)-N4 -(2-(이소프로필설포닐)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N2 -(3-(2-아세트아미노아세트아미도)페닐)-N4 -(2-(이소프로필설포닐)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N2 -(3-(2-아미노아세트아미도)페닐)-N4 -(2-(이소프로필설포닐)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
(S)-N2 -(3-(2-벤즈옥시포름아미도-2-메틸아세트아미도)페닐)-N4 -(2-(이소프로필설포닐)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
(S)-N2 -(3-(2-메틸-2-아미노아세트아미도)페닐)-N4 -(2-(이소프로필설포닐)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
(S)-N2 -(3-(2-이소프로필-2-아미노아세트아미도)페닐)-N4 -(2-(이소프로필설포닐)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(2-메톡시-4-(4-(4-메틸피페라진-1-일)피페리딘-1-일)페닐)-N 4-(2-(메틸설폰아미도)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N2 -(4-(4-히드록시피페리딘-1-일)페닐)-N 4-(2-(메틸설폰아미도)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(1-(1-메틸피페리딘-4-일)-1H-피라졸-4-일)-N 4-(2-(메틸설폰아미도)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(4-(4-메틸피페라진-1-일)페닐)-N 4-(2-(메틸설폰아미도)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(4-모르폴리노페닐)-N 4-(2-(메틸설폰아미도)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(2-메톡시-4-모르폴리노페닐)-N 4-(2-(메틸설폰아미도)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(2-메톡시-4-(4-(4-메틸피페라진-1-일)피페리딘-1-일)페닐)-N 4-(2-(디메틸포스피닐)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(4-(4-히드록시피페리딘-1-일)페닐)-N 4-(2-(디메틸포스피닐)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(1-(1-메틸피페리딘-4-일)-1H-피라졸-4-일)-N 4-(2-(디메틸포스피닐)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(4-(4-메틸피페라진-1-일)페닐)-N 4-(2-(디메틸포스피닐)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(2-메톡시-4-(4-메틸피페라진-1-일)페닐)-N 4-(2-(디메틸포스피닐)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(2-메톡시-4-(4-(N,N-디메틸아미노)피페리딘-1-일)페닐-N 4-(2-(디메틸포스피닐)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(2-메톡시-4-(4-메틸피페라진-1-일)페닐)-N 4-(2-메톡시포르밀)페닐-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(2-메톡시-4-(4-(4-메틸피페라진-1-일)피페리딘-1-일)페닐)-N 4-(2-(메톡시포르밀)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(4-(4-히드록시피페리딘-1-일)페닐)-N 4-(2-(메톡시포르밀)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N2 -(4-아미노설포닐페닐)-N4 -(2-(메톡시포르밀)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(4-모르폴리노페닐)-N 4-(2-(메톡시포르밀)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(4-(4-메틸피페라진-1-일)페닐)-N 4-(2-(메톡시포르밀)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(2-메톡시-4-(4-(피롤리딘-1-일)피페리딘-1-일)페닐)-N 4-(2-(메톡시포르밀)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(4-(피리딘-2-일메톡시)페닐)-N 4-(2-(메톡시포르밀)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N2 -(2-이소프로폭시-4-(4-히드록시피페리딘-1-일)페닐)-N 4-(2-(메톡시포르밀)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N2 -(2-에톡시-4-(4-히드록시피페리딘-1-일)페닐)-N 4-(2-(메톡시포르밀)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N2 -(4-(4-히드록시피페리딘-1-일설포닐)페닐)-N 4-(2-(메톡시포르밀)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(2-메톡시-4-(4-(4-메틸피페라진-1-일)피페리딘-1-일설포닐)페닐)-N 4-(2-(메톡시포르밀)페닐)- 5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(5-(4-메틸피페라진-1-일)피리드-2-일)-N 4-(2-(메톡시포르밀)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(2-메톡시-5-메틸-4-(1-메틸피페리딘-4-일)페닐)-N 4-(2-(메톡시포르밀)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(2-이소프로폭시-5-메틸-4-(1-메틸피페리딘-4-일)페닐)-N 4-(2-(메톡시포르밀)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(2-메톡시-4-모르폴리노페닐)-N 4-(2-(메톡시포르밀)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(2-메톡시-4-모르폴리노포르밀페닐)-N 4-(2-(메톡시포르밀)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N2 -(6-(4-히드록시피페리딘-1-일)피리딘-3-일)-N4 -(2-(메톡시포르밀)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(2-에톡시-4-(4-메틸피페라진-1-일)페닐)-N 4-(2-(메톡시포르밀)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(2-메톡시-4-(4-메틸피페라진-1-일)페닐)-N 4-(2-(이소부톡시포르밀)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N2 -(4-(4-히드록시피페리딘-1-일)페닐)-N 4-(2-이소부톡시포르밀)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(2-메톡시-4-(4-(4-메틸피페라진-1-일)피페리딘-1-일)페닐)-N 4-(2-이소부톡시포르밀)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N2 -(2-메톡시-4-(4-(피롤리딘-1-일)피페리딘-1-일)페닐)-N4 -(2-이소부톡시포르밀)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(2-메톡시-4-(4-메틸피페라진-1-일)페닐)-N 4-(3-(메톡시포르밀)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(2-메톡시-4-(4-(4-메틸피페라진-1-일)피페리딘-1-일)페닐)-N 4-(3-(메톡시포르밀)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N2 -(4-(4-히드록시피페리딘-1-일)페닐)-N 4-(3-(메톡시포르밀)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(4-(4-메틸피페라진-1-일)페닐)-N 4-(3-(메톡시포르밀)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(4-모르폴리노페닐)-N 4-(3-(메톡시포르밀)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(2-메톡시-4-(4-(피롤리딘-1-일)피페리딘-1-일)페닐)-N 4-(3-(메톡시포르밀)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N2 -(2-모르폴리노-5-피리딜)-N4 -(3-(메톡시포르밀)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(2-메톡시-(4-모르폴린-1-일)페닐)-N 4-(3-(메톡시포르밀)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(2-메톡시-4-(4-(4-메틸피페라진-1-일)피페리딘-1-일)페닐)-N 4-(2-(N-메틸아미노프로밀)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(2-메톡시-4-(4-(피롤리딘-1-일)피페리딘-1-일)페닐)-N 4-(2-(N-메틸아미노프로밀)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N2 -(4-아미노설포닐페닐)-N4 -(2-(N-메틸아미노프로밀)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(2-메톡시-4-(4-메틸피페라진-1-일)페닐)-N 4-(2-(메톡시포르밀)티엔-3-일)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(2-메톡시-4-(4-(4-메틸피페라진-1-일)피페리딘-1-일)페닐)-N 4-(2-(메톡시포르밀)티엔-3-일)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(4-(4-히드록시피페리딘-1-일)페닐)-N 4-(2-(메톡시포르밀)티엔-3-일)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(4-모르폴리노페닐)-N 4-(2-(메톡시포르밀)티엔-3-일)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(2-메톡시-4-모르폴리노페닐)-N 4-(2-(메톡시포르밀)티엔-3-일)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(4-(4-(4-메틸피페라진-1-일)피페리딘-1-일)페닐)-N 4-(2-(메톡시포르밀)티엔-3-일)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(2-에톡시-4-(4-메틸피페라진-1-일)페닐)-N 4-(2-(메톡시포르밀)티엔-3-일)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(2-메톡시-4-(4-(피롤리딘-1-일)피페리딘-1-일)-N 4-(2-(메톡시포르밀)티엔-3-일)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(2-메톡시-4-(4-(N,N-디메틸아미노)피페리딘-1-일)페닐-N 4-(2-(메톡시포르밀)티엔-3-일)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(2-메톡시-5-메틸-4-(1-메틸피페리딘-4-일)페닐)-N 4-(2-(메톡시포르밀)티엔-3-일)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(2-이소프로폭시-5-메틸-(4-(1-메틸피페리딘-4-일)페닐)-N 4-(2-(메톡시포르밀)티엔-3-일)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(N-(2-N,N-디메틸아미노아세틸)-5-메톡시인돌린-6-일)-N 4-(2-(메톡시포르밀)티엔-3-일)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(2-메톡시-4-)4-(4-메틸피페라진-1-일)피페리딘-1-일)페닐-N 4-(3-이소프로필설폰-1-일메틸-1H-피라졸-1-일)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(N-(2-N,N-디메틸아미노아세틸)-5-메톡시인돌린-6-일)-N 4-(3-이소프로필설폰-1-일메틸-1H-피라졸-1-일)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(2-메톡시-4-(4-(4-메틸피페라진-1-일)페닐-N 4-(3-이소프로필설폰-1-일메틸-1H-피라졸-1-일)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(4-(4-히드록시피페리딘-1-일)페닐)-N 4-(3-이소프로필설폰-1-일메틸-1H-피라졸-1-일)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(2-메톡시-4-(4-메틸피페라진-1-일)페닐-N 4-(2-(메틸티오)벤질)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(2-메톡시-4-(4-(4-메틸피페라진-1-일)피페리딘-1-일)페닐 )-N 4-(2-(메틸티오)벤질)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(4-(4-히드록시피페리딘-1-일)페닐-N 4-(2-(메틸티오)벤질)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(4-아미노설포닐페닐)-N 4-(2-(메톡시포르밀)페닐-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(2-메톡시-4-(4-메틸피페라진-1-일)페닐)-N 4-(2-(이소프로필티오)벤질)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(4-(4-히드록시피페리딘-1-일)페닐)-N 4-(2-(이소프로필티오)벤질)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(4-아미노설포닐페닐)-N 4-(2-(이소프로필티오)벤질)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(2-메톡시-4-(4-메틸피페라진-1-일)페닐)-N 4-(2-(메틸설포닐)벤질)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(2-메톡시-4-(4-(4-메틸피페라진-1-일)피페리딘-1-일)페닐)-N 4-(2-(메틸설포닐)벤질)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N2 -(4-(4-히드록시피페리딘-1-일)페닐)-N 4-(2-(메틸설포닐)벤질)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N2 -(4-아미노설포닐페닐)-N4 -(2-(메틸설포닐)벤질)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(4-(4-메틸피페라진-1-일)페닐)-N 4-(2-(메틸설포닐)벤질)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(2-메톡시-4-(4-메틸피페라진-1-일)페닐)-N 4-(2-(이소프로필설포닐)벤질)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(2-메톡시-4-(4-(4-메틸피페라진-1-일)피페리딘-1-일)페닐)-N 4-(2-(이소프로필설포닐)벤질)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(4-(4-히드록시피페리딘-1-일)페닐)-N 4-(2-(이소프로필설포닐)벤질)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(4-아미노설포닐페닐)-N 4-(2-(이소프로필설포닐)벤질)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(4-(4-메틸피페라진-1-일)페닐)-N 4-(2-(이소프로필설포닐)벤질)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(2-메톡시-4-(4-메틸피페라진-1-일)페닐)-N 4-(2,6-디클로로벤질)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(2-메톡시-4-(4-(4-메틸피페라진-1-일)피페리딘-1-일)페닐)-N 4-(2,6-디클로로벤질)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(4-(4-히드록시피페리딘-1-일)페닐)-N 4-(2,6-디클로로벤질)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(4-(4-메틸피페라진-1-일)페닐)-N 4-(2,6-디클로로벤질)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(2-메톡시-4-(4-메틸피페라진-1-일)페닐)-N 4-메틸-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(2-메톡시-4-(4-(4-메틸피페라진-1-일)피페리딘-1-일)페닐)-N 4-메틸-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(4-(4-히드록시피페리딘-1-일)페닐)-N 4-메틸-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(4-아미노설포닐페닐)-N 4-메틸-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(2-메톡시-4-모르폴리노포르밀페닐)-N 4-메틸-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(2-메톡시-4-(4-메틸피페라진-1-일포르밀)페닐)-N 4-메틸-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
7-클로로-N 2-(2-메톡시-4-(4-메틸피페라진-1-일)페닐)-N 4-메틸-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
7-클로로-N 2-(2-메톡시-4-모르폴리노포르밀페닐)-N 4-메틸-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(2-메톡시-4-(4-메틸피페라진-1-일포르밀)페닐)-N 4-에틸-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(2-메톡시-4-(4-(4-메틸피페라진-1-일)피페리딘-1-일)페닐)-N 4-에틸-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N2 -(4-(4-히드록시피페리딘-1-일)페닐)-N 4-에틸-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
7-브로모-N 2-(2-메톡시-4-(4-메틸피페라진-1-일포르밀)페닐)-N 4-에틸-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
7-브로모-N 2-(2-메톡시-4-(4-(4-메틸피페라진-1-일)피페리딘-1-일)페닐)-N 4-에틸 5H-피롤로[3,2-d]피리미딘-2,4-디아민;
7-브로모-N2 -(4-(4-히드록시피페리딘-1-일)페닐)-N 4-에틸-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
7-클로로-N 2-(2-메톡시-4-(4-메틸피페라진-1-일포르밀)페닐)-N 4-에틸-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
7-클로로-N 2-(2-메톡시-4-(4-(4-메틸피페라진-1-일)피페리딘-1-일)페닐)-N 4-에틸-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
7-클로로-N2 -(4-(4-히드록시피페리딘-1-일)페닐)-N 4-에틸-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(2-메톡시-4-(4-메틸피페라진-1-일포르밀)페닐)-N 4-시클로프로필-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(2-메톡시-4-(4-(4-메틸피페라진-1-일)피페리딘-1-일)페닐)-N 4-시클로프로필-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N2 -(4-(4-히드록시피페리딘-1-일)페닐)-N 4-시클로프로필-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(4-아미노설포닐페닐)-N 4-시클로프로필-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
7-브로모-N 2-(2-메톡시-4-(4-메틸피페라진-1-일포르밀)페닐)-N 4-시클로프로필-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
7-브로모-N 2-(2-메톡시-4-(4-(4-메틸피페라진-1-일)피페리딘-1-일)페닐)-N 4-시클로프로필-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
7-브로모-N2 -(4-(4-히드록시피페리딘-1-일)페닐)-N 4-시클로프로필-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
7-클로로-N 2-(2-메톡시-4-(4-메틸피페라진-1-일포르밀)페닐)-N 4-시클로프로필-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
7-클로로-N 2-(2-메톡시-4-(4-(4-메틸피페라진-1-일)피페리딘-1-일)페닐)-N 4-시클로프로필-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
7-클로로-N2 -(4-(4-히드록시피페리딘-1-일)페닐)-N 4-시클로프로필-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N2 -(4-(4-히드록시피페리딘-1-일)페닐)-4-모르폴리노-5H-피롤로[3,2-d]피리미딘-2-아민;
4-((2-(메톡시포르밀)페닐)티오)-N 2-(2-메톡시-4-(4-메틸피페라진-1-일)페닐)-5H-피롤로[3,2-d]피리미딘-2-아민;
4-((2-(메톡시포르밀)페닐)티오)-N 2-(2-메톡시-4-(4-(4-메틸피페라진-1-일)피페리딘-1-일)페닐)-5H-피롤로[3,2-d]피리미딘-2-아민;
4-((2-(메톡시포르밀)페닐)티오)-N 2-(4-(4-히드록시피페리딘-1-일)페닐)-5H-피롤로[3,2-d]피리미딘-2-아민;
4-((2-(메톡시포르밀)페닐)티오)-N 2-(4-아미노설포닐페닐)-5H-피롤로[3,2-d]피리미딘-2-아민;
4-((2-(메톡시포르밀)페닐)티오)-N 2-(2-메톡시-4-(4-(피롤리딘-1-일)피페리딘-1-일)페닐)-5H-피롤로[3,2-d]피리미딘-2-아민;
4-((2-(메톡시포르밀)페닐)옥시)-N 2-(2-메톡시-4-(4-메틸피페라진-1-일)페닐)-5H-피롤로[3,2-d]피리미딘-2-아민;
4-((2-(메톡시포르밀)페닐)옥시)-N 2-(2-메톡시-4-(4-(4-메틸피페라진-1-일)피페리딘-1-일)페닐)-5H-피롤로[3,2-d]피리미딘-2-아민;
4-((2-(메톡시포르밀)페닐)옥시)-N 2-(4-(4-히드록시피페라진-1-일)페닐)-5H-피롤로[3,2-d]피리미딘-2-아민;
4-((2-(메톡시포르밀)페닐)옥시)-N 2-(4-아미노설포닐페닐-5H-피롤로[3,2-d]피리미딘-2-아민;
5-메틸-N 2-(2-메톡시-4-(4-메틸피페라진-1-일)페닐)-N 4-(2-(메틸티오)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
5-메틸-N2 -(2-메톡시-4-(4-(4-메틸피페라진-1-일)피페리딘-1-일)페닐)-N4 -(2-(메틸티오)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
5-메틸-N2 -(4-(4-히드록시피페리딘-1-일)페닐)-N4 -(2-(메틸티오)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
5-메틸-N2 -(4-아미노설포닐페닐)-N4 -(2-(메틸티오)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
5-메틸-N2 -(2-에톡시-4-(4-(4-메틸피페라진-1-일)피페리딘-1-일포르밀)페닐)-N4 -(2-(메틸티오)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
5-메틸-N 2-(4-(4-메틸피페라진-1-일)페닐)-N 4-(2-(메틸티오)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
5-메틸-N 2-(2-메톡시-4-(4-메틸피페라진-1-일)페닐)-N 4-(2-(이소프로필티오)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
5-메틸-N 2-(2-메톡시-4-(4-(4-메틸피페라진-1-일)피페리딘-1-일)페닐)-N 4-(2-(이소프로필티오)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
5-메틸-N2 -(4-(4-히드록시피페리딘-1-일)페닐)-N4 -(2-(이소프로필티오)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
5-메틸-N2 -(4-아미노설포닐페닐)-N4 -(2-(메틸티오)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민, 5-메틸-N2 -(2-에톡시-4-(4-(4-메틸피페라진-1-일포르밀)피페리딘-1-일)페닐)-N4 -(2-(메틸티오)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
5-메틸-N 2-(2-메톡시-4-(4-메틸피페라진-1-일)페닐)-N 4-(2-(메틸설포닐)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
5-메틸-N 2-(2-메톡시-4-(4-(4-메틸피페라진-1-일)피페리딘-1-일)페닐)-N 4-(2-(메틸설포닐)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
5-메틸-N2 -(4-(4-히드록시피페리딘-1-일)페닐)-N4 -(2-(메틸설포닐)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
5-메틸-N2 -(4-아미노설포닐페닐)-N4 -(2-(메틸설포닐)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
5-메틸-N 2-(4-(4-메틸피페라진-1-일)페닐)-N 4-(2-(메틸설포닐)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
5-메틸-N2 -(2-에톡시-4-(4-히드록시피페리딘-1-일)페닐)-N4 -(2-(메틸설포닐)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
5-메틸-N 2-(2-메톡시-4-(4-메틸피페라진-1-일)페닐)-N 4-(2-(이소프로필설포닐)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
5-메틸-N 2-(2-메톡시-4-(4-(4-메틸피페라진-1-일)피페리딘-1-일)페닐)-N 4-(2-(이소프로필설포닐)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
5-메틸-N2 -(4-(4-히드록시피페리딘-1-일)페닐)-N4 -(2-(이소프로필설포닐)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
5-메틸-N2 -(4-아미노설포닐페닐)-N4 -(2-(이소프로필설포닐)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
5-메틸-N 2-(4-(4-메틸피페라진-1-일)페닐)-N 4-(2-(이소프로필설포닐)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
5-메틸-N2 -(2-에톡시-4-(4-히드록시피페리딘-1-일)페닐)-N 4-(2-(이소프로필설포닐)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
5-메틸-N2 -(2-에톡시-4-(4-(4-메틸피페라진-1-일포르밀)피페리딘-1-일)페닐)-N4 -(2-(이소프로필설포닐)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
5-메틸-N 2-(2-이소프로폭시-5-메틸-4-(1-메틸피페리딘-4-일)페닐)-N 4-(2-(이소프로필설포닐페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
5-메틸-N 2-(2-메톡시-5-메틸-4-(1-메틸피페리딘-4-일)페닐)-N 4-(2-(이소프로필설포닐페닐)- 5H-피롤로[3,2-d]피리미딘-2,4-디아민;
5-메틸-N 2-(2-메톡시-4-(4-(4-메틸피페라진-1-일)피페리딘-1-일)페닐)-N 4-(2-(메틸설폰아미도)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
5-메틸-N 2-(2-메톡시-4-(4-메틸피페라진-1-일)페닐)-N 4-(2-(디메틸포스피닐)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
5-메틸-N 2-(2-메톡시-4-(4-(4-메틸피페라진-1-일)피페리딘-1-일)페닐)-N 4-(2-(디메틸포스피닐)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
5-메틸-N 2-(4-(4-히드록시피페리딘-1-일)페닐)-N 4-(2-(디메틸포스피닐)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
5-메틸-N 2-(4-(4-메틸피페라진-1-일)페닐)-N 4-(2-(디메틸포스피닐)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
5-메틸-N 2-(1-(1-메틸피페리딘-4-일)-1H-피라졸-4-일)-N 4-(2-(디메틸포스피닐)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
5-메틸-N 2-(2-메톡시-4-(4-메틸피페라진-1-일)페닐)-N 4-(2-(메톡시포르밀)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
5-메틸-N 2-(2-메톡시-4-(4-(4-메틸피페라진-1-일)피페리딘-1-일)페닐)-N 4-(2-(메톡시포르밀)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
5-메틸-N2 -(4-(4-히드록시피페리딘-1-일)페닐)-N 4-(2-(메톡시포르밀)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
5-메틸-N 2-(2-메톡시-4-(4-(4-메틸피페라진-1-일)피페리딘-1-일포르밀)페닐)-N 4-(2-(메톡시포르밀)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
5-메틸-N 2-(2-메톡시-4-(4-메틸피페라진-1-일)페닐)-N 4-(3-(메톡시포르밀)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
5-메틸-N2 -(4-(4-히드록시피페리딘-1-일)페닐)-N 4-(3-(메톡시포르밀)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
5-메틸-N 2-(2-메톡시-4-(4-메틸피페라진-1-일)페닐)-N 4-(2-(메틸티오)벤질)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
5-메틸-N2 -(4-(4-히드록시피페리딘-1-일)페닐)-N 4-(2-(메틸티오)벤질)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
5-메틸-N2 -(4-아미노설포닐페닐)-N4 -(2-(메틸티오)벤질)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
5-메틸-N2 -(2-에톡시-4-(4-히드록시피페리딘-1-일)페닐)-N4 -(2-(메틸티오)벤질)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
5-메틸-N 2-(2-메톡시-4-(4-메틸피페라진-1-일)페닐)-N 4-(2-(이소프로필티오)벤질)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
5-메틸-N 2-(4-(4-히드록시피페리딘-1-일)페닐)-N 4-(2-(이소프로필티오)벤질)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
5-메틸-N 2-(4-아미노설포닐페닐)-N 4-(2-(이소프로필티오)벤질)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
5-메틸-N 2-(2-메톡시-4-(4-메틸피페라진-1-일)페닐)-N 4-(2-(메틸설포닐)벤질)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
5-메틸-N 2-(2-메톡시-4-(4-(4-메틸피페라진-1-일)피페리딘-1-일)페닐)-N 4-(2-(메틸설포닐)벤질)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
5-메틸-N2 -(4-(4-히드록시피페리딘-1-일)페닐)-N 4-(2-(메틸설포닐)벤질)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
5-메틸-N2 -(4-아미노설포닐페닐)-N4 -(2-(메틸설포닐)벤질)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
5-메틸-N 2-(4-(4-메틸피페라진-1-일)페닐)-N 4-(2-(메틸설포닐)벤질)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
5-메틸-N2 -(2-메톡시-4-(4-(4-메틸피페라진-1-일)피페리딘-1-일포르밀)페닐)-N4 -(2-(메틸설포닐)벤질)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
5-메틸-N2 -(2-에톡시-4-(4-히드록시피페리딘-1-일)페닐)-N 4-(2-(메틸설포닐)벤질)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
5-메틸-N 2-(2-메톡시-4-(4-메틸피페라진-1-일)페닐)-N 4-(2-(이소프로필설포닐)벤질)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
5-메틸-N 2-(2-메톡시-4-(4-(4-메틸피페라진-1-일)피페리딘-1-일)페닐)-N 4-(2-(이소프로필설포닐)벤질)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
5-메틸-N 2-(4-(4-히드록시피페리딘-1-일)페닐)-N 4-(2-(이소프로필설포닐)벤질)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
5-메틸-N 2-(4-아미노설포닐페닐)-N 4-(2-(이소프로필설포닐)벤질)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
5-메틸-N 2-(4-(4-메틸피페라진-1-일)페닐)-N 4-(2-(이소프로필설포닐)벤질)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
5-메틸-N 2-(2-메톡시-4-(4-메틸피페라진-1-일)페닐)-N 4-(2,6-디클로로벤질)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
5-메틸-N 2-(2-메톡시-4-(4-(4-메틸피페라진-1-일)피페리딘-1-일)페닐)-N 4-(2,6-디클로로벤질)- 5H-피롤로[3,2-d]피리미딘-2,4-디아민;
5-메틸-N 2-(4-(4-히드록시피페리딘-1-일)페닐)-N 4-(2,6-디클로로벤질)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
5-메틸-N 2-(4-(4-메틸피페라진-1-일)페닐)-N 4-(2,6-디클로로벤질)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
4-((2-(메톡시포르밀)페닐)옥시)-5-메틸-N 2-(2-메톡시-4-(4-메틸피페라진-1-일)페닐)-5H-피롤로[3,2-d]피리미딘-2-아민;
4-((2-(메톡시포르밀)페닐)옥시)-5-메틸-N 2-(2-메톡시-4-(4-(4-메틸피페라진-1-일)피페리딘-1-일)페닐)-5H-피롤로[3,2-d]피리미딘-2-아민;
4-((2-(메톡시포르밀)페닐)옥시)-5-메틸-N 2-(4-(4-히드록시피페리딘-1-일)페닐)-5H-피롤로[3,2-d]피리미딘-2-아민;
4-((2-(메톡시포르밀)페닐)옥시)-5-메틸-N 2-(4-아미노설포닐페닐)-5H-피롤로[3,2-d]피리미딘-2-아민 중 어느 하나인 청구항 1 내지 청구항 4 중 어느 한 항에 기재된 화합물, 그 입체 이성질체, 그 약학적으로 허용 가능한 염 또는 그 약학적으로 허용 가능한 용매 화합물. - 청구항 1 내지 청구항 4 중 어느 한 항에 기재된 화합물, 그 입체 이성질체, 그 약학적으로 허용 가능한 염 또는 그 약학적으로 허용 가능한 용매 화합물, 및 약학적으로 허용 가능한 담체, 희석제 또는 부형제를 포함하는, ALK 키나아제에 의해 매개되는 종양의 예방 또는 치료를 위한 약학 조성물.
- ALK 키나아제에 의해 매개되는 종양을 예방 또는 치료하는 약제의 제조에 사용하기 위한, 청구항 1 내지 청구항 4 중 어느 한 항에 기재된 화합물, 그 입체 이성질체, 또는 그 약학적으로 허용 가능한 염 또는 그 약학적으로 허용 가능한 용매 화합물을 포함하는 조성물.
- 청구항 9에 있어서,
상기 종양은 역형성 대세포 림프종, 염증성 근섬유 모세포종, 비소세포 폐암, 신경모세포종, 소세포 폐암, 폐선암, 췌장암, 유선암, 전립선암, 간암, 피부암, 상피세포암, 위장 간질 종양, 백혈병, 조직세포 림프종, 비인두암 중의 임의의 일종인, 조성물. - 청구항 5에 있어서,
상기 알킬설폰산염은 메틸설폰산염 또는 에틸설폰산염이며; 상기 아릴설폰산염은 벤젠설폰산염 또는 p-메틸벤젠설폰산염인, 화합물, 그 입체 이성질체, 그 약학적으로 허용 가능한 염 또는 그 약학적으로 허용 가능한 용매 화합물. - 청구항 6에 있어서,
상기 화합물은 이하의 화합물:
N2 -(2-메톡시-4-(4-메틸피페라진-1-일)페닐)-N4 -(2-(메틸티오)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N2 -(4-(4-히드록시피페리딘-1-일)페닐)-N4 -(2-(메틸티오)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N2 -(4-아미노설포닐페닐)-N4 -(2-(메틸티오)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N2 -(2-메톡시-4-(4-메틸피페라진-1-일)페닐)-N4 -(2-(이소프로필티오)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N2 -(4-(4-히드록시피페리딘-1-일)페닐)-N4 -(2-(이소프로필티오)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N2 -(4-아미노설포닐페닐)-N4 -(2-(이소프로필티오)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N2 -(2-메톡시-4-(4-메틸피페라진-1-일)페닐)-N4 -(2-(메틸설포닐)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N2 -(2-메톡시-4-(4-(4-메틸피페라진-1-일)피페리딘-1-일)페닐)-N4 -(2-(메틸설포닐)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N2 -(4-(4-히드록시피페리딘-1-일)페닐)-N4 -(2-(메틸설포닐)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N2 -(4-아미노설포닐페닐)-N4 -(2-(메틸설포닐)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N2 -(4-(4-메틸피페라진-1-일)페닐)-N4 -(2-(메틸설포닐)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N2 -(2-메톡시-4-(4-메틸피페라진-1-일)페닐)-N4 -(2-(이소프로필설포닐)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N2 -(4-(4-메틸피페라진-1-일)페닐)-N4 -(2-(이소프로필설포닐)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N2 -(2-메톡시-4-(4-(4-메틸피페라진-1-일)피페리딘-1-일)페닐)-N4 -(2-(이소프로필설포닐)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N2 -(4-(4-히드록시피페리딘-1-일)페닐)-N4 -(2-(이소프로필설포닐)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N2 -(4-아미노설포닐페닐)-N4 -(2-(이소프로필설포닐)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N2 -(2-이소프로폭시-5-메틸-(4-(1-메틸피페리딘-4-일)페닐-N4 -(2-(이소프로필설포닐)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N2 -(2-메톡시-5-메틸-(4-(1-메틸피페리딘-4-일)페닐-N4 -(2-(이소프로필설포닐)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N2 -(1-(1-메틸피페리딘-4-일)-1H-피라졸일-4-일-N4 -(2-(이소프로필설포닐)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(2-메톡시-4-(4-메틸피페라진-1-일)페닐)-N 4-(2-메톡시포르밀)페닐-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(2-메톡시-4-(4-(4-메틸피페라진-1-일)피페리딘-1-일)페닐)-N 4-(2-(메톡시포르밀)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(4-(4-히드록시피페리딘-1-일)페닐)-N 4-(2-(메톡시포르밀)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N2 -(4-아미노설포닐페닐)-N4 -(2-(메톡시포르밀)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(4-모르폴리노페닐)-N 4-(2-(메톡시포르밀)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(4-(4-메틸피페라진-1-일)페닐)-N 4-(2-(메톡시포르밀)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(2-메톡시-4-(4-(피롤리딘-1-일)피페리딘-1-일)페닐)-N 4-(2-(메톡시포르밀)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(4-(피리딘-2-일메톡시)페닐)-N 4-(2-(메톡시포르밀)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N2 -(2-이소프로폭시-4-(4-히드록시피페리딘-1-일)페닐)-N 4-(2-(메톡시포르밀)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N2 -(2-에톡시-4-(4-히드록시피페리딘-1-일)페닐)-N 4-(2-(메톡시포르밀)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N2 -(4-(4-히드록시피페리딘-1-일설포닐)페닐)-N 4-(2-(메톡시포르밀)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(2-메톡시-4-(4-(4-메틸피페라진-1-일)피페리딘-1-일포르밀)페닐)-N 4-(2-(메톡시포르밀)페닐)- 5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(5-(4-메틸피페라진-1-일)피리드-2-일)-N 4-(2-(메톡시포르밀)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(2-메톡시-5-메틸-4-(1-메틸피페리딘-4-일)페닐)-N 4-(2-(메톡시포르밀)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(2-이소프로폭시-5-메틸-4-(1-메틸피페리딘-4-일)페닐)-N 4-(2-(메톡시포르밀)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(2-메톡시-4-모르폴리노페닐)-N 4-(2-(메톡시포르밀)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(2-메톡시-4-모르폴리노포르밀페닐)-N 4-(2-(메톡시포르밀)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N2 -(6-(4-히드록시피페리딘-1-일)피리딘-3-일)-N4 -(2-(메톡시포르밀)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(2-메톡시-4-(4-메틸피페라진-1-일)페닐)-N 4-(2-(이소부톡시포르밀)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N2 -(4-(4-히드록시피페리딘-1-일)페닐)-N 4-(2-이소부톡시포르밀)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(2-메톡시-4-(4-(4-메틸피페라진-1-일)피페리딘-1-일)페닐)-N 4-(2-이소부톡시포르밀)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N2 -(2-메톡시-4-(4-(피롤리딘-1-일)피페리딘-1-일)페닐)-N4 -(2-이소부톡시포르밀)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(2-메톡시-4-(4-메틸피페라진-1-일)페닐)-N 4-(3-(메톡시포르밀)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(2-메톡시-4-(4-(4-메틸피페라진-1-일)피페리딘-1-일)페닐)-N 4-(3-(메톡시포르밀)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N2 -(4-(4-히드록시피페리딘-1-일)페닐)-N 4-(3-(메톡시포르밀)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(4-(4-메틸피페라진-1-일)페닐)-N 4-(3-(메톡시포르밀)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(4-모르폴리노페닐)-N 4-(3-(메톡시포르밀)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(2-메톡시-4-(4-(피롤리딘-1-일)피페리딘-1-일)페닐)-N 4-(3-(메톡시포르밀)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(2-메톡시-4-(4-(4-메틸피페라진-1-일)피페리딘-1-일)페닐)-N 4-(2-(N-메틸아미노프로밀)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(2-메톡시-4-(4-(피롤리딘-1-일)피페리딘-1-일)페닐)-N 4-(2-(N-메틸아미노프로밀)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(4-아미노설포닐페닐)-N 4-(2-(N-메틸아미노프로밀)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(2-메톡시-4-(4-메틸피페라진-1-일)페닐)-N 4-(2-(메톡시포르밀)티엔-3-일)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(2-메톡시-4-(4-(4-메틸피페라진-1-일)피페리딘-1-일)페닐)-N 4-(2-(메톡시포르밀)티엔-3-일)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(2-메톡시-4-(4-메틸피페라진-1-일)페닐-N 4-(2-(메틸티오)벤질)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(2-메톡시-4-(4-(4-메틸피페라진-1-일)피페리딘-1-일)-N 4-(2-(메틸티오)벤질)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(4-(4-히드록시피페리딘-1-일)페닐-N 4-(2-(메틸티오)벤질)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(4-아미노설포닐페닐)-N 4-(2-(메톡시포르밀)페닐-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(2-메톡시-4-(4-메틸피페라진-1-일)페닐)-N 4-(2-(이소프로필티오)벤질)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(4-(4-히드록시피페리딘-1-일)페닐)-N 4-(2-(이소프로필티오)벤질)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(4-아미노설포닐페닐)-N 4-(2-(이소프로필티오)벤질)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(2-메톡시-4-(4-메틸피페라진-1-일)페닐)-N 4-(2-(메틸설포닐)벤질)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(2-메톡시-4-(4-(4-메틸피페라진-1-일)피페리딘-1-일)페닐)-N 4-(2-(메틸설포닐)벤질)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N2 -(4-(4-히드록시피페리딘-1-일)페닐)-N 4-(2-(메틸설포닐)벤질)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N2 -(4-아미노설포닐페닐)-N4 -(2-(메틸설포닐)벤질)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(4-(4-메틸피페라진-1-일)페닐)-N 4-(2-(메틸설포닐)벤질)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(2-메톡시-4-(4-메틸피페라진-1-일)페닐)-N 4-(2-(이소프로필설포닐)벤질)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(2-메톡시-4-(4-(4-메틸피페라진-1-일)피페리딘-1-일)페닐)-N 4-(2-(이소프로필설포닐)벤질)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(4-(4-히드록시피페리딘-1-일)페닐)-N 4-(2-(이소프로필설포닐)벤질)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(4-아미노설포닐페닐)-N 4-(2-(이소프로필설포닐)벤질)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(4-(4-메틸피페라진-1-일)페닐)-N 4-(2-(이소프로필설포닐)벤질)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(2-메톡시-4-(4-메틸피페라진-1-일)페닐)-N 4-메틸-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(2-메톡시-4-(4-(4-메틸피페라진-1-일)피페리딘-1-일)페닐)-N 4-메틸-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(4-(4-히드록시피페리딘-1-일)페닐)-N 4-메틸-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(4-아미노설포닐페닐)-N 4-메틸-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(2-메톡시-4-모르폴리노포르밀페닐)-N 4-메틸-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(2-메톡시-4-(4-메틸피페라진-1-일포르밀)페닐)-N 4-메틸-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(2-메톡시-4-(4-메틸피페라진-1-일포르밀)페닐)-N 4-에틸-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(2-메톡시-4-(4-(4-메틸피페라진-1-일)피페리딘-1-일)페닐)-N 4-에틸-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(4-(4-히드록시피페리딘-1-일)페닐)-N 4-에틸-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(2-메톡시-4-(4-메틸피페라진-1-일포르밀)페닐)-N 4-시클로프로필-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(2-메톡시-4-(4-(4-메틸피페라진-1-일)피페리딘-1-일)페닐)-N 4-시클로프로필-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N2 -(4-(4-히드록시피페리딘-1-일)페닐)-N 4-시클로프로필-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
N 2-(4-아미노설포닐페닐)-N 4-시클로프로필-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
4-((2-(메톡시포르밀)페닐)티오)-N 2-(2-메톡시-4-(4-메틸피페라진-1-일)페닐)-5H-피롤로[3,2-d]피리미딘-2-아민;
4-((2-(메톡시포르밀)페닐)티오)-N 2-(2-메톡시-4-(4-(4-메틸피페라진-1-일)피페리딘-1-일)페닐)-5H-피롤로[3,2-d]피리미딘-2-아민;
4-((2-(메톡시포르밀)페닐)티오)-N 2-(4-(4-히드록시피페리딘-1-일)페닐)-5H-피롤로[3,2-d]피리미딘-2-아민;
4-((2-(메톡시포르밀)페닐)티오)-N 2-(4-아미노설포닐페닐)-5H-피롤로[3,2-d]피리미딘-2-아민;
4-((2-(메톡시포르밀)페닐)티오)-N 2-(2-메톡시-4-(4-(피롤리딘-1-일)피페리딘-1-일)페닐)-5H-피롤로[3,2-d]피리미딘-2-아민;
4-((2-(메톡시포르밀)페닐)옥시)-N 2-(2-메톡시-4-(4-메틸피페라진-1-일)페닐)-5H-피롤로[3,2-d]피리미딘-2-아민;
4-((2-(메톡시포르밀)페닐)옥시)-N 2-(2-메톡시-4-(4-(4-메틸피페라진-1-일)피페리딘-1-일)페닐)-5H-피롤로[3,2-d]피리미딘-2-아민;
4-((2-(메톡시포르밀)페닐)옥시)-N 2-(4-(4-히드록시피페라진-1-일)페닐)-5H-피롤로[3,2-d]피리미딘-2-아민;
4-((2-(메톡시포르밀)페닐)옥시)-N 2-(4-아미노설포닐페닐-5H-피롤로[3,2-d]피리미딘-2-아민;
5-메틸-N 2-(2-메톡시-4-(4-메틸피페라진-1-일)페닐)-N 4-(2-(메틸티오)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
5-메틸-N2 -(2-메톡시-4-(4-(4-메틸피페라진-1-일)피페리딘-1-일)페닐)-N4 -(2-(메틸티오)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
5-메틸-N2 -(4-(4-히드록시피페리딘-1-일)페닐)-N4 -(2-(메틸티오)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
5-메틸-N2 -(4-아미노설포닐페닐)-N4 -(2-(메틸티오)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
5-메틸-N2 -(2-에톡시-4-(4-(4-메틸피페라진-1-일)피페리딘-1-일포르밀)페닐)-N4 -(2-(메틸티오)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
5-메틸-N 2-(4-(4-메틸피페라진-1-일)페닐)-N 4-(2-(메틸티오)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
5-메틸-N 2-(2-메톡시-4-(4-메틸피페라진-1-일)페닐)-N 4-(2-(이소프로필티오)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
5-메틸-N 2-(2-메톡시-4-(4-(4-메틸피페라진-1-일)피페리딘-1-일)페닐)-N 4-(2-(이소프로필티오)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
5-메틸-N2 -(4-(4-히드록시피페리딘-1-일)페닐)-N4 -(2-(메틸티오)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
5-메틸-N2 -(4-아미노설포닐페닐)-N4 -(2-(메틸티오)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
5-메틸-N2 -(2-에톡시-4-(4-(4-메틸피페라진-1-일)피페리딘-1-일포르밀)페닐)-N4 -(2-(이소프로필티오)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
5-메틸-N 2-(2-메톡시-4-(4-메틸피페라진-1-일)페닐)-N 4-(2-(메틸설포닐)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
5-메틸-N 2-(2-메톡시-4-(4-(4-메틸피페라진-1-일)피페리딘-1-일)페닐)-N 4-(2-(메틸설포닐)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
5-메틸-N2 -(4-(4-히드록시피페리딘-1-일)페닐)-N4 -(2-(메틸설포닐)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
5-메틸-N2 -(4-아미노설포닐페닐)-N4 -(2-(메틸설포닐)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
5-메틸-N 2-(4-(4-메틸피페라진-1-일)페닐)-N 4-(2-(메틸설포닐)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
5-메틸-N2 -(2-에톡시-4-(4-히드록시피페리딘-1-일)페닐)-N4 -(2-(메틸설포닐)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
5-메틸-N 2-(2-메톡시-4-(4-메틸피페라진-1-일)페닐)-N 4-(2-(이소프로필설포닐)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
5-메틸-N 2-(2-메톡시-4-(4-(4-메틸피페라진-1-일)피페리딘-1-일)페닐)-N 4-(2-(이소프로필설포닐)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
5-메틸-N2 -(4-(4-히드록시피페리딘-1-일)페닐)-N4 -(2-(이소프로필설포닐)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
5-메틸-N2 -(4-아미노설포닐페닐)-N4 -(2-(이소프로필설포닐)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
5-메틸-N 2-(4-(4-메틸피페라진-1-일)페닐)-N 4-(2-(이소프로필설포닐)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
5-메틸-N2 -(2-에톡시-4-(4-히드록시피페리딘-1-일)페닐)-N 4-(2-(이소프로필설포닐)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
5-메틸-N2 -(2-에톡시-4-(4-(4-메틸피페라진-1-일)피페리딘-1-일포르밀)페닐)-N4 -(2-(이소프로필설포닐)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
5-메틸-N 2-(2-이소프로폭시-5-메틸-4-(1-메틸피페리딘-4-일)페닐)-N 4-(2-(이소프로필설포닐) 페닐 )-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
5-메틸-N 2-(2-메톡시-5-메틸-4-(1-메틸피페리딘-4-일)페닐)-N 4-(2-(이소프로필설포닐)페닐)- 5H-피롤로[3,2-d]피리미딘-2,4-디아민;
5-메틸-N 2-(2-메톡시-4-(4-메틸피페라진-1-일)페닐)-N 4-(2-(메톡시포르밀)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
5-메틸-N 2-(2-메톡시-4-(4-(4-메틸피페라진-1-일)피페리딘-1-일)페닐)-N 4-(2-(메톡시포르밀)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
5-메틸-N2 -(4-(4-히드록시피페리딘-1-일)페닐)-N 4-(2-(메톡시포르밀)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
5-메틸-N 2-(2-메톡시-4-(4-(4-메틸피페라진-1-일)피페리딘-1-일포르밀)페닐)-N 4-(2-(메톡시포르밀)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
5-메틸-N 2-(2-메톡시-4-(4-메틸피페라진-1-일)페닐)-N 4-(3-(메톡시포르밀)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
5-메틸-N2 -(4-(4-히드록시피페리딘-1-일)페닐)-N 4-(3-(메톡시포르밀)페닐)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
5-메틸-N 2-(2-메톡시-4-(4-메틸피페라진-1-일)페닐)-N 4-(2-(메틸티오)벤질)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
5-메틸-N2 -(4-(4-히드록시피페리딘-1-일)페닐)-N 4-(2-(메틸티오)벤질)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
5-메틸-N2 -(4-아미노설포닐페닐)-N4 -(2-(메틸티오)벤질)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
5-메틸-N2 -(2-에톡시-4-(4-히드록시피페리딘-1-일)페닐)-N4 -(2-(메틸티오)벤질)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
5-메틸-N 2-(2-메톡시-4-(4-메틸피페라진-1-일)페닐)-N 4-(2-(이소프로필티오)벤질)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
5-메틸-N 2-(4-(4-히드록시피페리딘-1-일)페닐)-N 4-(2-(이소프로필티오)벤질)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
5-메틸-N 2-(4-아미노설포닐페닐)-N 4-(2-(이소프로필티오)벤질)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
5-메틸-N 2-(2-메톡시-4-(4-메틸피페라진-1-일)페닐)-N 4-(2-(메틸설포닐)벤질)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
5-메틸-N 2-(2-메톡시-4-(4-(4-메틸피페라진-1-일)피페리딘-1-일)페닐)-N 4-(2-(메틸설포닐)벤질)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
5-메틸-N2 -(4-(4-히드록시피페리딘-1-일)페닐)-N 4-(2-(메틸설포닐)벤질)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
5-메틸-N2 -(4-아미노설포닐페닐)-N4 -(2-(메틸설포닐)벤질)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
5-메틸-N 2-(4-(4-메틸피페라진-1-일)페닐)-N 4-(2-(메틸설포닐)벤질)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
5-메틸-N2 -(2-메톡시-4-(4-(4-메틸피페라진-1-일)피페리딘-1-일포르밀)페닐)-N4 -(2-(메틸설포닐)벤질)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
5-메틸-N2 -(2-에톡시-4-(4-히드록시피페리딘-1-일)페닐)-N 4-(2-(메틸설포닐)벤질)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
5-메틸-N 2-(2-메톡시-4-(4-메틸피페라진-1-일)페닐)-N 4-(2-(이소프로필설포닐)벤질)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
5-메틸-N 2-(2-메톡시-4-(4-(4-메틸피페라진-1-일)피페리딘-1-일)페닐)-N 4-(2-(이소프로필설포닐)벤질)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
5-메틸-N 2-(4-(4-히드록시피페리딘-1-일)페닐)-N 4-(2-(이소프로필설포닐)벤질)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
5-메틸-N 2-(4-아미노설포닐페닐)-N 4-(2-(이소프로필설포닐)벤질)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
5-메틸-N 2-(4-(4-메틸피페라진-1-일)페닐)-N 4-(2-(이소프로필설포닐)벤질)-5H-피롤로[3,2-d]피리미딘-2,4-디아민;
4-((2-(메톡시포르밀)페닐)옥시)-5-메틸-N 2-(2-메톡시-4-(4-메틸피페라진-1-일)페닐)-5H-피롤로[3,2-d]피리미딘-2-아민;
4-((2-(메톡시포르밀)페닐)옥시)-5-메틸-N 2-(2-메톡시-4-(4-(4-메틸피페라진-1-일)피페리딘-1-일)페닐)-5H-피롤로[3,2-d]피리미딘-2-아민;
4-((2-(메톡시포르밀)페닐)옥시)-5-메틸-N 2-(4-(4-히드록시피페리딘-1-일)페닐)-5H-피롤로[3,2-d]피리미딘-2-아민;
4-((2-(메톡시포르밀)페닐)옥시)-5-메틸-N 2-(4-아미노설포닐페닐-5H-피롤로[3,2-d]피리미딘-2-아민 중 어느 하나인, 화합물, 그 입체 이성질체, 그 약학적으로 허용 가능한 염 또는 그 약학적으로 허용 가능한 용매 화합물. - 청구항 10에 있어서,
상기 종양은 역형성 대세포 림프종, 염증성 근섬유 모세포종, 비소세포 폐암이나 신경모세포종인, 조성물. - 청구항 8에 있어서,
상기 알칼리성 조건은 디이소프로필에틸아민, 트리메틸아민, 포타슘 카르보네이트, 또는 NaH에 의해 형성되고, 상기 산성 조건은 트리플루오로 아세트산 또는 염산에 의해 형성되는, 제조 방법. - 청구항 5에 기재된 화합물, 그 입체 이성질체, 그 약학적으로 허용 가능한 염 또는 그 약학적으로 허용 가능한 용매 화합물, 및 약학적으로 허용 가능한 담체, 희석제 또는 부형제를 포함하는, ALK 키나아제에 의해 매개되는 종양의 예방 또는 치료를 위한 약학 조성물.
- 청구항 6에 기재된 화합물, 그 입체 이성질체, 그 약학적으로 허용 가능한 염 또는 그 약학적으로 허용 가능한 용매 화합물, 및 약학적으로 허용 가능한 담체, 희석제 또는 부형제를 포함하는, ALK 키나아제에 의해 매개되는 종양의 예방 또는 치료를 위한 약학 조성물.
- ALK 키나아제에 의해 매개되는 종양을 예방 또는 치료하는 약제의 제조에 사용하기 위한, 청구항 5에 기재된 화합물, 그 입체 이성질체, 또는 그 약학적으로 허용 가능한 염 또는 그 약학적으로 허용 가능한 용매 화합물을 포함하는 조성물.
- ALK 키나아제에 의해 매개되는 종양을 예방 또는 치료하는 약제의 제조에 사용하기 위한, 청구항 6에 기재된 화합물, 그 입체 이성질체, 또는 그 약학적으로 허용 가능한 염 또는 그 약학적으로 허용 가능한 용매 화합물을 포함하는 조성물.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510210380.6A CN106188060A (zh) | 2015-04-29 | 2015-04-29 | 嘧啶并吡咯类化合物、其制备方法、药用组合物及其应用 |
CN201510210380.6 | 2015-04-29 | ||
PCT/CN2016/080127 WO2016173477A1 (zh) | 2015-04-29 | 2016-04-25 | 嘧啶并吡咯类化合物、其制备方法、药用组合物及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20170141783A KR20170141783A (ko) | 2017-12-26 |
KR102075697B1 true KR102075697B1 (ko) | 2020-03-02 |
Family
ID=57198161
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020177034588A KR102075697B1 (ko) | 2015-04-29 | 2016-04-25 | 피리미딘피롤 화합물, 그 제조 방법, 약학 조성물 및 그 응용 |
Country Status (8)
Country | Link |
---|---|
US (1) | US10508118B2 (ko) |
EP (1) | EP3290420B1 (ko) |
JP (1) | JP6606561B2 (ko) |
KR (1) | KR102075697B1 (ko) |
CN (2) | CN106188060A (ko) |
AU (1) | AU2016255936B2 (ko) |
TW (1) | TWI650322B (ko) |
WO (1) | WO2016173477A1 (ko) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107801397B (zh) * | 2015-02-13 | 2021-07-30 | 达纳-法伯癌症研究所公司 | Lrrk2抑制剂及其制备和使用方法 |
KR102110573B1 (ko) * | 2015-08-13 | 2020-05-13 | 베이징 한미 파마슈티컬 컴퍼니 리미티드 | Irak4억제제 및 이의 용도 |
CN108276410B (zh) * | 2017-01-06 | 2021-12-10 | 首药控股(北京)股份有限公司 | 一种间变性淋巴瘤激酶抑制剂及其制备方法和用途 |
CN107312006B (zh) * | 2017-06-28 | 2019-11-15 | 郑州大学第一附属医院 | 吡咯并嘧啶类衍生物及其应用 |
CN109384782A (zh) * | 2017-08-04 | 2019-02-26 | 厦门大学 | 取代五元并六元杂环类化合物、其制备方法、药物组合及其用途 |
CN109575045B (zh) * | 2017-09-28 | 2021-02-12 | 南京红云生物科技有限公司 | 噻吩并嘧啶类化合物、其制备方法、药用组合物及其应用 |
KR101992621B1 (ko) | 2017-12-07 | 2019-09-27 | 주식회사 온코빅스 | 암세포 성장 억제 효과를 나타내는 신규한 피리미딘 유도체 및 그를 포함하는 약제학적 조성물 |
WO2019112344A1 (ko) * | 2017-12-07 | 2019-06-13 | 주식회사 온코빅스 | 암세포 성장 억제 효과를 나타내는 신규한 피리미딘 유도체 및 그를 포함하는 약제학적 조성물 |
US10508113B2 (en) | 2018-03-12 | 2019-12-17 | Abbvie Inc. | Inhibitors of tyrosine kinase 2 mediated signaling |
CN110526914B (zh) * | 2018-05-25 | 2022-02-08 | 首药控股(北京)股份有限公司 | 一种alk抑制剂的多晶型物及其制备方法 |
EP3842435A4 (en) * | 2018-09-20 | 2022-05-11 | Hanmi Pharm. Co., Ltd. | NEW SULFONAMIDE DERIVATIVE PRESENTING A FUSED PYRIMIDINE SKELETON, HAVING AN INHIBITOR EFFECT OF EPIDERMAL GROWTH FACTOR RECEPTOR MUTATION |
KR102377007B1 (ko) * | 2018-09-20 | 2022-03-22 | 한미약품 주식회사 | 상피세포 성장인자 수용체 돌연변이 저해 효과를 갖는 신규 융합 피리미딘 골격 설폰아마이드 유도체 |
CN112771032B (zh) * | 2018-10-29 | 2023-01-03 | 江苏先声药业有限公司 | 作为第四代egfr抑制剂的嘧啶吡唑类化合物 |
CN111170996B (zh) * | 2018-11-09 | 2021-12-28 | 天津大学 | 具有alk抑制活性的嘧啶衍生物及其合成方法和应用 |
CN113717156B (zh) * | 2020-05-25 | 2023-05-09 | 南京红云生物科技有限公司 | Egfr抑制剂、其制备方法及用途 |
CN114105887B (zh) * | 2021-09-16 | 2023-12-01 | 沈阳药科大学 | 一种氨基嘧啶衍生物及其制备方法和用途 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006122003A2 (en) | 2005-05-05 | 2006-11-16 | Ardea Biosciences, Inc. | Diaryl-purine, azapurines and -deazapurines as non-nucleoside reverse transcriptase inhibitors for treatment of hiv |
WO2009079412A2 (en) | 2007-12-14 | 2009-06-25 | Ardea Biosciences Inc. | Reverse transcriptase inhibitors |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3144903B2 (ja) * | 1991-08-21 | 2001-03-12 | エーザイ株式会社 | 縮合ピリミジン誘導体 |
PT896822E (pt) * | 1997-08-05 | 2003-07-31 | Pfizer Prod Inc | 4-aminopirrolo (3,2-d)pirimidinas como antagonistas do receptor de neuropeptideo y |
JP5298187B2 (ja) * | 2008-04-07 | 2013-09-25 | アイアールエム・リミテッド・ライアビリティ・カンパニー | タンパク質キナーゼ阻害剤としての化合物および組成物 |
AU2009238590A1 (en) * | 2008-04-22 | 2009-10-29 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
LT2300013T (lt) * | 2008-05-21 | 2017-12-27 | Ariad Pharmaceuticals, Inc. | Fosforo dariniai kaip kinazių inhibitoriai |
US8946239B2 (en) * | 2008-07-10 | 2015-02-03 | Duquesne University Of The Holy Spirit | Substituted pyrrolo, -furano, and cyclopentylpyrimidines having antimitotic and/or antitumor activity and methods of use thereof |
WO2012045195A1 (en) * | 2010-10-09 | 2012-04-12 | Abbott Laboratories | Pyrrolopyrimidines as fak and alk inhibiters for treatment of cancers and other diseases |
KR102063098B1 (ko) * | 2011-10-03 | 2020-01-08 | 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 | 암 치료를 위한 피롤로피리미딘 화합물 |
CN104177363B (zh) * | 2013-05-24 | 2018-06-05 | 江苏先声药业有限公司 | 双环杂环胺类Hedgehog信号通路抑制剂 |
CN106065017B (zh) * | 2013-09-18 | 2018-06-01 | 北京韩美药品有限公司 | 抑制btk和/或jak3激酶活性的化合物 |
US10087195B2 (en) * | 2014-05-28 | 2018-10-02 | Shanghai Fochon Pharmaceutical Co., Ltd. | Certain protein kinase inhibitors |
-
2015
- 2015-04-29 CN CN201510210380.6A patent/CN106188060A/zh active Pending
-
2016
- 2016-04-25 AU AU2016255936A patent/AU2016255936B2/en active Active
- 2016-04-25 WO PCT/CN2016/080127 patent/WO2016173477A1/zh active Application Filing
- 2016-04-25 CN CN201680003385.4A patent/CN107074866B/zh active Active
- 2016-04-25 EP EP16785908.1A patent/EP3290420B1/en active Active
- 2016-04-25 JP JP2017556806A patent/JP6606561B2/ja active Active
- 2016-04-25 KR KR1020177034588A patent/KR102075697B1/ko active IP Right Grant
- 2016-04-25 US US15/570,119 patent/US10508118B2/en active Active
- 2016-04-28 TW TW105113392A patent/TWI650322B/zh active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006122003A2 (en) | 2005-05-05 | 2006-11-16 | Ardea Biosciences, Inc. | Diaryl-purine, azapurines and -deazapurines as non-nucleoside reverse transcriptase inhibitors for treatment of hiv |
WO2009079412A2 (en) | 2007-12-14 | 2009-06-25 | Ardea Biosciences Inc. | Reverse transcriptase inhibitors |
Non-Patent Citations (3)
Title |
---|
Bioorganic & Medicinal Chemistry Letters, 24, pp. 3486-3492 (2014) 1부.* |
Collect. Czech. Chem. Commun., 68, pp.779-791(2003) 1부.* |
Pharmaceutical Chemistry Journal, 22, pp.135-141(1988) 1부.* |
Also Published As
Publication number | Publication date |
---|---|
EP3290420A4 (en) | 2018-12-05 |
AU2016255936A1 (en) | 2017-11-23 |
KR20170141783A (ko) | 2017-12-26 |
AU2016255936B2 (en) | 2018-12-13 |
JP6606561B2 (ja) | 2019-11-13 |
CN107074866B (zh) | 2019-06-07 |
JP2018514559A (ja) | 2018-06-07 |
US10508118B2 (en) | 2019-12-17 |
CN107074866A (zh) | 2017-08-18 |
TWI650322B (zh) | 2019-02-11 |
US20180312508A1 (en) | 2018-11-01 |
EP3290420A1 (en) | 2018-03-07 |
CN106188060A (zh) | 2016-12-07 |
TW201638092A (zh) | 2016-11-01 |
EP3290420B1 (en) | 2020-12-09 |
WO2016173477A1 (zh) | 2016-11-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102075697B1 (ko) | 피리미딘피롤 화합물, 그 제조 방법, 약학 조성물 및 그 응용 | |
CN107793413B (zh) | 嘧啶杂环化合物及其制备方法和应用 | |
WO2016054987A1 (zh) | Egfr抑制剂及其制备和应用 | |
WO2021043116A1 (zh) | 联苯类化合物及其制备方法和医药用途 | |
CN107739370B (zh) | 吡咯酮类brd4蛋白抑制剂的制备方法以及用途 | |
CN111961034A (zh) | 用作ret激酶抑制剂的化合物及其应用 | |
KR20190141203A (ko) | C5-아닐리노퀴나졸린 화합물 및 암의 치료에서의 이의 용도 | |
EP3476846A1 (en) | Novel heterocyclic derivative compound and use thereof | |
TW201934546A (zh) | 嘧啶類化合物、其製備方法及其醫藥用途 | |
WO2020125759A1 (zh) | 作为wnt信号通路抑制剂的化合物及其医学应用 | |
CN110790749A (zh) | 一种含氮杂环化合物、药物组合物以及其用途 | |
CN115536656A (zh) | 作为hpk1抑制剂的杂环化合物 | |
BR112020019111A2 (pt) | Derivados de imidazolidin-2-ona substituída como inibidores de prmt5 | |
CN111909101A (zh) | 一种egfr激酶抑制剂及其在制备抗癌药物方面的应用 | |
WO2022041491A1 (zh) | 一种靶向EGFR突变的吡咯并[2,3-d]嘧啶衍生物及其制备方法和用途 | |
CN111116585B (zh) | 具有c-MET激酶抑制活性化合物、制备方法、组合物及用途 | |
JP2021515768A (ja) | オキサジノキナゾリンおよびオキサジノキノリン系化合物、ならびに調製方法およびその使用 | |
WO2022148439A1 (zh) | 作为bcl-2抑制剂的杂环化合物 | |
CN111620873B (zh) | 一类含哌啶的吡咯并[2,3-d]嘧啶衍生物及其制备和用途 | |
CN113831344A (zh) | 炔苯基苯酰胺类化合物及其应用 | |
WO2023046114A1 (zh) | 蝶啶酮衍生物及其应用 | |
CN115803325B (zh) | 一种egfr抑制剂及其制备方法和应用 | |
TWI807343B (zh) | 取代喹唑啉類化合物、藥物組合物及應用 | |
WO2023011299A1 (zh) | 嘧啶-4,6-二胺衍生物及其制备方法和药学上的应用 | |
WO2023040996A1 (zh) | 氮杂吲唑大环化合物及其用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |